Evaluating digital vascular perfusion and platelet dysfunction in Raynaud’s phenomenon and systemic sclerosis by Pauling, John
        
University of Bath
PHD
Evaluating digital vascular perfusion and platelet dysfunction in Raynaud’s








Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 22. May. 2019
 
 
Evaluating digital vascular perfusion 
and platelet dysfunction in Raynaud’s 











A thesis submitted for the degree of Doctor of Philosophy 
University of Bath 








Attention is drawn to the fact that copyright of this thesis rests with the author. A 
copy of this thesis has been supplied on condition that anyone who consults it is 
understood to recognise that its copyright rests with the author and that they must 
not copy it or use material from it except as permitted by law or with the consent of 
the author. 
 
This thesis may be made available for consultation within the University Library and 
may be photocopied or lent to other libraries for the purposes of consultation. 
 i 
Abstract 
Raynaud’s phenomenon (RP) describes excessive vasoconstriction of the digital 
microvasculature in response to cold exposure and emotional stress. RP is typically the 
earliest clinical manifestation of systemic sclerosis (SSc); a complex multisystem disease of 
unknown aetiology characterized by vasculopathy, inflammation and fibrosis. Vasculopathy 
is considered an essential pre-requisite to tissue remodeling, characterized by excessive 
collagen synthesis and tissue fibrosis, which occurs in the skin and other organs of patients 
with SSc. 
There is mounting evidence associating platelets with important biological functions beyond 
primary haemostasis. Upon activation, platelets release a large array of mediators 
implicated in vasoconstriction, inflammation and fibrosis, which has led me to consider the 
contribution of platelets to the pathogenesis of both RP and SSc. 
The principal aim of this thesis is to explore the impact of targeted anti-thrombotic therapy 
on digital microvascular function, platelet activation, oxidative stress and eicosanoid 
biosynthesis in RP and SSc. It is not possible to examine the impact of anti-platelet therapy 
on microvascular function, without first identifying sensitive methods for assessing digital 
microvascular function in humans. I shall report the findings of work examining established 
(infrared thermography) and novel (laser speckle contrast imaging) methods for the 
objective assessment of digital microvascular function in RP and SSc. I shall critically 
appraise the application of these methods alongside subjective patient self-report 
assessment of digital vascular function. I shall examine associations between digital 
vascular function, platelet activation, oxidative stress and eicosanoid biosynthesis between 
primary RP and SSc. I shall also report the findings of an investigator-led early phase 
clinical trial of targeted anti-thrombotic medication in RP and SSc. 
The major findings of this study were highlighting the strengths and limitations of 
established and novel methods for objective microvascular assessment in RP and SSc, and 
the poor agreement that exists between objective and subjective methods for assessing RP 
severity. I have identified similarities and differences in platelet activation and eicosanoid 
biosynthesis in primary RP and SSc. I shall present evidence of apparent efficacy of 
asasantin retard therapy on subjective, but not objective, assessments of digital 
microvascular function; the relevance of which shall be discussed in detail. 
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Chapter 1.0  Introduction 
'The head was completely withered, of a uniform shade of bronze, exactly
 
resembling the colour of an ancient icon painting; the nose
 
was as thin as 
a knife-blade; the lips had almost disappeared—only the teeth and eyes 
gave any gleam of light... At the chin, where
 
the quilt was folded back, two 
tiny hands of the same bronze
 
colour slowly moved their fingers up and 
down like little sticks.
 
And the face seemed all the more awesome to me 
because I could
 
see that a smile was striving to appear on it, to cross its 
metallic
 
cheeks—was striving and yet could not spread.'  
With a shock, after the woman had said, '"Master, don't you recognize
 
me?"'... he realizes that she is Lukeria, who ten years before
 
had been 
'the greatest beauty among all the servants in our
 
house, tall, buxom, 
white-skinned and rosy-cheeked, who used
 
to laugh and sing and 
dance!'. But she says, '"Don't you
 
pity me too much...I sing songs even 
now."' 
Turgenev 
Living Relic 1874 
Sketches from a Hunter's Album, translated by Richard Freeborn.  




This early literary description of systemic sclerosis (SSc) is striking, not least for the accuracy 
of the clinical features described, but also for its portrayal of the remarkable courage and 
tenacity that exemplifies patients afflicted by this devastating illness. The pathological 
hallmark of SSc is dysregulated tissue remodelling and excessive fibrosis. As indicated in the 
description of Lukeria above, fibrosis of the skin (leading to use of the synonym scleroderma) 
is the most clinically visible manifestation of established disease. Vascular dysfunction is 
typically the earliest manifestation of the disease and thought to represent an essential 
 2 
prerequisite to subsequent disease characteristics. Raynaud’s Phenomenon (RP) is typically 
the presenting vascular feature of SSc and can manifest several years prior to the 
emergence of additional organ-specific features of SSc. RP describes episodic excessive 
vasoconstriction of the digital vessels in response to cold exposure and emotional stress. RP 
is common and typically occurs as an isolated phenomenon in otherwise healthy individuals 
(primary RP), with only a small minority of patients progressing to SSc.  
 
The origin of this thesis was to evaluate platelet function in primary RP and SSc, and to 
explore the biological and peripheral microvascular effects of targeted anti-platelet therapy in 
primary RP and SSc.  
 
In this chapter I shall describe the clinical features and pathogenesis of RP and SSc. I shall 
review the potential contribution of platelets to vascular function, inflammation and tissue 
remodeling in RP and SSc. I shall report the evidence to support platelet dysfunction in 
primary RP and SSc, before critically appraising the findings of previous studies of anti-
platelet agents in these conditions. I shall outline some of the limitations of available 
subjective assessment of peripheral vascular function in RP and SSc, and discuss the use of 
objective non-invasive microvascular imaging techniques in the assessment of digital 
vascular function. The chapter will close with a summary of the key research hypotheses and 
main objectives I wish to address in this thesis. 
 
1.2 Raynaud’s Phenomenon 
 
1.2.1 Clinical Features of Raynaud’s Phenomenon 
Maurice Raynaud (1834-1881, Figure 1.1 and 1.2) is generally credited with providing the 
earliest detailed description of episodic excessive vasoconstriction of digital vessels in 
response to cold exposure and emotional stress, to which he has become eponymously 
associated (Herrick, 2005, Wigley, 2002, Raynaud, 1862). Vasoconstriction in response to 
cold exposure is an important component of thermoregulation, leading an early 20th Century 
physician to dryly observe ‘we are all subjects of Raynaud’s phenomena to a greater or 
lesser degree’ (Hutchinson, 1901). Hutchinson advocated replacement of the original term 
disease with the alternative suffix “phenomenon”, and reserving use of the term for people in 
whom the degree of vasoconstriction is disproportionate to the precipitating stimulus.  
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Figure 1.1 Maurice Raynaud (1834-1881).  
Raynaud’s & Scleroderma Association, 2011 Maurice Raynaud (1834-1881) [online]. RSA, 
Alsager, UK. Available from: http://www.raynauds.org.uk/raynauds/why-the-name [accessed 
21st March 2012]  
 
 
1)   
Figure 1.2  Thesis of Maurice Raynaud, 1862. 
Medarus, 2012. Raynaud_These [online] Medarus, France. Available from: 
http://www.medarus.org/Medecins/MedecinsTextes/raynaud_maurice.htm [accessed online 
21st March 2012] 
 
Attacks of RP are typically associated with distinct cutaneous colour changes, reflecting the 
perfusion and oxygenation of sequestered blood within affected tissues during attacks. 
Blanching (white phase) occurs as a result of profound vasoconstriction of the digital arteries, 
pre-capillary arterioles and cutaneous arteriovenous anastamoses (AVAs) (Figure 1.3). This 
can be accompanied by digital cyanosis (blue phase) secondary to de-oxygenation of 
sequestered blood within affected tissue (Figure 1.3). Digital ischaemia is sometimes 
followed by a post-occlusive reactive hyperaemia during re-perfusion leading to erythema of 
the digits (red phase) (Wigley, 2002). Typically, a history of increased insensitivity to cold and 
the presence of 2 colour changes is sufficient, but not essential, to consider a diagnosis of 
RP (Brennan et al., 1993). The digits of the hands and feet are typically affected areas but 
other commonly affected sites include the nose, ears, cheeks and nipples. RP attacks are 
typically accompanied by ischaemic pain and paraesthesia, which can impair function. Other 
early observations of RP included bilaterality of the phenomenon, absence of gangrene of 
the digits and presence of adjacent palpable pulses (Allen, 1932). 
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Figure 1.3 The hands of a patient with RP secondary to SSc.  
There is blanching and cyanosis of the digits representing the typical appearances of RP. The waxy appearance of the skin of 
the fingers is a consequence of cutaneous fibrosis (sclerodactyly). In addition, there is shortening of the index fingers 




1.2.2 Epidemiology or Raynaud’s phenomenon 
RP usually occurs as an isolated phenomenon, referred to as primary RP. There is a strong 
predilection for females. The prevalence of primary RP varies according to geographical 
variation in climate (Maricq et al., 1997). For example, population based studies in the UK 
have estimated the prevalence of RP within the general population of 11% and 19% for men 
and women respectively, in comparison with a prevalence of only 3.7% in a Spanish 
population (Silman et al., 1990, Riera et al., 1993). In approximately 10% of cases of RP, 
there is an associated vascular, haematological, neurological or autoimmune disease, for 
which the term secondary RP is applied (Riera et al., 1993). Secondary RP can be 
associated with more profound peripheral vascular dysfunction, sometimes resulting in 
critical digital ischaemia and tissue necrosis. Approximately half of patients referred to 
secondary care for evaluation of RP symptoms have secondary RP (Edwards, 1990). The 
majority of patients with secondary RP have an underlying autoimmune condition although 
clinicians must remain vigilant to alternative causes and we have reported non-rheumatic 
examples of secondary RP that have presented to rheumatology services for further 
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investigation (Pauling et al., 2010, Flower et al., 2010). Older age at presentation and 
involvement of the thumbs have been identified as specific risk factors for secondary RP 
(Chikura et al., 2010). The presence of antibodies to ubiquitously expressed auto-antigens 
and nailfold capillaroscopic changes are useful markers for future progression to connective 
tissue disease (CTD), particularly SSc (Koenig et al., 2008). Approximately 13% of patients 
with RP referred to secondary care without features of CTD at presentation subsequently 
develop SSc (Koenig et al., 2008). 
 
1.2.3 Pathogenesis of Raynaud’s Phenomenon 
 
‘To sum up in a more definite form, I would say that in the present state of our 
knowledge, local asphyxia of the extremeties ought to be considered as a 
neurosis characterised by enormous exaggeration of the excito-motor energy of 
the grey parts of the spinal cord which control the vaso-motor innervation.’ 
 
Maurice Raynaud 
New Researches of the nature and treatment of local asphyxia of the extremeties. 1874 
Selected Monographs, The New Sydenham Society, 1888 
Translated by Thomas Barlow, MD 
 
Raynaud correctly observed the absence of an obliterative vasculopathy, enabling episodic 
attacks to occur and completely resolve. He sensibly concluded that there must be an 
important contribution of neural innervation of the digital vessels in the development of RP. 
Great strides have been made over the last 30 years to elucidate the pathogenesis of RP, 
which is not yet fully understood. Abnormalities within the vessel wall (primarily the 
endothelium), the autonomic control of vascular smooth muscle tone and intravascular 
factors reciprocally modulate each other, resulting in the clinical features of RP, and making 
it difficult to treat the phenomenon by targeting one individual pathway in isolation (Herrick, 
2005). Important pathophysiological differences are thought to exist between primary RP and 
RP secondary to SSc, despite the similarity in clinical presentation early in the course of SSc. 
 
Vessel wall abnormalities 
Primary RP is generally considered a functional disorder although minor structural 
abnormalities such as increased capillary dimensions have been identified on direct 
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visualization of the nailfold capillaries (Bukhari et al., 2000). In SSc, structural abnormalities 
are more pronounced with histopathological evidence of endothelial damage, intimal 
thickening and smooth muscle hypertrophy, resulting in progressive luminal obliteration 
(Herrick, 2005). The endothelium has an important role in mediating vascular tone through 
the production of vasoactive mediators. There is evidence to support an imbalance in 
endothelial production of vasodilators (such as NO and prostacyclin) and vasocontrictors 
(primarily endothelin) in RP favouring vasoconstriction (Herrick, 2005). Impaired endothelial 
dependent vasodilation occurs in both primary RP and SSc, although to a greater extent in 
SSc (Herrick, 2005).  
 
Neural control of vascular tone 
The autonomic nervous system is of particular importance in thermoregulation and RP 
pathogenesis. Both autonomic and peripheral nerve dysfunction has been shown to occur in 
SSc in comparison with primary RP and healthy controls (Klimiuk et al., 1988, Schady et al., 
1991). Vasoconstriction to noradrenaline may be enhanced due to increased expression of 
2C-adrenoceptors in digital arteries of patients with RP and SSc following cold exposure 
(Herrick, 2005). Biopsy specimens have also identified impaired vasodilatation due to a 
significant reduction in the number of vasodilatory calcitonin gene-related peptide (CGRP) 
immunoreactive neurons in skin from patients with primary RP and SSc compared with 




Vascular tone is also influenced by an array of intravascular factors including shear stress, 
haemorrheological abnormalities, circulating sex hormones, oxidative stress and the action 
of circulating cells such as platelets. Indeed, intravascular abnormalities can be the direct 
cause of secondary RP in conditions such as cold agglutinin disease (Flower et al., 2010). 
All are thought to make important contributions to the pathogenesis of both primary RP and 
SSc. A comprehensive description of the potential contribution of platelets to the 
pathogenesis of RP and SSc is provided in section 1.4.3. 
 
1.2.4 Management of Raynaud’s phenomenon 
Identifying and managing the cause of RP can occasionally completely alleviate symptoms 
of RP e.g. cold agglutinin disease. In both primary RP and RP secondary to CTD, the 
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central components of management include advice on avoidance of precipitating or 
aggravating factors, alleviating acute episodes and the use of drugs to prevent 
vasoconstriction or promote vasodilatation. All patients are educated on cold avoidance 
measures and the importance of maintaining core temperature. The use of gloves and local 
heat packs can reduce the frequency and duration of RP attacks. Smoking cessation advice 
is given to all smokers with RP. There is RCT evidence to support the use of drugs 
designed to prevent vasoconstriction including selective serotonin reuptake inhibitors 
(SSRIs) such fluoxetine (Coleiro et al., 2001) and angiotensin II antagonists such as 
losartan (Dziadzio et al., 1999). Despite anecdotal reports, the endothelin receptor 
antagonists (ERA) have not been shown to be effective for RP symptoms in well-designed 
RCTs (Nguyen et al., 2010). Studies have also identified a role for drugs that promote 
vasodilation including calcium channel antagonists (Thompson et al., 2001), prostacyclin 
(McHugh et al., 1988), phosphodiesterase inhibition (Shenoy et al., 2010) and nitrates (Teh 
et al., 1995, Anderson et al., 2002). 
 
1.3 Systemic sclerosis  
SSc is a rare complex disease of unknown aetiology characterized by vasculopathy, fibrosis 
and inflammation. The hallmark of the disease is the overproduction and accumulation of 
extracellular matrix proteins such as collagen leading to progressive fibrosis of affected 
organs. This is most clinically evident in the skin, which becomes thickened and loses its 
elasticity leading to early and continued use of the synonym “scleroderma” (from the greek 
roots skleros meaning hard and derma relating to skin). As previously discussed, RP is 
typically the presenting feature of SSc and can predate the onset of other clinical 
manifestations by several years. Approximately 12.6% of patients referred to secondary care 
for assessment of RP symptoms subsequently develop SSc (Koenig et al., 2008). Activation 
of the immune system is a notable early feature of SSc and the identification of 
autoantibodies to ubiquitously expressed antigens and the use of nailfold capillaroscopy (to 
proivide in vivo evidence of microvascular dysfunction) facilitates the early identification of 




1.3.1 Early recognition and descriptions of systemic sclerosis 
There were several reports of induration and thickening of the skin in the 18th and 19th 
century which utilised the term ‘scleroderma’. Retrospective analysis of these reports 
suggest many were likely to represent alternative diagnoses in which skin thickening occurs; 
most notably a likely case of ‘scleroedema’ reported by Curzio in 1753 (Benedek and 
Rodnan, 1982). The range of distinct disease entities characterised by skin thickening 
continues to cause diagnostic error and uncertainty to this day. In the appendix to his English 
translation of Raynaud’s original thesis and subsequent essays, Thomas Barlow describes a 
series of cases which were almost certainly SSc, accurately associating the vascular and 
fibrotic components of the disease. In one case he describes;  
 
‘a women who for 5 years had suffered during the winter with hard yellowish 
patches on the extremeties, which subsided on the return of spring. Ultimately 
the fingers were permanently altered in that the extremeties became cold, 
hard, somewhat unsensitive and decidedly atrophied. The last phalanges were 
contracted in a state of semi-flexion….The patient was liable to crises from 
time to time during which the finger reddened and became painful, then 
ulceration occurred and tardy cicatrisation with loss of substance. After each 
crisis the affected digit became a little more atrophied and deformed than 
before. There was no trace of scleroderma in other parts of the body’  
 
Thomas Barlow, 1888 
Author’s appendix 
Selected Monographs, The New Sydenham Society, 1888 
 
In the mid 20th century, in recognition of the major visceral involvement that occurs in SSc, 
Goetz first proposed use of the term “progressive systemic sclerosis” noting: 
 
Obviously the term ‘scleroderma’ should be abandoned. ‘Scleroderma’ is only 
the obvious and striking symptom of a generalized disease and the most 
serious symptoms actually arise in the viscera.  
 
Goetz, 1945, as cited in (Benedek and Rodnan, 1982)  
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Much of the late 20th Century was devoted to sub-classifying this heterogeneous disease 
according to the extent of skin involvement, and recognition of the importance of such 
classification in terms of major organ manifestations, serological biomarkers and prognosis 
(LeRoy and Medsger, 2001, LeRoy et al., 1988). 
 
1.3.2 Clinical features of systemic sclerosis 
The varied clinical features of SSc led to delayed appreciation that they represented 
heterogeneous clinical manifestations of the same disease entity. It is easiest to consider the 
clinical features of SSc in terms of the sequalae of the main pathophysiological events 
driving the disease; vasculopathy, fibrosis and inflammation.    
 
Vacsulopathy 
Microvascular dysfunction is considered an essential pre-requisite for subsequent clinical 
manifestations of the disease and RP occurs in virtually all patients with systemic sclerosis 
(LeRoy, 1996). Peripheral microvascular dysfunction in SSc is typically more pronounced 
than in primary RP. In addition to excessive vaso-reactivity to cold exposure, there is 
structural remodelling of the vessels with endothelial damage, intimal and adventitial 
thickening, smooth muscle hypertrophy and eventual obliteration of the vessel lumen. This 
leads to more persistent and profound tissue ischaemia, presenting as tissue necrosis in the 
form of digital ulceration (DU) or, in severe cases, critical digital necrosis and gangrene 
(Pauling et al., 2011a). Vascular dysfunction can occur in other vascular beds, most notably 
the lungs (pulmonary arterial hypertension [PAH]) and kidneys (scleroderma renal crisis 
[SRC]), which are leading causes of SSc-associated mortality. Whilst often clinically silent, 
vasculopathy can also be demonstrated in the tissue of organs complicated by fibrosis such 
as the gastrointestinal tract.  
 
Fibrosis 
Skin fibrosis is the most striking visible manifestation of the disease. SSc is typically sub-
classified into 2 distinct variants according to the extent of cutaneous involvement. In limited 
cutaneous SSc (lcSSc), skin thickening is restricted to the face and extremities (distal to the 
elbows and knees) and is slowly progressive (LeRoy et al., 1988). In diffuse cutaneous SSc 
(dcSSc), skin thickening is more widespread and pronounced, with the potential for greater 
subsequent morbidity including joint flexion contractures in the hands and a restrictive lung 
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defect secondary to thickening of the skin of the chest wall. Fibrosis occurs elsewhere 
including, in order of decreasing frequency, the lungs, gastrointestinal tract and heart. 
Progressive fibrosis can result in organ failure, which remains a major cause of morbidity and 
mortality. The extent of cutaneous disease can help predict other SSc organ-specific 
manifestations. For example, lung fibrosis more oftenly occurs in dcSSc, whereas PAH is 
more commonly found in lcSSc. Such clinical associations, whilst helpful, are not absolute 
and any particular organ manifestation can occur in either lcSSc or dcSSc. Indeed, internal 
organ manifestations can occur in the absence of skin involvement (systemic sclerosis sine 
scleroderma [ssSSc]) highlighting the systemic nature and marked heterogeneity of the 
disease. For example, we have reported life-threatening PAH as the presenting feature of 
ssSSc (Pauling et al., 2008).  
 
Inflammation 
Activation of the immune system in SSc is evident by the early presence of auto-antibodies 
to ubiquitously expressed nuclear antigens. A detailed description of the various auto-
antibodies that are found in SSc and their clinical relevance is beyond the scope of this 
thesis but has been reviewed elsewhere (Pauling, 2012). SSc-specific auto-antibodies 
provide vital prognostic information for clinicians that can facilitate earlier detection of 
disease manifestations e.g. SRC in patients carrying anti-RNA polymerase antibodies and 
PAH in patients carrying anti-nucleolar autoantibodies (Penn and Denton, 2008, Steen, 
2005). Associations between auto-antibody carriage and disease manifestations are not 
absolute and unexpected disease associations do occasionally occur e.g. SRC in 
association with anti-centromere autoantibodies (ACA). Clinically evident immune 
dysfunction can be demonstrated by the presence of active inflammation in tissues including 
the joints (typically a non-erosive symmetrical polyarthropathy), tendons and muscle 
(typically a low-grade and often sub-clinical myositis) (Eisenberg, 2008).  
 
1.3.3 Epidemiology of systemic sclerosis 
The disease prevalence varies with geographical location and period of data acquisition. For 
example, the reported prevalence of SSc using data acquired from the hospital records from 
a single centre (Memphis and Shelby counties, USA) increased from 40 per million between 
1947-52 and 280 per million between 1962-68. The highest estimated prevalence of SSc 
has been identified in a small population of Choctaw Native Americans in Oklahoma (660 
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per million), in whom a high prevalence of a polymorphism of the fibrillin gene has been 
identified. In a recent study, the prevalence of SSc within a large North American population 
was estimated at 276 cases per million adults with an annual incidence of 19.3 new cases 
per million adults per year (Mayes, A&R,2003). Both prevalence (315.1 vs 224.7 per million) 
and incidence (23.7 vs 18.3 cases per million per year) of SSc is greater in black compared 
with white patients. Furthermore, black patients are 1.86 times more likely than non-black 
patients to have dcSSc. Even allowing for variation in study design, it would appear the 
prevalence of SSc in the US is higher than that of the UK. Comparable studies in the UK 
have estimated the adjusted prevalence at between 30.8 and 82 per million (Silman, Br J 
Rheumatol, 1988; Allcock, Rheumatology, 2004). The condition has a higher propensity for 
women, possibly reflecting the contribution of sex hormones, pregnancy-related events or 
gender-specific environmental exposures (Barnes, 2012). In the UK, the ratio between 
female to male is 5.2:1 and the ratio between limited to diffuse disease 4.7:1. Prevalence 
estimates in the UK have also risen in recent studies, which probably reflects increased 
recognition of patients with limited disease in recent studies. An unexpectedly low ratio of 
limited to diffuse disease (1.5:1) in early epidemiological studies would support this notion 
(Silman, Br J Rheumatol, 1988).  
 
1.3.4 Pathogenesis of Systemic Sclerosis 
The pathogenesis of SSc is complex and a detailed description is beyond the scope of this 
thesis. The pathogenesis is best considered as a triad of vascular injury, cellular and 
humoral autoimmunity, and connective tissue remodelling (leading to dysregulated fibrosis). 
These distinct pathophysiological processes are heavily inter-related and reciprocally 
modulate each other as the disease evolves. 
 
Similar to many autoimmune diseases, the development of SSc is thought to follow a gene-
environment interaction. Putative external triggers include toxins (e.g. silica, solvents and 
vinyl chloride) and infections (e.g. cytomegalovirus, parvovirus B19 and Epstein-Barr virus) 
although the cause in most cases is unknown. As previously discussed, polymorphisms of 
the fibrillin gene have been identified within populations with a high prevalence of dcSSc 
associated with anti-topoisomerase positive autoantibodies. Fibrillins play important roles in 
the storage and activation of growth factors including TGF-. Mutation of the fibrillin gene is 
also responsible for the tight-skin mouse-1 (the most widely studied experimental animal 
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model of SSc). Other genetic associations in SSc have been identified which relate to genes 
responsible for the production of pro-inflammatory mediators such as cytokines (e.g. IL-1ß 
and IL-2) (Hunzelmann and Brinckmann, 2010). 
 
LeRoy, in his seminal paper of 1975, presented his ‘vascular hypothesis’ speculating that 
vascular dysfunction was an essential pre-requisite to late fibrotic manifestations of SSc 
(Campbell and LeRoy, 1975). This hypothesis is supported clinically by the early presence 
of RP, increased vascular permeability (sausage fingers) and telangiectasia in SSc. The 
vascular endothelium (a vital single cell thick layer of endothelial cells that regulate 
coagulation and fibrinolysis, vascular permeability and vascular tone) is thought to be a 
primary target in SSc (Kahaleh, 2012a). Endothelial cell (EC) injury (secondary to toxins, 
autoimmunity, microbial agents and/or ischaemia/reperfusion injury) help propagate a 
vicious cycle of vascular dysfunction favouring vasoconstriction and tissue hypoxia. A 
dysfunctional endothelium increases vascular permeability facilitating the migration of 
leukocytes leading to perivascular extracellular matrix (ECM) remodelling (Kahaleh, 2012a). 
The relationship between vasculopathy and fibrosis is complex. Chronic ischaemia and 
tissue hypoxia promote increased formation of growth factors (e.g. transforming growth 
factor  [TGF-] and connective tissue growth factor [CTGF]) by fibroblasts attracted by EC 
cytokines (Hunzelmann and Brinckmann, 2010). TGF- is thought to represent a key 
cytokine driving fibrosis in SSc, leading to the trans-differentiation of fibroblasts to 
myofibroblasts and increased collagen synthesis (Hunzelmann and Brinckmann, 2010). 
Platelet-derived growth factor (PDGF) is another important driver of fibrosis in SSc and shall 
be described later (see sections 1.4.3 and 1.4.4). These factors also play an important role 
in angiogenesis, which is also impaired in SSc. Histological analysis of early skin lesions 
demonstrates fibrosis occurring first around vessels, characterised by a dense peri-vascular 
infiltration of T cells, monocytes and activated fibroblasts (Hunzelmann and Brinckmann, 
2010). In the late stages of the disease, fibrotic regions are characterised by a hypocellular 
connective tissue and an altered composition of the ECM characterised by excessive 
collagen deposition (Hunzelmann and Brinckmann, 2010).  
 
No direct pathogenic role has yet been identified for the antibodies targeting ubiquitously 
expressed autoantigens that characterise SSc. There has been considerable interest in 
autoantibodies directed to candidate cells (e.g. endothelial cells), cell surface receptors (e.g. 
PDGF receptors) or extracellular matrix (ECM) proteins (e.g. fibrillin-1) which may 
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eventually provide a direct link between autoantibodies and endothelial damage and 
downstream fibrotic cell-signalling in SSc. The potential contribution of platelets to the 
pathogenesis of SSc will be described in section 1.4.3.  
1.3.5 Management of systemic sclerosis 
The outcome of therapeutic studies of SSc over the last 50 years has been largely 
disappointing and it remains one of few rheumatic diseases in which a range of effective 
disease modifying therapies has yet to emerge. Effective treatments targeting clinical 
manifestations of SSc are available and widely used e.g. the use of proton pump inhibitors 
to manage gastro-oesophageal reflux secondary to upper gastrointestinal dysmotility. A 
limited number of treatments directly targeting pathogenic mechanisms have been studied 
and in recognition of the central role of the immune system, much work has focused on 
immunomodulatory treatments. For many years, D-Penicillamine was the “anchor drug” in 
SSc before the disappointing findings of a large double-blind study led many to question its 
safety and efficacy (Wollheim, 2012). Glucocorticoids are largely avoided (in high dosage at 
least) in light of their potential to precipitate a SRC. Studies of methotrexate and 
cyclophosphamide have reported modest treatment efficacy in trials of fibrotic complications 
of SSc (Pope et al., 2001, Hoyles et al., 2006, Tashkin et al., 2006). The eagerly anticipated 
findings of the European Scleroderma Observational Study evaluating outcomes in SSc 
patients treated with methotrexate, mycophenolate mofetil or cyclophosphamide will 
hopefully provide further insight into the role of immunosuppressive regimes in the treatment 
of SSc. Large multicentre randomized trials of human autologous stem cell transplantation 
have recently reported potentially promising findings on mortality in early diffuse SSc (van 
Laar, 2012). The results of studies of recombinant human monoclonal antibodies to TGF- 
and tyrosine kinase inhibition (imatinib mesylate) to augment downstream mediators of 
TGF- and PDGF have failed to live up to expectations. The findings of early investigative 
studies of other ‘biological agents’ such as rituximab (anti-CD20 B cell depletion) and 
tocilizumab (anti-IL6) are potentially more promising.  
 
Arguably the most effective disease modifying treatment for SSc has been angiotensin 
converting enzyme inhibitors (ACEi) which have significantly reduced the morbidity and 
mortality associated with SRC in SSc (Steen and Medsger, 2007). Targeting the renin-
angiotensin pathway has been less effective for managing peripheral vascular complications 
in SSc (Dziadzio et al., 1999, Gliddon et al., 2007). Meta-analyses have indicated the 
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effectiveness of dihydropiridine-type calcium-channel blockers in the management of 
primary RP and RP in SSc (Thompson and Pope, 2005, Thompson et al., 2001). 
Intravenous prostanoids are effective for RP symptoms and improve DU healing in SSc 
(Wigley et al., 1994, McHugh et al., 1988). The use of selective serotonin re-uptake 
inhibitors (SSRIs) has also been shown to reduce the impact of RP symptoms in SSc 
(Coleiro et al., 2001). The advent of endothelin-receptor antagonists (ERA) and 
phosphodiesterase inhibitors may provide the first opportunity to modify the disease course 
of vascular complications of SSc. For example, bosentan has been shown to reduce the 
frequency of DU and improve exercise capacity, functional class and some haemodynamic 
measures in SSc-PAH (Kowal-Bielecka et al., 2009). 
 
1.4 Platelets  
1.4.1 Platelet structure and contents 
 
Platelets were recognised by various physicians across Europe in the 18th century, but it is 
Bizzozzero who is credited with the first detailed description of their structure and 
significance as the central component of the cellular mechanisms responsible for primary 
haemostasis in 1882 (Ribatti and Crivellato, 2007). He termed these cells piastrine (Italian 
for small plates). It was not until 1906 that it was established that platelets were derived 
from megakaryocytes within the bone marrow, and much of the early part of the 20th century 
was devoted to establishing their role in the coagulation cascade and haemostasis. Indeed, 
for much of this period, haemostasis was thought to represent their sole function despite 
observations as early as 1896 for their phagocytic capacity (Klinger, 1997).   
 
Platelets (or thrombocytes) are anucleate cytoplasts formed following cytoplasmic 
fragmentation from megakaryocytes under the control of humoral agents such as 
thombopoietin. Megakaryocytes are primarily formed in the bone marrow although 
fragmentation can occur in other organs such as the lung. The normal platelet count is 
between 150 and 350x109/L (Kamath et al., 2001). Platelets have a lifespan of 8-10 days. 
Resting platelets are smooth biconcave discoid structures with a diameter of 1-3m and 
volume of 5-6 fl (Kamath et al., 2001). Despite the lack of a nucleus, platelets are capable of 
a small amount of protein synthesis due to the presence of megakaryocyte-derived 
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messenger RNA. Platelets contain around 35 round or oval -granules which contain 
factors synthesized during megakaryocyte development and those endocytosed from 
plasma via the open canalicular system (OCS) following formation. In addition platelets 
contain around 2-7 dense bodies, which contain their own factors important in haemostasis 
and inflammation. Table 1.1 lists some of the major contents of platelet granules. Platelets 
also contain a dense tubular system, important in the regulation of calcium stores and 
arachidonic acid metabolism (namely the production of thromboxane A2 [TxA2]). The release 
of platelet-derived factors is facilitated by the OCS, sometimes referred to as the 2-way 
street owing to its equally important participation in exo- and endocytosis of particulate 
matter (Klinger, 1997). 
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Adapted from references (Gurney et al., 2002, Kamath et al., 2001) 
 
1.4.2 Platelet activation, adhesion and aggregation in primary haemostasis 
In resting conditions the endothelium attempts to avoid platelet activation through the 
release of mediators such as NO, endothelial nucleotidases (ADPases3) and prostacyclin 
that inhibit platelet activation. The von Willebrand factor (vWF) is a cell-adhesion molecule 
that facilitates binding between endothelial cells and collagen in the sub-endothelial 
basement membrane. Damage to the endothelial surface, such as following trauma, leads 
to exposure of collagen, tissue factor and vWF to platelets. The chief binding sites for 
collagen on platelets are the GpVI receptors (which have an important role in TxA2 
                                               
3 ADPases reduce local concentration of ADP through the conversion of ADP to adenosine, which itself further inhibits platelet function 
via adenosine receptors on the platelet surface 
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synthesis and release) and GpIa/IIa receptors (important in platelet adhesion), directly 
inducing granule release. TxA2 release upregulates GpIIb/IIIa expression (the chief binding 
site of vWF and fibrinogen), that also promotes platelet activation. 
 
There are several important circulating platelet activators such as adenosine diphosphate 
(ADP), adenosine triphosphate (ATP), thrombin, adrenaline and thromboxane. A schematic 
outlining the key intracellular signalling pathways (and therapeutic targets) involved in 
platelet activation is presented in Figure 1.4.  
 
ADP binds to the P2Y1 and P2Y12 G-protein coupled purinergic receptors. The P2Y12 is 
considered the more important ADP receptor and induces platelet activation by 
antagonizing adenylyl cyclase activity and suppressing cAMP formation. The P2Y12 receptor 
is coupled to Gi2 which inhibits adenylyl cyclase and cytosolic cyclic adenosine 
monophosphate (cAMP) production (Kahner et al., 2006). cAMP is an important modulator 
of release of calcium from intracellular stores (and modulation of actin cytoskeleton 
dynamics involved in platelet shape change). In addition, P2Y12 receptor activation 
modulates platelet activation and granule release through phosphoinositide-3-kinases 
(PI3K) (Kahner et al., 2006). 
 
The P2Y1 receptor is a G protein coupled receptor (GPCR) coupled to Gq that activates 
phospholipase 2 (PLC2). PLC2 regulates production of inositol triphosphate (IP3) and 
diacyl glycerol (DAG) which leads to calcium release from intracellular stores and protein 
kinase C (PKC) activation (Kahner et al., 2006). P2Y1 activation is an essential component 
of shape change induction and platelet aggregation (Kahner et al., 2006).  
 
Endothelial nucleotidases (e.g. CD39 and CD73) lead to extracellular breakdown of ATP 
and ADP to adenosine. Adenosine is a potent vasodilator and inhibitor of platelet activation 
due to its GPCR activation of adenylyl cyclase and increased intracellular production of 
cAMP. Adenosine is taken up by cells such as erythrocytes via equilibrative transporters 
(Johnston-Cox and Ravid, 2011). Purinergic signaling pathways in platelets can be targeted 
to reduce platelet activation e.g. P2Y12 inhibition (clopidogrel) and adenosine reuptake 
inhibition (dipyridamole) (Figure 1.4). 
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Figure 1.4 Schematic outlining principal purinergic and intracellular signalling pathways 
involved in platelet activation.  
 
The red text boxes and arrows indicate pharmacological methods for inhibiting platelet 
activation. ADP, adenosine diphosphate; ATP, adenosine triphosphate; TxA2, thromboxane 
A2; PLC2, phospholipase 2; PIP2, phosphatidylinositol 4,5-biphosphate; IP3, inositol 
triphosphate; DAG, diacyl glycerol; PKC protein kinase C; ER endoplasmic reticulum; 
cAMP, Cyclic adenosine monophosphate; PLA2, phospholipase A2; Ca2+, calcium; ENTs, 
equilibrative transporters; AA, arachidonic acid; PGI2, prostaglandin I2; AMP, adenosine 
monophosphate; PDE, phosphodiesterase; PI3K, phosphoinositide-3-kinases (PI3K) 
 








ATP acts at non-selective ligand-gated cation channels (P2X1 receptors). Activation of P2X1 
receptors results in early shape change (discoid to spherical) following transient influx of 
calcium. The more significant function of P2X1 receptor activation is to potentiate calcium 
signaling downstream of other GPCR activation e.g. P2Y1 (Figure 1.4).  
 
Adrenaline is another platelet activator that inhibits adenylyl cyclase, via -2 adrenergic 
receptors on the platelet surface. Thrombin is a potent activator of platelets via protease-
activated receptors 1 and 4 (PAR-1 and PAR-4) that are components of a 7-transmembrane 
group of GPCR that influence intracellular signaling within platelets (figure 1.4). Upon 
activation, platelets undergo a shape change, first becoming spherical before developing 
finger-like pseudopodes to assume a stellate shape. These events help promote the 
recruitment of platelets to the exposed subendothelial surface where the platelets adhere 
and aggregate leading to the formation of a platelet plug. Platelet aggregation is achieved 
using vWF and fibrinogen as bridging agents between platelets. The release of factors such 
as TxA2 and ADP from activated platelets further potentiates local platelet activation, 
endothelial adhesion and aggregation, leading to the formation of the platelet plug and 
secondary coagulation. The vasoconstrictive properties of platelet-derived mediators such 
as TxA2 and serotonin further limit blood loss following injury. 
 
1.4.3 The potential contribution of platelets to the pathogenesis of Raynaud’s 
phenomenon and systemic sclerosis 
 
The biological actions of platelets are known to extend beyond primary haemostasis and 
there is now a greater appreciation of the shared characteristics of platelets and immune 
cells. Platelets release a surprisingly large array of mediators, many of which have 
important roles in inflammation, tissue repair and vascular function (Table 1.2).  
 
These factors are either synthesized within the cells upon activation, or stored and released 
from cytoplasmic granules as previously discussed in section 1.4.1. There is strong 
phylogenetic evidence to suggest the precursors of mammalian platelets provided the front 
line in microbial defence and wound healing (Weyrich et al., 2003). The Atlantic Horseshoe 
Crab (Limulus polyphemus) is a marine arthropod and “living fossil” that has evolved little 
over 445 million years. It’s single nucleated circulating cell (ameobocyte) that contains 
bacterial infection and achieves primitive wound sealing through the release of clotting 
 20 
factors from cytoplasmic granules and local aggregation (Weyrich et al., 2003). Despite the 
emergence of more specialised innate and acquired immunity, mammalian platelets have 
retained the ability to bind, encapsulate and destroy an array of pathogens in humans 
suggesting preserved inflammatory functions (Klinger, 1997). There is a growing 
appreciation of the potential contribution of platelets to diseases ranging from asthma 
(Kornerup and Page, 2007), inflammatory bowel disease (Danese et al., 2004), cystic 
fibrosis (O'Sullivan and Michelson, 2006) and cancer (Nash et al., 2002). 
 
Unsurprisingly, a considerable body of work has evaluated associations between platelet 
function, and RP and SSc. In this section I shall provide a conceptual framework upon 
which to consider the potential contribution of platelets in RP and SSc, by discussing the 
role of key platelet-derived mediators in chemotaxis, cellular adhesion, altered vascular 
resistance, altered vascular permeability, angiogenesis, matrix degradation, and fibrosis. A 
schematic diagram of the putative influence of platelet-derived mediators in the 
pathogenesis of SSc is presented in Figure 1.5. 
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Table 1.2 Platelet derived mediators associated with inflammation, vascular function 
and tissue re-modelling.  
 
Inflammatory mediators 
Nitric oxide * 
Thromboxane A2 * 
Serotonin * 
Prostanoids (PGD2, PGE2, PGF2) * 
Platelet activating factor 
Platelet factor 4 
-Thromboglobulin 
P-selectin 
Soluble CD40 ligand 
Adenosine * 
Adenine nucloetides * 
Histamine * 
Neutrophil activating peptide-2 
Matrix Metalloproteinases 1, 2 and 9 
IL-1 and IL-8 
Monocyte chemoattractant protein-3 
Macrophage inflammatory protein-1 
12-Hydroxyeicosatetraenoic acid 
RANTES (regulated upon activation, 
normal T-cell expressed and secreted) 





Platelet derived growth 
factors (PDGF)-A, B, C, D * 
Transforming growth factor-
B1 and B2 
Epidermal growth factor 
Granulocyte-macrophage 
colony-stimulating factor 
Vascular endothelial growth 
factor A and C 
Insulin like growth factor-1 
Brain derived neurotrophic 
factor 
Basic fibroblast growth 
factor 
Hepatocyte growth factor 
 
* also potently vasoactive. Adapted from references (O'Sullivan and Michelson, 





Figure 1.5 Putative role of platelet-derived mediators in the pathogenesis of systemic sclerosis.  
TxA2, thromboxane A2; ECM, extracellular matrix; TG, -thromboglobulin; PF-4, Platelet factor 4; IL-1, Interleukin 1; IgG, immunoglobulin; 5-HT, 5-hydroxy tryptamine (serotonin); TGF-, transforming 
growth factor ; PDGF, platelet derived growth factor; CTGF, connective tissue growth factor; MMP-1 & 2, matrix metalloproteinases 1 & 2; RANTES, Regulated upon Activation Normal T cell Expressed and 
Secreted; MIP-1, Macrophage Inflammatory Protein-1; ENA-78, epithelial neutrophil activating protein-78; sCD40L, soluble CD40 ligand; ROS, reactive oxygen species 
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Chemotaxis 
Platelets are a rich source of RANTES (Regulated upon Activation Normal T cell Expressed 
and Secreted; CCL5), platelet factor 4 (PF-4; CXCL4), -thromboglobulin (-TG) and ENA-
78 (epithelial neutrophil activating protein-78; CXCL5) (Klinger, 1997, Weyrich et al., 2003). 
Each has important leukocyte-chemoattractant properties attracting neutrophils, eosinophils, 
monocytes and fibroblasts to sites of inflammation (Deuel et al., 1981, Gurney et al., 2002, 
Weyrich et al., 2003).  
 
Cellular adhesion 
The outermost layer of platelets (the glycocalyx) is made of glycoprotein’s and has a vital 
role in adhesion, aggregation and leukocyte recruitment. The glycocalyx changes following 
platelet activation. For example, P-selectin translocates from the intracellular granule 
membrane to receptors on the glycocalyx following activation. P-selectin (also known as 
CD62p, GMP140 and PADGEM) is a single-chain trans-membrane glycoprotein from a 
family of important cell adhesion molecules (CAMs) whose names derive from “selective” 
and “lectins” (carbohydrate recognising proteins).  They are classified according to the 
primary cell-type responsible for their production e.g. L-selectin derived from leukocytes. P-
selectin translocates to the platelet membrane (the glycocalyx) following activation, 
facilitating adhesion, aggregation and leukocyte recruitment. P-selectin is the primary 
receptor for interaction between platelets and monocytes, neutrophils, memory T-cells and 
natural killer cells, modulating chemokine and cytokine expression in these cells (Klinger, 
1997). It also facilitates neutrophil rolling, arrest and transmigration across the endothelial 
surface as well as potentiating their action by inhibiting leukocyte apoptosis (O'Sullivan and 
Michelson, 2006, Weyrich et al., 2003, Gurney et al., 2002). 
 
Immune cell activation 
Platelet granules release several important pro-inflammatory mediators. For example, 
dense bodies secrete ATP which enhances the oxidative burst in neutrophils and serotonin 
which has an important influences on T-cell responses, vascular permeability, and fibroblast 
mitogenesis (Klinger, 1997). Alpha granules secrete many pro-inflammatory factors 
including immunoglobulins, PDGF and cationic proteins (Klinger, 1997). An important 
platelet-derived pro-inflammatory cytokine is the CD40 ligand (CD154, CD40L). CD40 is a 
phosphoylated glycoprotein of the tumour necrosis factor superfamily found on B cells, 
monocytes, macrophages and non-haemopoeitic cells including endothelial cells and 
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smooth muscle cells (Vogel and Noelle, 1998). Activation of this receptor by its ligand 
(CD40L) has important roles in thrombosis, oxidative stress and both humoral and cell-
mediated immune responses (Vogel and Noelle, 1998, Urbich et al., 2002, Henn et al., 
2001). The cytoplasm of platelets are the predominant source of sCD40L, and may account 
for up to 90% of circulating levels (Chen et al., 2005). Expression and cleavage of sCD40L 
occurs within seconds of ADP-induced platelet activation, appears distinct to granule 
secretion and is not responsive to treatment with aspirin (in contrast to clopidogrel) 
(Hermann et al., 2001, Henn et al., 1998).  Platelet derived sCD40L leads to increased B 
cell production of immumoglobulins (IgG) in vivo highlighting a potential importance of 
platelet activation in the adaptive immune response (Cognasse et al., 2007). In addition, 
sCD40L stimulates endothelial cell production of reactive oxygen species, chemokines and 
facilitates the recruitment of leukocytes following increased expression of cellular adhesion 
molecules ICAM-1 and VCAM-1 (Henn et al., 1998, Henn et al., 2001). Other important 
platelet-derived cytokines such as IL-1 further modulate immune pathways (Postlethwaite 
and Chiang, 2007). 
 
The eicosanoids are lipid-signalling molecules derived from 20-carbon essential fatty acids 
such as arachidonic acid (AA). They play central roles in inflammation and immunity, in 
addition to being potently vasoactive. The dense tubular system of platelets is a major site 
of pro-inflammatory leukotriene and prostaglandin synthesis. Eicosanoid metabolism by 
other inflammatory cells can be influenced by platelet-leukocyte interactions. For example, 
the transcellular passage of AA from platelets can promote formation of PMN-derived pro-
inflammatory leukotrienes e.g. LTB-4 and platelet mediated metabolism of PMN-derived 
eicosanoids (O'Sullivan and Michelson, 2006, Klinger, 1997). 
 
Angiogenesis 
Platelets are a rich source of pro-angiogenic growth factors including vascular endothelial 
growth factor (VEGF), fibroblast growth factor (FGF), angiopoietin 1, insulin-like growth 
factor (IGF-1) and platelet derived growth factor (PDGF) (Weyrich et al., 2003). These 
compete with the anti-angiogenic properties of other platelet-derived mediators such as PF-
4, and transforming Growth Factor  (TGF-). Their opposing angiogenic actions may be of 
particular significance in SSc, which is characterised by both capillary loss and dysregulated 




Leukocyte recruitment, angiogenesis and fibrosis can only occur at sites of inflammation 
following controlled degradation of the extracellular matrix (ECM). Platelets promote matrix 
degradation by secretion of matrix metalloproteinases (MMP-1 and MMP-2) in addition to 
augmenting the degradative activity of other cell types (e.g. production of MMP-9 following 
platelet-monocyte interactions and the effects of platelet-derived CD40 ligand on endothelial 
proteolytic activity) (Weyrich et al., 2003). Platelet-derived IL-1 is also an important mediator 
of the degradation of the sub-endothelial matrix facilitating further extravasation of 
leukocytes (Klinger, 1997). 
 
Fibrosis 
Platelets are a major source of circulating transforming growth factor  (TGF-), which is 
secreted from alpha granules on activation, and has important roles in the growth and 
differentiation of fibroblasts, wound repair, angiogenesis, immune tolerance and 
inflammation (Lev et al., 2007). Platelet-derived growth factor (PDGF) is another important 
platelet-derived regulator of angiogenesis, myofibroblast differentiation, vasoconstriction 
and smooth muscle proliferation (Liakouli et al., 2011, Trojanowska, 2008). PDGF-receptors 
are present on the surface of fibroblasts, and stimulate type I collagen-gene expression and 
conversion to a myofibroblast phenotype (Trojanowska, 2008). Similarly, connective tissue 
growth factor (CTGF, CCN2) is also released from activated platelets and has similar roles 
to TGF- ß in extracellular matrix re-modeling and fibrosis.  
 
Vascular tone and permeability 
Platelets produce a panel of vasoactive mediators that can promote vasoconstriction 
(thromboxane, serotonin, PDGF and dinucleoside polyphophates) and vasodilation (nitric 
oxide), although the balance of vascular tone favours vasoconstriction. Thromboxane A2 
(TxA2) is a particularly powerful vasoconstrictor, in addition to promoting further platelet 
activation. It is produced in platelets from prostaglandin H2 (via thromboxane synthetase), 
synthesized from AA by platelet cyclo-oxygenase (COX). It has also been proposed that 
platelet derived mediators may influence production of vasoactive mediators by other cell 
types such as endothelial production of the potent vasoconstrictor endothelin-1 (Matsumura 
et al., 1994). 
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1.4.4 Evidence of platelet dysfunction in SSc 
With growing appreciation of the contribution of platelets to vasoconstriction, inflammation 
and tissue re-modeling, it is unsurprising that platelets have attracted attention for their 
potential pathogenic role in RP and SSc. In this section, I shall describe the existing 
evidence to support excessive platelet activation in Raynaud’s phenomenon and systemic 
sclerosis, ranging from early studies of platelet aggregability and circulating platelet-derived 
mediators, to the fascinating findings of recent studies exploring the potential direct 
pathogenic role of platelets in established murine models of SSc. I shall review established 
anti-platelet treatments available and critically appraise the findings of previous therapeutic 
studies evaluating the use of such agents in RP and SSc.  
 
Platelet number and structure 
The platelet count in primary RP and SSc is generally within normal range. Cases of SSc 
associated with thrombocythaemia or thrombocytopenia are typically the result of other 
disease manifestations or overlap features e.g. vasculitis, malignancy, microangiopathic 
haemolytic anaemia (Frayha et al., 1980). One study did identify a higher total platelet count 
in whole blood from patients with the CREST variant of SSc compared with healthy controls 
(Price et al., 1991). In this study, the MPV and PDW did not differ between SSc and healthy 
controls (Price et al., 1991). In contrast, a recent study has demonstrated an increased MPV 
in primary RP compared with healthy controls (Shemirani et al., 2012). 
 
Platelet aggregation 
The vast majority of studies have identified increased ex vivo platelet aggregability to a 
panel of agonists including adrenaline (Hutton et al., 1984), ADP (Wilkinson et al., 1989, 
Cuenca et al., 1990, Lau et al., 1993), collagen (Goodfield et al., 1988, Wilkinson et al., 
1989, Lau et al., 1993, Goodfield et al., 1993), serotonin (5-HT) (Beretta et al., 2008, Biondi 
and Marasini, 1989) and AA (Reilly et al., 1986) in both primary RP and SSc, in comparison 
with healthy controls. Furthermore, patients with RP and SSc are less sensitive to the 
inhibitory effects of PGI2 and PGE1 on platelet aggregation compared to healthy donor 
platelets (Hutton et al., 1984, Belch et al., 1985). Under-representation of a genetic 
polymorphism in the 5-HT receptor gene that blunts intracellular responses to 5-HT has 
been noted in patients with SSc and leads to increased aggregation to 5-HT (Beretta et al., 
2008). In contrast, one study failed to show differences in aggregation to a panel of agonists 
(ADP, collagen and PAF) when comparing HC and SSc (Price et al., 1991). It was 
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postulated that harvesting of ‘exhausted’ platelets from the circulation may explain the 
findings, although long disease duration, limiting recruitment to patients with the CREST 
(Calcinosis, Raynaud’s phenomenon, (o)Esophageal dysmotility, Sclerodactyly and 
Telangiectasia) variant of SSc and the small study size may also account for the disparity in 
their findings with other studies (Price et al., 1991). There have been conflicting reports from 
studies evaluating the impact of disease duration on platelet aggregability in SSc (Friedhoff 
et al., 1984, Biondi and Marasini, 1989). Increased platelet aggregability appears to be more 
pronounced in SSc compared with primary RP (Cuenca et al., 1990, Biondi and Marasini, 
1989, Wilkinson et al., 1989). Indeed, one study that solely evaluated primary RP failed to 
identify differences in aggregation to the agonists AA, ADP, PAF compared with healthy 
controls (Dowie et al., 1990). The differences in platelet responses between SSc and 
primary RP may explain the more profound microvascular compromise that characterises 
RP associated with SSc. 
 
Platelet granule release products 
PF-4 and ß-TG were amongst the first alpha granule products found to be elevated in SSc 
(Hutton et al., 1984, Seibold and Harris, 1985, Lima et al., 1991, Macko et al., 2002, Reilly 
et al., 1986, Kahaleh et al., 1982, Cuenca et al., 1990). There are conflicting reports as to 
whether circulating ß-TG and PF4 levels are associated with specific clinical disease 
characteristics in SSc (Seibold and Harris, 1985, Malia et al., 1988, Herrick et al., 1996). 
Circulating levels of ß-TG are lower in primary RP compared with SSc and there are 
conflicting reports as to whether levels differ between primary RP and HC (Seibold and 
Harris, 1985). ß-TG and PF-4 have been identified in the bronchoalveolar lavage (BAL) fluid 
of subjects with scleroderma lung disease (particularly early in disease course) in contrast 
to HC and SSc patients without ILD, providing an attractive link between platelet activation 
and the site of tissue injury (Kowal-Bielecka et al., 2005). The pulmonary circulation is highly 
relevant to platelet biology because megakaryocytes release their platelets on arrival in the 
lungs, providing an attractive hypothesis linking platelet activation within the lungs and the 
high incidence of pulmonary complications in SSc and other lung diseases associated with 
increased platelet activation (O'Sullivan and Michelson, 2006).  
 
The von Willebrand factor (vWF) is a large multimeric glycoprotein produced by many cells 
including endothelial cells and platelets, facilitating platelet adhesion and aggregation. 
Several studies have reported increased circulating levels of vWF in SSc, variously 
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reporting their pathological significance in terms of either platelet or endothelial cell 
activation (Herrick et al., 1996, Kahaleh et al., 1981, Blann et al., 1993, Blann et al., 1995, 
Ames et al., 1997, Iannone et al., 2008, Mannucci et al., 2003, Cerinic et al., 2003). It has 
been proposed that a deficiency of the metalloprotease responsible for the cleaving of vWF 
may contribute to higher circulating levels of vWF in SSc (Mannucci et al., 2003). Circulating 
supra-normal multimers of vWF have also been identified in SSc (but not healthy controls) 
and decrease in number following aspirin therapy, suggesting the vWF multimers are 
platelet derived (Mannucci et al., 1989). Circulating vWF levels in SSc have been 
associated with various organ-specific complications including pulmonary vascular disease 
(Matucci-Cerinic et al., 1990, Scheja et al., 1994), pulmonary fibrosis (Kumanovics et al., 
2008) and diffuse cutaneous involvement (Blann et al., 1993, Ames et al., 1997). There are 
conflicting reports as to whether levels of circulating vWF are also raised in primary RP 
(Marasini et al., 1992, Marasini et al., 2000, Herrick et al., 1996). 
 
Increased expression of PDGF within BAL fluid (and skin) of patients with SSc has been 
demonstrated (Ludwicka et al., 1995, Yamakage et al., 1992). Circulating PDGF levels have 
been found to be raised in SSc and may account for increased mitogenic activity (Hummers 
et al., 2009, Riccieri V, 2011). In contrast, other studies have failed to identify increased 
circulating PDGF in the plasma of SSc compared to healthy controls.(Solanilla et al., 2009, 
Silveri et al., 2001, Dunbar et al., 1993) Furthermore, PDGF is not secreted in higher 
amounts from activated platelets from patients with SSc compared with healthy controls 
following activation (Solanilla et al., 2009). Cross-talk between TGF-ß and PDGF is thought 
to make an important contribution to fibrosis in SSc (Trojanowska, 2008). For example, 
TGF-ß up-regulates expression of PDGF receptors on scleroderma fibroblasts (Yamakage 
et al., 1992). TGF-ß is another constituent of platelet alpha granules and is considered a 
key cytokine in the pathogenesis of pulmonary and dermal fibrosis in SSc (Atamas and 
White, 2003). TGF-ß was originally identified in the alpha granules of platelets (Lev et al., 
2007). A recent study has identified associations between platelet count and aggregability 
with plasma levels of TGF- (Peracoli et al., 2008). Like PDGF, there are increased levels of 
TGF-ß in BAL fluid from patients with SSc compared with healthy controls (Ludwicka et al., 
1995). There have been conflicting reports as to whether circulating levels of TGF- ß are 
elevated in SSc compared with healthy controls (Dziadzio et al., 2005, Solanilla et al., 2009, 
Snowden et al., 1994). 
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As previously mentioned, the majority of sCD40L is platelet-derived and sCD40L has 
attracted interest as a potential biomarker in SSc due to its potential contribution to 
inflammation and fibrosis (Doran and Veale, 2008). Increased expression of CD40L on CD4 
(+) activated T lymphocytes has been demonstrated in SSc (Valentini et al., 2000). The 
CD40L-CD40 interaction has also been shown to be important in the formation of auto-
antibodies to topoisomerase-I in SSc (Kuwana et al., 1995). Increased circulating sCD40L 
levels have been identified in the plasma and serum of patients with SSc (Allanore et al., 
2005a, Komura et al., 2004). Elevated levels of sCD40L may be associated with a more 
vascular phenotype (PAH and DU disease) (Allanore et al., 2005a). It has been proposed 
that platelet activation at the site of endothelial damage may be responsible for the local 
release of VEGF and secondary disordered angiogenesis that occurs in SSc (Solanilla et 
al., 2009). Circulating plasma levels of VEGF are higher in SSc compared with PRP and 
healthy controls although VEGF is produced by a variety of cell types including endothelial 
cells, fibroblasts and leukocytes in addition to platelets (Solanilla et al., 2009, Hummers et 
al., 2009, Kuryliszyn-Moskal et al., 2005, Distler et al., 2002). Elevated circulating VEGF 
levels have been associated with vascular features including pulmonary arterial 
hypertension, the Raynaud’s severity score and the presence of giant capillaries on nailfold 
capillaroscopy, but may confer some protection against ischaemic tissue injury such as 
digital ulceration (Hummers et al., 2009, Pendergrass et al., 2010, Distler et al., 2002).  
 
Other granule contents are stored, but not synthesized in platelets and hence circulating 
levels may not reflect platelet activation (Kamath et al., 2001). For example, 5-HT is 
synthesized by enterochromaffin cells within the gastrointestinal tract and serotonergic 
neurons within the central nervous system, however the majority of circulating serotonin is 
stored and released from platelets upon activation. Serotonin is a potent vasoconstrictor 
and promotes fibrosis, attracting attention for it’s potential contribution to the pathogenesis 
of SSc (Seibold, 1985). Circulating levels of 5-HT in primary RP and SSc have revealed 
contrasting results (Coffman and Cohen, 1994, Biondi et al., 1988). Platelet 5-HT levels are 
lower in the CREST variant of SSc compared with healthy controls which may represent the 
harvesting of ‘exhausted’ platelets following in vivo platelet activation and degranulation in 
SSc (Klimiuk et al., 1989a). A genetic polymorphism of the serotonin (5-HT2A) receptor gene 
that blunts intracellular responses to serotonin may protect against the development of SSc 
(Beretta et al., 2008). Plasma levels of other platelet granule constituents such as the matrix 
metalloproteinases have also been found to be elevated in SSc (Hummers et al., 2009). 
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Whilst the above studies provide evidence of an association between increased platelet 
activation and SSc (and possibly primary RP), few of the studies confirm a direct pathogenic 
role of platelets in these conditions. 
 
Platelet membrane glycoproteins 
Several studies have identified higher circulating levels of the soluble form of P-selectin (sP-
selectin) in SSc compared with healthy controls (Olewicz-Gawlik et al., 2010, Blann et al., 
2003, Sfikakis et al., 1999, Iannone et al., 2008, Gruschwitz et al., 1995). sP-selectin values 
correlate with circulating levels of vWF in SSc, particularly in diffuse cutaneous disease 
(Blann et al., 2003). Increased expression of P-selectin (CD62P) in the stratum granulosum 
of skin biopsies has been reported in patients with SSc compared with healthy controls, 
particularly early in the course of their disease (Koch et al., 1993, Gruschwitz et al., 1995). 
Platelet surface P-selectin expression is increased in SSc compared with HC and primary 
RP, and falls in response to prostacyclin administration (Pamuk et al., 2007, Solanilla et al., 
2009). The endothelin receptor antagonist bosentan has also been shown to reduce 
circulating levels of sP-selectin and other adhesion molecules in patients with SSc to levels 
seen in healthy controls (Iannone et al., 2008). In contrast, P-selectin expression is not 
increased in primary RP, although platelet-monocyte and platelet-neutrophil interactions are 
enhanced providing evidence of enhanced platelet-leukocyte interactions in both primary 
RP and SSc compared with healthy controls (Pamuk et al., 2007). A recent study identified 
reduced expression of GpIIb/IIIa receptors on the platelets of patients with primary RP, the 
authors proposing this may be the consequence of enhanced thrombocytopoiesis in an 
environment of persistent platelet activation (Polidoro et al., 2010). 
 
Eicosanoid biosynthesis 
Circulating TxB2 levels are higher in SSc compared with HC (Herrick et al., 1996, Wilkinson 
et al., 1989). Similarly, urinary levels of 2-3 dinor TxB2 (a stable urinary metabolite of TxB2) 
are elevated in SSc compared with HC, and rise in response to total body cooling. Local 
cooling (forearm and hand) does not have the same influence on TxA2 biosynthesis (Hutton 
et al., 1984, Sakamoto et al., 1999). Studies evaluating plasma levels of TxB2 in primary RP 
have yielded conflicting results (Dowie et al., 1990) Leukocytes can also synthesize TxA2 
and elevated expression of genes encoding thromboxane synthase has been identified in 




Platelet-monocyte and platelet-neutrophil complexes are present in greater numbers of both 
PRP and SSc when compared with healthy controls (Pamuk et al., 2007). The formation 
and stability of adhesion bonds necessary for platelet-leukocyte interactions is regulated by 
phosphitidylinositol-3 kinase (PI 3-K). It has been postulated that T-cell auto-reactivity to 
collagen I may account for the enhanced activity of PI 3-K in SSc platelets (Postlethwaite 
and Chiang, 2007). 
 
Platelet-derived microparticles 
Microparticles are small membrane bound vesicles with important pro-inflammatory and pro-
thrombotic functions released from activated or dying cells. Increased circulating levels of 
platelet-derived microparticles have been identified in SSc (and mixed connective tissue 
disease) and are independently associated with symptoms of RP in connective tissue 
disease (Oyabu et al., 2011). 
 
Experimental models of systemic sclerosis 
Genetic and chemically induced animal models of systemic sclerosis have been developed, 
particularly in the context of skin and lung fibrosis. Much of the experimental work 
undertaken has explored pro-fibrotic signaling pathways and until recently, few studies had 
considered the contribution of platelets to the clinical phenotype in such models. In recent 
years, studies are beginning to emerge that have begun to address this shortfall. For 
example, Dees et al. have identified the important role of platelet-derived serotonin (5-HT) in 
the induction of ECM synthesis and fibrosis secondary to TGF-/Smad signaling mediated 
by 5-HT2B receptors which are themselves over-expressed in the skin of patients with SSc 
(Dees et al., 2011). Targeting the 5-HT2B receptor through pharmacological inhibition, or 
genetic nullification of the 5-HT2B receptor, ameliorates inducible and genetic experimental 
models of fibrosis. Furthermore, inhibition of platelet activation with the P2Y12 receptor 
antagonist clopidogrel decreased dermal thickening, collagen content and number of 
activated fibroblasts in the skin of both Tsk-1 and bleomycin-challenged mice (Dees et al., 
2011). Platelet trapping appears to be an important initiating event in chemically-induced 
murine models of fibrosis (Piguet and Vesin, 1994, Piguet et al., 1997). Komura et al. neatly 
demonstrated reduced dermal fibrosis and decreased generation of anti-topoisomerase-I 
autoantibodies in the tight skin mouse (Tsk-1) following blockade of the CD40/CD40L but 
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did not consider the implications of their findings in terms of the potential pathogenic role of 
platelets to this interaction (Komura et al., 2008).  
 
The recent development of animal models exhibiting characteristic microvascular and 
fibrotic features of SSc, such as the fos-related antigen 2 (Fra-2) transgenic mouse, provide 
exciting novel opportunities to evaluate the contribution of platelets to both vascular and 
tissue remodelling in animal models of SSc. To date, no studies specifically exploring the 
contribution of platelets in these novel animal models of SSc have been undertaken.  
 
1.4.5 Use of anti-platelet agents in the management of RP and SSc 
 
The evaluation of anti-platelet therapy has been a largely neglected area of therapeutics in 
RP and SSc (Herrick, 2005). A summary of the therapeutic studies evaluating the use of 
anti-platelet agents in RP is presented in Table 1.3. 
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Table 1.3. Summary table of previous clinical trials evaluating the use of anti-platelet therapy in the management of RP and SSc 
PRP, primary Raynaud’s phenomenon; SRP, secondary Raynaud’s phenomenon; SSc, systemic sclerosis; PEP, photoelectric plethysmography; ASA, aspirin; DIP, dipyridamole; 
RCT, randomized controlled trial; CREST, Calcinosis, Raynaud’s, (o)Esophageal dysmotility, Sclerodactyly, Telangiectasia; TG, -thromboglobulin; vWF, von Willebrand’s 
factor; COX, cyclo-oxygenase; PF-4, Platelet factor 4; TI, thermographic index; LTG, longitudinal thermal gradient; TxB2, thromboxane B2; sig, significant; PGF1, Prostagalndin 
F1 
 
Authors Year Study Medication Patients Study 
Design 
Endpoints Outcome and Comments 
Kahelah et al. 1982 ASA(150mg every 3
rd
 
day) and DIP 
(400mg/day) 
SSc (n=10) Open-label Platelet aggregates and B-TG levels Reduction in platelet aggregates and B-TG levels 
No assessment of clinical efficacy 
Jones et al.  1983 3 weeks Dazoxiben 
100mg qds vs. 
placebo 
Severe RP 
(n=8, 2 patients 
had positive 





Severity of RP symptoms and pain (4 
point scales). 
Skin temperature (thermistor) and 
digital blood flow (plethysmography) 
No significant improvement following treatment. 
Belch et al.  1983 Dazoxiben 100mg qds 20 patients with 





Subjective RP symptom severity  
Thermographic assessment of digital 
skin temperature 
Plasma TxB2 
Improvement in 7/11 patients following 
dazoxiben (cf: 1/9 placebo) 
Early (2 week) sig improvement in thermographic 
analysis (reversed at 6 weeks) 
Significant reduction in plasma TxB2 
Coffman et al.  1984 Dazoxiben 100mg qds 
vs. placebo 







Patient diary of frequency, pain 
intensity and duration of RP attacks 
Fingertip blood flow, capillary flow, 
systolic blood pressure and 
radioisotope disappearance rate 
Decrease in number of RP attacks and 
percentage attack-free days in PRP group 
 
Trend for increased fingertip blood flow following 
dazoxiben 
Luderer et al. 




et al., 1984)  
1984 Dazoxiben 100mg qds 
vs. placebo for 2 
weeks 









Frequency, duration and intensity of 
RP attacks 
Both in vivo and ex vivo TxB2 and 6 
keto PGF1 formation 
Digital and forearm blood flow 
(plethysmography). Capillary blood 
flow (radioisotope disappearance rate) 
Decreased in vivo and ex vivo TxB2 production.  
 
Increased ex vivo 6 keto PGF1.  
 
No change in digital vascular or clinical 
outcomes. 










Number, severity and duration of RP 
attacks 
10cm pain VAS 
Forearm blood flow 
(plethysmography), hand temperature 
(thermography), digital blood flow 
(photoplethysmography) 
Significant reduction in pain VAS 
No improvement in vascular assessments.  
Small study. The authors questioned dose of 
study medication.  




SSc (n=28) Double 
Blind RCT  
Multisystem endpoints evaluated as 
better, same or worse  
No improvement in clinical or laboratory 
endpoints at 1 year 
Exclusion of CREST patients 
Highly damped subjective clinical endpoints 
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Authors Year Study Medication Patients Study 
Design 
Endpoints Outcome and Comments 
Tindall et al.  1985 Acute effects of 4 
doses of dazoxiben 














Finger blood flow (plethysmography), 
capillary blood cell velocity 
(videomicroscopy) and finger skin 
temperature (radiometry) during cold 
challenge 
 
Local TxB2 and 6-oxo-PGF1 
production during cold challenge 
(healthy controls only) 
Significantly increased finger blood flow 15 
minutes post-cold challenge after dazoxiben in 
patients. 
Increased 6-oxo-PGF1 production following 
dazoxiben. Cold challenge increased local TxB2 
production (reduced 65% following dazoxiben) 
*No improvement in finger skin temperature or 
capillary blood cell velocity in subset of patients 
who also entered 12 week placebo-controlled 
double blind RCT extension 
Destors et al.  1986 6 weeks Ticlodipine 







Weekly frequency of RP attacks. 
Subjective 3 point ordinal scale; RP 
improved, same or worse 
No improvement versus placebo. 
Heterogeneous population.  
Major placebo effect (65% reported improvement 
in RP) 
Van der Meer et 
al.  
1987 Aspirin 80mg od + 
placebo/ Aspirin 80mg 












Severity of RP (subjective) 
PEP during cooling and re-warming 
Platelet count and morphology 
LTA to ADP 
Plasma BTG and PF-4 levels 
Significant reduction in plasma BTG and PF-4 
after treatment with ASA/Placebo and 
ASA/Dipyridamole.  
 
Majority of patients had primary RP 
Lau et al. 1991 ICI 192,605 (a TxB 
receptor antagonist) 
vs. placebo 1 and 
placebo 2 







over study  
Platelet aggregation to Thromboxane 
mimetic (U46619) 
Laser Doppler flowmetry (LDF) 
response to warming/cooling/re-
warming 
Significant inhibition of platelet aggregation 
No significant differences in LDF perfusion at 
baseline or following cooling. 
Significantly higher perfusion during re-warming 
following treatment vs. one of placebo arms only 
(possible confounding hang-over effect from 
active arm) 
Pancera et al.  1997 Picotamide (300mg 






Number and severity of RP attacks. 
Digital blood flow (plethysmography) 
No response to picotamide. Significant 
improvement in clinical and plethysmographic 
endpoints following losartan. 
Easter et al.  2005 Aspirin (600mg) PRP (n=15) Open-label Endothelial dependent vasodilation 
assessed using laser Doppler  
Aspirin potentiates endothelial dependent 
vasodilation in PRP 
Aspirin may affect production of endothelial-
derived vasoconstrictor COX products 
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Aspirin 
Aspirin is the most commonly used anti-platelet agent, irreversibly acetylating COX-1 
suppressing platelet production of TxA2 for the duration of the platelet’s lifespan (due to the 
lack of platelet RNA necessary to resynthesize COX-1). Low-dose aspirin (40mg/day) is 
sufficient to reduce serum TxB2 levels by over 90% (after one week’s treatment) with 
associated decreased platelet aggregability (Tohgi et al., 1988). Endothelial cells, 
meanwhile, rapidly resynthesize COX preserving production of endothelial COX-derived 
prostaglandins such as PG-I2 (prostacyclin: a potent vasodilator) despite treatment with low 
dose aspirin (Jaffe and Weksler, 1979, Tohgi et al., 1992, Moncada, 2006). No studies have 
specifically evaluated the long term safety or clinical efficacy of aspirin therapy in primary 
RP or SSc. A small number of studies have demonstrated potentially useful biological 
effects of aspirin within these patient groups. For example, low dose aspirin reduces 
circulating amounts of supranormal vWF mulitmers in SSc (Mannucci et al., 1989). Aspirin 
has also been shown to potentiate endothelium-dependent vasodilation measured using 
laser Doppler in patients with primary RP, possibly due to the reduced synthesis of 
endothelium-derived vasoconstrictor COX products (Easter and Marshall, 2005). In contrast, 
other studies have demonstrated persistent expression of P-selectin and platelet-leukocyte 
interactions in patients with SSc despite treatment with aspirin (Agache et al., 2007, Pamuk 
et al., 2007). This may be the result of persistent platelet activation secondary to non-COX 
derived platelet activators, such as collagen expression on damaged endothelial surfaces in 
SSc. 
 
Thromboxane signalling inhibition 
After promising pilot work, subsequent therapeutic trials of TxA2 synthetase inhibitors 
(primarily dazoxiben) in the treatment of RP yielded generally disappointing results (Table 
1.3) (Coffman and Rasmussen, 1984, Belch et al., 1983, Jones and Hawkey, 1983, Rustin 
et al., 1984, Luderer et al., 1984, Tindall et al., 1985, Pancera et al., 1997). These 
treatments effectively suppress TxA2 formation, with the added benefit of re-directing AA 
metabolism into prostacyclin production (Belch et al., 1983, Luderer et al., 1984, Tindall et 
al., 1985). Several studies of TxA2 synthetase inhibition have incorporated objective 
microvascular imaging techniques (such as thermography); although only 2 have reported 
improvements following therapy (Belch et al., 1983, Tindall et al., 1985). Pancera et al. 
failed to identify improvement in clinical severity or objective vascular function 
(plethysmography) in primary RP following picotamide therapy (inhibits both the synthesis 
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and receptor of TxA2) (Pancera et al., 1997). The effects of a specific thromboxane receptor 
antagonist in a small number of patients with SSc (n=8) revealed a significant reduction in 
aggregation to a thromboxane mimetic (U46619) but no significant alteration in digital 
perfusion assessed using LDF, although a hang-over effect following treatment with the 
active drug may have confounded the findings within the placebo arms (Lau et al., 1991). 
Whilst the findings of the aforementioned studies fail provide strong support for antagonisng 
TxA2 signalling, it is important to note the chief limitations of these early studies that 
included their small size, inclusion of a heterogeneous mix of primary and secondary RP, 
and the lack of validated endpoints by which to assess peripheral vascular function in RP. 
 
Adenosine diphosphate (ADP) signalling inhibition 
P2Y12 receptor inhibitors (e.g. Clopidogrel, Ticlodipine) block ADP-dependent platelet 
activation. Only one study has considered this class of treatments for the management of 
Raynaud’s phenomenon and failed to identify any clinical improvement in a heterogeneous 
population of RP patients after 6 week’s therapy with ticlodipine (Destors et al., 1986). This 
study did not evaluate the effects of ticlodipine on laboratory markers of platelet function or 
incorporate any objective measures of vascular perfusion. The previously discussed study 
by Dees et al. meanwhile would support further assessment of P2Y12 receptor inhibition on 
the dermal and visceral fibrosis in SSc (Dees et al., 2011).  
 
Adenosine reuptake inhibition 
Platelets and endothelial cells indirectly produce adenosine as a breakdown product of ATP. 
Adenosine is a potent vasodilator and powerful inhibitor of platelet aggregation. 
Dipyridamole antagonises the nucleoside transporter responsible for the uptake of 
adenosine, thereby inhibiting platelet function (Kim and Liao, 2008). In addition, 
dipyridamole actively promotes vasodilation through the direct local effects of adenosine 
and selective inhibition of phosphodiesterase (potentiating the action of local NO) (Kim and 
Liao, 2008). Additional pleiotropic effects of dipyridamole include increased endothelial 
prostacyclin production, antioxidant properties and anti-inflammatory actions such as 
inhibition of the monocyte-platelet interaction and reduced recruitment and activation of 
leukocytes at sites of injury (Kim and Liao, 2008). It is therefore an attractive potential 
therapeutic agent in SSc. Dipyridamole has been shown to selectively reduce mitogenic 
activity in the sera of patients with systemic sclerosis, possibly by reducing PDGF secretion 
(Takehara et al., 1987, Takehara et al., 1990). Studies evaluating the effects of 
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dipyridamole (with and without aspirin) on circulating platelet aggregates and levels of α-
granule release products (PF-4 and ß-thromboglobulin) have yielded conflicting results 
(Takehara et al., 1990, Kahaleh et al., 1982). 
 
The results of two randomised controlled trials (RCT) evaluating treatment with combination 
aspirin and dipyridamole therapy in patients with RP were disappointing (Beckett et al., 
1984, van der Meer et al., 1987). The first evaluated combination aspirin (975 mg/day) and 
dipyridamole (225 mg/day) for 1 year in 28 patients with early SSc, and failed to identify 
improvements in clinical endpoints. Limitations of the study included small study size (n=14 
in each arm) and subjective insensitive endpoints. For example, peripheral vascular 
assessment was based upon a physician clinical assessment and rated as same, better or 
worse. The dosing was possibly sub-optimal with the high-dose aspirin capable of inhibiting 
endothelium-derived prostacyclin synthesis along with a relatively low dose of dipyridamole 
(Moncada, 2006). A subsequent double-blind RCT study evaluated the short-term effects of 
aspirin (80mg daily), combination aspirin (80mg daily) and dipyridamole (300 mg/day) or 
placebo in a heterogeneous population of RP (18 primary and 7 secondary RP; only one of 
whom had SSc) (van der Meer et al., 1987). This study revealed a significant reduction in 
aggregation to ADP, and reduced circulating BTG and PF-4 following treatment with aspirin 
alone or in combination with dipyridamole (van der Meer et al., 1987). Subjective (patient 
classified response to therapy as improved, unchanged or worsened) and objective 
(photoelectric plethysmography) measures of peripheral vascular function did not improve 
following therapy with either aspirin alone or combination aspirin/dipyridamole (van der 
Meer et al., 1987). These findings are disappointing as this combination of anti-platelet 
agents is the most attractive in terms of therapeutic potential in RP/SSc in view of their 
direct vasodilatory, anti-oxidant and anti-fibrotic potential.  
 
Pleiotropic anti-platelet effects of other drugs 
It has been suggested that the clinical benefits of a raft of treatments commonly used for the 
management of RP symptoms including prostacyclin,(McHugh et al., 1988, Solanilla et al., 
2009) calcium channel blockers (Wigley et al., 1987, Malamet et al., 1985), piracetam 
(Moriau et al., 1993), fluoxetine (Coleiro et al., 2001), ketanserin (Seibold, 1985) and Ginkgo 
Biloba (Stucker et al., 1997) are thought to be in part the result of the pleiotropic effects of 
such treatments on platelet function.  
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1.4.6 Challenges in establishing a role for anti-platelet therapy in RP and SSc 
The results of early clinical trials of anti-platelet agents in RP and SSc have been generally 
disappointing. It would be premature to conclude that such studies confirm the lack of 
efficacy of anti-platelet agents, particularly in SSc. Major limitations of these studies include 
small study sizes, short study duration and the incorporation of a heterogeneous mix of RP 
patients (the majority of whom had primary RP).  Whilst platelet activation may contribute to 
both immune dysfunction and fibrosis in SSc, the slowly progressive nature of tissue fibrosis 
would require long-term RCTs involving large numbers of patients to demonstrate the 
efficacy of anti-platelet therapy for such patients. The use of experimental models of fibrosis 
such as the previously discussed work by Dees et al. provides an exciting opportunity to 
establish a proof-of-concept in pre-clinical studies (Dees et al., 2011). Evaluating the 
contribution of platelets to vascular function in RP and SSc is more feasible in clinical 
practice. The lack of sensitive and validated clinical and vascular endpoints by which to 
evaluate digital vascular function was a major limitation of previous therapeutic trials of anti-
platelet agents. The emergence of validated clinical outcome measures and novel methods 
for objectively assessing vascular function in RP and SSc provides the opportunity to re-
appraise the vascular effects of anti-platelet therapy in such patients. It is to quantifying 
peripheral vascular function in RP and SSc that I shall now divert our attention. 
 
1.5 Quantifying digital vascular function in the assessment 
of RP and SSc 
 
Due to the episodic nature of RP, objective assessment of digital vascular function can not 
easily be undertaken in the clinical setting. This has led to reliance upon subjective patient 
self-reports and it remains standard practice for clinicians to appraise the efficacy of new 
treatments for RP in clinical practice by simply enquiring as to whether or not the patient 
feels the treatments have been beneficial for their symptoms. With novel vasoactive 
treatments costing in excess of £21K per annum, there is an urgent need for validated 
assessment tools for the quantification of digital vascular function in RP. In this section, I 
shall describe the various subjective and objective methods that have emerged for the 
assessment of digital vascular function in RP and SSc. To better understand such methods, 
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I will first describe healthy cutaneous vascular anatomy and physiology in humans, with 
particular reference to the digits. 
 
1.5.1. Normal digital cutaneous vascular anatomy and physiology 
The cutaneous circulation has functions beyond nutritional support including wound repair, 
immunity and thermoregulation, which are of particularly importance when considering 
vascular physiology within the digits. The radial and ulnar arteries are the principle large 
vessels supplying oxygenated blood to the hand. Distal to the wrist, these arteries divide 
and anastamose in the deep and superficial palmer arches. From these arches arise the 
common palmer digital arteries that supply the proper digital arteries extending into the 
digits (Figure 1.6). The palmer tissues of the digits are supplied by small palmer branches 
arising from the main digital arteries (Voche and Merle, 1996). The dorsal aspect of the 
fingers, measnwhile, are supplied proximally by terminal branches of the dorsal metacarpal 
artery at the MCP and distally by dorsal cutaneous branches arising from the proper palmer 
digital arteries (Endo et al., 1992). The nailbed has proximal and distal arterial arches 
formed from anastamoses of branches of the digital arteries. From these arterioles arise a 
capillary loop system that can be directly visualised at the nailfold (which is the basis of 
nailfold capillaroscopy).  
 
All areas of skin have an arcade of arterioles at the interface between the dermis and 
deeper structures. Arterioles arise from this arcade and ascend into the superficial dermis. 
Capillary loops arising from this second network of arterioles extend into the sub-papillary 
plexus at the dermal-epidermal interface. The capillaries drain into venules and the deeper 
veins that accompany the arteriolar supply within the dermis (Rhoades, 2009). 
 
It has long been recognised that the cutaneous circulation is not uniform across the body. 
The advent of non-invasive measures of microvascular function allowed, for the first time, 
the assessment of the variability of cutaneous blood flow across the body. Tur et al. used 
photopulse plethysmography and laser Doppler velicometry to measure basal skin blood 
flow at 52 anatomical sites, identifying regions in the hands and face for which cutaneous 
perfusion was much higher (Tur et al., 1983).  
  
 40 
Figure 1.6 Macrovascular circulation to the hand.  






The regions identified by Tur et al. can be broadly separated into glabrous (from Latin for 
hairless) and non-glabrous areas. Glabrous skin differs anatomically due to the presence of 
multiple arterio-venous anastamoses (AVAs). These thick walled, low resistance vessels 
allow blood to pass directly from arterioles to venules. Alteration of vascular tone within 
these AVAs can have substantial effects on cutaneous blood flow. Non-glabrous skin has 
few, if any, AVAs (Charkoudian, 2003). The sympathetic nervous system is responsible for 
control of AVA function and the cutaneous circulation. Under ambient temperatures 
significant sympathetic mediated vasoconstriction is required to maintain basal tone of the 
vascular smooth muscle. Blockade of sympathetic function leads to maximal cutaneous 
vasodilation and cessation of sympathetic noradrenergic activity is an important mediator of 
vasodilatation in response to heat.  
 
α-1 adrenoceptors are the predominant receptor type on the larger arteries and arterioles. 
Selective α-1 adrenoceptor antagonists such as doxazosin are potent vasodilators of these 
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vessels and are effective in the management of macrovascular diseases such as 
hypertension. α2-adrenergic receptors are the predominant adrenergic receptor residing on 
terminal arterioles, venules, veins and AVAs and are of greater importance in 
thermoregulation and microvascular disorders such as Raynaud’s phenomenon (section 
1.2.3). α2-adrenergic receptors promote vascular wall contraction through influx of 
extracellular calcium through voltage-dependent (dihydropyridine sensitive) channels which 
can be antagonised using dihydropyridine calcium channel antagonists such as nifedipine 
(Pollock et al., 1996).  
 
In a warm environment dilated AVAs can provide the pathway for 80% of digital blood flow, 
making a crucial contribution to thermoregulation. The remaining 20% of blood passes 
through the capillary bed where metabolic exchange can take place. This is usually 
described as the nutritional blood supply. The skin’s relatively low metabolic activity requires 
relatively low perfusion to meet its nutritive needs (around 40mls/min) and hence the large 
shifts in cutaneous perfusion (up to 2.8L/min) which occur are primarily to facilitate thermal 
homeostasis at times of increased heat generation (e.g. exercise). In ambient conditions 
basal cutaneous blood flow is around 400mls/min. Following cold exposure, AVAs virtually 
close following α2-adrenergic receptor stimulation, diverting the majority of cutaneous blood 
flow away from the dermis. The nutritional capillary vascular bed remains patent in all but 
the most extreme cold exposure to prevent cutaneous ischaemic necrosis (Berlin and Pehr, 
2004, Charkoudian, 2003, Krogstad et al., 1995, Rhoades, 2009). Glabrous regions within 
the fingertips and nailbeds are densely populated with AVAs providing an important role in 
thermoregulation (Baran, 2003). The dorsum of the hand is less densely populated with 
AVAs (non-glabrous skin) resulting in lower blood flow relative to glabrous regions under 
ambient conditions when AVAs are dilated. The varied cutaneous perfusion within the digits 
at rest and altered response to cold exposure forms the basis of non-invasive assessment 
of digital vascular function in RP and SSc (section 1.5.3).  
1.5.2 Subjective patient self-reports for the assessment of digital vascular function in 
Raynaud’s phenomenon 
The episodic nature of RP attacks prevents useful objective assessment of disease activity 
in the clinical setting, leading to a reliance on patient self-report. In early therapeutic studies 
of RP, treatment efficacy was often reported by asking patients to categorise responses 
following treatment using nominal scales such as better, same or worse (Yamaoka, 1987, 
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Martin et al., 1981, Dowd et al., 1982, Clifford et al., 1980). Analyses were largely 
descriptive and used comparisons of the proportion of patients represented in each group. 
These self report measures were gradually superceded by linear psychometric scales such 
as rating scales and visual analogue scales (VAS) which provided the opportunity to 
quantify and explore specific components of RP such as pain intensity and the severity of 
attacks (McHugh et al., 1988, Kyle et al., 1985, Kyle et al., 1992, Klimiuk et al., 1989b). 
Latterly, the use of diary cards has facilitated quantification of the frequency and duration of 
RP attacks, often incorporating VAS scores of RP severity (Selenko-Gebauer et al., 2006, 
Herrick et al., 2000, Dziadzio et al., 1999, Coleiro et al., 2001). The Raynaud’s Condition 
Score (RCS) diary was originally developed for 2 separate studies of oral iloprost (Black et 
al., 1998, Wigley et al., 1998). This diary collected daily information over a 2 week period of 
the frequency and duration of RP attacks whilst also incorporating a 10 point rating scale 
(the Raynaud’s Condition Score, RCS) that enabled patients to report the severity of their 
RP that day (Black et al., 1998, Wigley et al., 1998). The RCS diary performed well in a post 
hoc analysis of the validity, feasibitlity and reliability of the tool (Merkel et al., 2002). The 
RCS diary has been recommended for use for the subjective assessment of digital vascular 
function in therapeutic trials of RP and SSc (Merkel et al., 2003, Khanna et al., 2008). 
Additional description of the development, validation and use of the RCS diary can be found 
in sections 2.3.3 and 5.1.  
 
There are major limitations to reliance on self-report measures of RP severity. These tools 
are subjective, influenced by health beliefs and psychological factors and sensitive to 
placebo effect. They require a prolonged period of assessment and are laborious for 
patients (with the subsequent potential for ‘diary fatigue’). Furthermore, the frequency, 
duration and severity of RP attacks are likely to be influenced by both seasonal variation in 
environmental temperature and the effectiveness of coping strategies adopted by patients to 
avoid the conditions responsible for RP attacks and ameliorate attacks when they occur. 
There are additional challenges using the RCS diary in SSc. Habituation to digital ischaemia 
occurs along with difficulty distinguishing acute attacks of RP from background digital 
ischaemia (secondary to irreversible morphological vascular changes) which can lead to 
underestimation of the extent of digital vascular dycfunction.  These limitations have led to 
considerable work to develop objective methods for assessing digital vascular function. 
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1.5.3 Established objective non-invasive assessment tools of digital microvascular 
function in RP and SSc 
 
A variety of non-invasive microvascular imaging tools have been developed to objectively 
assess digital vascular function and they are already recommended for the classification of 
conditions such as primary Raynaud’s phenomenon (RP) and systemic sclerosis (SSc) 
(LeRoy and Medsger, 2001). As previously discussed, structural vascular morphology can 
be assessed in vivo using nailfold capillaroscopic assessment of capillary loops (Herrick and 
Cutolo, 2010). This approach is of particular value in identifying patients at risk of SSc early 
in the course of the disease, but does not allow assessment of digital vascular response 
following treatment. To this end, various methods for the dynamic assessment of digital 
vascular function have emerged (often incorporating a cold challenge in an attempt to 
recreate the conditions responsible for RP attacks). I shall not describe all the available 
methods in detail here but shall devote some attention to infrared thermography (IRT) which 
is the most widely evaluated technique (sometimes considered the “silver standard”) and 
laser-derived methods which have emerged over the last 30 years. Some knowledge of the 
basic physics of electromagnetic radiation, heat transfer, the Doppler effect and light 
interference is assumed. Similarly, a comprehensive discussion regarding the mathematical 
principles adopted in quantifying tissue perfusion using laser techniques has been 
described previously and is beyond the scope of this thesis (Briers, 2007, Briers, 2001, 
Briers, 2006, Briers, 1996a). 
 
Infrared thermography 
Radiation describes the process by which energy is transmitted through objects or space. 
Objects radiate thermal energy through electromagnetic waves (EMW). The 
electromagnetic spectrum (EMS) has been arbitrarily divided into distinct bands according 
to wavelength, extending between radiowaves (with the longest wavelengths) and gamma 
rays (the shortest). The “visible spectrum” of the EMS is a narrow band (390-750nm) of EM 
radiation that can be detected by the human eye. Infrared (IR, from the latin infra, below) 
radiation is electromagnetic radiation (EMR) with a wavelength between 700nm and 300 
micrometres (spanning the limit of visual perception at short wavelengths to “microwave” 
radio wavelengths at the long-wavelength end of the IR spectrum). The IR spectrum 
includes most of the thermal radiation emitted by objects at near room temperature. 
Mammals at around 300 Kelvin emit radiation of a wavelength of around 10 micrometers in 
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the far infrared. Wein’s displacement law implies that as an object’s temperature increases, 
the shorter the wavelength at which it will emit most of its radiation. Around the “visible 
spectrum”, this phenomenon is occasionally observed e.g. when a metal object becomes 
‘red hot’.  Infrared thermography (IRT) cameras quantify IR emissivity to estimate the 
surface temperature of an object. The temperature of the human skin increases with 
increasing perfusion, allowing IRT to provide a safe, non-invasive, indirect measure of 
vascular function (Ammer, 2009).  
 
A large number of studies have reviewed the use of IRT in the assessment and diagnosis of 
RP. A detailed description of this work is beyond the scope of this thesis but has been 
reviewed previously by others including myself (Pauling, 2010b). The longitudinal thermal 
gradient within the hands has consistently performed well as an endpoint for both 
diagnosing and differentiating between disease states in RP. This gradient provides 
information on AVA function within the fingertips. In healthy digital vascular function, 
perfusion is greater at the fingertips (due to dilation of the thermoregulatory AVAs described 
in section 1.5.1) leading to a positive thermal gradient (Figure 1.7). In RP and SSc, a 
negative longitudinal thermal gradient arises due to excessive vasoconstriction of digital 
AVAs (Figure 1.7 and 1.8). Various methods for calculating this gradient have been 
developed including the “longitudinal temperature difference” (Schuhfried et al., 2000), 
“distal-dorsal difference” (Anderson et al., 2007) and the “combined thermal gradient” (Ring, 
1990 , Ring, 1988). Many thermographic protocols incorporate a local cold challenge (e.g. 
placing the hands in a cooled water bath at 15-20°C for 60s) to allow dynamic assessment 
of digital vascular function during the conditions typically responsible for an attack of RP in 
vivo (Figure 1.8).   
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Figure 1.7 Examples of thermal images in a healthy control and a patient with systemic sclerosis.  
On each image regions of interest have been placed over the dorsum of the hands (proximal [dorsal] region) and over the digits to allow calculation of the 
longitudinal thermal gradient (or distal dorsal difference). 
Thermal images obtained from our laboratory with proximal and distal regions of interest are marked (adapted from (Ring et al., 1981)). A) Healthy control (right 
proximal mean surface temperature 33.23°C, right distal mean temperature 34.05°C, gradient +0.82°C). B) Systemic sclerosis (right proximal mean surface 
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Figure 1.8 Examples of baseline assessment and re-warming curves following cold challenge in a healthy control (HC) and a 
patient with SSc.  
Data collected from our laboratory. In the HC there is a positive distal-dorsal thermal gradient at baseline and rapid rewarming of the fingertips following cold 
challenge. In SSc the distal-dorsal thermal gradient is negative at baseline and there is delayed re-warming of fingertips following cold challenge. Baseline skin 
temperature and response to cold challenge over the dorsum of the hands is similar for both patients reflecting the absent contribution of thermoregulatory AVAs 






































Due to initial difficulties in obtaining and analysing thermal images, many early studies 
incorporating a cold challenge were restricted to a single post-cold challenge thermographic 
assessment (Ring et al., 1981). The ability to capture multiple thermographic images with 
modern IRT cameras has allowed repeated assessment following cold challenge and 
mapping of re-warming curves (Figure 1.8). This has led to the emergence of additional 
parameters such as the maximum gradient of recovery, maximum re-warming percentage 
and the lag time to commencement of re-warming which have been used successfully in 
discriminating between disease states in RP (O'Reilly et al., 1992). It remains unclear 
whether baseline assessment of the longitudinal thermal gradient alone has comparative, if 
not superior, discriminatory capacity in differentiating between disease states in RP, to 
those parameters derived from the re-warming curve characteristics (Schuhfried et al., 
2000, Anderson et al., 2007, Clark et al., 1999). The additional diagnostic value derived 
from undertaking a standardised cold challenge assessment is unclear, although it 
unquestionably provides information on dynamic vascular responses that baseline 
assessment alone can not provide (Pauling et al., 2011b, Pauling, 2010a). There are 
several limitations to IRT, particularly when considering the effects of the cold challenge. 
IRT assessment following cold challenge fails to consider the influence of conductive and 
convective heat exchange on surface skin temperature, unrelated to vascular perfusion. 
Translation of altered microvascular tone into changes of surface skin temperature is 
influenced by the thermal capacity of the surrounding tissue, limiting the temporal resolution 
of IRT. The spatial resolution, meanwhile, is influenced by thermal conduction of heat from 
adjacent and/or deeper tissues, which may not be a true reflection of superficial cutaneous 
perfusion. 
 
Several studies have attempted to use IRT as an endpoint in the evaluation of treatments 
for RP (McHugh et al., 1988, Dziadzio et al., 1999, Coleiro et al., 2001), although no effort 
has been made to systematically review these studies to establish a preferred 
thermographic parameter for use in therapeutic trials of RP. As a result, IRT has remained a 
largely experimental endpoint in clinical trials of RP (Merkel et al., 2003). 
 
Laser Doppler imaging of vascular function 
When there is relative movement between the source of a wave and an observer, the 
frequency of the wave changes. Christian Doppler (1803-53) was the first to describe this 
effect in 1842. The audible drop in pitch as an object fitted with a siren travels towards us 
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which we are all well acquainted with is the commonly reported example of a Doppler shift 
in action. The magnitude of the frequency change elicited through the Doppler effect can be 
used to calculate the velocity of an object. Light scattered from moving particles within a 
stationary object causes a similar shift in frequency in relation to non-shifted light from 
stationary matter. Lasers (Light Amplification by Stimulated Emission of Radiation) are 
highly amplified coherent radiation of one or more discrete frequencies. When lasers are 
focussed on an object, the manner in which the reflected radiation is scattered will be 
influenced by both the surface of the object and the presence of moving particles within the 
object (such as blood cells in the skin). The emergence of lasers in the 1960’s, along with 
the mathematical application of Doppler principles, led to the development of laser Doppler 
imaging (Briers, 2007, Briers, 2001). The high frequencies of light waves render them 
difficult to measure directly. It is, however, possible to measure the beat frequency 
generated by interference between the original light source and the shifted reflected wave. 
This frequency shift (or beat frequency) is much lower than the frequency of the original 
waves and therefore provides a more accessible means of estimating the velocity of 
particles within objects (Briers, 2001). Laser Doppler relies on certain assumptions such as 
the object remaining stationary and the isotropic distribution of light within the illuminated 
tissue (Ruth, 1994). Perfusion should be strictly defined as volume per unit area per unit 
time, however, as no laser instrument is capable of directly measuring blood flow, 
measurements derived from laser imaging tools are typically described in arbitrary flux units. 
 
The first laser Doppler devices (laser Doppler flowmetry [or velocitometry], LDF) measured 
blood flow at a single point using a contact probe. The major limitations of this approach 
were its limited spatial resolution and poor repeatability (due to the challenge of attaching 
the LDF probe in the same place at each assessment). The tissue contact associated with 
laser Doppler flowmetry (LDF) may also influence flux measurement, damage tissue and 
precludes assessment of perfusion at inaccessible sites such as the retina (Ruth, 1994).  
 
The need for non-contact tools that could map perfusion of tissue over a larger area led to 
the development of laser Doppler perfusion imaging (LDPI). This technique uses a non-
contact scanning laser that measures blood cell velocity at multiple single points, generating 
a 2-dimensional map of tissue perfusion (Briers, 2001). LDPI overcame some of the 
limitations of LDF, although the temporal resolution was limited by prolonged scanning 
times (initially lasting up to several minutes) precluding useful assessment of cutaneous 
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microvascular responses to physiological stimuli (Stewart et al., 2005, Roustit et al., 2010b, 
Briers, 2001). 
 
1.5.4 Laser speckle contrast imaging (LSCI) 
 
Laser speckle contrast imaging (LSCI) is a novel non-invasive microvascular imaging 
modality that provides near real-time dynamic vascular assessment over large areas of 
tissue (Briers, 1996a, Briers, 2006, Briers, 2001). The historical development, mathematical 
assumptions and processing techniques used as part of laser speckle contrast imaging 
(LSCI) have been described elsewhere (Draijer et al., 2009, Briers, 2007, Briers, 2001, 
Briers, 1996b, Briers, 2006, Briers, 1996a). I shall not emulate this work other than providing 
a brief introduction to the principle of LSCI but will instead devote my attention to previous 
work applying this technique within the field of cutaneous vascular physiology. 
 
Background to laser speckle imaging 
Laser speckle is a random interference effect that was originally regarded as an optical 
nuisance, limiting resolution in techniques such as holography (Briers, 2001, Briers, 2006). 
Directing a laser source at an object (such as a wall) generates a speckle pattern following 
scattered reflection from the uneven surface. If the object remains static then this speckled 
interference pattern will not change. Movement of the object, or of particles within an object, 
meanwhile will alter the scattering of light as it strikes the object leading to speckle variation 
and a subsequent reduction in speckle contrast. From the study of the temporal statistics of 
the speckle fluctuations, information can be gathered on the degree of motion within the 
object. This principle forms the basis of laser speckle contrast imaging (LSCI). On face 
value, the physics of LCSI appear distinct from laser Doppler however the dynamic (blurred) 
speckle pattern produced following the interaction of laser light with moving particles within 
an illuminated object is primarily the result of Doppler shifts and the mathematical formulae 
used to interpret images do not differ greatly from those used in laser Doppler imaging 
(Briers, 2001). 
 
The study of time-varying speckle can be applied to the study of blood flow within living 
tissues. Within areas of high blood flow, the contrast of the speckle becomes blurred, 
whereas areas of relatively lower perfusion have the appearance of a more static contrast 
speckle pattern (Stern, 1975). Fercher and Briers adopted this principle to develop single 
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exposure speckle photography which could be used to map, but not quantify, tissue 
perfusion (Briers and Fercher, 1982). The advent of digital imaging and processing has 
allowed real time quantification of speckle contrast (and hence vascular flux) along with the 
generation of a false colour map of speckle contrast. Speckle contrast is quantified by 
calculating the ratio of the standard deviation to the mean of the intensities recorded for 
each pixel within squares of 5x5 or 7x7 pixels (Briers, 2006). This technique was initially 
termed LASCA (LAser Speckle Contrast Analysis) and its chief strengths were its simplicity 
and low cost (Briers, 2006). Early LASCA cameras were limited by a restricted field of view 
which suited early studies examining cerebral and retinal perfusion in animal models 
(Durduran et al., 2004). The extended field of view provided by modern cameras (e.g. the 
Moor FLPI LSCI) has greatly increased the potential clinical application of the method and 
over last 5 years there has been a considerable growth in the number of studies evaluating 
the use of LSCI to measure tissue perfusion (Figure 1.9). 
Figure 1.9 Number of publications of studies evaluating LSCI retrieved from the US National 
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LSCI and LDI respond differently to the optical characteristics of an illuminated object. LDI 
perfusion flux values increase with increasing tissue absorption whereas LSCI flux values 
demonstrate a slight decrease (Forrester et al., 2004). Furthermore, the depth of tissue 
penetration is dependent on the wavelength of the laser used. The deepest penetration is 
achieved using infrared (>700nm, several mm penetration), red (~630nm, about 1-2 mm), 
green (~530, around 0.15mm) and virtually none for blue (Briers, 2006). This may provide 
an attractive opportunity to study microvascular function at varying levels within the skin 
such as comparing superficial nutritive capillary flow compared with deeper vascular 
function within the dermis and thermoregulatory AVA function. Modern LSCI devices (such 
as the moorFLPI) uses a laser wavelength of 775nm achieving a depth of penetration in 
human skin of approximately 1mm. LDPI scanners have variable laser wavelengths of 
between 633nm and 830nm providing depth of penetration of between 0.1 and 2mm. These 
differences prevent direct comparison of flux values elicited using the 2 techniques on 
different tissues, although assessment of relative changes in tissue perfusion overcomes 
such concerns.  
 
Use of laser speckle imaging in the assessment of cutaneous perfusion 
The limited processing capability of early LASCA cameras restricted use to retinal or 
cerebral perfusion in animal models. More recent studies have extended the use of LSCI to 
the evaluation of cutaneous perfusion (Ruth, 1994, Forrester et al., 2002, Bezemer et al., 
2010, Roustit et al., 2010b, Murray et al., 2009, Forrester et al., 2004). A recent study has 
successfully applied LSCI to demonstrate impaired endothelium-dependent vasodilatory 
responses in patients with cardio-metabolic disease (Cordovil et al., 2012). Several studies 
have compared LSCI with other non-invasive microvascular imaging tools including nail fold 
capillaroscopy (NC) (Bezemer et al., 2010, Murray et al., 2009), LDPI (Stewart et al., 2005, 
Forrester et al., 2004, Forrester et al., 2002, Millet et al., 2011) and LDF (Roustit et al., 
2010b).  
 
Good correlation between LSCI and LDF was identified in the dynamic assessment of 
forearm perfusion in healthy volunteers (Roustit et al., 2010b). As expected, subsequent 
studies identified superior reproducibility with LSCI compared to LDF due to the challenges 
correctly re-positioning the LDF probe (Tew et al., 2011, Roustit et al., 2010a). Comparison 
of LSCI and LDPI in the dynamic assessment of cutaneous perfusion has been undertaken 
in healthy controls (Millet et al., 2011, Forrester et al., 2002) and the evaluation of burn 
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injuries (Stewart et al., 2005). There is strong correlation between the 2 imaging modalities 
(Forrester et al., 2002, Stewart et al., 2005, Millet et al., 2011). The improved temporal 
resolution favours LSCI (Stewart et al., 2005, Forrester et al., 2002). LSCI has also been 
shown to have a lower inter-site variability compared with LDPI (Millet et al., 2011). LSCI 
has also demonstrated superior reproducibility to LDPI (Roustit et al., 2010a). 
 
Comparison of dynamic assessment of perfusion at the nailfold using both LSCI and 
capillary red blood cell velocity measured using sidestream dark field (SDF) imaging (i.e. 
capillary microscopy) has also been undertaken in healthy controls with good correlation 
between the 2 techniques (Bezemer et al., 2010). No previous studies have compared IRT 
and LSCI in the assessment of cutaneous vascular function.  
 
Use of laser speckle imaging in RP and SSc 
Only one previous study has evaluated the use of LSCI in scleroderma spectrum disorders. 
LSCI assessment of perfusion at the nailfold of the non-dominant ring finger was 
undertaken in healthy controls and patients with RP and SSc (Murray et al., 2009).  No 
significant differences were observed between groups and there was poor correlation 
between LSCI and NC at the nailfold, although the choice of site may have accounted for 
these findings. As previously discussed, morphological vascular changes occur at the 
nailfold in SSc which include neoangiogenesis (e.g. elongated dilated and tortuous vessels) 
which may have influenced perfusion values at the nail fold. Reproducibility of LSCI in this 
study was poor (ICC 0.15) although repeatability was assessed in a relatively small number 
of subjects (n=5) and reproducibility needs to be re-evaluated in larger studies (Murray et 
al., 2009). To date, no studies have evaluated the use of LSCI in the dynamic assessment 
of vascular function in RP or SSc.  
 
1.6 Hypotheses 
Understanding the influence of platelets on vascular function, inflammation and tissue re-
modelling provides an attractive conceptual framework to consider the potential contribution 
of platelets to the pathogenesis of RP, particularly in the context of SSc. There is a 
considerable body of evidence associating excessive platelet activation in both RP and SSc. 
Recent work has begun to consider the potential direct pathogenic effects of platelets in 
 53 
animal models of SSc. The findings of such studies suggest the release of growth factors 
from platelets may make an important contribution to downstream pro-fibrotic signalling.  
 
The results of previous therapeutic trials of anti-platelet therapy in RP and SSc have been 
disappointing. Major limitations of these studies include small study sizes, short study 
duration and the incorporation of a heterogeneous mix of RP patients (the majority of whom 
had primary RP).  The lack of sensitive and validated clinical and vascular endpoints by 
which to evaluate digital vascular function and other clinical manifestations of SSc was an 
additional major limitation of these early trials. Anti-platelet agents have revolutionized the 
management of cardiovascular diseases, although it is unlikely that similarly designed 
studies to those undertaken in RP and SSc could have provided evidence of their efficacy. 
We feel it is premature to conclude that previous studies confirm the lack of efficacy of anti-
platelet agents in these conditions.  
 
Due to the high cost and lack of industry motivation to support such work, it is feared that 
major trials of anti-platelet therapy in RP and SSc may never be undertaken. This is 
disappointing considering the low cost, established safety and widespread availability of 
anti-platelet agents. Animal models, despite their many limitations, may provide a useful 
pre-clinical model to elucidate the key platelet-derived mediators in SSc and the anti-platelet 
treatments (or combination of agents) that offer the greatest therapeutic. We feel there is 
also a role for further proof-of-concept clinical trials in humans.  The emergence of validated 
clinical vascular endpoints and non-invasive microvascular imaging techniques now provide 
the opportunity to re-appraise the effects of anti-platelet therapy on peripheral vascular 
function in these related conditions. In addition to re-appraising established clinical and 
objective vascular endpoints (namely IRT) in clinical trials, novel microvascular imaging 
modalities such as LSCI may have an important role in future exploratory studies and 
further validation work of this technique in RP and SSc is now needed.  
 
The principal hypotheses of this thesis can be broadly summarized into the following 
categories: 
 
1. Objective measurement of digital vascular function (with established and novel 
methods such as IRT and LSCI) has advantages over subjective self-report in the 
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assessment of RP activity and should be at the core of future therapeutic trials of 
RP.  
2. LSCI is a novel method for the objective assessment of digital vascular function in 
the both diagnosis and assessing treatment efficacy in RP and SSc. 
3. Platelets are central to the cellular mechanisms driving vascular dysfunction in RP, 
particularly in the context of SSc. 
4. The competing action of platelet and endothelial derived vasoactive mediators are 
associated with clinical and objective vascular endpoints of digital vascular function 
in primary RP and SSc. 
5. The combination of aspirin and dipyridamole in asasantin retard, through their 
effects on platelet function, eicosanoid biosynthesis and oxidative stress, can 
improve peripheral vascular function in primary RP and SSc. 
 
1.7 Aims 
In order to explore these hypotheses, the principal aims of each chapter of this thesis are 
outlined below: 
 
2) In chapter 2 I shall outline the materials and methods used to undertake the work 
in this thesis. 
3) In chapter 3 I shall systematically review the use of IRT as an endpoint in 
previous clinical trials of Raynaud’s phenomenon and systemic sclerosis. 
4) In chapter 4 I shall report the findings of early validation work exploring the use 
of LSCI (and IRT) in the dynamic assessment of digital vascular function in 
healthy volunteers. 
5) In chapter 5 I shall extend this validation work reporting the findings of work 
evaluating clinical vascular endpoints and the use of LSCI (and IRT) in the 
dynamic assessment of digital vascular function in patients with primary RP and 
SSc.  
6) In chapter 6 I shall evaluate determinants of platelet function, eicosanoid 
biosynthesis and oxidative stress in primary RP and SSc, and explore 
associations with subjective and objective vascular endpoints. 
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7) In chapter 7 I shall report the findings of an exploratory proof-of-concept study 
evaluating the biological, clinical and microvascular effects of asasantin retard 
therapy in the management of primary RP and SSc. 
8) In chapter 8 I shall bring together the findings of the previous chapters and 
discuss their relevance in the context of existing knowledge and future work. 
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Chapter 2.0   Materials and Methods 
2.1 Materials 
2.1.1 Chemical Reagents 
Name of reagent     Supplier 
Adenosine-5-Diphosphate (ADP)   Alpha Laboratories, UK 
Arachidonic Acid (AA)    Alpha Laboratories, UK 
2,6-Di-tert-butyl-4-methylphenol (BHT)  Sigma-Aldrich, UK 
Hydrochloric acid (HCL, A.C.S grade, 12N)  Sigma-Aldrich, UK 
Sodium Hydroxide (NaOH, A.C.S grade, 10N) Sigma-Aldrich, UK 
HEPES 5 (Reagent Grade, M.W. 238.3)  Sigma-Aldrich, UK 
Ethanol (200 proof, >99.5% A.C.S grade)  Sigma-Aldrich, UK 
2.1.2 Buffers and Solutions 
1 N HCL 8.2ml 12.2 N HCL in 91.8 ml ddH2O 
10 N NaOH      4.8g NaOH in 12 ml ddH2O 
1.2 N NaOH/0.5 M HEPES 75ml ddH2O + 12 ml 10 N NaOH + 
11.9g HEPES (made up to 100ml with 
ddH2O) 
2,6-Di-tert-butyl-4-methylphenol (BHT)  2.5 mg in 500 L ethanol 
2.1.3 Equipment 
Thermovision camera     FLIR systems, Sweden 
FLIR A40 camera6     FLIR systems, Sweden 
Full-Field Laser Perfusion Imager    Moor Instruments, UK 
Bio Data PAP-4 Aggregation Profiler   Alpha Laboratories, UK 
Jouan BR4i Centrifuge    Jouan, UK 
Zenit SP+ Plate reader    A. Menarini Diagnostics, Italy 
HTIII Spectrophotometer Anthos Labtec Instruments Ltd. 
Wellwash 4 MK 2 Thermo Fisher Scientific 
                                               
5 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
6 This camera was used for 2 assessments only following equipment malfunction September 2011 (see section 2.4.1) 
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Titramax 100 Orbital microplate shaker  Heidolph instruments 
Agilent 5973 Inert Mass Selective Detector  Agilent Tech, Santa Clara, CA 
Agilent 6890n Network GC system    Agilent Tech, Santa Clara, CA 
DB-1701 fused silica capillary column   J and W Scientific, Folsom CA  
2.1.4 Commercial kits 
Human soluble CD40 ligand ELISA   R&D systems, UK 
Human soluble p-selectin ELISA   R&D systems, UK 
Human TGF- ELISA     R&D systems, UK 
 
2.2 Patient recruitment 
2.2.1 Regulatory approval 
Ethical approval was obtained for the work involving healthy controls from Bath Research 
Ethics Committee (Bath REC 09/H010/79). The Clinical Trial of an Investigational Medicinal 
Product (CTIMP) received ethical approval from the South West 3 REC (reference number: 
10/H0106/69). The CTIMP received approval from the Medicines and Healthcare products 
Regulatory Agency (MHRA). We sought guidance from the Human Tissue Authority prior to 
the storage of plasma and urine as part of this study. The study did not require an HTA 
license for storage of samples as the study had NHS REC approval. Each study received 
approval from the Royal National Hospital for Rheumatic Diseases (RNHRD) Research and 
Development (R&D) committee.  
2.2.2 Healthy controls 
Healthy Controls were recruited from the staff of the RNHRD. Healthy subjects aged 18-75 
years were approached for inclusion in the study. Participants were issued with a participant 
information sheet (PIS, Appendix 1) and given the opportunity to discuss the study prior to 
enrollment. Subjects with hypertension were eligible if they had remained on a stable dose 
of vasodilator medication for the previous month. Subjects were excluded if they fulfilled 
proposed clinical criteria for RP (Brennan et al., 1993), were pregnant or had a history of 
peripheral vascular disease, diabetes or other conditions associated with secondary RP. All 
participants provided informed written consent (Appendix 2). Further details regarding study 
design and recruitment can be found in section 4.3.2. 
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2.2.3 Prospective patient recruitment 
All patients with primary RP and SSc were recruited to a single prospective study with 
several sub-studies (which shall be reported sequentially in Chapters 5-7). An outline of the 
study design incorporating a flow chart of the contribution of patinets at each of the study is 
presented in Figure 2.1.  
Figure 2.1.  Summary of study design.   
The initial 2-week run-in phase forms the basis of the work described in chapters 5 and 6. 
Eligible patients were given the opportunity to enter the second interventional stage of the 
study, which involved open-label use of asasantin retard prior to a post-treatment 









   Stage 1              Stage 2 






All patients recruited to the study could take part in the cross-sectional microvascular 
imaging work that is described in Chapter 5. Participants had to fulfill strict eligibility criteria 
to take part in individual subsequent components of the study. For example, patients were 
unable to take part in the cross-sectional study exploring platelet function in primary RP and 
SSc if they were already receiving anti-platelet therapy (full eligibility criteria reported in 
section 6.3.1). Patients with a history of duodenal ulceration meanwhile were unable to 
enter the interventional phase of the study (when they receive asasantin retard). Full details 
of eligibility criteria for the interventional study are outlined in section 7.3.2. For this reason, 
participant numbers become smaller as the results chapters progress. 







Microvascular imaging study - Chapter 5 
Interventional trial assessing resonses to 
asasantin retad - Chapter 7 
 Platelet function, eicosanoid 
biosynthesis and oxidative 
stress - Chapter 6 
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Potential participants were identified using the RNHRD CTD database and from the 
outpatient clinic department of the RNHRD. All patients were initially provided with a PIS 
outlining the trial (Appendix 3) along with study interest form (Appendix 4) which they could 
return in an enclosed stamp addressed envelope. If interested, arrangements were made 
for prospective participants to attend the unit to discuss the study in further detail. To reduce 
the burden of multiple visits on participants, the screening visit could coincide with the first 
assessment if they chose to. All participants were asked to provide informed written consent 
(Appendix 5) before taking part in the study. Further details regarding study design and 
recruitment can be found in sections 5.3.1, 6.3.1 and 7.3.1. 
 
2.3 Patient characteristics and clinical endpoints 
2.3.1 Patient demographics and clinical phenotype 
 
Patient demographics 
Information on patient demographics and clinical phenotype were recorded following direct 
questioning and a review of the medical case notes. Patient demographics included age, 
gender, smoking history (current, previous and never, including an estimate of pack-year [1 
pack year representing the equivalent of 20cpd for 1 year] history) and disease duration 
(defined as both year of onset of RP symptoms and year of physician diagnosis) were 
recorded. 
 
Clinical phenotype of patients with SSc 
Details of the classification and eligibility criteria used to recruit patients with primary RP and 
SSc can be found in sections 5.3.2, 6.3.1 and 7.3.1.  
 
Patients with SSc were classified according to extent of cutaneous involvement was 
classified according to the LeRoy and Medsger criteria (LeRoy et al., 1988). In brief, lcSSc 
comprises skin changes distal to the elbows, knees and clavicles i.e. forearms, hands, 
calves, feet and face. In dcSSc, skin thickening is present proximal to these sites e.g. 
thighs, upper arms and torso (LeRoy et al., 1988). In the absence of documented skin 
involvement, the term limited SSc (lSSc) was adopted as previously described (LeRoy and 
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Medsger, 2001). The extent of skin thickening was not assessed clinically but the highest 
previous modified Rodnan skin score (mRSS, section 2.3.4), where documented, was 
recorded (Clements et al., 1993).  
 
Clinical evidence or a documented history of calcinosis and/or telangiectasia was recorded. 
A past history of digital ischaemic complications was based on a previously documented 
history of either digital ulceration (DU) or digital pitting (DP). A diagnosis of ILD required 
previously reported characteristic findings on HRCT or lung biopsy.  The results of most 
recent pulmonary function tests (forced vital capacity [FVC] and diffusing capacity [DLco]) 
undertaken within the last five years were documented.  A diagnosis of pulmonary arterial 
hypertension (PAH) required a mean pulmonary artery pressure of >25mmHg on right heart 
catheter (Badesch et al., 2009). Cardiac involvement was based on a documented history of 
any cardiac involvement, other than ischaemic heart disease, and included left ventricular 
dysfunction, arrhythmias, myocardial fibrosis, or pericardial effusion. Upper GI involvement 
was defined as a documented clinical history of symptomatic gastro-oesophageal reflux 
(GORD) and/or dysphagia, endoscopic evidence of GORD or stricture, or abnormal 
peristalsis/transit on oesophageal manometry and/or barium swallow.  Patients were 
documented as having lower GI involvement if there was a recorded history of chronic 
frequent and/or loose stools, faecal incontinence or a documented history of intestinal 
pseudo-obstruction.  A scleroderma renal crisis (SRC) was defined as the new onset of 
hypertension accompanied by acute renal failure. Muscle involvement required the 
presence of an unexplained elevation in serum creatine kinase and/or characteristic 
changes on muscle biopsy. Joint involvement was considered present if there was a 
documented history of inflammatory arthritis (erosive or non-erosive). 
 
Serological assessment of patients with SSc 
The results of serological analysis, based upon indirect immunfluorescence studies using a 
rapidly dividing human laryngeal epithelial cell carcinoma cell line (HEp-2 cells), followed, 
where appropriate, by immunoblotting and/or immunoprecipitation to aid further 
characterisation of SSc-specific autoantibodies, was recorded. 
2.3.2 The Scleroderma Health Assessment Questionnaire 
The Scleroderma Health Assessment Questionnaire (SHAQ) is a modified version of the 
Stanford Health Assessment Questionnaire Disability Index (HAQ-DI) that is recommended 
 61 
for use in clinical trials of SSc (Merkel et al., 2003, Steen and Medsger, 1997). The 20-item 
HAQ-DI is a patient self-report of disability. It is divided into eight domains: dressing and 
grooming, arising, eating, hygiene, reach, grip and activity.  Patients rate their ability to 
perform these activities of daily living on a scale from 0 (without difficulty) to 3 (unable to 
do).  The use of aids or devices to assist with these activities is also recorded.  The HAQ-DI 
score is calculated by dividing the summed component scores by the number of 
components answered and yields a score between 0 (no disability) to 3 (severe disability) 
(Fries et al., 1982, Bruce and Fries, 2003). The SHAQ has been demonstrated to have high 
face validity and good test-retest reliability in SSc (Steen and Medsger, 1997). The SHAQ 
comprises a standard HAQ-DI along with six visual analogue scales relating to the major 
organ manifestations of SSc (pain, gastrointestinal, respiratory, Raynaud’s, digital ulceration 
and a patient global assessment) each of which is converted into comparable 0-3 scores 
(Steen and Medsger, 1997). The VAS RP of the SHAQ is recommended for use in both the 
provisional core set of outcome measures for clinical trials of SSc and by OMERACT7 
(Khanna et al., 2008). An example of the SHAQ used in this study can be found in Appendix 
6. 
2.3.3 The Raynaud’s Condition Score 
The Raynaud’s Condition Score (RCS) forms part of an RP attack diary completed by 
patients over 14 days (Black et al., 1998). Each day, patients record the number and 
duration in minutes of each RP attack. Patients also record a separate RCS, which is a daily 
self-report assessment of the impact of RP symptoms using 0-10 ordinal scale. Patients are 
encouraged to consider the number, duration, severity and impact on functional capacity 
when completing the RCS. The RCS (and the frequency and duration of daily RP attacks 
derived from the diary) has been used successfully in multicentre clinical trials and is the 
recommended outcome measure for use in clinical trials of SSc (Merkel et al., 2002, Merkel 
et al., 2003). Patients taking part in the study were issued with a RCS diary and coached on 
its completion. Each page of the diary was numbered to help participants. Spare pages 
were provided in case of error, or should participants experience greater than 12 attacks in 
a single day. The mean daily frequency of RP attacks, duration of attacks and RCS score 
were calculated over the 2 week period. Participants were required to have correctly 
completed 70% of the diary (i.e. at least 10 days) for the results to be used in subsequent 
analysis. On occasions were the RCS score had been left blank (when no attacks of RP had 
                                               
7 See section 4.1.4 for further details 
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occurred) it was confirmed with participants whether or not this indicated a score of 0. An 
example of a single day from the RCS diary used in this study can be found in Appendix 7. 
2.3.4 The modified Rodnan skin score (mRSS) 
The modified Rodnan skin thickness skin score (also referred to as the TSS) has been 
validated and is recommended for use in clinical trials of SSc (Merkel et al., 2003, Clements 
et al., 1993). Skin thickening is evaluated by palpation of the skin at seventeen sites of the 
body (fingers, hands, forearms, arms, feet, legs, thighs, face, chest and abdomen) and 
scored using a 0-3 ordinal scale (0=normal, 1=mild thickening, 2=moderate thickening, 
3=severe thickening). The mRSS is a simple composite score ranging from 0-51 (Clements 
et al., 1993). The mRSS was not assessed during the study. Instead, the medical notes 
were scrutinized for the highest previous recorded mRSS. The reason for this was because 
the natural history of diffuse cutaneous SSc is for there to be a gradual improvement in skin 
thickening (and mRSS) over time. As such the mRSS at a single timepoint sometimes 
provides less information on the overall disease phenotype than the highest previously 
recorded mRSS. All previous mRSS assessments had been undertaken by a single trained 
assessor (Sister S. Brown). 
2.4 Digital vascular assessments 
2.4.1 Cold challenge assessment 
All assessments were undertaken by the same assessor (JDP) between 0900hrs and 1230hrs 
in a temperature-controlled laboratory within the clinical measurement department of the 
Royal National Hospital for Rheumatic Disease. Subjects were asked to attend in light 
clothing  (exposed the forearms) and asked to refrain from consumption of tobacco, alcohol 
caffeine and vigorous exercise for 4 hours prior to the assessment time. On arrival, subjects 
were acclimatised for a period of 20 minutes at 23°C +/- 0.5°C (with the exception of 
assessment 3 in healthy control study reported in Chapter 4) in a climate-controlled 
laboratory. Where possible, jewellery and watches were removed. Subjects were seated 
comfortably in the examination chair with their hands placed in front of them on a vacuum-
stiffened beanbag on a table in front of the participants at waist height. A vacuum-stiffened 
beanbag ensured the hands remained stationary, and maintained participant comfort, for 
the duration of the assessment. Subjects sat with their right hand dorsum facing up and left 
hand volar surface facing up to allow simultaneous assessment of different regions of 
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interest (ROI) within the hands to be undertaken (Figure 2.2). The IRT camera was 
manually focussed to maximise image quality. Simultaneous assessment of digital vascular 
function using IRT and LSCI was undertaken at baseline over a 3-minute period. The 
subject then placed both hands into cellophane gloves (to avoid evaporative cooling during 
re-warming phase) and from, their seated position, submerged both hands up to the level of 
the radio-carpal joints into a water bath cooled to 15°C (+/- 0.1°C) for a period of 60 
seconds. The gloves were removed and hands placed back into baseline position. In the 
event of direct contact between the skin and water, the hands were gently dabbed dry using 
a paper towel before re-positioning them on the vacuum-stiffened beanbag.  
Figure 2.2 Set-up of patient during cold challenge assessment8 
The IRT camera is attached to a stand with an orthogonal distance of ~80cm between the scan head and the patient’s hands. 
The LSCI is angled at ~30º at a distance of ~30cm from the hands. The hands are supported using a vacuum stiffened bean 
bag placed on a table in front of the seated participant. The left hand is positioned palm up where as the right hand is palm 
down. The red container is the water bath that is cooled to 15ºC for the cold challenge. On the shelf next to the sink is the 




                                               
8 written consent obtained for use of image  
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Continuous assessment of digital vascular function using both IRT and LSCI was 
undertaken for a period of 15 minutes following cold challenge. This signified the end of the 
assessment. 
Significant thought was given to the temperature of the cold challenge. A waterbath of 15°C 
has been successfully used by other groups and may represent the optimum temperature to 
elicit a cold-induced vasoconstrictor response (Anderson et al., 2007). The temperature 
chosen for cold challenge tests is not considered to be critical provided the test is 
standardised across subjects. Higher temperatures of 20°C have been used (McHugh et al., 
1988, Ring et al., 1981). Temperatures above 20°C (approaching room temperature) would 
generally be considered to provide too mild a stimulus to promote vasoconstriction. 
Temperatures below 15°C is arguably too great a cold challenge and should be avoided for 
the following reasons; Firstly, this level of stimulus can be unnecessarily uncomfortable for 
patients with RP (leading to a degree of pain-mediated sympathetic activation). Secondly, at 
temperatures of 10-13C or below vascular smooth muscle cells lose some of their 
muscular contractility, in addition to a sudden reduction in the release of neurotransmitters 
from sympathetic nerves innervating AVAs, leading to vasodilation (Lewis, 1930). This cold 
induced vasodilatation (CIVD) was first described by Lewis (Hunting Reaction) and 
manifests itself as reddening of exposed skin. CVID is a commonly encountered symptom in 
healthy individuals during cold weather (Lewis, 1930).  Cold-induced vasodilation usually 
occurs after 5-10 minutes cold exposure. It helps maintain forearm blood flow, nutritive 
perfusion, manual dexterity and tactile sensitivity during brief cold exposure at the potential 
cost of risking a fall in core temperature and hypothemic complications after prolonged 
exposure (Daanen, 2003). People regularly encountering cold exposure through work or 
sports can develop an enhanced CIVD response. 
2.4.2 Infrared Thermography (IRT) 
IRT assessment of surface skin temperature was undertaken using a camera attached to an 
upright stand with an orthogonal distance of ~80cm from the subject’s hands. The majority 
of images were captured using a Thermovision (FLIR systems, Danderyd, Sweden) camera. 
Following an equipment malfunction (15/09/2011), 2 assessments (~1% of total) were 
undertaken using a replacement camera (FLIR Thermovision A40 camera). Subsequent 
calibration studies led to the application of a correction factor (multiply by 1.064 and subtract 
1.475) to ensure comparable findings in temperature values using the 2 cameras (e.g. 30ºC 
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was adjusted to 30.4ºC). Thermal images of the hands were taken at 13seconda intervals 
for a period of 3 minutes at baseline and for 15 minutes following cold challenge. All images 
were processed using the commercially available CTHERM software (Version 2.3, 
University of Glamorgan). An example of a thermal image from a patient with SSc is 
provided in Figure 2.3. 
  
                                               
a Allowing for subsequent delay for shutter closure and processing, setting the CTHERM computer software at an image 
capture rate of 10 seconds led to a real time image capture rate of 13 seconds. 
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Figure 2.3. Example of IRT image from a patient with SSc following cold challenge.  
Skin emissivity is converted into a colour scale with blue areas representing low surface temperatures and red areas 
representing warmer, better perfused regions. The colour scale on the right of the image provides a guide to surface skin 
temperature at individual areas.  The left forearm is suppinated with the volar aspect of the hand (the palm) facing the camera. 
The right forearm is pronated with the dorsum of the hand facing the camera. Regions of interest (ROI) can be placed over 




2.4.3 Laser Speckle Contrast Imaging (LSCI) 
All LSCI assessments of digital vascular perfusion was undertaken using a Full-Field Laser 
Perfusion Imager (Moor Instruments FLPI, Axminster, UK). Image analysis was undertaken 
using the accompanying moorFLPI Imager software version 2.0. The laser wavelength of 
moorFLPI is 775nm. Assessment of digital perfusion using the moorFLPI LCSI was 
undertaken simultaneously with IRT. The laser head was placed at a standardised distance 
of ~30cm (+/- 2cm) although distance between laser head and skin has not been shown to 
significantly influence flux values (Mahe et al., 2011). The laser was maintained at an angle 
of ~30° (+/- 2.5°) to the hands as recommended. The polarising filter orientation was 
adjusted to minimise specular reflections (mirror-like reflection from shiny surfaces such as 
the nails). The sample rate was fixed at 25 Hz (with single values of flux calculated every 
40ms). The time constant (which influences absolute flux values) was set at 1.0 second to 
minimise noise relating to the pulsatility of the cardiac cycle and minor hand movements. As 
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with other laser-based imaging modalities e.g. Doppler and flowmetry, LSCI quantifies 
perfusion in arbitrary flux units (fu). Unlike other laser based imaging modalities, the 
moorFLPI is not hazardous to the eye and laser safety goggles are not required to be worn 
by the operator or patient. The moorFLPI incorporates a diverging infra-red laser beam 
having accessible power below the limits of Class 1 as defined in IEC60825-1:2001. Images 
were taken continuously during the assessment and then sub-divided into individual images 
at 13 second intervals (to correspond with IRT assessment). An example of typical 
appearance of images taken using LSCI in a patient with SSc before and following cold 
challenge are presented in Figure 2.4. 
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Figure 2.4 Typical appearance of images taken using LSCI before and following cold 
challenge in a patient with SSc 
Continuous LSCI assessment is edited into multiple images at 13 second intervals. The images presented demonstrate 
perfusion in a patient with SSc during 3-minute baseline and following cold challenge. No images are available between 
images 14 and 22 as this was the period of the cold challenge. Speckle contrast is converted into a colour scale with red areas 
representing high flux (perfsuion) and blue areas representing lower flux as indicated on accompanying flux scale (on the left 
hand side of the image). The values on the flux scale are arbitrary flux units with higher values indicating greater perfusion. 
The restricted field of view precluded assessment of the whole of the hands as was achieved using IRT. Note the stable and 
higher perfusion at baseline compared to following cold challenge. Regional differences in perfusion are also evident and shall 
be discussed in later chapters. Image 11 at baseline demonstrates the unfortunate consequence of movement artefact on the 





2.4.4 Image analysis 
Imaging software for both IRT and LSCI enabled mean temperature (°C) and arbitrary flux 
units (fu) to be calculated over pre-defined identically sized regions of interest (ROI). In 
contrast to IRT which could visualise the entire surface of both hands, the LSCI camera’s 
field of view was limited to approximately 20cm x 10cm allowing visualisation of the middle 
fingers of both hands when placed along side each other (Figure 2.4 for examples of 
images obtained). Three ROI were chosen for analysis: the dorsal aspect of right middle 
fingertip (ROI 1), dorsal aspect of the middle phalanx of the right middle finger (ROI 2), and 
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the palmer aspect of left middle fingertip (ROI 3) (the ROIs are demonstrated in Figure 4.1).a 
These ROIs were chosen to allow comparison between dorsal vs. palmer assessment of 
digital perfusion, and to allow evaluation of tissue perfusion between different regions of the 
hands known to differ anatomically by the presence, or absence of arteriovenous 
anastamoses (section 1.5.1). Using data generated at 13 second intervals before and 
following cold challenge it was possible to assess perfusion at specific time points and 
compile re-warming/reperfusion curves for subsequent analyses. The same endpoints were 
chosen for both IRT and LSCI. These included absolute measurements such as baseline 
(abbreviated hereafter as B), immediately following cold challenge (t0), at 5 minute intervals 
post-cold challenge (t5, t10 and t15) and the maximum measurement during re-warming 
(Max). Dynamic assessments dependent on the characteristics of the 
reperfusion/reperfusion curve were also assessed. These included maximum % recovery 
(R%max, calculated as [Max - t0]/(B – t0) x100). The maximum gradient of re-warming 
(Gmax) for the reperfusion/reperfusion curves was also calculated. For illustrative purposes, 
an example of a re-warming curve generated using IRT, highlighting some of the endpoints 
evaluated is presented in Figure 2.5. 
  
                                               
a The ring finger of the right hand was used to assess perfusion at ROIs 1 and 2 for one patient who had previously 
undergone amputation due to ischaemic complications of his SSc. 
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Figure 2.5. An illustrative example of a typical re-warming curve generated at ROI1 using 
infrared thermography (IRT) highlighting endpoints evaluated.  
B, baseline assessment at 23°C; t 0, assessments immediately following 60s cold challenge at 15°C; Gmax, maximum 
gradient of re-warming/reperfusion; Max, maximum surface temperature / flux during 15 minute re-warming period; R%max, 
represents the maximum percent recovery during reperfusion following cold challenge and is calculated as (Max - t0)/(B – t0) 
x100 (equates to approximately 101% in this example).  
 
2.5 Blood and urine collection 
2.5.1 Collection of whole blood  
All participants provided informed written consent to blood collection. Blood collection was 
undertaken by Dr J Pauling who is medically trained and experienced at phlebotomy. Blood 
samples were drawn at the end of the cold challenge assessment to ensure all platelet 
function analyses were undertaken within 1 hour of sample collection and within the 2-4 
hour recommended time-frame (Harrison, 2005). Local cooling (such as the cold challenge 
undertaken in our experiments) is not thought sufficient to precipitate significant in vivo 
platelet activation (Hutton et al., 1984). Platelets are susceptible to ex-vivo activation and 
desensitisation during collection and the preparation of PRP.  Blood was collected from the 
antecubital fossa using a 21 gauge needle and Vacutainer  system. Early tourniquet 
release was used to minimise artefactual platelet activation (Harrison, 2005). The choice of 
anticoagulant for platelet studies is important. For example, anticoagulation with calcium 
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chelation is not suitable for aggregometry studies as it would interfere with calcium 
dependent platelet activation. Blood for platelet aggregometry was gently anticoagulated in 
3.2% sodium citrate in a ratio of 1:9 (1 part anticoagulant to 9 parts blood). All samples were 
stored at room temperature and processed within 1 hour of collection. Blood for circulating 
biomarkers was gently anticoagulated in K2EDTA and stored on ice prior to sample 
processing (in accordance with recommendations of the ELISA manufacturer).  
The initial ~8mls of blood was not used for platelet studies (as recommended); the first 
~5mls was drawn into a serum separation tube (SSTII) and the subsequent ~3mls was 
collected into K2EDTA. These samples were sent, anonymised with the unique identifier 
code (e.g. ART001JDP), to the Royal United Hospital laboratory for assessment of full blood 
count (FBC), Plasma Viscosity (PV) and urea and electrolytes (U&E). A further ~7mls was 
collected in K2EDTA bottles (x2) and ~7mls in 3.2% sodium citrate bottles (x3) for platelet 
function analyses. Immediate gentle mixing ensured effective anti-coagulation. Citrated 
blood was kept at room temperature whereas EDTA blood was placed in ice prior to further 
sample preparation. Blood and urine samples were transferred within a secure specimen 
transport carrier (in accordance with local policy) to the Bath Institute for Rheumatic Disease 
(BIRD) research laboratory by Dr J Pauling for processing.  
2.5.2 Extraction of Platelet Rich Plasma (PRP) 
Platelet rich plasma (PRP) was prepared by centrifuging citrated blood at 150 x gravity (g) 
(equates to 970rpm) for 10 minutes at room temperature. The plasma layer was examined 
for red cells which if present, prompted a further centrifugation at 150 x g for 5 minutes. 
Using a plastic transfer pipette the supernatant (PRP) was carefully transferred to a test 
tube labeled PRP, which was capped and left to stand at room temperature. The resulting 
2.7-3mls of PRP was generally sufficient to undertake 6 platelet aggregometry analyses 
(see section 2.7.5).  
2.5.3 Extraction of Platelet Poor Plasma (PPP) 
Following removal of the PRP, the remaining citrated blood sample was centrifuged at 2500 
x g (2900 rpm) for 20 minutes at room temperature. The platelet poor plasma (PPP) layer 
was inspected for haemolysis and transferred to a plastic tube labeled PPP. 
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2.5.4 Extraction of Platelet Free Plasma (PFP)  
Platelet Free Plasma (PFP) was prepared by centrifuging EDTA blood collected (within 30 
minutes and stored on ice) at 1000 x g (2400rpm) for 15 minutes at 8-10C. The plasma 
layer was transferred into a test tube and immediately centrifuged at a greater speed of 
3000 x g (4100rpm) for 10 minutes in an attempt to remove all remaining platelets (Christie, 
2008). To avoid multiple freeze thaw cycles when assaying multiple biomarkers, PFP 
samples was stored in x3 1ml screw-top storage tubes. 
2.5.5 Collection and preparation of urine 
Participants were issued a plastic universal container to provide a fasting mid-stream urine 
sample on the morning of their 2nd (and 3rd when applicable) assessment. The urine 
samples were stored at the Bath institute for Rheumatic Diseases for later batch analysis of 
eicosanoid metabolites. Urine was stored both unaltered (x3, 1ml storage tubes) and 
containing 10L of the antioxidant 0.005% BHT to prevent ex vivo lipid peroxidation which 
could influence F2-isoprostane synthesis (x3, 1ml storage tubes).  
2.5.6 Labelling and storage of samples 
All plasma and urine samples were anonymised with a unique patient identifier code (e.g. 
ART001JDP), sample details, and date of collection in accordance with the requirements of 
the Ethics committee. An electronic record of the sample details was recorded on a 
password protected Microsoft Access Research Sample Database in accordance with local 
policy. To avoid multiple freeze thaw cycles when assaying for multiple biomarkers, samples 
were stored in 1ml screw-top storage tubes. In total, 6 urine samples were stored (3 
containing 10L of 0.005% BHT), 1 citrated platelet poor plasma and 3 EDTA plasma 
samples. All samples were stored at -80C for subsequent batch analysis. The study 
number was written on the screw-top to facilitate sample identification and as a fail-safe 
mechanism should sample labels be lost. An electronic record of the sample details is 
recorded on a password protected Microsoft Access Research Sample Database in 
accordance with local policy. This is accessed using my BIRD account log-in details  S-
drive  Research Daybook  Research Samples. A log of all samples uploaded onto the 
research sample database is also made in the research daybook which remains behind 
locked doors in the BIRD research laboratory. 
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2.6 External laboratory investigations 
2.6.1 Blood samples 
The initial 8mls of blood was not used for platelet studies; the first ~5mls is drawn into a 
serum separation tube (SSTII) and the subsequent ~3mls is collected into K2EDTA 
vacutainer tubes. These samples were anonymised and sent for analysis of Full Blood 
Count (FBC), plasma viscosity (PV), and serum creatinine (Cr) at the accredited 
haematology and biochemistry diagnostic laboratories of the Royal United Hospital, Bath. 
Written reports of the results of these investigations were sent to the Chief Investigator (J 
Pauling) for review and documentation within the case report forms (CRF). 
2.7 Platelet aggregometry 
Since its development in the early 1960’s by Born, light transmission aggregometry (LTA) 
has long been considered the “gold standard” of platelet function analyses (Born and Cross, 
1963, Born, 1962). 
2.7.1 Technique and Choice of Agonists 
LTA provides a quantitative analysis of the degree of aggregation stimulated by a panel of 
agonists such as adenosine diphosphate (ADP), arachidonic acid (AA), collagen and 
adrenaline. The use of varying concentrations of these agonists allows the assessment of 
dose response curves. The principle of LTA has been well described elsewhere (Harrison, 
2005). In brief, a sample of PPP is placed in the aggregometer and set as 100% light 
transmission. A PRP sample is incubated between a light source and luminometer, which is 
set as the 0% light transmission. A known concentration of agonist is spiked into the PRP 
activating the platelets and stimulating aggregation. Upon addition of the agonist, the 
platelets first undergo a shape change. The increased surface area of the platelets initially 
decreases light transmission that can occasionally be identified on the aggregation trace. As 
aggregation ensues, the light transmission increases as the plasma changes from cloudy to 
clear. The rate and extent of aggregation can be read from the subsequent trace. Examples 
of the macroscopic appearance of PPP, PRP and PRP following the addition of agonist are 
presented in Figure 2.6. An example of typical aggregation traces to varying concentrations 
of the agonist ADP is presented in Figure 2.7. Platelet function analysis using LTA is limited 
by the supply of platelet rich plasma. As such, significant thought was given to both the 
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choice of agonists and concentrations used in this study.9 A panel of agonists has emerged 
for use in LTA and includes many of the agents responsible for platelet activation in vivo 
such as adenosine diphosphate (ADP), arachidonic acid (AA), collagen, and adrenaline 
(see section 1.4.2 for mechanisms of action). Each agonist provides specific information 
regarding platelet activation pathways. 
 
Agonists are usually categorized as either strong or weak agonists. Strong agonists e.g. 
thrombin, thromboxane and collagen directly induce platelet aggregation and platelet 
granule secretion. Weak agonists, such as ADP and adrenaline meanwhile can induce 
aggregation without necessarily inducing granule secretion (a primary wave of aggregation). 
At low agonist concentrations, ADP-mediated aggregation is reversible and de-aggregation 
can be observed as a reduction in light transmission following primary wave aggregation. If 
the working concentration of ADP is sufficient to precipitate storage granule release during 
platelet aggregation, an irreversible secondary wave of aggregation can occur. Adrenaline is 
another weak agonist. 
Figure 2.6. The macroscopic appearance of A) Platelet Poor Plasma (PPP), B) Platelet Rich 
Plasma (PRP) and C) PRP following the addition of agonist. 
The initial cloudy of appearance of PRP (B) is lost following the addition of agonist which leads to the formation of visible 
clumps of aggregated platelets (C). The turbidity assumes the appearance of PPP (A) achieved through high-speed 




                                               
9
 I am very grateful for the advice and support of Professor Paul Harrison from the University of Oxford for his 
advice and guidance on the use of LTA and choice of agonists. 
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Collagen, thrombin, TxA2 and its precursor AA are strong agonists of platelet aggregation 
and are associated granule release with a single wave of aggregation. Ristocetin is an 
antibiotic and agonist, but stimulates platelet agglutination as opposed to aggregation. 
 
We chose to evaluate platelet aggregation responses to ADP for the following reasons. 
Aspirin therapy abolishes the secondary wave, thereby influencing responses to high 
working concentrations of ADP (e.g. 10l/L and 5l/L) in LTA analyses. At lower working 
concentrations (e.g. 2.5l/L and 1.25l/L), ADP provides an ex vivo assessment of P2Y1 
and P2Y12 G-protein receptor signaling. Dipyridamole has several modes of action (see 
section 1.4.5) including inhibition of phosphodiesterase enzymes responsible for the 
breakdown of cyclic AMP (cAMP). Increasing intracellular cyclic AMP levels, and thereby 
reducing platelet responses to ADP. For this reason, previous studies have used ADP in ex 
vivo aggregometry studies assessing platelet responses to dipyridamole (e.g. (Gregov et al., 
1987) In addition, dipyridamole inhibits re-uptake of adenosine increasing adenosine A2-
receptor-mediated activation of adenylate cyclase further increasing intra-platelet cAMP 
(Figure 1.4).10 
 
Arachidonic acid (AA) is the obvious choice for the quantification of platelet responses to 
COX inhibition (Gachet, 2008). Whilst COX inhibition with low-dose aspirin effectively 
suppresses platelet synthesis of thromboxane, exogenous AA can still stimulate platelet 
aggregation through the production of non-enzymatic oxidative products of AA metabolism 
such as the F2-isoprostanes. The use of AA had an unintended advantage of identifying 
patients who had inadvertently received treatment with COX inhibitors (aspirin and NSAIDs) 
during the run-in phase of the study. Patients in whom aggregation did not occur in 
response to AA were contacted to clarify their drug history. The many OTC remedies 
available for corysal illnesses and musculoskeletal pain make it very easy for patients to 
inadvertently receive treatment with COX inhibitors. 
                                               
10
 This effect is best observed ex vivo using whole blood impedance aggregometry as impaired re-uptake of 
adenosine by erythrocytes is the major source of increased local concentrations of adenosine following 
treatment with dipyridamole. 
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2.7.2 Use of adenosine diphosphate as agonist 
Adenosine-5-Diphosphate (ADP) was reconstituted at room temperature using 1ml of 
purified water and stored for a maximum of 30 days at 2-8C in its original tightly sealed 
container. This concentration was 2 x 10-4 M. In view of the 1:10 dilution with PRP, this 
provided a working concentration for the aggregometry study of 2 x 10-5 M (equivalent 
concentration 20mol/L). A series of 1:1 dilution steps with 50l of purified water allowed 
subsequent agonist working concentrations of 10mol/L, 5mol/L and 2.5mol/L to be 
prepared at the time of analysis for use in aggregometry analyses.  
2.7.3 Use of arachidonic acid as agonist 
Arachidonic acid (AA) was reconstituted at room temperature using 0.5ml of purified water 
and stored for a maximum of 8 weeks at <20C in its original tightly sealed container. This 
reconstituted AA provided a working concentration for the aggregometry study of 
1.64mmol/L. A single of 1:1 dilution step with 50l of purified water prepared at the time of 
analysis allowed a second agonist working concentration of 0.82mmol/L (equivalent 
concentration 250l/mL) to be used for a second aggregomety analysis.  
2.7.4 Platelet Aggregometry Procedure 
Platelet aggregometry (PA, also known as Light Transmission Aggregometry, LTA) is 
generally regarded to be the “gold standard” of platelet function analyses. All platelet 
aggregometry studies were undertaken using the Bio Data PAP-4 Aggregation Profiler 
(Alpha Laboratories). Four channels allow simultaneous performance of aggregation profiles 
with automated 0% and 100% baselines. The printed results provide aggregation patterns 
and report slope value (maximum gradient of aggregation) and final percent aggregation. 
The 5-minute percent aggregation can be read manually using time bars present on the 
printed report.  
 
All PA studies complied with guidelines developed through the Clinical and Laboratory 
Standards Institute consensus process.(CLSI, 2008) All LTA studies were undertaken within 
1 hour of sample collection.(Harrison, 2005) An aggregometer blank (100%) was prepared 
using 0.5ml of PPP into a siliconized11, flat bottomed 8.75 x 50mm cuvette (Alpha 
Laboratories).  0.45mls of PRP was pipetted into additional cuvettes, which were incubated 
at 37C for 3 minutes before adding a plastic coated macro stir bar (stir speed 920-940rpm). 
                                               
11
 Platelets are activated on negatively charged surfaces such as glass 
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It remains unclear whether adjusting PRP for platelet count (through dilution with PPP) is 
required in LTA studies. Adjusting PRP for platelet count does not appear to affect platelet 
aggregation (Mani et al., 2005). We undertook all analyses using native PRP samples for 
the following specific reasons; it is inappropriate to adjust the platelet count in the PRP 
samples for analyses using AA and the use of PPP-adjusted PRP is known to alter the local 
environment of the platelets potentially falsifying the results. The platelet count of all 
subjects was assessed separately. The 100% and 0% baselines were set using PPP and 
PRP samples respectively. 0.05mls of agonist was pipetted directly into the PRP samples, 
carefully avoiding the reagent from running down the side of the cuvette. We allowed the 
aggregation pattern to generate for 5 minutes. The maximum % aggregation, %aggregation 
at 5 minutes and slope of aggregation were recorded from the aggregation trace and 
automated analysis respectively. An example of typical aggregation patterns to decreasing 
concentrations of ADP is illustrated in Figure 2.7.  
2.7.5 Insufficient sample12 
 
Seven millilitres of citrated plasma typically yields approximately 3mls of PRP easily 
allowing 6 PA studies (2.7mls PRP required) to be performed.  On occasions, we noted 
insufficient PRP sample to undertake the full complement of PA studies. In such instances, 
a decision was made to attempt to preserve the lower doses of agonists (in most cases) at 
the expense of higher doses (e.g. 20mol/L ADP and 1.64mmol/L AA) on the basis that 




                                               
12
 This was not noted on initial training exercises prior to commencement of the study and only became apparent after 
commencement of the study. In the early stages of the study, there were occasions when the lower concentrations of agonists 
were excluded as opposed to the higher doses which accounts for some of the missing data in the LTA analyses reported in 
section 6.4.1. 
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Figure 2.7 Examples of aggregometry curves using varying concentrations of the agonist 
adenosine diphosphate (ADP).  
20mol/L, B) 10mol/L C) 5mol/L and D) 2.5mol/L ADP. The arrows indicate the moment the samples were spiked with 
agonist. A light transmission deflection of 2-4% is the result of the diluting effects of the agonist. The small rebound is the 
result of platelet shape change following early platelet activation. Note the rapid extensive primary waves of aggregation to 
higher concentrations of ADP. At the lower concentration of 5mol/L, there are distinguishable primary and secondary waves 
of aggregation (representing initial aggregation to ADP and a secondary wave following platelet granule release). Following 
addition of the lowest concentration of ADP (2.5mol/L), there is no secondary wave of aggregation and subsequent reversal 
of the primary wave due to failure to stimulate granule release and subsequent de-aggregation during the 5-minute period 
following addition of the agonist. 
 
 
2.7.6 Quality Control Assessments of PAP-4 Aggregometer  
 
Details of Quality Control assessments undertaken to ensure acceptable instrument 
functionality and operator expertise can be found in Appendix 8. 
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2.8 Plasma biomarkers of platelet activation 
2.8.1 Choice of circulating biomarkers13 
Each plasma biomarker was assessed using commercially available kits, which employed a 
quantitative sandwich enzyme linked immunosorbent assay (ELISA) technique. All reagents 
and controls were prepared as directed. PFP samples were not diluted (unless stated) as 
the expected concentrations of each plasma biomarker were generally well within the range 
of the standard curve generated using the standards. In addition to running known control 
values on each plate, additional QA work was undertaken by calculating the coefficient of 
variation (CV) for each assay to establish inter-assay and intra-assay reliability; the results 
of which are outlined below.  
2.8.2 Soluble P-selectin ELISA 
Soluble P-selectin (sP-selectin) levels were assessed using a commercially available ELISA 
(R&D systems, UK). In brief, plasma samples were pipetted into the plate wells. The sP-
selectin binds to a monoclonal antibody which has been pre-coated onto the microplate 
wells. An enzyme-linked (horse radish peroxidase) polyclonal antibody specific for sP-
selectin was added to the wells (sandwiching the immobilized sP-selectin) followed by a 
1hour incubation period. After removal of unbound conjugated antibody (aspirate and wash 
x3), a substrate solution (stabilized tetramethylbenzidine) was added that develops colour 
proportional to the quantity of bound sP-selectin concentration. Colour development was 
stopped (using an acid solution provided with the ELISA kit) and intensity measured using 
the Zenit SP+ plate reader (A. Menarini Diagnostics, Italy). An automated standard curve 
was plotted using supplied standards. The quality of the assay was assessed using controls 
of known value obtained from R&D systems. All samples were run in duplicate and an 
average of the 2 values used for final analysis. The intra-assay and inter-assay reliability 
CVs for the sP-selectin assays were 8.57% and 8.73% respectively. 
2.8.3 Soluble CD40 ligand ELISA 
Soluble CD40 ligand (sCD40L) levels were assessed using a commercially available ELISA 
plate (R&D systems, UK). In brief, undiluted plasma samples were pipetted into the plate 
                                               
13 In addition to the assays described, attempts were made to measure Platelet Derived Growth Factor BB (PDGF-BB) levels 
using a commercially available ELISA plate (R&D systems, UK). The initial assay was successful with control values within 
target range. We made several attempts at assaying the 2
nd
 batch of samples using the same kit but struggled to establish 
reliable standard curves. It was felt the data was not strong enough for inclusion in the final thesis.  
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wells. The sCD40L binds to a monoclonal antibody which has been pre-coated onto the 
microplate wells (during 2 hour incubation at RT on a horizontal orbital microplate shaker 
with a 0.12” orbit, set at 500 rpm. The samples were then aspirated and washed 4 times. An 
enzyme-linked (horseradish peroxidase) polyclonal antibody specific for sCD40L was added 
to the wells (sandwiching the immobilized sCD40L) followed by a further 2 hour incubation 
period at room temperature on the shaker. After removal of unbound conjugated antibody 
(aspirate and wash x4), a substrate solution was added that develops colour proportional to 
the quantity of bound sCD40L concentration. The substrate solution was a combination of 
stabilized hydrogen peroxide and stabilized tetramethylbenzidine that were mixed within 15 
minutes of use. Colour development was stopped (using 2N sulphuric acid stop solution 
provided with the ELISA kit) and intensity measured using a HTIII Spectrophotometer plate 
reader. An automated standard curve was plotted using supplied standards. The quality of 
the assay was assessed using controls of known value obtained from R&D systems. All 
samples were run in duplicate and an average of the 2 values used for final analysis. The 
intra-assay and inter-assay reliability CVs for the sCD40L assays were 13.43% and 23.12% 
respectively. 
2.8.4 Transforming Growth Factor  (TGF-) ELISA 
Transforming Growth Factor  (TGF-) levels were assessed using a commercially available 
ELISA plate (R&D systems, UK). TGF- is secreted as an inactive latent complex. Plasma 
TGF- was activated using an acidification process (10 minutes incubation of 80L PFP 
sample with 40L of 1 N HCL) followed by a neutralization process (addition of 40L of 1.2 
N NaOH/0.5 M HEPES) in polypropylene test tubes prior to assay. 50L  of activated 
sample was added to each well. Activated TGF- binds to a monoclonal antibody pre-
coated onto the microplate wells during 2 hour incubation. After washing (x4), an enzyme-
linked polyclonal antibody specific for TGF-1 was added to the wells (sandwiching the 
immobilized TGF-). Subsequent washes (x4) removed unbound antibody-enzyme reagents 
before the addition of a substrate solution that develops colour proportional to the quantity 
of bound TGF-. The substrate solution was a combination of stabilized hydrogen peroxide 
and stabilized chromogen (tetramethylbenzidine) which were mixed together within 15 
minutes of use. Colour development was stopped (using a stop solution of diluted 
hydrochloric acid provided with the kit) and intensity measured using the Zenit SP+ plate 
reader (A. Menarini Diagnostics, Italy). A standard curve was plotted using supplied 
standards. The quality of the assay was assessed using controls of known value obtained 
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from R&D systems. All samples were run in duplicate and an average of the 2 values used 
for final analysis. The intra-assay and inter-assay reliability CVs for the TGF- assays were 
9.65% and 16.84% respectively. 
2.9 Urinary biomarkers of eicosanoid biosynthesis 
All eicosanoid analysis was undertaken using established techniques at the worlds leading 
eicosanoid research laboratory in collaboration with Professor Ginger Milne at Vanderbilt 
University Medical Center in Nashville, Tennessee (Morrow and Roberts, 2002, Morrow and 
Roberts, 1999, Milne et al., 2007). Quality control samples were analysed within each batch 
and all fell within the laboratories acceptable range.  
2.9.1 Measurement of urinary F2-Isoprostanes 
To analyse F2-isoprostane levels, 1.0 ng of [2H4]-15-F2t-IsoP ([
2H4]-8-iso-PGF2a; Cayman 
Chemical, Ann Arbor, MI) internal standard is first added to 0.200 ml of each sample of 
urine in 5mL water.  The solution is adjusted to pH 3 with 1N HCl.  The sample is then 
applied to a C-18 Sep-Pak cartridge that has been prewashed with 5 ml methanol and 5 ml 
0.01N HCl.  The cartridge is then washed with 10 ml 0.01N HCl, followed by 10 ml heptane, 
and compounds are then eluted with 10 ml ethyl acetate:heptane (50:50, v/v).  The eluate is 
applied to a silica Sep-Pak cartridge prewashed with ethyl acetate (5 ml).  It is rinsed with 5 
ml ethyl acetate and compounds eluted with 5 ml ethyl acetate:methanol (50:50, v/v).  The 
eluate is dried under nitrogen.  Compounds are converted to the pentafluorobenzyl (PFB) 
esters by the addition of 40 μl of a 10% solution of pentafluorobenzyl bromide in acetonitrile 
and 20 μl of a solution of 10% diisopropylethanolamine in acetonitrile and allowed to 
incubate for 30 min at 37oC.  Reagents are dried under nitrogen and the residue 
reconstituted in 30 μl chloroform and 20 μl methanol and chromatographed on a silica TLC 
plate to 13 cm in a solvent system of chloroform:methanol (93:7, v/v).  The methyl ester of 
PGF2α is chromatographed on a separate lane and visualized with 10% phosphomolybdic 
acid in ethanol by heating.  The Rf of PGF2α methyl ester in this solvent system is 0.15.  
Compounds migrating in the region 1 cm below the PGF2α standard to 1.0 cm above the 
standard are scraped from the TLC plate, extracted with 1 ml ethyl acetate, and dried under 
nitrogen.  Following TLC purification, compounds are converted to trimethylsilyl (TMS) ether 
derivatives by addition of 20μl N,O-bis(trimethylsilyl)trifluoroacetamide and 10μl 
dimethylformamide.  The sample is incubated at 37oC for 10 minutes and then dried under 
nitrogen.  The residue is re-dissolved for GC/MS analysis in 20μl undecane that has been 
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stored over a bed of calcium hydride. GC/NICI-MS is carried out on an Agilent 5973 Inert 
Mass Selective Detector that is coupled with an Agilent 6890n Network GC system (Agilent 
Labs, Torrance, CA) that is interfaced with an Agilent computer (Milne et al., 2007). GC is 
performed using a 15 m, 0.25 um film thickness, DB-1701 fused silica capillary column (J 
and W Scientific, Folsom CA).  The column temperature is programmed from 190o to 300oC 
at 20oC per minute.  
The major ion generated in the NICI mass spectrum of the PFB ester, TMS ether 
derivative of F2-IsoPs is the m/z 569 carboxylate anion [M-181 (M-CH2C6F5)].  The 
corresponding ion generated by the [2H4]-15-F2t-IsoP internal standard is m/z 573.  Levels of 
endogenous F2-IsoPs in a biological sample are calculated from the ratio of intensities of the 
ions m/z 569 to m/z 573. Employing this assay, the lower limit of detection of F2-IsoPs is in 
the range of 4pg using an internal standard with a blank of 3 parts per thousand.  The 
precision of this assay in biological fluids is +6% and the accuracy 94%. 
2.9.2 Measurement of urinary 2,3-dinor-6-keto-PGF1 
Urinary 2,3-dinor-6-keto-PGF1 is the major urinary metabolite of prostacyclin (PGI2, PGI-M). 
To 3 ml of urine is added 1 ng [2H4]-2,3-dinor-6-keto-PGF1. It is then acidified to pH 3 with 
1N HCl and allowed to stand at room temperature for 5 min. Under these conditions, 2,3-
dinor-6-keto-PGF1 exists essentially entirely as a lactone.  The sample is then applied to a 
C18 Sep-Pak preconditioned with 5 ml methanol followed by 5 ml 0.01N HCl. The sample is 
rinsed with 10 ml 0.01N HCl followed by 10 ml heptane.  The sample is then eluted with 10 
ml ethyl acetate-heptane (50/50, v/v). The eluate is dried over 10 g of anhydrous sodium 
sulfate and the solvent evaporated under nitrogen. The residue is reconstituted in 1 ml of 
dichloromethane and washed twice with 2 ml of a 50mM sodium borate buffer (pH 8.1), 
discarding the aqueous layer after each wash. At this step, 2,3-dinor-6-keto-PGF1 still 
remains in the lactone form and does not extract into the aqueous phase. Non-lactonized 
fatty acids that are present as carboxylate anions, however, are readily extracted into the 
buffer layer. Subsequently, the organic phase is dried under nitrogen and reconstituted in 50 
l of acetonitrile.  To this is added 200 l of a 3% solution of methoxyamine hydrochloride in 
water and the mixture is incubated for 45 min at room temperature. This step results in 
opening of the lactone ring of the molecule and simultaneous derivatization of the keto 
group. The sample is then extracted with 1 ml of dichloromethane and dried under nitrogen. 
The residue is derivatized to the pentafluorobenzyl (PFB) ester by the addition of 40 l PFB 
bromide (10% by volume in acetonitrile) and 20 l N,N-diisopropylethylamine (10% by 
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volume in acetonitrile) and is incubated for 20 min at 37°C. The sample is then dried under 
nitrogen and reconstituted in 50 l of methanol. It is applied to a silica TLC plate and 
developed to the top in a solvent system of ethyl acetate-methanol (98/2, v/v). The 
methyloxime, PFB ester derivative of 6-keto-PGF1 (5 pg) is chromatographed as a TLC 
standard on a separate lane and visualized with 10% phosphomolybdic acid after heating. 
The 6-keto-PGF1 derivative is used as a TLC standard rather than derivatized 2,3-dinor-6-
keto-PGF1 to avoid any contamination of the biological samples. Using this solvent system, 
the 2 methyloxime isomers of derivatized 6-keto-PGF1 are visualized with an Rf = 0.25 for 
the upper band and Rf = 0.21 for the lower band. Derivatized 2,3-dinor-6-keto-PGF1 
migrates in a nearly identical manner with an Rf = 0.25 for the upper band and Rf = 0.22 for 
the lower band. The compounds in the sample migrating 1 cm on either side of the point 
midway between the two methyloxime isomers of derivatized 6-keto-PGF1 are scraped 
from the silica and eluted with 1 ml of ethyl acetate. The sample is then dried under nitrogen 
and converted to a trimethylsilyl (TMS) ether derivative by addition of 20 l  BSTFA and 10 
l dimethylformamide. The samples are incubated at 37°C for 10 min and dried under 
nitrogen. The residue is redissolved for GC-MS analysis in 10 l of undecane which has 
been stored over a bed of calcium hydride. 
GC/NICI-MS is carried out on an Agilent 5973 Inert Mass Selective Detector that is 
coupled with an Agilent 6890n Network GC system that is interfaced with an Agilent 
computer.  The GC is performed using a 15 m, 0.25 mm film thickness, DB-1701 fused 
silica capillary column (J and W Scientific, Folsom CA).  The column temperature is 
programmed from 190o to 300oC at 20oC per minute. The major ion generated in the NICI 
mass spectra of the methyloxime, PFB ester, TMS ether derivative of 2,3-dinor-6-keto-
PGF1 is m/z 586 which represents the M - 181 (M - CH,C,F,) carboxylate anion. For the 
deuterated standard, the corresponding ion is mlz 590. Quantification of endogenous 2,3-
dinor-6-keto-PGF1 in a urine sample is accomplished by selected-ion monitoring analysis of 
the ratio of intensities of mlz 586 to mlz 590.  The interday variability for each assay is < 
10%.  The precision for the assay is ±5% while the accuracy for this assay is 98%.   
2.9.3 Measurement of urinary 11-dehyro-TxB2 
For analysis, to 3 ml of urine is added 3.0 ng of [2H4]-11-dehydro-TxB2 (Cayman Chemical, 
Ann Arbor, MI) internal standard.  The solution is adjusted to pH 3 with 1N HCl.  The sample 
is then applied to a C-18 Sep-Pak cartridge that has been prewashed with 5 ml methanol 
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and 5 ml 0.01N HCl.  The cartridge is then washed with 10 ml 0.01N HCl, followed by 10 ml 
20% methanol in 0.01N HCl, and the analyte is then eluted with 10 ml ethyl acetate.  The 
eluate is dried under nitrogen.  The residue is re-dissolved in methanol:water (1:16, v/v) and 
then adjusted to a pH of 2.5.  The sample is allowed to stand for 30 minutes at room 
temperature.  The analyte is extracted from this solution using 1 ml of ethyl acetate that is 
then transferred to a microcentrifuge tube and dried under nitrogen.  The sample is re-
constituted in 50 μl ethyl acetate and then purified on a silica TLC plate to 13 cm using a 
solvent of ethyl acetate:acetone:acetic acid (97:3:2, v/v/v).  PGD2 is chromatographed on a 
separate lane as a reference standard and visualized with 10% phosphomolybdic acid in 
ethanol by heating.  The Rf of PGD2 in this solvent system is 0.40.  Compounds migrating in 
the region 1 cm below the PGD2 standard to 1.0 cm above the standard are scraped from 
the TLC plate, extracted with 1 ml ethyl acetate, and dried under nitrogen. Compounds are 
then converted to the PFB esters by the addition of 40 μl of a 10% solution of 
pentafluorobenzyl bromide in acetonitrile and 20 μl of a solution of 10% 
diisopropylethanolamine in acetonitrile and allowed to incubate for 30 min at 37oC.  
Reagents are dried under nitrogen and the residue reconstituted in 50 μl ethyl acetate and 
chromatographed on a silica TLC plate to 13 cm in a solvent system of ethyl 
acetate:heptane (60:40, v/v).  The PFB ester PGD2 is chromatographed on a separate lane 
as a reference standard and visualized with 10% phosphomolybdic acid in ethanol by 
heating.  The Rf of PGD2 PFB ester in this solvent system is 0.23.  Compounds migrating in 
the region 1.3 cm below the PGF2α standard to 0.7 cm above the standard are scraped from 
the TLC plate, extracted with 1 ml ethyl acetate, and dried under nitrogen.  Following TLC 
purification, compounds are converted to trimethylsilyl (TMS) ether derivatives by addition of 
20 μl N,O-bis(trimethylsilyl)trifluoroacetamide and 10 μl dimethylformamide.  The sample is 
incubated at 37oC for 10 minutes and then dried under nitrogen.  The residue is re-dissolved 
for GC/MS analysis in 20 μl undecane that has been stored over a bed of calcium hydride. 
GC/NICI-MS is carried out on an Agilent 5973 Inert Mass Selective Detector that is 
coupled with an Agilent 6890n Network GC system (Agilent Labs, Torrance, CA) that is 
interfaced with an Agilent computer.2  GC is performed using a 15 m, 0.25 um film 
thickness, DB-1701 fused silica capillary column (J and W Scientific, Folsom CA).  The 
column temperature is programmed from 190o to 300oC at 20oC per minute. The major ion 
generated in the NICI mass spectrum of the PFB ester, TMS ether derivative of 11-dehyro-
TxB2 is the m/z 511 carboxylate anion [M-181 (M-CH2C6F5)].  The corresponding ion 
generated by the [2H4]- 11-dehyro-TxB2 internal standard is m/z 515.  Levels of endogenous 
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11-dehyro-TxB2 in a biological sample are calculated from the ratio of intensities of the ions 
m/z 511 to m/z 515. Employing this assay, the lower limit of detection of 11-dehyro-TxB2 is 
in the range of 10pg using an internal standard with a blank of 3 parts per thousand.  The 
precision of this assay in biological fluids is +7% and the accuracy 90%. 
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Chapter 3 - Use of infrared thermography as an 
endpoint in therapeutic trials of Raynaud’s 




In section 1.5 I have outlined the importance of quantification of peripheral vascular 
dysfunction to evaluate response in therapeutic trials in RP. The episodic nature of RP 
attacks has led to a dependence on self-report assessment of the frequency, duration and 
severity of RP symptoms. These tools are subjective, sensitive to placebo effect, time 
consuming, require a prolonged period of assessment and influenced by seasonal variation 
in environmental temperature. Furthermore, the frequency, duration and severity of RP 
attacks are influenced by the effectiveness of coping strategies adopted by patients to avoid 
the conditions responsible for RP attacks and shorten the duration attacks when they occur. 
 
A major limiting factor of studies assessing efficacy in therapeutic studies of Raynaud’s 
phenomenon is the lack of validated objective outcome tools for the assessment of digital 
vascular function. Currently, only patient self-reports and physician global assessments of 
RP severity are recommended by OMERACT (see section 4.1.2 for further details) for use 
in therapeutic trials of Raynaud’s phenomenon (Merkel et al., 2003). Of the methods that 
have been evaluated to attempt to objectively assess digital vascular function, the most 
widely assessed has been IRT. IRT has the advantage of providing sensitive, quantifiable 
and responsive data regarding vascular function. Thermographic protocols for RP 
assessment often incorporate a local cold stress test (CST) to allow dynamic assessment of 
vascular function, whilst attempting to simulate the conditions responsible for an attack of 
RP in vivo. Despite the many trials that have incorporated IRT, no consensus has emerged 
on the preferred thermographic protocol and/or endpoints for use in clinical trials of RP. 
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3.2 Objectives  
 
In this chapter, I shall report the findings of a systematic review of all the previous 
therapeutic trials of RP that have incorporated IRT as an endpoint. I shall describe and 
critique the various thermographic protocols and endpoints adopted and highlight potential 
areas for future research. 
 
3.3 Methods 
3.3.1 Study selection 
To ensure comprehensive study identification, our search criteria extended to all articles 
reporting the use of IRT in the context of RP and SSc-spectrum disease. Initial searches 
indicated this was necessary to capture all studies using IRT as an outcome measure, 
despite identifying a large number of primarily diagnostic or unrelated studies (e.g. relating 
to morphoea). A systematic search of the literature, limited to the English language and 
articles published between 1975 and the present day, was performed using the MEDLINE®, 
EMBase®, AMED® databases accessed via the NHS National Health Resources on March 
9th 2011. The search terms used were: (Thermography) AND (CREST OR Scleroderma OR 
systemic sclerosis OR Raynaud’s). For completion, an additional search was undertaken 
using PubMed® on 21st October 2011. The following keywords and medical subject heading 
(MeSH) terms were used: (Thermography [all fields] OR Thermal [all fields]) AND 
(Raynaud’s [all fields] OR CREST [all fields] OR sclerosis, progressive systemic [all fields] 
OR scleroderma [all fields]). These 2 separate searches were undertaken to ensure all 
relevant articles were identified during the search phase of the study. An additional hand 
search for relevant articles cited in these papers was also performed.  
 
The study selection process comprised two rounds. The first was based on the titles and 
abstracts of the studies identified following the preliminary searches. Diagnostic studies, 
those investigating conditions other than RP or SSc (such as morphoea) or studies of 
paediatric disease were excluded. Similarly, review articles, editorials, comments, 
conference abstracts and individual case reports were excluded from analysis unless they 
specifically reported the findings of a clinical trial. Studies incorporating methods other than 
non-contact IRT for the measurement of cutaneous temperature (e.g. contact thermistors) 
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were also excluded. The full text of each relevant article identified in the first round was 
retrieved and reviewed. Studies fulfilling the above exclusion criteria, or those lacking 
sufficient information to facilitate further analysis were subsequently excluded.  
 
3.3.2 Data extraction 
One investigator (Dr John D. Pauling, JDP) was responsible for selecting and reviewing 
articles based on title and abstract. The full text of studies selected for further consideration 
were reviewed by 2 investigators (JDP and Dr Jacqueline A. Shipley, JAS). Data was 
systematically extracted using a pre-designed proforma to record year of publication, study 
design, study size, patient characteristics, intervention, clinical endpoints and outcome, 
together with thermographic endpoints and outcome. In addition, each study was scored 
independently by 2 investigators (JDP and JAS) for methodological quality using the well-
described Jadad scoring method (scale 0-5) (Jadad et al., 1996). Where agreement was not 
present following independent assessment, the full text was re-reviewed by both assessors 
and consensus reached. In particular, studies were only awarded a point for describing 
withdrawals and dropouts if this was explicitly stated in the text, even if the results 
presented would suggest no patients had dropped out of the trial. In accordance with 
previous studies, Jadad scores of 0-2 and 3-5 were considered low and high quality 
respectively.  
 
3.3.3 Study analysis 
An analysis of all studies was undertaken to describe their key characteristics in terms of 
study design, intervention and clinical/thermographic parameters used. Relatively small 
study numbers and significant variation in study design, therapeutic intervention, imaging 
protocols and thermographic endpoints precluded any useful attempt at statistical pooling of 
results as part of a formal meta analysis. Nonetheless, some indication of the utility of 
specific thermographic parameters can be derived from evaluating agreement between the 
outcomes of clinical and thermographic endpoints of digital vascular function following 
intervention. A secondary analysis was therefore undertaken focussing on agreement 
between clinical and thermographic outcomes within studies. Studies failing to adequately 
report the outcome of clinical and/or thermographic endpoints, or those with small sample 
sizes (n13), were excluded from the secondary analysis to ensure this targeted the larger, 





3.4.1 Article selection 
A flowchart summarising the outcome of the search process used to identify publications for 
final analysis is presented in Figure 3.1. Of the 294 articles identified from the original 
searches, 37 were deemed appropriate for full text analysis. Of these publications, a further 
6 were excluded on review of the full text; four due to the use of contact thermocouples 
rather than IRT (Belch et al., 1981, Ranieri et al., 1993, Arosio et al., 1991), one review 
article (Wouda, 1987), and one which failed to report the methods or outcome of thermal 
imaging (Lukac J, 1991). We could not obtain the manuscript for one study using either our 
institutional subscriptions or inter-library loans service (which included access to all journals 
held within the British Library) (Merla et al., 2002). Two additional publications were 
identified following a subsequent hand search prompted by citations identified in the full-text 
of other selected articles and were included in subsequent analysis. This resulted in a full-
text review of 32 studies. Twenty studies were excluded from the secondary analysis 
(evaluating agreement between clinical and thermographic endpoints) due to small sample 
size (n13) and/or an insufficient description of clinical and/or thermographic endpoints 
(Yamaoka, 1987, Wesseling et al., 1981, Stratton et al., 1997, Shawket et al., 1991, 
Selenko-Gebauer et al., 2006, Ring and Bacon, 1977, Rademaker et al., 1989, Meloni et al., 
1987, Martin et al., 1981, Maeda et al., 1998, Kyle et al., 1985, Kyle et al., 1992, Klimiuk et 
al., 1989b, Katoh et al., 1992, Kan et al., 2002, Ishigatsubo et al., 2010, Gush et al., 1987, 
Cooke et al., 1997, Balogh et al., 2002, al-Awami et al., 2001). The key characteristics and 
findings of the 32 studies included in the analysis are summarised in Table 3.1.  
3.4.2 Study population 
The 32 publications identified following the literature search represent the study of 654 
patients with Raynaud’s phenomenon, the majority of whom had a diagnosis of SSc (326, 
49.8%) or primary RP (230, 35.2%). The remaining patients (98, 15%) had RP associated 
with other conditions, typically other rheumatic diseases such as rheumatoid arthritis, mixed 
connective tissue disease and systemic lupus erythematosis.  
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Figure 3.1. Literature search strategy and identification of relevant publications 
The column on the left reports the outcome of the NHS Health Information Resources Search (including AMED, Medline and 
EMBase search indexes) whereas the column on the right reports the outcome of the search that solely used a publicly 
available Medline interface (PubMed). These 2 separate searches were undertaken to ensure identification of all studies 




Many studies incorporated a heterogeneous mix of RP patients, and these studies did not 
generally undertake sub-analyses that specifically compared disease groups. Other studies 
used more homogeneous groups of either primary RP (e.g. (Schlager et al., 2011, Hirschl et 
al., 2004, Hirschl et al., 2002)) or SSc (e.g. (Herrick et al., 2000)). IRT did not appear to 
perform better in one disease group than the other although the small number of studies 
incorporating a homogenous disease cohort, and the range of interventions, precluded any 
useful comparison along these lines. 
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Table 3.1. Summary table of the studies reporting the use of infrared thermography (IRT) as an endpoint in clinical trials of 
Raynaud’s phenomenon. 
 
DU, digital ulceration; CREST, calcinosis, Raynaud’s, Esophageal dysmotility, Sclerodactyly, Telangiectasia; CST, cold stress test; PRP, primary Raynaud’s phenomenon; SSc, systemic sclerosis; 
RP, Raynaud’s phenomenon; T, temperature; VAS, Visual Analogue Scale; PG-E1, Prostaglandin E1; SHAQ, Scleroderma Health Assessment Questionnaire; PG-I2, Prostaglandin I2; CGRP, 













Intervention Clinical endpoint Clinical improvement IRT protocol IRT endpoint Thermographic Response 
Ring, 
1977 
Open-label 0 6/0/0 Inositol nicotinate 
3g daily for >2 
months  
Not assessed  IRT at baseline, week 1, week 3, 
week 7 and 9 months 
“Thermographic index” of 
dorsal aspect of three middle 
fingers and dorsum of hands  










Open label 0 26/2/18 72 hours IV PG-E1 Patient rated RP better, same or 
worse.  
 
Pain assessed using 10cm VAS and 
a 4-point scale. 
 
Ulceration and ischaemic changes 
documented 
25/26 improved during infusion. 
21/26 improved at 2 weeks and 
17/26 improved at 6 weeks 
Significant improvement in pain VAS 
at 2 weeks. Healing occurred in 
most patients with ulcers. 
IRT at baseline, during, immediately 
after and at 2 and 6 weeks post 
treatment 
 
One hand subjected to CST with 
assessments before and at 4 and 10 
minutes post-CST (20°C for 60s) 
Average T values from spot 
measurements with an infra 
red radiometer of 6 areas of 
dorsum of fingers and 5 areas 
of dorsum of hands 
 
 
Significant increase in hand/finger T 
during, after, at 2 weeks, and at 6 weeks 
 






0 12/0/12 3 day treatment 
period with PG-E1 
vs. placebo  
Patients rated hand symptoms as 
better, same or worse,  
 
Pain (10cm VAS) in 7 patients. 
Marked improvement in hand 
symptoms following  PG-E1  
 
Pain VAS improved following PG-E1 
IRT assessments at baseline, daily 
during treatment period and at 2 
weeks post treatment. 
 
CST (20°C for 60s) pre and post 
infusion, with images taken at 
baseline, 4 and 10 minutes post-
CST 
T of dorsum of hand and 
proximal interphalangeal joints 
used to calculate  
‘themographic index’ (method 
of calculating TI not reported) 
 
Significant improvement in mean 
thermographic index during therapy and at 
2 weeks. Effects of cold challenge not 









3 7/4/2 Acute effects of 
sublingual and oral 
isoxsurprine vs. 
placebo 
Not assessed  IRT at baseline and during 20 
minutes cooling (hands placed on 
cooling plate at 6°C) and every 5 
minutes during subsequent 30 
minutes re-warming 
% change in T over cross-
section of all fingers of left 
hand during cooling after 
treatment 
Significantly decreased cooling following 






Open-label 1 20/2/0 Inositol nicotinate 
1g qds for 36 
weeks 
VAS scores (0-100) for coldness, 
pain, numbness, burnings. 
Approximate duration of attacks (self 
report) 
 
Significant improvement in coldness, 
pain and numbness VAS scores, 
and reported duration of attacks 
post-treatment 
IRT at -1, 0, 1, 3, 5, 12, 24 & 36 
weeks. IRT pre and 10 minutes post 
CST (20°C for 60s).  
TG (T of fingers – dorsum of 
hands) at baseline and 10 
minutes post-CST  
Significant reduction in the magnitude of 
the post-CST TG following treatment. No 
change in baseline TG.  
Dowd, 
1982  
Open-label 1 25/0/25 IV prostacyclin 
over 72 hours 
Subjective 3 point scale (better, 
same, worse) for warmth, cold 
intolerance and stiffness 
 
Pain (10cm VAS) 
 
Frequency and duration of attacks 
Significant improvement in pain 
VAS.  
 
Response to treatment in 21/24 
participants. Effects lasted from 4-28 
weeks. 
Both IRT (n=14) and radiometry  
(n=10) performed at baseline, during 
infusion, immediately after and 2 
weeks post treatment.  
 
CST (20°C for 60s) of one hand 
undertaken as part of thermographic 
and radiometric assessment with 
assessments prior to, immediately 
following and at 1 minute intervals 
until 10 minutes post-CST. 
  
Radiometry used spot 
measurements (6 dorsum of 
fingers, 5 dorsum of hands)  
 
IRT Mean hand and finger T 
at baseline and following CST 
with calculation of 
“Thermographic index” to 
quantify vascular response to 
CST. 
Significant increase in T of hands and 
fingers during, immediately after and at 2 
weeks post infusion using IRT.  
 
Radiometry revealed increased hand and 
finger T during, but not after infusions. 
 
Improvement in Thermographic Index only 




Open label 1 10/2/6 
 
 
3 consecutive day 




Pain (0-10 VAS) 
 
Subjective description of change in 
frequency of RP attacks and 
temperature of hands 
 
Non-significant reduction in VAS 
 
Improvement in 9/10 
 
IRT at baseline and 2 week intervals 
following treatment.  
Pattern of 15 minutes equilibration at 
room temperature (20°C), 3 minute 
warming of right hand at 37°C 
followed by CST (20°C for 60s) to 
right hand, with IRT images acquired 
pre and post equilibration, post CST 
and at 5 min intervals for 
subsequent re-warming  
Discriminant function value 
(DFV) obtained by comparing 
mean temperature change of 
the index finger 10 minutes 
following CST and mean 
longitudinal TG along index 
finger during re-warming 
Improvement in DFV in majority of patients 
with sustained improvement at 12 weeks 





















Not assessed  IRT images of right index finger at 
30 minutes and 15 minutes prior to, 
and at 15 minute intervals (up to 90 
minutes) following nifedipine 
 







Open-label 0 9/0/3 2 hours IV 
prostacyclin 
derivative (CS-
570) BD for 2-4 
weeks 
 
Subjective 3 point scale (better, 
same, worse) 
changes to digital ulceration, skin 
ulceration an ischaemic changes 
7/9 “better” with improvement in 
frequency, severity and duration of 
attacks 
skin ulcers markedly improved 
IRT of hands and feet at baseline, 
and following treatment 




Open-label 1 11/3/3 
 
10 day placebo 
cycle followed by 





Subjective response (length, 
number, severity of attacks) 
following treatment 
 
presence of ulcers 
10/11 “good or excellent effects” 
 
4/5 healing of digital ulcers 
IRT at baseline and post-CST (17°C 
for 3 minutes), before and after 
treatment 
Time to re-establish basal 
surface temperature following 
CST 






3 29/3/26  Infusions of  
iloprost or placebo 
over 6 hours on 3 
consecutive days. 
6 weeks between 
treatments arms 
Frequency, duration and severity (1-
3 scale) of RP attacks 
Pain (1-2 scale) 
Patient global assessment on 
effectiveness 
Active lesions on hands and feet 
recorded at each assessment. 
Sig improvement in frequency, 
severity and patient global 
assessment of effectiveness 
following iloprost compared to 
placebo. 
No difference in lesion healing 
between the iloprost and placebo. 
IRT (radiometry or thermography) 
assessments of the dorsum of both 
hands at baseline and 10 minutes 
post-CST (20°C for 60s). 
Assessments undertaken before, 
immediately following 3
rd
 infusion, 2 
weeks and 6 weeks. 
Mean T of dorsum of hands 
and fingers. Calculation of TG 
at baseline and 10 minutes 
post-CST. Combined thermal 
index (TI) calculated by 
adding TG at baseline with TG 
at 10 minutes post-CST 
Significant difference between placebo 
and iloprost was for the change in thermal 















4 23/0/23 3 days iv iloprost 
at baseline and 
additional single 
infusion at 8 
weeks, or 
nifedipine 30mg 
for 4 weeks 
followed by 60mg 
for 8 weeks 





Significant improvement following 
both treatments during study. 
 
IRT assessment at baseline, weeks 
4, 8, 12 and 16 
Mean hand temperature for 15 
minutes after CST (20°C 60s).  
Increase in mean finger T following iloprost 






Open label 1 11/0/11 
 
Treatment with IV 
followed by oral 
ketanserin  
Digital pain score (10cm VAS) on 
entry and 1 week  
VAS (10cm) for warmth and sensory 
symptoms in affected limb, and body 
warmth 
Grading of number of digits affected 
by digital ulceration, calcinosis and 
digital pitting, on entry, 24hrs, 7 days 
Improvement in VAS scores for pain, 
limb and body warmth 
 
Ulcer healing in all 6 patients with 
active DU at entry into study. 
Bolometric and thermographic 
assessments at baseline, 24 hours 
and 1 week 
 
Mean index finger T 
(thermography) 
 
Mean finger pulp temperature 
(bolometry) 
Significant improvements in finger 











3 6/6/0 Single 3 hour 
infusion of -
CGRP vs. PG-I2,  
No clinical endpoints described in 
methods 
It is reported that thermographic 
data correlated well with subjective 
improvements from patient reports 
of the number and severity of 
attacks 
IRT at baseline, following warming 
(37°C for 3 minutes) and following 
CST (20°C for 60s) at time points 0, 
1, 5, 10, 15, 20 minutes.  CST 
analysis done before, immediately 
after, day 3 and day 14 post 
treatment 
Total change in T compared 
with immediately post-CST of 
the five digits of the right hand 
during 20-minute re-warming 
period. 
No difference in re-warming seen 
immediately post infusion. Significant 
improvement in extent of re-warming 3 







4 13/8/4 IV iloprost over 6 
hours on 3 
consecutive days 
vs. placebo 
Frequency of RP attacks 
Duration of RP attacks 
Severity (1-3 scale) of RP attacks 
Patient global assessment of RP 
response to treatment at each 
assessment. 
Significant improvement in 
frequency but not duration or 
severity of RP attacks for iloprost vs. 
placebo 
No significantly improvement in 
global assessment 
Baseline, day 4, 2 weeks and 6 
weeks. 
Fifteen minutes acclimatisation at 
ambient 20°C followed by 3 minute 
warming of both hands at 37°C, 
followed by 1 minute CST (20°C for 
60s) to right hand with images 
collected immediately after and at 5 
min intervals during subsequent re-
warming 
Mean hand re-warming scores 
calculated by averaging the 
re-warming that occurred at 4 
time points over 20 minutes 
post-CST relative to hand 
temperature within 1 minute of 
CST 
 
No significant differences between 
baseline and subsequent assessments for 
placebo vs. iloprost 
Katoh, 
1992 
Open label  0 4/0/1 Acute and short 
term effects of 
multiple infusions 
of IV  PG-E1 
 
Pain and colour score of worst 
lesion (1-5 scale) 
Improvement in scores at 6, 24, 48, 
72, 168  hours reported.   
IRT of hands at baseline, 10, 30 and 
60 minutes 
T of “worst lesion” Significant increase in T 60 minutes 




h et al., 
1995)(Te














Frequency of RP attacks 
 
Severity of RP attacks (separate 
assessments of pain, numbness and 
colour change scored as none, mild, 
moderate or severe) 
  
Severity of RP (0-10 VAS) at 
baseline and following treatment 
periods 
Improvement in frequency and 
severity of RP attacks 
IRT images at baseline and 
following treatment periods. Dorsum 
of hands 2 hours after application of 
patch, and following CST (15°C for 
60s) 
 
DDD (dorsum of hands and 
distal regions of index, middle, 
ring and little fingers). 
Distal interphalangeal joint 
measurements used to 
calculate: 
Mean T immediately following 
CST 
Lag period before the onset of 
re-warming 
Maximum % recovery over 10 
minutes post-CST 











0 13/0/13 Digital 
sympathectomy 
Retrospective questionnaire 
assessments of digital pain score (0-
4 VAS), presence of digital ulcers 
and pitting scars count, and global 
outcome score (0-3) pre and post 
surgery 
 
Significant improvement in pain 
score, ulcer score and global 




IRT at baseline, 5 and 10 minutes 
post-CST (no details of nature of 
cold challenge) 
Baseline wrist to fingertip TG 
Mean change in gradient 5 
minutes post cold challenge 
Mean change in gradient 10 
minutes post cold challenge 
Improvement in mean change in TG 10 
minutes post-CST only (p<0.06) 
Cooke, 
1997 
Open-label 0 4/4/0 Autologous blood 
transfusions 
following ex vivo 
heating, ozonation 
and UV light 
therapy 
Subjective improvement in severity 
and duration of attacks 
Improvement persisting for at least 3 
months post treatment reported 
IRT images of hands at baseline and 
immediately following autologous 
blood transfusion prior to, day after 
and 3-4 weeks post 










Open label 0 24/0/17 Acute effects of 
electrical 
acupuncture 
Not assessed  IRT assessments at baseline, 10, 45 
and 60 minutes following electrical 
acupuncture 
Surface T of dorsum of 
hands/fingers 








1 52/25/27 Losartan 50mg od 
vs. nifedipine 
20mg bd. 6 weeks 
 
Frequency and severity of RP 
attacks (0-10 VAS) 
Significant reduction in frequency 
and severity of attacks following 
losartan only 
 
IRT Ax at weeks 0 and 6 weeks. IRT 
images at baseline, immediately 
following CST (15°C 60s), 5 and 10 
minutes post-CST 
 
Mean fingertip T at baseline, 
immediately following cold 
stress and 5 minute and 10 
minutes  post-CST 
No improvement in recovery 10 minutes 


















Frequency of RP attacks 
Duration of RP attacks 
Subjective report of RP severity 
(better, same or worse) 
No improvement 
 
Dorsal aspect of hands at baseline 
and following CST (15°C for 60s) 
Measurement over DIP joints of 
index, middle and ring fingers over 
15 minute re-warming 
Mean T at baseline, 
Max. T recovery gradient 
Lag period before the onset of 
re-warming 









2 53/26/27 6-week treatment 
periods with 
fluoxetine 20mg 
OD vs. nifedipine 
LA 40mg OD. 6 
weeks  
Frequency and 
severity of RP attacks (0-10 VAS) 
Sig reduction in frequency and 
severity of attacks following 
fluoxetine only 
IRT Ax at weeks 0 and after each 6-
week treatment period. IRT images 
at baseline, immediately following 
CST (15°C 60s) and 10 minutes 
post-CST 
 
Mean T of hands at baseline, 
immediately following CST 
(15°C 60s) and 10 minutes 
post-CST  
 
% re-warming at 10 minutes. 
No difference at baseline 
 
Significant improvement in % re-warming 




Open-label 0 40/11/11 
 
10 sessions of 
LLLT over 6 weeks 
Frequency and severity of RP 
attacks (0-10 VAS) 
Significant improvement in VAS 
scores at 6 weeks and 3 months 
Baseline and 6 weeks and 3 months 
a) basal fingertip skin T b) 
immediately after 1 minute warm 
challenge (immersion of gloved 
hands in water at 39°C), and c) 
measurements immediately after 
CST (20°C for 60s). Recovery 
temperatures were measured 10 
and 20 minutes later. 
Recovery T after cold 
exposure 
Significant improvement at 6 weeks 














3 18 /18/0 
 
 
LLLT vs. placebo 
(5 sessions per 
week for 3 weeks) 
 
 
Frequency of RP attacks 
 
Intensity of RP attacks (1-5 VAS) 
Improvement in intensity but not 
frequency of RP attacks 
IRT images of the dorsal aspect of 
both hands at baseline and following 
CST (20°C for 60s) at beginning of 
the study and following each 
treatment period  
Mean TG between MCP and 
fingertip for all fingers 20 
minutes post -CST 
 
Number of fingers with TG <-
1°C 10 minutes post-CST 
TG significantly reduced post-CST 
following LLLT compared to placebo. 
 
No significant difference in the number of 
fingers with gradient <-1°C 10 minutes 







 7/7/0 Adventitial 
stripping of radial 
and ulnar arteries  
Questionnaire 1-year post surgery.  
Qualitative assessment of pain, 
frequency and duration of RP 
attacks. QoL 0-10 VAS. 
Questionnaire assessment of ulcers, 
use of gloves and fridge/cold 
tolerance 
Reduction in severity of all 
parameters reported. Improvement 
in QoL VAS in all subjects.  
IRT assessment at baseline, 3 and 6 
months following surgery. 
Qualitative assessment of 
thermographic appearances of 
dorsum of hands at baseline, 
immediately post-CST (20°C 
60s), and 5 and 10 minutes 
post-CST. 
Reduced vasoconstriction reported in 3/5 
patients and enhanced re-warming post-






0 25/0/25 Nitro-glycerine 
(NTG) patch 
applied to one 
wrist 
Nil N/A IRT assessment of the dorsal aspect 
of both hands at baseline.  
Change in the fingertip T of 
the coldest digit on each hand 
at baseline and one hour 
following application of NTG 
patch 
Significant improvement in fingertip T 














10 sessions of 
LLLT vs. sham 
laser placebo 
Frequency of RP attacks 
Severity of RP attacks (0-10 VAS) 
Significant improvement in 
frequency and severity of RP 
following both LLLT and placebo 
(more pronounced improvement in  
the LLLT group) 
 
IRT at baseline and 6 weeks 
a) Baseline 
b) Immediately after 1 minute warm 
challenge (immersion of gloved 
hands in water at 39°C)  
c) Measurements immediately post-
CST (20°C for 60s)  
d) Measurements 10 and 20 minutes 
post-CST 
Change in basal fingertip skin 
T 20 minutes post-CST  
Significantly reduced change in fingertip T 











3 48/48/0 3 weeks LLLT vs. 
placebo 
Frequency and intensity (5 point 
VAS) of RP attacks 
Significant decreases in frequency 
and intensity of RP attacks following 
LLLT compared to placebo. 
IRT assessments at baseline and 
following treatment periods. IRT 
image of dorsal hands  taken pre 
and for 20 minutes post-CST (20°C 
for 60s) 
The mean TG of all fingers, 
the maximum TG and number 
of fingers with DDD <-1°C at 
20 minutes post CST 
Non significant trend towards improvement 








bd weeks 0-4, 
125mg bd weeks 
5-12  
Frequency, duration and severity (1-
3) of RP attacks. The SHAQ and 
pain VAS (0-10) VAS)  
Descriptive analysis of improvement 
in RP activity, pain VAS and 
number/severity of RP attacks.  
IRT Ax at weeks 0 and 16. 
 
IRT images of dorsum of hands at 
baseline and 20 minutes post-CST 
(20°C, ?duration) 
No specific IRT endpoint IRT images presented for subjective 
analysis. No quantifiable thermographic 
endpoints reported.  
Ishigatsu
bo, 2010 




Pain VAS (0-10) and 
ulcer size  
Descriptive report of pain VAS and 
ulcer size responses over 24 weeks 
post-transplantation. Pictorial 
examples of ulcer healing 
presented.  
IRT protocol not reported IRT endpoints not reported Thermal images demonstrating increased 
perfusion post-transplantation from one 
patient presented. 
Thermographic improvement reported in 5 
of 8 patients. 
Shlager, 
2011 
Open-label 0 26/26/0 Auricular 
electroacupunctur
e, 6 sessions over 
6 weeks 
Frequency (diary monitoring) and 
severity (0-10 VAS) of RP attacks 
Significant improvement in 
frequency and severity of attacks at 
3, 6 and 24 weeks 
IRT assessments of volar aspect of 
patient hands at baseline, 3, 6 and 
24 weeks.  
Fingertip skin T before and 
following CST (20°C for 60s).  
No change.   
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3.4.3 Study size 
Study size was generally small with a median participant number of 15.5 (inter-quartile range 
8.75 to 26.75). Fifty percent of the studies consisted of greater than 15 subjects whilst ten 
studies (31.3%) consisted of fewer than 10 subjects.  
3.4.4 Study design 
A variety of methodological approaches were used, although the majority of studies were 
open-label in design (19/32, 59.4%). There were 10 (31.3%) randomised double-blind, 
placebo-controlled (or cross-over studies), 2 single-blind studies and one retrospective study. 
3.4.5 Study quality 
The majority of studies (22/32, 68.8%) would be considered of low quality according to the 
Jadad score (0-2). Seven studies had a Jadad score of 3 and three had a Jadad score of 4.  
 
3.4.6 Date of publication 
The studies are evenly distributed in terms of date of publication with 1 study in the 1970’s, 
12 studies in the 1980s, 8 studies in 1990s and 11 studies since 2000.  
3.4.7 Intervention 
A large variety of interventions had been assessed including pharmacological treatments 
(22/32, 68.7%), complementary therapies (6/32, 18.7%), surgical intervention (2/32, 6.3%) 
and autologous blood product transfusions (2/32, 6.3%). The most commonly evaluated 
pharmacological agent was exogenous prostanoid therapy (9/32, 28.1%). Most classes of 
pharmaceutical drug commonly used in the management of Raynaud’s phenomenon have 
been evaluated thermographically in clinical trials, one notable exception being 
phosphodiesterase inhibition.  
3.4.8 Technical aspects 
As anticipated, a wide variety of brands and models of infrared camera were used in the 
studies, precluding any evaluation of study quality on the basis of equipment used. 
3.4.9 Clinical endpoints 
The majority of studies incorporated clinical as well as thermographic endpoints. Many early 
studies adopted categorical descriptions from patients regarding RP severity following 
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intervention (e.g. much better, better, no change, worse etc.) or visual analogue scales (VAS) 
scores assessing pain levels associated with RP attacks (Martin et al., 1981, Clifford et al., 
1980). More recent studies have incorporated quantitative assessments of RP severity using 
VAS and RP diaries recording attack frequency, duration and severity. Interestingly, none of 
the studies have used the recommended Raynaud’s Condition Score (RCS), originally 
proposed in 1998 and recommended for use in clinical trials of RP since 2003 (Merkel et al., 
2003). Modified versions of the RCS, collecting information on the frequency and duration of 
RP attacks have been used, presumably for practical reasons relating to study design. 
3.4.10 Thermographic protocol  
The majority of studies incorporated a period of acclimatisation in a quiet temperature-
controlled laboratory prior to thermographic assessment. Temperature measurement of the 
dorsum of the hands was undertaken in most studies although measurement of the volar 
aspect of the fingers has also been described (Schlager et al., 2011). The majority of 
thermographic protocols incorporated a CST (22/32, 68.8%), usually achieved through the 
submersion of gloved hands into a water bath. The conditions of the CST varied, although the 
most commonly used protocol involved a cold challenge of 20°C for 60s (14/32, 43.8%). The 
use of cooled contact plates to promote vasoconstriction has also been evaluated (Wesseling 
et al., 1981). Several studies incorporated an additional period of digital warming prior to 
evaluation of the CST (Kyle et al., 1992, Kyle et al., 1985, Shawket et al., 1991, al-Awami et 
al., 2001, al-Awami et al., 2004).  
3.4.11 Thermographic endpoints 
Two principle methods have emerged for the reporting of thermographic endpoints; absolute 
temperature values of the hands and/or fingers from distinct regions of interest, and/or 
thermal gradients derived from either the difference between the mean temperatures of the 
dorsum of the hand and of the fingers, or the longitudinal thermal gradient along individual 
digits. These parameters could be derived from baseline assessment alone although 
thermographic protocols incorporating a local cold challenge were also able to report 
additional thermographic parameters describing responses to cold exposure. These included 
absolute temperature values before and after cold challenge (Clifford et al., 1980, Dowd et 
al., 1982, Rademaker et al., 1989, Dziadzio et al., 1999, Coleiro et al., 2001, al-Awami et al., 
2001, al-Awami et al., 2004, Schlager et al., 2011), percent recovery indices such as 
maximum percent recovery during 10 minutes re-warming period post-CST (Coleiro et al., 
2001), or longitudinal thermal gradients at specific time-points following cold challenge 
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(Hirschl et al., 2002, Hirschl et al., 2004, Kyle et al., 1992, McHugh et al., 1988, Ring and 
Bacon, 1977, Ring et al., 1981, Stratton et al., 1997). If sufficient thermographic assessments 
are undertaken following the cold challenge, attempts can be made to quantify the 
characteristics of the re-warming curve using parameters such as the lag-time to re-warming 
and maximum percent recovery (Herrick et al., 2000, Teh et al., 1995). Additional 
thermographic parameters derived from the re-warming curve characteristics such as area 
under the curve and maximum gradient of re-warming that have been successfully applied in 
diagnostic studies have not yet been evaluated as endpoints in therapeutic trials of RP. A few 
studies, notable for their small sample sizes, used qualitative assessment of the appearances 
of the thermal images alone to attempt to demonstrate response to therapy (Selenko-
Gebauer et al., 2006, Ishigatsubo et al., 2010, Balogh et al., 2002). 
3.4.12 Agreement between clinical and thermographic endpoints 
Improvement in both clinical and thermographic endpoints 
The majority of studies (18/32, 56.3%) reported improvements in both clinical and 
thermographic outcome measures following intervention. Nine of these studies involved small 
patient numbers (n13) (Stratton et al., 1997, Selenko-Gebauer et al., 2006, Meloni et al., 
1987, Martin et al., 1981, Klimiuk et al., 1989b, Katoh et al., 1992, Cooke et al., 1997, Balogh 
et al., 2002, Kyle et al., 1985). A further two studies failed to substantiate evidence for 
thermographic improvement with supportive data (Rademaker et al., 1989, al-Awami et al., 
2001). The extent to which one can critically appraise the thermographic parameters used in 
these 11 studies is questionable.  
 
The remaining 7 studies are worth further consideration. Three of these studies (1 blinded) 
evaluated the use of prostanoids such as prostacyclin (PG-I2) and prostaglandin E2 (PG-E2) in 
studies of greater than 20 patients (McHugh et al., 1988, Dowd et al., 1982, Clifford et al., 
1980). These par-enterally administered agents are amongst the most potent vasodilators 
and recommended for use in severe RP or for the emergency management of ischaemic 
complications in SSc (Kowal-Bielecka et al., 2009). Clinical endpoints in these studies 
included pain VAS, subjective categorical variables (better, same, worse), documenting 
ulcerative complications, and the frequency, duration and severity of RP attacks. Two studies 
used the average temperature of hands/fingers at baseline to demonstrate improved 
peripheral vascular function following therapy, but failed to demonstrate any treatment effect 
in the parameters following the CST (Dowd et al., 1982, Clifford et al., 1980). In contrast, 
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McHugh et al. did not identify improvements in baseline thermal imaging following iloprost 
therapy but did identify a reduced thermal gradient (dorsum of fingers – dorsum of hands) 10 
minutes post-CST indicative of a suppressed vasospastic response to cold exposure 
(McHugh et al., 1988). The remaining 4 studies evaluated a range of interventions including 
inositol nicotinate, serotonin re-uptake inhibition and low level laser therapy (LLLT) (Ring et 
al., 1981, Hirschl et al., 2002, Coleiro et al., 2001, al-Awami et al., 2004). Ring et al. identified 
significant improvements in VAS scores for coldness, pain and numbness VAS scores, and a 
significant reduction in the estimated duration of vasospastic incidents post-treatment (Ring et 
al., 1981). This was accompanied by a significant reduction in the magnitude of the thermal 
gradient 10 minutes post-CST (the same endpoint used in the aforementioned study by 
McHugh et al.) (McHugh et al., 1988, Ring et al., 1981). Coleiro et al. used an open-label 
randomised cross over study design to demonstrate a reduction in the frequency and severity 
of RP attacks following fluoxetine therapy (Coleiro et al., 2001). This was accompanied by a 
significant improvement in percent re-warming 10 minutes post-cold challenge. There was no 
improvement in baseline hand temperature following treatment (Coleiro et al., 2001). A 
double-blind study of LLLT undertaken by Hirschl et al. demonstrated improvement in the 
intensity of RP attacks accompanied by an improvement in the mean longitudinal temperature 
gradient across all fingers at 20 minutes post-CST (Hirschl et al., 2002). The number of digits 
with a pathological thermal gradient of <-1°C 10 minutes post-CST did not improve following 
LLLT (Hirschl et al., 2002). A similarly designed study, also evaluating LLLT, demonstrated 
significant improvements in the frequency and severity of RP attacks in both the LLLT and 
placebo arms (al-Awami et al., 2004). In this study a corresponding improvement in the 
fingertip skin temperature post-cold challenge was demonstrated following LLLT but not 
placebo (al-Awami et al., 2004). 
Improvement in clinical endpoints alone 
Six studies (6/32, 18.8%) identified improvements in clinical endpoints that were not 
accompanied by improvements in thermographic parameters (Yamaoka, 1987, Dziadzio et 
al., 1999, Hirschl et al., 2004, Kyle et al., 1992, Schlager et al., 2011, Teh et al., 1995). Two 
studies were excluded from further analysis due to small study numbers (n13) (Yamaoka, 
1987, Kyle et al., 1992). Of the remaining studies, two were double-blind RCTs, one 
evaluating transdermal Glycerine Tri-Nitrate (Teh et al., 1995), and the other LLLT (Hirschl et 
al., 2004). Thermographic endpoints in these studies included distal-dorsal gradients, number 
of digits with a DDD of <-1°C, characteristics of re-warming curves and mean fingertip 
temperature following cold challenge. Interestingly, the study evaluating LLLT was 
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undertaken by the same group that had demonstrated improvements of both clinical and 
thermographic parameters in an earlier similarly designed study involving fewer patients 
(Hirschl et al., 2002, Hirschl et al., 2004). Of the remaining 2 studies, one was an open label 
study without a control group (auricular electroacupuncture) and the other an open-label 
study with a control arm consisting of an established therapy (losartan vs. nifedipine). In each 
of these studies, it is possible the beneficial effect of the investigational treatment 
(electroacupuncture and losartan) may have arisen from patient’s expectations concerning 
the treatment rather than from the treatment itself (Dziadzio et al., 1999, Schlager et al., 
2011).  
The remaining studies 
Six studies failed to report any clinical endpoints, often when evaluating the acute digital 
vascular effects of therapeutic intervention (Gush et al., 1987, Kan et al., 2002, Maeda et al., 
1998, Ring and Bacon, 1977, Shawket et al., 1991, Wesseling et al., 1981). Another small 
study failed to undertake statistical analysis of clinical or thermographic outcomes, instead 
providing pictorial examples of ulcer healing and figures presenting the evolution of ulcer size 
and pain VAS for each patient during the study period (Ishigatsubo et al., 2010). A well-
designed study by Herrick et al., failed to identify improvements in either clinical or 
thermographic endpoints, possibly reflecting true inefficacy of the intervention (combination 
antioxidants and allopurinol) (Herrick et al., 2000). No studies reported an improvement in 




The present paper is the first to systematically review the previous therapeutic studies of 
Raynaud’s phenomenon that have incorporated IRT as an outcome measure. Comparison 
between studies is limited by variation in study design, intervention, IRT protocols and 
endpoints, precluding any attempt at formal meta-analysis. Nonetheless, we have been able 
to provide a detailed description of the various methods incorporated in previous studies that 
can help influence the design of future work. No single method has emerged as the preferred 
thermographic parameter for use in clinical trials. We have attempted to highlight promising 
thermographic parameters by reporting those studies in which agreement was present 
between subjective clinical endpoints and thermographic parameters. Thermographic 
parameters including absolute temperature measurements at baseline, longitudinal thermal 
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gradients and percent re-warming following cold challenge have been used in studies 
reporting agreement between clinical and thermographic endpoints. The major limitation of 
considering the value of thermographic endpoints based upon their correlation with patient 
self-report is that objective and subjective assessments may provide differing information on 
digital vascular function in patients with RP.  
 
IRT, along with other non-invasive microvascular imaging modalities, is not currently included 
in the proposed core set of outcome measures of vascular dysfunction in clinical trials of RP 
and SSc, although the urgent need for objective biomarkers of vascular function has been 
highlighted (Merkel et al., 2003). The outcome measures currently recommended for use in 
clinical trials are patient self-reports or physician global assessments. There are obvious 
limitations to a reliance on subjective endpoints. Patient self-reports of RP severity, usually 
taking the form of a diary of frequency, duration and severity of attacks carry several 
limitations. They are subjective, time consuming, poorly completed, and influenced by 
seasonal variation in environmental temperature and strategies adopted by patients to avoid 
conditions necessary for an attack of RP. It is our experience that patients with profound 
peripheral vascular dysfunction, as is commonly seen in SSc, have a tendency to under-
report RP severity in self-reports. This may be the result of habituation and difficulty 
discerning discreet RP attacks from chronic basal vascular compromise associated with 
progressive structural microvascular dysfunction. Furthermore, psychosomatic testing has 
revealed distinct personality traits between patients with primary and secondary RP which 
could influence self-report measures of RP severity between the 2 groups (Bayle et al., 
1990). The extent of placebo effect noted in previous therapeutic studies highlights a major 
disadvantage of using self-reports when assessing RP severity. Large randomised controlled 
studies incorporating diary cards have reported statistically significant improvements in the 
Raynaud’s Condition Score (RCS), duration and frequency of RP attacks of up to 60% in 
placebo arms (Black et al., 1998, Belch et al., 1995, Nguyen et al., 2010). “Diary fatigue” may 
contribute to a lower rate of self-report as studies progress. Whatever the cause, it becomes 
increasingly difficult to identify differences in between-group comparisons in the presence of 
such stark responses following placebo therapy.  
 
Non-invasive microvascular assessment tools, such as IRT, have the advantage of providing 
a rapid, quantitative, objective measure of digital vascular dysfunction upon which to guide 
diagnostic and therapeutic decisions. Any placebo effect might be expected to be lower using 
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objective microvascular imaging tools compared with self-reports. Furthermore, the use of 
standardised microvascular imaging protocols, incorporating an acclimatisation period prior to 
assessment, may help negate the influence of seasonal variation in environmental 
temperature and the coping strategies adopted by patients to avoid cold, which influence self-
reports. Several other non-invasive microvascular imaging techniques such as laser Doppler, 
plethysmography, digital artery pressure have been used in therapeutic trials of RP. We have 
not attempted to consider such methods in this chapter as it would have greatly extended the 




To date, no single thermographic parameter has emerged as a preferred endpoint for clinical 
trials. The ongoing evaluation of microvascular imaging tools such as IRT in clinical trials of 
RP, alongside recommended self-report tools such as the RCS, is necessary noting the 
potential advantages of objective microvascular imaging tools over self-report. Such work 
needs to define the true nature of what each outcome measure actually informs us regarding 
digital vascular function. The creation of a consensus panel of experts to form 
recommendations on a standardised approach to the use of IRT in future clinical trials of RP 
is needed. This would encourage the use of high quality thermographic protocols and 




Chapter 4 The Validity and Reliability of LSCI the 
dynamic assessment of digital vascular function in 
healthy controls 
 
"In physical science the first essential step in the direction of learning any subject is to find 
principles of numerical reckoning and practicable methods for measuring some quality 
connected with it. I often say that when you can measure what you are speaking about, and 
express it in numbers, you know something about it; but when you cannot measure it, when 
you cannot express it in numbers, your knowledge is of a meagre and unsatisfactory kind; it 
may be the beginning of knowledge, but you have scarcely in your thoughts advanced to the 
state of Science, whatever the matter may be."  
 




A review of the background to LSCI and previous studies evaluating the use of LSCI in the 
assessment of cutaneous perfusion was presented in section 1.5.4. To date, no studies have 
evaluated the use of LSCI in the assessment of digital vascular responses to local cold 
challenge. Furthermore, no studies have directly compared the use of LSCI with IRT in the 
dynamic assessment of digital vascular function. There has also been relatively little work 
evaluating the repeatability of LSCI in the assessment of digital vascular function. In this 
chapter we shall describe preliminary work undertaken to evaluate the validity and reliability 
of LSCI in the assessment of digital vascular function in healthy controls. This preliminary 
work has helped influence the design of subsequent work in patients with primary RP and 
SSc that will be reported in subsequent chapters.  
 
To better appreciate the context of the work undertaken in this chapter, I will first take the 
opportunity to discuss the process of validating outcome measures, using established 
assessment tools used in SSc as illustrative examples. I shall briefly describe the role of 
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OMERACT and the Scleroderma Clinical Trials Consortium (SCTC) in evaluating outcome 
measures for use in clinical trials of rheumatic diseases. 
 
4.1.1 Validation and reliability testing of novel measurement tools 
All measurement techniques use a practical test (an operationalization) to assess a theory or 
concept (a construct) (Trochim, 2006). A commonly used example is the use of height or 
weight to assess the size of an object. Whilst these 2 operationalizations clearly provide 
different information regarding the construct, in many instances there will be good correlation 
between the 2 techniques and each can help an independent observer derive conceptual 
meaning from the values obtained.  If a new tool were developed to assess an objects size, 
we would want to be sure of the validity and reliability of that test before we would accept the 
results of using such a device with confidence. If the test results were to correlate well with 
other tests of the construct (such as height and weight), then we would derive some 
confidence of the validity of that measure. Should the new tool provide consistent readings on 
each occasion, we would be reassured of the reliability of the test. 
 
Validity 
Methodological literature routinely makes reference to the different forms of “validity” in the 
context of outcome assessment tools. These terms create confusion and I will define the 
various terms and methods utilised here, using established methods for the assessment SSc 
as examples.  
 
When considering RP, a basic construct might be defined as the greater the vascular 
insufficiency, the more intrusive the ischaemic symptoms experienced by the individual. In 
this instance, an operationalization such as the RCS diary should reflect the subjective 
experience of RP symptoms experienced by a subject. Face validity is a component of 
construct validity which considers whether the operationalization taken “on face value” 
appears to relate to your construct (Trochim, 2006). The RCS diary achieves this by 
considering the average daily frequency, duration and impact of RP symptoms in sufferers. If, 
for example, the RCS diary had ignored such considerations and instead evaluated neck 
pain, immediate concerns would have been raised regarding its face validity. Face validity is 
not easily objectively assessed making it a weak but important component of a construct’s 
validity (Trochim, 2006). Content validity assesses the operationalization against relevant 
content domain for a particular construct. For example, a novel patient questionnaire for the 
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diagnosis of Raynaud’s phenomenon would appear to lack content validity if it failed to 
consider the essential clinical attributes of an RP attack such as “episodes relating to cold 
exposure” or “the presence of digital cutaneous colour change”.  
 
Criterion-related validity assesses the performance of an operationalization against specific 
criteria and is commonly divided into 4 domains; predictive, concurrent, convergent and 
discriminant validity. Predictive validity concerns the ability of an operationalization to predict 
what we would expect it to predict from our theory (Trochim, 2006). For example, we might 
theorise that severe digital ischaemia in SSc leads to digital ulceration. We could test the 
predictive validity of the RCS diary by comparing the daily frequency, duration and impact of 
RP attacks (assessed using the RCS diary) in SSc patients with and without DU. Concurrent 
validity assesses the ability of an operationalization to distinguish between groups. For 
example, we would expect the modified RSS to provide higher scores in patients with lcSSc 
compared to dcSSc despite each group falling within the same disease spectrum. The results 
of discriminatory testing such as this are more powerful if they can distinguish between 
groups that are otherwise very similar (such is the case in the example provided above) 
(Trochim, 2006). Convergent validity relates to the ability of an operationalization to provide 
similar information (converge upon) to an alternative operationalization measuring the same 
concept. For example, the RCS might be expected to correlate with other self-report 
measures of RP severity such as the Scleroderma HAQ RP VAS. Discriminant validity is the 
opposite of convergent validity and assesses the ability of an operationalization to provide 
information that is not similar to (divergent from) that obtained from other operationalizations 
that you would expect to provide different information based on your construct (Trochim, 
2006). For example, you might hope that the RCS diary was not influenced by psychological 
factors such as depression. This could be evaluated by assessing correlation between 
anxiety/depression scores and the RCS diary (a poor correlation in this instance would 
demonstrate good discriminant validity). 
 
Reliability 
The reliability of an operationalization relates to the consistency or repeatability of a particular 
measurement. A measure is reliable if it provides the same result each time. For example, if 
the RCS could only provide information on digital vascular function, it would be expected that 
RP severity at 2 time-points would be repeatable, providing no external factors such as 
therapeutic intervention had influenced digital vascular function. The reliability of a test is 
 105 
influenced by error, which is typically classified as either random or systematic error. Random 
error describes factors that randomly affect values obtained using an operationalization and 
should not have consistent effects across a sample group. Random error increases the 
variability of data creating unwanted “noise” (Trochim, 2006). Random error in the context of 
the RCS diary might include the variability introduced by patients when documenting duration 
of RP attacks. Identical RP attacks of 7 minutes duration may be accurately recorded as 7 
minutes, rounded up to 10 minutes or rounded down to 5 minutes. A multitude of factors may 
influence the behaviour of respondents and across a large sample group this will increase 
variability of the data but should not affect the outcome across the group. Systematic error 
affects results in a more predictable manner and alters both the result and variability of the 
test (Trochim, 2006). For example, if seasonal variation in environmental temperatures 
affects the outcome of the RCS diary, then systematic error would influence the results of a 
therapeutic study using the RCS diary that recruited all patients during the winter and 
assessed efficacy during the summer.  
 
Reliability is assessed by calculating the covariance of 2 observations of the same measure. 
A perfectly reliable measure would provide a correlation coefficient of 1 whereas a perfectly 
unreliable measure would give a score of zero. A reliability coefficient of 0.8 suggests that 
80% of the score relates to an ability of the measures to provide a true score and 20% error 
(Trochim, 2006). When a test involves independent observers, the inter-observer reliability 
provides information on the variation of assessments between observers. Similarly, it is 
important to consider the intra-observer reliability (the variation in assessment undertaken by 
the same observer on 2 occasions), particularly when there is a subjective component. An 
example is the use of the mRSS (section 2.3.4) to assess skin thickening in SSc.  The intra-
observer reliability is within 4 (of 51) whereas the inter-observer reliability is lower with 
variation of  6 points (Furst, 2008). The test-retest reliability (or repeatability) assesses the 
reliability of an operationalization to provide the same assessment of a construct on 2 
separate occasions. The result is influenced heavily by the interval between assessments, 
particularly in physiological studies in humans. The aforementioned example of the potential 
impact on seasonal variation on the outcome of the RCS diary is a good example of potential 
systematic error affecting repeatability when the interval between assessments is extended. 
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4.1.2 Evaluating outcome measures for use in therapeutic trials of SSc 
OMERACT (Outcome MEasures in Rheumatoid Arthritis Clinical Trials) was developed in 
1992 to better define a core set of outcome measures for clinical trials of rheumatoid arthritis 
(RA). OMERACT is a network of rheumatologists, epidemiologists and statisticians whose 
chief aim is to support the use of valid measures of response in clinical trials. The original 
initiative in RA provided the template for subsequent OMERACT groups to consider outcome 
measures for other rheumatic diseases such as SSc (Merkel et al., 2003, Furst, 2008, Furst 
et al., 2007). Central to the process of assessing outcome measures is the OMERACT filter 
which evaluates many of the key components of validation described above under the 
auspices of 3 main themes; truth, discrimination and feasibility. “Truth” questions the ability of 
an outcome tool to measure what is intended and encompasses aspects of face, content, 
construct and criterion validity. “Discrimination” assesses the ability of an outcome measure 
to discriminate between disease states at a single time point and identify changes over time, 
and encompasses issues surrounding reliability and responsiveness to change. “Feasibility” 
considers the utility of the tool within constraints set by time, affordability and interpretation. 
The work of OMERACT has been extended by the SCTC who have proposed a core set of 
outcome measures for clinical trials of SSc (Khanna et al., 2008). To date, no objective non-
invasive microvascular imaging tools have been recommended for use in clinical trials of SSc, 




The chief objective of the work undertaken in this chapter was to evaluate the validity and 
reliability of LSCI in the dynamic assessment of digital vascular perfusion. To this end, the 
specific objectives were to assess the convergent validity, repeatability and responsiveness 
to change of LSCI by evaluating; 1) the correlation between IRT and LSCI at baseline 
assessment, and following a standardised cold challenge, 2) the reproducibility of the two 
techniques, 3) the spatial resolution of each technique in assessing cutaneous perfusion 
across different regions of the digits, and 4) responsiveness of each technique to a reduction 
in ambient room temperature.  
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4.3 Subjects and Methods 
4.3.1 Study population 
Members of staff from the RNHRD and BIRD, aged between 18-75 years, were approached 
for potential inclusion as healthy controls in the study. Potential participants were issued with 
a participant information sheet (PIS, Appendix 1) and given the opportunity to discuss the 
study prior to enrollment. Subjects were excluded if they fulfilled proposed criteria for RP 
(Brennan et al., 1993), had a history of conditions associated with secondary RP or illnesses 
that might influence digital vascular function such as diabetes or peripheral vascular disease. 
Subjects with controlled hypertension were eligible if they had remained on a stable dose of 
vasodilator medication for the previous calendar month. All participants provided informed 
written consent (Appendix 2) and the study received prior approval from the Bath Research 
Ethics Committee (see section 2.2.1 for further details). 
 
4.3.2 Study Design 
Participants attended on 3 occasions at approximate weekly intervals (median 8 days, 
interquartile range 7-15 days). The temperature of the room was maintained at 23°C (+/- 
0.5°C) throughout assessments 1 and 2 to assess repeatability. Assessment 3 was 
undertaken at a lower room temperature of 18°C (+/- 0.5°C) to evaluate vascular 
responsiveness to physiological stimulus. At each visit participants underwent simultaneous 
assessment of digital vascular function using IRT and LSCI at baseline and following a 
standardised cold challenge test, as described in section 2.4. 
4.3.2 Image analysis 
IRT and LSCI images were analysed as described in section 2.4.4. An example of 
characteristic IRT and LSCI images before and after cold challenge highlighting the ROIs 
chosen for assessment is presented in Figure 4.1.  
 
The vascular endpoints chosen in this work included mean perfusion (skin temperature using 
IRT and arbitrary flux values obtained using LSCI) during baseline assessment (abbreviated 
hereafter as B), immediately following cold challenge (t0) and maximum measurement during 
re-warming (Max). The characteristics of the re-warming/reperfusion curves were used to 
evaluate the maximum % recovery (R%max, calculated as [Max - t0]/[B – t0] x100) and the 
maximum gradient of re-warming (Gmax). For illustrative purposes, an example of a re-
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warming curve generated using IRT, highlighting each of the endpoints used, is presented in 
Figure 2.4. An example of a typical re-perfusion curve generated using LSCI is presented in 
Figure 4.2. 
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Figure 4.1. Example images taken using Infrared thermography (IRT) and Laser Speckle Contrast Image (LSCI).  
A) IRT image baseline with colour scale; B) IRT immediately following cold challenge; C) Corresponding LSCI at baseline (red areas correspond to regions of high flux/perfusion, blue 
regions indicate low flux/perfusion); D) LSCI immediately following cold challenge. The ROIs used for the purposes of this work are numbered and demonstrated on image C. The 
temperature scale for thermal images is placed next to the images on the right side. A colour scale and associated flux values for LSCI can be found in Figure 2.4. 
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4.3.3 Statistical analysis 
All data is presented as median values and interquartile ratio, unless otherwise stated. The 
interquartile ratio (calculated as interquartile range / median) was used to facilitate comparison 
of the variation of data between the 2 assessment tools. Correlation between LSCI and IRT 
was assessed using Spearman’s rank correlation coefficient (rs). Comparison between 
different ROIs for both IRT and LSCI utilised the Wilcoxon signed-rank test. Reproducibility 
(between visits 1 and 2) was assessed using intra-class correlation co-efficient (ICC) to allow 
comparison between imaging techniques (Shrout and Fleiss, 1979). Various recommendations 
have been made concerning the interpretation of ICC values but ranges which have previously 
been adopted have suggested an ICC value of <0.4 generally indicates poor reproducibility, 
0.4-0.75 represents fair to good reproducibility and >0.75 indicates excellent reproducibility 
(Sampat et al., 2006). Changes in response to reduction in ambient room temperature (visit 3 
vs. visit 1), was assessed using Wilcoxon signed-rank test, and the use of Cohen’s d effect 
sizes to facilitate comparison of the magnitude of response between assessment tools. All 
data was analysed using SPSS version 17.0 and a p value of <0.05 was considered 
statistically significant.   
Figure 4.2. An illustrative example of a typical reperfusion curve at baseline and following 
cold challenge (15°C for 60s) at ROI 3 using laser speckle contrast imaging (LSCI). 
























4.4 Results  
4.4.1 Subjects 
Fifteen healthy volunteers (1 male) from within our institution were recruited to the study. One 
female subject had a necessary change to hypertensive medication between visits 1 and 2 
requiring withdrawal from the study. The mean age of the remaining subjects was 44.3 years 
(+/- SD 11.9 years). There was one previous and one current smoker (who refrained from 
smoking on the morning of assessments). Two subjects remained on stable doses of 
vasodilator therapy (irbesartan and atenolol respectively) during the study for underlying 
hypertension. Of the 13 females, 8 were pre-menopausal (4 of whom were taking hormonal 
contraception) and 5 post-menopausal. 
4.4.2 Descriptive data from IRT and LSCI 
Data generated from each ROI using IRT and LSCI for visit 1 is presented in Table 4.1. There 
was greater variation between subjects in the data generated with LSCI compared to IRT, as 
reflected in the considerably higher interquartile ratios (IQRs 0.03-0.62 vs. 0.25-1.57 for IRT 
and LSCI respectively). IQRs were also greater for dynamic parameters (i.e. Gmax and 
R%max), suggesting greater variability in data generated from dynamic parameters (i.e. the 
re-warming/reperfusion curve characteristics) compared to the absolute measurements (e.g. 
B and t0). Another notable finding was the higher R%max using LSCI in comparison with the 
more damped IRT (~125% vs. 102%) for which the post-ischaemic hyperaemic phase is less 




Table 4.1. Infrared thermography (IRT) and Laser Speckle Contrast Imaging (LSCI) data 
for visit 1 (23°C ambient temperature).  
All values expressed as median (interquartile ratio). ROI, Region Of Interest; B, baseline assessment at 23°C; t 0, assessments 
immediately following 60s cold challenge at 15°C; Max, maximum surface temperature / flux during 15 minute re-warming 
period; R%max, maximum percent recovery during reperfusion following cold challenge; Gmax, maximum gradient of re-
warming/reperfusion. 
† 
p<0.05 vs. ROI 2 for IRT,
 ‡
 p=0.001 vs. ROI 3 for IRT 
*
 p=0.04 vs. ROI 2 for LSCI, 
 **
 p<0.005 vs. ROI 2 for LSCI,  
¶
 p=0.048 vs. ROI 3 for LSCI 
 
 





















































































































4.4.3 Correlation between LSCI and IRT 
Correlation coefficients for pooled data of all assessments, and individual regions of interest, 
are presented in table 4.2. For pooled data, moderate correlations existed between IRT and 
LSCI for absolute measurements at baseline and following cold challenge, and the re-
warming curve characteristics (rs values 0.53 to 0.65, P<0.00001). Secondary analysis 
comparing correlation between IRT and LSCI for different ROI identified greater correlation 
(moderate to high) at ROIs 1 and 3 (the fingertips) compared with the more proximal ROI 2 
where there was low or no correlation between IRT and LSCI, with the exception of recovery 
max % (rs 0.61, p<0.05). Similar correlation between IRT and LSCI was present at 10 and 15 
minutes following cold challenge (absolute data presented in Table 5.4). 
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Table 4.2. Correlation between IRT and LSCI for pooled data from all visits and all 
regions of interest (ROI), and for individual ROI (visits 1 and 2).  
B, baseline assessment at 23°C; t 0, assessments immediately following 60s cold challenge at 15°C; Max, maximum surface 
temperature / flux during 15 minute re-warming period; R%max, maximum percent recovery during reperfusion following cold 
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ROI 1. Visits 1 & 2 (n=28) 0.58 * 0.81 *** 0.72 *** 0.69 ** 0.61 * 
ROI 2. Visits 1 & 2 (n=28) 0.13 0.18 0.38 * 0.61 * 0.21 
ROI 3. Visits 1 & 2 (n=28)  0.58 * 0.64 ** 0.65 ** 0.45 * 0.65 ** 
 
4.4.4 Reproducibility 
Data generated at visit 2 is presented in Table 4.3.  
Table 4.3. Infrared thermography (IRT) and Laser Speckle Contrast Imaging (LSCI) data 
for visit 2 (23°C ambient temperature).  
IRT and LSCI data expressed in °C and arbitrary flux units respectively unless stated. All values expressed as median 
(interquartile ratio). B, baseline assessment at 23°C; t 0, assessments immediately following 60s cold challenge at 15°C; Max, 
maximum surface temperature / flux during 15 minute re-warming period; R%max, maximum percent recovery during 
reperfusion following cold challenge; Gmax, maximum gradient of re-warming/reperfusion. 
 
 





















ROI 2 34 (0.08) 22.6 (0.10) 34.5 (0.09) 101.9 (0.1) 3.74 (0.61) 


















ROI 2 133 (0.72) 82 (0.32) 154 (0.66) 113 (0.91) 39 (0.79) 
ROI 3 908 (0.27) 270 (0.77) 881 (0.32) 116 (0.63) 320 (0.64) 
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The ICC values derived from comparing assessments 1 and 2 are presented in Table 4.4. 
Reproducibility of absolute measurements using IRT between visits 1 and 2 was generally 
excellent, as indicated by the high ICC values (all >0.68, table 3). ICC values for dynamic 
assessments using IRT were lower but remained good or excellent (ICCs ~0.7). 
Reproducibility of LSCI was similarly excellent at ROIs 1 and 3 (i.e. the fingertips), but 
reproducibility was generally lower for the R%max (ICC ~0.5 for LSCI cf. ~0.7 for IRT). 
Reproducibility was excellent at ROI 2 at baseline for both IRT and LSCI (ICC~0.85), 
although there was possibly some loss of reproducibility using LSCI at ROI 2 following cold 
challenge when compared to IRT. This was particularly evident for the % recovery indices 
with good reproducibility for IRT compared with poor to fair reproducibility for LSCI at ROI 2 
(ICCs 0.67 vs. 0.45 respectively). 
Table 4.4 Reproducibility of IRT and LSCI between visits 1 and 2 for each region of 
interest.  
All data expressed as intra-class correlation coefficients (ICC). B, baseline assessment at 23°C; t 0, assessments immediately 
following 60s cold challenge at 15°C; Max, maximum surface temperature / flux during 15 minute re-warming period; R%max, 
maximum percent recovery during reperfusion following cold challenge; Gmax, maximum gradient of re-warming/reperfusion. 
 
 
4.4.5 Variation between regions of interest 
There were generally no differences between measurements at ROIs 1 and 3 (dorsal and 
volar aspects of fingertips) using either IRT or LSCI (Table 4.1). Where present, the 
magnitude of any differences was modest, only achieving statistical significance immediately 
after cold challenge for IRT (median 22.6C vs. 21.4C, P=0.001) and for Maximum flux 
following local cold challenge for LSCI (median 753fu vs. 883fu, P=0.048, Table 4.1). This 





 ROI 1      0.83     0.84     0.79     0.67 0.82 
IRT ROI 2 0.83 0.74 0.81 0.67 0.89 
 ROI 3 0.96 0.68 0.92 0.80 0.77 
 ROI 1      0.89      0.85     0.88      0.57 0.83 
LSCI ROI 2 0.88 0.64 0.65 0.45 0.66 
 ROI 3 0.84 0.65 0.95 0.50 0.89 
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suggests similar perfusion at the dorsal and palmer aspect of the fingertips, and would not 
support a methodological preference for assessing digital vascular perfusion at either site.  
 
Significant differences in LSCI flux values between ROI 2 and those measured at ROIs 1 and 
3 were demonstrated for all static assessments and Gmax (P<0.005 for all comparisons, 
Table 4.1). In contrast, the ability of IRT to identify differences in surface skin temperature at 
ROI 2 were limited to baseline at ROI1 (P=0.001), maximum temperature at ROI1 following 
cold challenge (P=0.006) and Gmax at ROIs 1 and 3 (P values of 0.04 and 0.03 respectively). 
The reduced capacity of IRT in distinguishing variation in perfusion across different regions of 
the digit may account for the poor correlation between LSCI and IRT at ROI 2 discussed 
previously. The R%max did not differ significantly between ROIs for IRT. There was a higher 
R%max at ROI 2 compared with ROI 1 for LSCI (153% vs. 125%, P=0.04) possibly caused 
by lower baseline flux at ROI2 allowing modest increases in perfusion during re-warming to 
be translated into more exaggerated relative changes. 
4.4.6 Response to reduction in ambient room temperature 
Data generated from each ROI using IRT and LSCI for visit 3 (reduced ambient room 
temperature) are presented in Table 4.5.  
 
The effect sizes of the differences between visits 1 and 3 are presented in Table 4.6. There 
were significant reductions in surface skin temperature between visits 1 and 3 for all absolute 
IRT endpoints (and Gmax at ROIs 2 and 3) with correspondingly high effect sizes (e.g. the 
temperature at ROI 1 at baseline reduced from 34.1 to 30.2, p=0.001, ES -1.17. Table 4.6). In 




Table 4.5. Infrared thermography (IRT) and Laser Speckle Contrast Imaging (LSCI) 
results for visit 3 (ambient room temperature 18°C).  
All values expressed as median (interquartile ratio). ROI, Region of Interest; B, baseline assessment at 23°C; t 0, assessments 
immediately following 60s cold challenge at 15°C; Max, maximum surface temperature / flux during 15 minute re-warming 
period; R%max, maximum percent recovery during reperfusion following cold challenge; Gmax, maximum gradient of re-
warming/reperfusion. 
† p<0.05, ‡ p<0.005 vs. visit 1 
 
 
Similarly, LSCI identified significant reductions in the majority of absolute flux values in 
response to reduction in ambient room temperature (Table 4.5) and when failing to achieve 
statistical significance, strong trends were present (e.g. ROI1 at t0, 389fu for visit 1 vs. 193fu 
for visit 3, p=0.09). This indicates LSCI was capable of measuring vascular responses elicited 
by the reduced ambient temperature.  
 
  








































































































































Table 4.6. Responsiveness to total body cooling (visit 1 vs. visit 3) presented as 
Cohen’s d effect sizes.  
IRT, infrared thermography; LSCI, laser speckle contrast imaging; ROI, region of interest; B, baseline assessment at 23°C; t 0, 
assessments immediately following 60s cold challenge at 15°C; Max, maximum surface temperature / flux during 15 minute re-
















The magnitude of the response measured using LSCI was lower than that identified using 
IRT, as reflected in the lower corresponding effect sizes (e.g. in contrast to the earlier 
example using IRT, LSCI flux at ROI 1 at baseline only reduced from 657.9 to 536.6, 
p=0.001, ES -0.85, Tables 4.5 and 4.6). In contrast with IRT, a significant change in the 
R%max was identified using LSCI at ROI1 (125% vs. 80%, p=0.03, ES -0.43) 
4.5 Discussion 
 
The present study is the first to make direct comparison between LSCI with IRT in the 
dynamic assessment of digital microvascular function. Most of the previously reported studies 
of LSCI have evaluated microvascular function in the retina or brain cortex of animals (Briers, 
2006). Only recently has attention diverted to its potential application in the assessment of the 
cutaneous circulation, and little work has focussed on peripheral vascular function (section 
1.5.4).  
 






















ROI 2 -1.33  -1.36  -1.08  0.31  -0.74  



















ROI 2 -0.84  -1.01  -0.98  -0.42  -0.95  
ROI 3 -0.82  -0.55  -1.14  -0.76  -0.89  
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We have identified moderate to strong correlation between absolute assessments made with 
LSCI and IRT at the fingertips (ROI 1 and 3) at baseline and following cold challenge. It is 
important to note that the high coefficients of correlation should be interpreted as indicating a 
close relationship between the 2 techniques, but can not evaluate agreement since the 2 
techniques do not measure the same parameter (Bland and Altman, 1986).  
 
Correlation between the 2 techniques is weaker for dynamic parameters generated during re-
warming (R%max and Gmax), and little or no correlation between LSCI and IRT was 
identified from measurements overlying the dorsal aspect of the middle phalanx (ROI 2). 
Differences in the capacity of the 2 techniques to identify important variation in cutaneous 
perfusion within different regions of the digit are likely to account for these findings. LSCI 
identified significantly lower perfusion measured at the middle phalanx (ROI 2) when 
compared to the fingertips (ROI 1 and 3). These findings may be the result of a lower density 
of thermoregulatory AVAs within the non-glabrous skin overlying ROI2 (section 1.5.1). These 
findings are of interest as it has been proposed that LSCI lacks the penetration of IRT and 
conventional laser Doppler, possibly only allowing assessment of perfusion within the 
superficial nutritive bed. Our findings suggest LSCI, at the wavelengths used by the 
MoorFLPI (775nm), may indeed be capable of identifying variation in tissue perfusion defined 
by the presence and function of AVAs. This may be due to the influence of AVA function on 
perfusion in superficial nutritive vessels or alternatively, it is possible the penetration of LSCI 
is greater than previously thought. In contrast, IRT measurements of skin temperature (which 
are influenced by thermal conduction from adjacent deep and superficial tissue) appears to 
lack the capacity to differentiate perfusion between AVA-rich and AVA-poor areas of the skin.  
 
The relative paucity of significant differences between ROIs 1 and 3 (using both techniques) 
suggest cutaneous perfusion and vascular responses within the palmer and dorsal aspects of 
the fingertips is similar, and would not support a preference for either the palmer or dorsal 
aspects of the fingertips when assessing digital vascular function. Participants found it more 
comfortable and easier to maintain their hand in a static position when they had their 
forearms pronated, which may provide an advantage to using the dorsal aspect of the hands 
to assess digital vascular perfusion.  
 
Reproducibility of LSCI has previously been evaluated with conflicting results. One study 
identified superior reproducibility of cutaneous perfusion at the forearm with LSCI compared 
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with both LDPI and LDF (ICCs 0.66 vs. 0.51 and 0.28 respectively) (Roustit et al., 2010b). In 
contrast, Murray et al. identified poor reproducibility using LSCI (ICC 0.15) although repeat 
assessments were only undertaken in a small number of subjects (n=5) (Murray et al., 2009). 
We have demonstrated generally excellent reproducibility of absolute measurements of both 
techniques, particularly at baseline. Reproducibility was generally better for the IRT, although 
differences were not stark and this finding was not entirely unexpected considering the highly 
damped nature of thermographic assessment. This issue raises a particular limitation with 
LSCI. In contrast to IRT, LSCI is responsive to physiological variation in autonomic function 
e.g. deep breathing, in addition to movement artefact. We attempted to address these 
limitations by setting the image processing time constant to 1 second (reducing variability 
secondary to the cardiac cycle) and by using a vacuum-stiffened beanbag to reduce 
movement artefact. Reproducibility was poorer using parameters derived from the re-warming 
curve characteristics (e.g. R%max) than absolute measurements for both techniques, but 
particularly with LSCI (see below for further discussion). 
 
Our final objective compared responsiveness of each technique to a reduction in ambient 
room temperature. There was a significant reduction in absolute temperatures obtained using 
IRT at baseline, and following cold challenge, in response to reduction in ambient room 
temperature with corresponding high effect sizes. The R%max using IRT, meanwhile, failed 
to respond to a reduction in ambient room temperature highlighting a potential pitfall in the 
use of this parameter in therapeutic studies of digital vascular perfusion. The response of 
LSCI to reduction in ambient room temperature was generally less pronounced than IRT, 
although there was still strong evidence of increased vascular tone following cooling. 
Responsiveness of LSCI to reduced ambient room temperature at ROI 2 appears greater 
than at the fingertips on initial review of effect sizes (Table 4.6). These findings require further 
consideration, as it seems unlikely that regions characterised by such low perfusion could 
represent the optimum site for the assessment of vascular responsiveness to therapeutic or 
physiological intervention. The apparent greater responsiveness of IRT must also be 
interpreted with some caution owing to potential non-vascular effects of conductive and 
convective heat transfer from the surface of the digits (discussed in section 1.5.3). This 
consideration is highly pertinent for the many previous thermographic studies of digital 
perfusion that have incorporated a local cold challenge without questioning the potential 
contribution of environmental heat transfer in dictating the subsequent response to cold 
exposure. As discussed in chapter 3, the application of IRT to assess digital vascular function 
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in therapeutic studies of RP has been largely disappointing. Further work comparing IRT and 
LSCI responses to locally applied vasoactive mediators is needed to establish whether LSCI 
offers greater potential in this field.  
 
We have identified potential disadvantages of parameters generated from reperfusion curve 
characteristics such as the R%max and Gmax when compared to absolute measurements in 
the assessment of digital vascular function. These indices may fail to identify differences in 
vascular function apparent from analysis of the absolute values. For example, a relatively 
smaller degree of re-warming / reperfusion may be sufficient to achieve 100% recovery in a 
subject with poorly perfused digits at baseline which respond modestly to cold challenge, 
whereas incomplete re-warming/reperfusion may be apparent in subjects with high perfusion 
at baseline, and marked reduction in response to cold exposure, who fail to re-achieve 
baseline values despite achieving near maximal vasodilatation. 
 
There were limitations to this work that must be considered. Despite its small size, it was well 
conducted and has helped identify associations and trends that has influenced the design of 
subsequent larger work evaluating the use of LSCI in primary RP and SSc that will be 
described in the following chapters. Our cohort was somewhat heterogeneous with only a 
single male volunteer and one current smoker. Similarly, there were differences in female 
hormone status amongst the volunteers that may have influenced microvascular reactivity. 
We do not feel the primary objectives of the study were negatively influenced by failing to 
manufacture a more homogeneous cohort through adoption of stricter eligibility criteria. 
Indeed, the decision to recruit consecutive willing healthy participants was made in an 
attempt to provide a representative real-life experience of the use of LSCI in clinical practice. 
The chief limitation was the extent to which the findings can be generalised to the population 
of interest (patients with RP and SSc). Further validation work of LSCI within these patient 
populations will form a major component of the next chapter.  
4.6 Conclusions 
This study has contributed to a growing body of work exploring the potential application of 
LSCI as a novel non-invasive microvascular assessment tool for the dynamic assessment of 
digital microvascular function. We are the first to compare LSCI with IRT (the historical “gold 
standard” in microvascular imaging terms) in the dynamic assessment of digital vascular 
perfusion. The highly damped IRT provides lower inter-individual variation and greater 
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reproducibility, which may have contributed to the successful application of IRT in the 
classification of disease states (Anderson et al., 2007), however the reduced spatial and 
temporal resolution of IRT might have limited the use of IRT in therapeutic trials of RP 
(Merkel et al., 2003, Herrick and Clark, 1998). Additional work is needed to evaluate the 
potential for LSCI to measure cutaneous AVA responses and autonomic function, which 
could be of major value in the assessment of cutaneous vascular disorders such as RP. 
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Chapter 5  Evaluating vascular outcome measures in 
Raynaud’s phenomenon and systemic sclerosis 
5.1 Introduction 
 
I have described the various subjective and objective vascular outcome measures used in the 
assessment of digital vascular function in RP and SSc in section 1.5 and elsewhere. I have 
largely restricted this review to validated self-report assessments, IRT and laser-derived 
techniques. There are additional established (e.g. digital plethysmography) and novel (e.g. 
optical coherence tomography) techniques for the assessment of vascular function, which 
have not been considered within the remit of this thesis. Whilst researching these techniques, 
I have often found it curious that whilst much work has compared two distinct imaging 
modalities, few studies have directly compared the outcomes of subjective and objective 
microvascular imaging tools. It would be unwise to assume that these 2 approaches provide 
similar information on peripheral vascular function. This is highlighted in the outcome of 
studies exploring the peripheral vascular effects of ERA therapy in SSc. ERA therapy has 
been shown to reduce the burden of DU in SSc (Korn et al., 2004) and studies of ERA 
therapy incorporating objective assessment of peripheral vascular function (LDF, LDPI and 
IRT) have consistently demonstrated improvements in digital blood flow following ERA 
therapy (Rosato et al., 2010, Selenko-Gebauer et al., 2006, Dunne et al., 2006). And yet, 
despite anecdotal evidence of improved RP symptoms, studies incorporating self-report 
assessment of RP activity in patients with SSc (including the RCS diary) have so far failed to 
demonstrate any improvement following ERA therapy (Rosato et al., 2010, Nguyen et al., 
2010). Such findings lead one to question the value of self-reports in the assessment of 
digital vascular function. To consider the validity of patient self-reports, one should first 
consider the exercises that led to their validation and widespread use.  
 
Validation of the RCS diary 
The RCS diary was originally developed for use in 2 concurrent RCTs evaluating oral iloprost 
in RP (Wigley et al., 1998, Black et al., 1998). The RCS diary evaluates the frequency, 
duration and impact of RP attacks over a 2-week period. Each day, patients record the 
number and duration in minutes of each RP attack (Appendix 7). Patients also record a 
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separate RCS, which is a daily self-report assessment of the impact of RP symptoms using 0-
10 ordinal scale. Patients are encouraged to consider the number, duration, severity and 
impact on functional capacity when completing the RCS. The RCS (and the frequency and 
duration of daily RP attacks derived from the diary) has been used successfully in multicentre 
clinical trials and is the recommended outcome measure for use in clinical trials of SSc 
(Merkel et al., 2002, Merkel et al., 2003) (Appendix 7 for example of day sheet from RCS 
diary). Formal validation of the RCS diary was undertaken subsequently using clinical trial 
data from the study reported by Wigley et al. (Merkel et al., 2002). This validation exercise 
identified associations between the presence of DU and the overall RCS score, but not the 
frequency and duration of RP attacks. The RCS diary-related variables demonstrated 
moderate effect sizes (0.33-0.60) following oral iloprost (Merkel et al., 2002). Reproducibility 
was evaluated by examining the variability of the RCS diary parameters during the relatively 
stable post-intervention period, comparing assessments at weeks 6 and 12. Reliability 
(calculated as the standard deviation of the differences in comparison with the baseline 
range) fell within 4.6% and 10.3% of the baseline range (Merkel et al., 2002). The portability 
of the diary led to a high acceptance and completion rate amongst patients, supporting the 
feasibility of the outcome measure. This validation work gained subsequent support from 
OMERACT and the RCS diary was included in the core set of outcome measures of 
peripheral vascular function in clinical trials of SSc (Merkel et al., 2003). Using Dephi and 
Nominal Group techniques, the Scleroderma Clinical Trials Consortium (SCTC) have also 
included the RCS diary in a provisional core set of response measures for clinical trials of 
systemic sclerosis (Khanna et al., 2008).  
 
Further examination of the published findings of the original clinical trials reveals some 
additional interesting findings. For example, whilst Black et al. did not report the date range of 
recruitment, they did report an increase in the mean minimum and maximum daily 
temperatures of +5°C and +8°C at 12 weeks follow-up (Black et al., 1998). It is likely this may 
have accounted for some of the improvement observed in RCS diary parameters following 
intervention although this was not explicitly stated. There was differing interpretation of the 
placebo effect across the 2 studies. Black et al. reported an acceptable placebo effect of ~15-
20%, in comparison to a physician global assessment response to placebo of ~40-50% 
(Black et al., 1998). In contrast, Wigley et al. expressed concern at the extent of the placebo 
response with 41.7% of participants reporting a 50% improvement in the duration of RP 
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attacks, and 24.5% of participants reporting >50% improvements in the frequency of RP 
attacks and RCS score, following placebo intervention (Wigley et al., 1998).  
 
The RCS diary is recommended for use in therapeutic trials of RP, and yet little attention has 
focussed on determinants of the RCS diary. For example, previous studies have not 
compared the use of the RCS diary in primary RP and SSc patients, or compared the results 
of the RCS diary with other patient self-reports of peripheral vascular function e.g. the SHAQ 
RP VAS. Moreover, previous studies have not specifically explored the influence of age, 
gender and seasonal variation on the outcome of the RCS diary parameters. Of particular 
interest, no previous studies have investigated the relationship between the RCS diary 
parameters and objective assessment of digital vascular function.  
5.2 Aims and Objectives 
The aims of this chapter can be broadly split into 2 parts. Part 1 will evaluate factors that 
influence the outcome of subjective (RCS diary) and objective (using IRT and LSCI) 
assessment of peripheral vascular function in RP and SSc (and the relationship between 
subjective and objective methods of assessing peripheral vascular function). Part 2 shall 
extend the validation work of LSCI commenced in the previous chapter and evaluate the 
discriminatory capacity of IRT and LSCI in differentiating between primary RP and SSc. The 
specific objectives of each of these 2 parts are outlined below: 
 
Part 1 Evaluation of factors that influence the outcome of subjective and objective 
assessment of peripheral vascular function in RP and SSc 
 
1) Inter-relationship of individual components of RCS diary in primary RP and SSc and 
differences between disease groups 
2) Relationship between individual components of RCS diary and outcomes of SHAQ in 
patients with SSc 
3) Influence of age, gender, vasodilatory therapy and season on parameters of RCS 
diary in patients with primary RP and SSc 
4) Influence of age, gender, vasodilatory therapy and season on outcome of objective 
assessment of peripheral vascular function using IRT and LSCI in patients with 
primary RP and SSc 
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5) Correlation between subjective (RCS diary) and objective (IRT and LSCI) assessment 
of digital vascular function in primary RP and SSc 
 
Part 2 Further validation work of LSCI in the assessment of digital vascular function in 
primary RP and SSc and evaluation of the discriminatory capacity of IRT and LSCI in 
differentiating between primary RP and SSc 
 
1) Correlation between IRT and LSCI in the assessment of digital vascular function in 
primary RP and SSc 
2) Reproducibility of IRT and LSCI in the assessment of digital vascular function in 
primary RP and SSc 
3) Discriminatory capacity of IRT and LSCI to differentiate between perfusion at distinct 
ROI (differing anatomically by the presence or absence of AVAs) 
4) Discriminatory capacity of IRT and LSCI to differentiate between HC, primary and SSc 
 
5.3 Subjects and Methods 
5.3.1 Patient identification and screening 
Patients with primary RP and SSc were targeted as outlined in section 2.2.3. A total of 180 
patients were sent an information pack containing a PIS and study interest form. One 
hundred and two (56.7%) patients returned the study interest form.  Of those 70 (68.6%) 
patients expressed an initial interest in taking part in the study. Five patients later withdrew 
their interest following further discussion (e.g. unable to commit to study visits), 3 did not 
respond to requests to arrange screening and 1 failed to attend a scheduled screening visit. A 
further 11 potential participants were excluded prior to screening (6 due to preliminary pre-
screening discussion which established they did not fulfill inclusion criteria, 3 patients who 
were acutely unwell or had recently received new treatments for their SSc, 1 patient who was 
pregnant and 1 who was already taking part in an interventional study) The remaining 50 
patients attended a screening assessment between December 2010 and February 2012. Six 
patients were excluded who did not fulfill inclusion criteria (for either primary RP (n=3) or SSc 
(n=3)). All participants provided informed written consent and the study received prior 
approval from the South West 3 Research Ethics Committee (Reference 10/H0106/69). 
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5.3.2 Eligibility criteria 
 
Inclusion criteria 
All patients were aged between 18-75 years, with a diagnosis of either SSc or primary RP. 
Patients with SSc fulfilled either the ARA criteria and/or the LeRoy and Medsger criteria for 
early SSc (Masi, 1980, LeRoy and Medsger, 2001). In brief, the ARA criteria require the 
presence of either 1 major or 2 minor criteria. The major criterion is skin thickening, tightening 
and induration affecting any part of the body proximal to the metacarpophalangeal (MCP) and 
metatarsophalangeal (MTP) joints. Minor criteria include sclerodactyly (skin thickening 
restricted to distal to the MCP and MTP joints), digital pitting scars (secondary to digital 
ischaemia) and bi-basilar pulmonary fibrosis (Masi, 1980). These original criteria attracted 
criticism as they restricted classification to patients with established disease. LeRoy and 
Medsger subsequently proposed additional classification criteria to capture patients with early 
disease (LeRoy and Medsger, 2001). The LeRoy and Medsger criteria incorporated 
microvascular imaging modalities such as nailfold capillaroscopy (NC) and the presence of 
auto-antibodies, to identify patients with SSc prior to the emergence of cutaneous disease 
and/or other organ specific manifestations of SSc such as ILD. In brief, patients require either 
objective evidence of RP (either direct observation of any 2 of pallor, cyanosis or suffusion, or 
objective evidence of delayed recovery following cold challenge e.g. using IRT), in addition to 
either SSc-selective autoantibodies and/or characteristic abnormalities on NC. Alternatively, if 
there is only subjective history of RP (requiring 2 distinct colour changes) then both SSc-
selective autoantibodies and NC abnormalities are required to fulfill the classification criteria 
(LeRoy and Medsger, 2001). 
 
Primary RP was defined as at least 2 episodes of fingertip localized notable blue and/or 
sequential blue and white discoloration, in conjunction with pain upon cold exposure or 
emotional stress within one week of examination and a previous negative anti-nuclear 




Subjects were excluded from all aspects of the study if they were pregnant or breastfeeding 
(women of child bearing age will be required to practice a medically acceptable method of 
birth control throughout the study period). Patients who had undergone surgical 
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sympathectomy in the last 12 months, or had received new medications used for the 
treatment of RP or SSc in the 2 months preceding the trial period were excluded (this 
included the recent administration of selective serotonin reuptake inhibitor even if used for 
other licensed indications e.g. depression due to their vasoactive effects (Coleiro et al., 
2001)). Vasodilators used for the treatment of hypertension were required to be maintained at 
a constant dose throughout the study period. 
5.3.3 Study design and endpoints 
Participants attended on 2 occasions, exactly 2 weeks apart. At the first visit information was 
collected from the participant and their medical records relating to age, gender, smoking 
history, medication usage and clinical phenotype (section 2.3.1). Patients with SSc were also 
asked to complete the SHAQ (section 2.3.2).  At each visit participants underwent 
simultaneous assessment of digital vascular function using both IRT and LSCI at baseline 
and following the standardised cold challenge test described previously (section 2.4). The 
temperature of the microvascular imaging suite was maintained at 23°C (+/- 0.5°C) for each 
assessment. The conditions of the assessment were exactly the same as for assessments 1 
and 2 in the healthy control group described in Chapter 4, to facilitate direct comparison 
between results of the separate studies. IRT and LSCI images were analysed using the 
regions of interest (ROIs) described in section 2.4.4. In view of the advantages of absolute 
assessments over parameters derived from the re-warming curve characteristics identified in 
Chapter 4, the vascular endpoints chosen for this work included mean perfusion (skin 
temperature using IRT and arbitrary flux values obtained using LSCI) during baseline 
assessment (abbreviated hereafter as B), immediately following cold challenge (t0) and at 5-
minute intervals for a period of 15 minutes following cold challenge (t5, t10 and t15 
respectively). The endpoints derived from the characteristics of the re-warming/reperfusion 
curves such as Max, R%max and Gmax described in 4.3.2 were not assessed in this work 
due to the perceived limitations of these endpoints identified and discussed previously 
(section 4.5). In addition, a secondary analysis of thermographic data included calculating the 
longitudinal thermal gradient (a modified version of the “distal dorsal difference”). This was 
calculated by subtracting the temperature of the skin overlying the middle finger MCP from 
the temperature at ROI1 (a negative value indicating lower temperature at the fingertips and 
peripheral microvascular compromise).  
 
At the end of the cold challenge at assessment 1, patients were issued with a 2 week RCS 
diary and given tuition on its completion (section 2.3.3). Patients returned the diary and 
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underwent an identical cold challenge assessment at week 2, which signified the end of this 
component of the study. 
 
To explore the effect of season on vascular outcomes, patients were subsequently divided 
according to date of enrollment into study (April to September vs. October to March) into 2 
groups relating to Spring/Summer and Autumn/Winter.  
5.3.4 Statistical analysis 
All data is presented as median values (and interquartile range [IQR]) unless otherwise 
stated. Correlation between LSCI and IRT was assessed using Spearman’s rank correlation 
coefficient (rs). Between group comparisons of unpaired data used the Mann Whitney U test. 
Comparison of paired data (e.g. comparison between different ROIs for both IRT and LSCI) 
used the Wilcoxon signed-rank test. Reproducibility (between assessments 1 and 2) was 
assessed using intra-class correlation co-efficient (ICC) to allow comparison between imaging 
techniques (Shrout and Fleiss, 1979). Various recommendations have been made concerning 
the interpretation of ICC values but ranges which have previously been adopted have 
suggested an ICC value of <0.4 generally indicates poor reproducibility, 0.4-0.75 represents 
fair to good reproducibility and >0.75 indicates excellent reproducibility (Sampat et al., 2006). 
 
All data was analysed using SPSS version 18.0. All tests were two-tailed and a p value of 
<0.05 was considered statistically significant.   
 
Despite the large number of individual comparisons, no Bonferroni adjustment correction 
factor was applied to the analyses. Where relevant, I have highlighted statistically significant 
associations which may have occurred as a result of type I error and I have guarded against 






5.4.1 Patient demographics 
Forty-three patients (34 female) were enrolled into the study. There were 25 patients with 
SSc and 18 patients with primary RP. The baseline demographics of the cohort are presented 
in Table 5.1.  
Table 5.1 Baseline demographics of patients 
* Mann-Whitney U test used for comparing distribution across groups and Fisher’s exact test to compare frequencies of 
categorical data between groups 
 
 Primary RP, n=18 SSc, n=25 p value* 
Age in years, median (interquartile 
range) 
51.7 (19.3) 59.2 (19.8) 0.03 
Age at RP onset in years, median 
(interquartile range) 
20 (24) 35 (19) 0.02 
Age at diagnosis in years, median 
(interquartile range) 
43 (6) 45 (19) 0.61 
Gender 
     Male, n (%) 











     Any, n (%) 
     Calcium antagonist 
     ACEi 
     SSRI 



















Smoking history, n (%) 
     Never 
     Ex 













Season enrolled, n (%) 
      Autumn/Winter 











There were significant differences between patients with primary RP and SSc for age (51.7 
vs. 59.2 years, p=0.03), age at RP onset (20 vs. 35 years, p=0.02) and use of ACEi (0% vs. 
28%, p=0.03). As expected, there were no patients with primary RP taking ERA. The overall 
proportion of patients taking vasodilator therapy was similar in both SSc and primary RP 
(12/25 and 5/18 respectively, p=0.22). One patient used nifedipine (a calcium channel 
antagonist) on an as needed basis but did not require treatment in the weeks leading up to, or 
during, their participation in the study. For the purposes of the analysis it was therefore 
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assumed they were not receiving nifedipine therapy. There were no differences in gender or 
smoking history between groups. The distribution of patients with primary RP and SSc was 
similar for patients enrolled in Spring/Summer and Autumn/Winter. Two patients (1 with 
primary RP and 1 with SSc) did not attend for a second cold challenge assessment 
preventing the assessment of reproducibility in these participants. The disease characteristics 
of the patients with SSc are presented in Figure 5.1.  
Figure 5.1 Clinical phenotype of patients with SSc.  
lcSSc, limited cutaneous SSc; dcSSc, diffuse cutaneous SSc; lSSc, limited SSc; DU, digital ulceration; DP, digital pitting; GI, 




The majority of patients had lcSSc (22/25, 88%) and its associated clinical features. For 
example, digital ischaemic lesions were common (DU or DP were present in 12/25, 48%). As 
expected there were relatively few patients with associated PAH or ILD (Figure 5.1). The 
majority of patients carried anti-centromere autoantibodies (ACA, n=15, 34.9%) followed by 
anti-Scl-70 (n=4, 9.3%), anti-U3-RNP (n=3, 7%) with the remaining 3 patients carrying anti-
U1-RNP, anti-Th and uncharacterized ANA respectively. Four (9.3%) patients failed to 
adequately complete or return the RCS diary (2 males with SSc, 1 male with primary RP and 
1 female with SSc). No microvascular imaging data was available for the left hand of one 
patient with primary RP due to shoulder discomfort preventing him maintaining his left arm in 
a suppinated position for the duration of the study. No data was available from the right 
middle finger of one patient with SSc because of previous amputation for critical ichaemic 
complications. The 4th (ring) finger was used as an alternative for vascular assessments for 
this subject as discussed previously (Section 2.4.4). 







































Evaluation of factors that influence the outcome of subjective and objective 
assessment of peripheral vascular function in RP and SSc 
 
5.4.2 Inter-relationship of individual components of RCS diary in primary RP and SSc 
and the differences in RCS outcomes between primary RP and SSc 
Across the whole cohort of primary RP and SSc the median RCS score was 2.00 (IQR 2.6). 
The median daily duration and frequency of RP attacks was 22.1 (46.9) minutes and 1.54 
(2.13) attacks respectively. There was high correlation between the individual components of 
the RCS diary (Spearman’s Rho 0.62-0.78, p<0.001 for all comparisons, Table 5.2). There 
were no significant differences in the individual parameters of the RCS diary between patients 
with primary RP and SSc (Figure 5.2).  
Table 5.2 Associations between individual components of RCS diary and SHAQ 
patient self reports  
All associations are expressed as Spearman’s Rho. n=39 for internal associations of the RCS diary (pooled data for primary RP 
and SSc). n=23 for associations between RCS diary and SHAQ in patients with SSc. § p<0.001 ∫ p<0.005   p<0.05 
 
 














RCS  0.62§ 0.71§ 0.53 0.58
∫ 0.61∫ 0.83§ 0.46 0.69
§ 0.51 
Dur  0.78§ 0.23 0.64
∫ 0.48 0.58∫ 0.26 0.47 0.31 
Freq  0.26 0.55 0.34 0.54 0.32 0.46 0.27 
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Figure 5.2 Differences in RCS diary outcomes between patients with SSc and primary RP 
n=22 for SSc and n=17 for primary RP. A) RCS score, B) median daily duration of RP attacks (minutes) and C) median daily 
frequency of RP attacks. The bold lines indicate the median value and boxplots indicate IQR. The whiskers reveal range of 




 quartiles respectively and equals the range in most instances. Outliers 
are depicted as circles if their value sits between 1.5(IQR) and 3(IQR) of the quartile. Outliers are depicted as stars if their 





5.4.3 Relationship between individual components of RCS diary and outcomes of 
SHAQ in patients with SSc 
There was moderate correlation between the RCS score and the HAQ-DI in patients with SSc 
(Rho 0.51, p=0.013, Table 5.2, Figure 5.3). There was no correlation between the HAQ-DI 
and either the frequency or duration of RP attacks reported using the RCS diary (Table 5.2). 
There were significant correlations between the RCS score and each of the organ-specific 
VAS from the SHAQ. The strength of these relationships varied between good and excellent 
(Spearman’s rho between 0.46-0.83, p<0.05 for all associations, Table 5.2).  




For example, there was moderate to high correlation between each individual component of 
the RCS diary and the SHAQ RP Visual Analogue Scale (VAS, Rho 0.54-0.83, p<0.05). 
Associations between individual parameters of the RCS diary and the SHAQ DU VAS 
meanwhile were generally weak and/or non-significant in patients with SSc (Spearman’s Rho 
0.26-0.46, Table 5.2). A documented history of DU and/or DP (n=12) in patients with SSc was 
not associated with significant differences in the RCS score (median 2.3 vs. 0.83, p=0.47), 
duration (37.9 vs. 19.3 minutes, p=1.00) or frequency (2.6 vs. 0.86, p=0.50) of RP attacks, 
compared with patients with SSc without a history of DU/DP (n=13). 
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5.4.4 Influence of age, gender, vasodilatory therapy and season on parameters of RCS 
diary in patients with primary RP and SSc 
 
Males were significantly more likely to have failed to complete the diary adequately than 
females (3/9, 33.3% vs. 33/34, 97.1%, p=0.024). Males reported a significantly lower 
frequency of RP attacks (median daily frequency 0.82 vs. 1.93, p=0.031, Figure 5.4). The 
median daily duration of RP attacks (13.75 vs. 26.14 minutes, p=0.33) and RCS score (1.06 
vs. 2.00, p=0.38) were lower in males than females, but did not achieve statistical 
significance. 
 
Figure 5.4 Impact of gender on mean daily frequency of RP attacks 
Males (n=6) vs. females (n=33). The bold lines indicate the median value and boxplots indicate IQR. The whiskers 









There was no correlation between age and the RCS score (rho -0.03, p=0.86), frequency of 
RP attacks (rho -0.08, p=0.65) or duration of RP attacks (rho 0.1, p=0.54). The RCS score 
was higher in those patients receiving vasodilator therapy although this trend failed to achieve 
statistical significance (median 2.14 vs. 1.57, p=0.058). This may reflect patients with more 
intrusive symptoms seeking therapy. Vasodilator therapy did have any effect on frequency or 
duration of RP attacks.  
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The RCS scores were lower in the Spring/Summer (median scores 1.57 vs. 2.29, p=0.024, 
Figure 5.5). The daily frequency of RP attacks did not differ between Autumn/Winter and 
Spring/Summer (median 1.54 vs. 1.21 respectively, p=0.673). There was a strong trend for a 
higher daily duration of RP attacks during Autumn/Winter but this association failed to 
achieve statistical significance (median daily duration 37.69 vs. 19.29 minutes, p=0.152). 
 
 
Figure 5.5 Impact of season on mean daily RCS score in patients with primary RP and SSc  
n=39. The bold lines indicate the median value and boxplots indicate IQR. The whiskers reveal range of data 




 quartiles respectively and equals the range in most instances. 
Outliers are depicted as circles if their value sits between 1.5(IQR) and 3(IQR) of the quartile. Outliers are depicted 
as stars if their value is 3(IQR) from the adjacent quartile. 
 
 
5.4.5 Influence of age, gender, vasodilatory therapy and season on outcome of 
objective assessment of peripheral vascular function using IRT and LSCI in patients 
with primary RP and SSc 
I identified a number of statistically significant negative correlations between age and 
perfusion of the digits assessed using both LSCI and IRT. The association between 
advancing age and lower cutaneous perfusion was most evident at the palmer aspect of the 
digit (ROI3, Table 5.3). The Spearman Rho values were generally low (all rs<0.43) and the 
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relationship between age and digital cutaneous perfusion in RP should be re-evaluated in a 
larger number of patients to confirm this possible trend.  
 
Digital perfusion assessed using IRT was significantly higher in males compared to females 
for the majority of assessments at each ROI, at both baseline and during re-warming (Figure 
5.6 provides an example using ROI2 at baseline and following cold challenge). Similarly, the 
majority of assessments of digital perfusion undertaken using LSCI revealed significantly 
higher perfusion in males compared to females (one notable exception being perfusion 
assessed using LSCI at ROI1 at baseline [median for males 437.9 vs. 345.9 fu for females, 
p=0.353]). Where failing to achieve statistical significance, strong trends were typically 
present (e.g. at ROI3 at baseline [median perfusion 758.2 vs. 491.6, p=0.065], and similar 
trends for ROI1 at t5, t10 and t15 [p values between 0.07 and 0.13]).  
Table 5.3 Correlation between age and perfusion at ROI3 assessed using IRT and LSCI 
at baseline and following cold challenge.  
B, baseline assessment at 23°C; t 0, assessments immediately following 60s cold challenge at 15°C; t5, perfusion 5 minutes 
post cold challenge etc. All values expressed as Spearman’s rho (rs). 
 


































Figure 5.6 Influence of gender on IRT assessment of skin temperature at ROI2 at 
baseline and following cold challenge 
B, baseline assessment at 23°C; t 0, assessments immediately following 60s cold challenge at 15°C; t5, perfusion 
5 minutes post cold challenge etc. The bold lines indicate the median value and boxplots indicate IQR. The 




 quartiles respectively and equals the 
range in most instances. Outliers are depicted as circles if their value sits between 1.5(IQR) and 3(IQR) of the 




In contrast to self-report assessment of digital vascular function, there was no association 
between vasodilator use and objective assessment of cutaneous perfusion using either IRT 
or LSCI.  
 
With the exception of perfusion at ROI1 immediately following cold stress (249 fu [277.5] in 
Autumn/Winter vs. 173 fu [108] in Spring/Summer, p=0.043), there were no consistent 
associations between season and digital vascular function assessed using LSCI. The 
paradoxical higher perfusion identified during colder seasons in this comparison suggests this 
was a statistical anomaly (possibly related to the large number of individual comparisons 
undertaken). Similarly, there were no associations between season and skin temperature at 
baseline and/or following cold challenge for IRT assessments of the dorsal aspect of the 
finger at ROIs 1 and 2. In contrast, the surface skin temperature was consistently significantly 
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higher at ROI3 during Spring/Summer compared with Autumn/Winter, at baseline and at t5, 
t10 and t15 following cold challenge (Figure 5.7, p<0.05 for each comparison). The reasons 
for these findings are not immediately evident but may include differences in core 
temperature and homeostasis in warmer months. 
 
Figure 5.7 Influence of seasonal variation on skin temperature at the palmer aspect of 
the left middle finger pulp (ROI3) assessed using IRT.  
B, baseline assessment at 23°C; t 0, assessments immediately following 60s cold challenge at 15°C; t5, perfusion 5 
minutes post cold challenge etc. The bold lines indicate the median value and boxplots indicate IQR. The whiskers 




 quartiles respectively and equals the range in 
most instances. Individual outliers are numbered and depicted as circles if their value sits between 1.5(IQR) and 






5.4.6 Correlation between RCS diary parameters and objective assessment of digital 
vascular function using IRT and LSCI in primary RP and SSc 
 
There were no correlations identified between any of the parameters of the RCS score diary 
and non-invasive microvascular imaging assessment using LSCI or IRT assessment at any 
ROI, at baseline and/or following cold challenge (Table 5.4 for examples of correlation 
coefficients between individual RCS diary parameters and LSCI assessment of perfusion at 
ROI1 before and following cold challenge). 
Table 5.4 Correlation between individual parameters of the RCS diary and objective 
assessment of digital mircovascular function using LSCI at ROI 1, at baseline and 
following cold challenge, for both primary RP and SSc.  
B, baseline assessment at 23°C; t 0, assessments immediately following 60s cold challenge at 15°C; t5, perfusion 5 minutes 
post cold challenge etc. All values expressed as Spearman’s rho (rs). p>0.05 for all comparisons.  
 
 B t0  t5 t10 t15 
Duration of RP attacks 0.05 -0.2  0.01 0.08 0.07 
Frequency of RP attacks 0.02 -0.19  -0.08 0.02 0.02 







Further validation work of LSCI in the assessment of digital vascular function in 
primary RP and SSc and evaluation of the discriminatory capacity of IRT and LSCI in 
differentiating between primary RP and SSc 
 
Descriptive data for both IRT and LSCI for each ROI at baseline and following cold challenge 
are presented in Table 5.5. This table incorporates data from healthy controls reported in 
Chapter 4. The following analyses use pooled data from primary RP and SSc unless 
otherwise stated. 
 
Table 5.5 Infrared thermography (IRT) and Laser Speckle Contrast Imaging (LSCI) data 
for patients with SSc and primary RP at assessment 1.  
All values expressed as median (interquartile range). ROI, Region Of Interest; na, not assessed; B, baseline assessment 
at 23°C; t0, assessments immediately following cold challenge; t5, perfusion 5 minutes post cold challenge etc. na, not 
available 
 
§ p<0.05 vs. ROI 2; ¶ p<0.05 vs. ROI 3;  * p=0.007 vs. primary RP; 
† 
p<0.05 vs. primary RP; 
‡ 
p<0.05 vs. SSc 
 




































ROI 2 30.8 (7.3) 21.4 (2.9) 24.4 (7.9) 25 (9.7) 26.7 (11.1) 






 25.9 (9.4) 
 
Primary RP 
ROI 1 31.4 (8.0)
 ¶




 31.4 (11) 32.4 (10.8) 
ROI 2 30.8 (6.6) 21.5 (3.5) 25.2 (7.2) 30.4 (10.5) 31.7 (10.6) 
ROI 3 29.5 (6.7) 20.7 (3.1)
 §








 na 34.1 (3.5) 
† ‡
 34.2 (1.7) 
† ‡
 
ROI 2 33.4 (2.2) 
† ‡
 22.1 (1.0) na 33.7 (4.3) 
† ‡
 33.7 (2.3) 
† ‡
 
ROI 3 33.3 (3.3) 
† ‡
 21.4 (1.0) na 33.7 (5.6) 
† ‡




































ROI 2 235 (306) * 79 (84) 100 (269) 132 (391) 128 (364) 






















































ROI 1 658 (185)
 † ‡
 389 (198) 
† ‡
 na 723 (233) 
† ‡
 646 (350) 
‡
 
ROI 2 126 (114) 
‡
 94 (64) na 134 (111) 125 (99) 
 ROI 3 748 (314) 
†
 301 (271) 
†





5.4.7 Correlation between IRT and LSCI in the assessment of digital vascular function 
in primary RP and SSc 
Using pooled data from primary RP and SSc, there was moderate to excellent correlation 
between assessments of digital vascular function using IRT and LSCI at all ROIs at baseline 
and at all time-points following cold challenge (Table 5.6). The lowest correlations were 
generally identified immediately post-cold challenge although rs values were still suggestive of 
close agreement between the 2 techniques (t0, Spearman’s Rho values 0.577-65). 
 
Table 5.6. Correlation between IRT and LSCI for each ROI at baseline and following 
cold challenge for both primary RP and SSc.  
B, baseline assessment at 23°C; t0, assessment immediately following cold challenge; t5, 5 minutes post-cold challenge etc.  
All values expressed as Spearman’s rho (rs). p<0.01 for all comparisons. 
n=43 (unless stated) B t0  t5 t10 t15 
ROI 1  0.725 0.615**  0.813 0.843 0.748 
ROI 2  0.702 0.577**  0.837 0.827 0.809 







5.4.8 Reproducibility of IRT and LSCI in the assessment of digital vascular function in 
primary RP and SSc 
 
The outcome of reproducibility analysis using pooled data for patients with both primary RP 
and SSc is presented in Table 5.7. The ICC values were generally lower than we had 
identified in HC in the previous chapter (Table 4.4). Nonetheless, the majority of ICC values 
fell with the 0.55-0.7 range suggesting good to excellent reproducibility of the 2 techniques. 
Reproducibility was generally good but lower than had been found in healthy controls (table 
4.4). Reproducibility of LSCI was comparable, if not superior, to IRT. The highest ICC values 
were found immediately following cold challenge using LSCI at ROIs 1 and 3 (0.86 and 0.79 
respectively). This suggests a reproducible nadir of digital perfusion to the intensity of the 
cold challenge irrespective of other factors influencing vascular function on the day of 
assessment. The lowest ICC values were recorded for LSCI at 10 and 15 minutes post cold 
challenge (e.g. 0.3 for ROI2 at 15 minutes and 0.34 for ROI at 10 minutes). This may reflect 
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greater variation in digital vascular responses during re-warming in comparison to more 
stable perfusion at baseline (following 20 minute acclimatization) and immediately following 
cold challenge (as discussed above). 
 
Table 5.7. Reproducibility of IRT and LSCI for each ROI at baseline and following cold 
challenge for both primary RP and SSc.  
All data expressed as intra-class correlation coefficients (confidence intervals). B, baseline assessment at 23°C; t0, assessment 
immediately following cold challenge; t5, 5 minutes post-cold challenge etc. All values expressed as ICC (with 95% confidence 




B t0  t5 t10 t15 
ROI 1 




















































5.4.9 Discriminatory capacity IRT and LSCI to differentiate between perfusion at 




LSCI perfusion values were significantly higher at ROIs 1 and 3 compared with ROI 2 for all 
time-points in patients with primary RP (Table 5.5), as was demonstrated in healthy controls 
in the last chapter. This trend was less pronounced in patients with SSc, indicating greater 
similarity in perfusion between glabrous and non-glabrous regions, possibly secondary to 
AVA dysfunction in patients with SSc. Perfusion was also significantly lower at ROI1 
compared with ROI3 at baseline and 10 and 15 minutes post cold challenge in patients with 
SSc, but not primary RP. One possible explanation is that capillary dropout and avascular 
regions at the nailfold in patients with established SSc (such as those typically found on 
nailfold capillaroscopy) leads to lower perfusion at the dorsal aspect of the fingertip compared 
with the palmer aspect in SSc. Patients with SSc experience ulcerative complications on the 
dorsal and palmer aspects of the fingers to an equal extent, leading to uncertainty regarding 




In contrast to healthy controls, patients with SSc had significantly lower skin temperatures at 
the distal ends of the fingers (ROIs 1 and 3) compared to proximal regions (e.g. ROI 2) at 
both baseline and for the majority of assessments post cold challenge (Table 5.5). This 
probably underpins the success of the longitudinal thermal gradient in the diagnostic 
assessment of RP (Schuhfried et al., 2000, Clark et al., 1999, Anderson et al., 2007). Where 
present, significant differences between ROIs 1 and 3 with skin temperature at ROI 2 (e.g. 
baseline assessment for ROI 1) were usually the result of a negative distal dorsal difference 
secondary to lower perfusion at distal regions (as opposed to higher perfusion identified in 
normal subjects). Differences in surface skin temperature between ROI 2 and both ROIs 1 
and 3 in primary RP were less marked (and only following cold challenge), but when present 
also revealed a negative thermal gradient. In contrast to LSCI, there was little difference 
between perfusion assessed using IRT at ROIs 1 and 3 in patients with SSc. In primary RP, 
however, skin temperature was significantly lower at ROI 3 at baseline, t0 and t5 compared 
with ROI 1 despite similar perfusion between these sites at the same time-points using LSCI. 
Potential reasons for these findings are not clear. 
5.4.10 Discriminatory capacity of IRT and LSCI to differentiate between HC, primary 
and SSc 
 
There were significant differences in digital perfusion assessed using IRT between healthy 
controls (Table 5.5) and both primary RP and SSc at all ROIs at baseline and at 10 and 15 
minutes post-cold challenge. The discriminatory capacity of IRT was lost at t0, perhaps 
suggesting the nadir in skin temperature immediately post cold challenge is similar 
irrespective of disease states. The discriminatory capacity of LSCI differs and provides an 
interesting insight into the strengths and limitations of the 2 techniques. LSCI could also 
discriminate between healthy controls and both primary RP and SSc at baseline and during 
reperfusion at ROI 1. The discriminatory capacity of LSCI to distinguish disease states at ROI 
3 was limited to identifying differences between healthy controls and primary RP but, 
interestingly, not SSc. This was due to the unexpectedly higher perfusion at ROI3 in patients 
with SSc compared with primary RP. As had been noted with primary RP, patients with SSc 
had unexpectedly higher perfusion at ROI2 at baseline compared to healthy controls (235 vs. 
126, p=0.035). Another interesting observation using LSCI, when comparing healthy controls 
with primary RP and SSc, was the improved discriminatory capacity of perfusion values at t0 
within glabrous regions (ROIs 1 and 3). Despite similar digital skin temperatures at t0 across 
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disease groups, flux values were significantly greater in healthy controls compared with both 
SSc and primary RP at ROI1, and compared with primary RP at ROI3.  
 
Neither IRT or LSCI was consistently able to discriminate between primary RP and SSc at 
any ROI, either at baseline or following cold challenge (Figure 5.8 for example of LSCI data, 
Table 5.5 for descriptive data). The one exception was perfusion assessed using LSCI at ROI 
2 at baseline, which, paradoxically, was significantly greater in SSc compared with primary 
RP (235fu vs. 124fu, p=0.007) and may have occurred by chance. Digital skin temperature 
assessed using IRT was generally lower in SSc but differences failed to achieve statistical 
significance. 
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Figure 5.8 Differences in LSCI flux values between primary RP and SSc, at baseline and 
following cold challenge.  
RMP = ROI1; RMMP = ROI2 and LMP = ROI3. B, baseline assessment at 23°C; t 0, assessments immediately following 
60s cold challenge at 15°C; t5, perfusion 5 minutes post cold challenge etc. The bold lines indicate the median 





quartiles respectively and equals the range in most instances. Individual outliers are numbered and depicted as 
circles if their value sits between 1.5(IQR) and 3(IQR) of the quartile. Outliers are depicted as stars if their value is 




Significant differences between primary RP and SSc were achieved following a secondary 
analysis of thermographic data when the longitudinal thermal gradient (a modified version of 
the “distal dorsal difference”) was calculated by subtracting the temperature of the skin 
overlying the middle finger MCP with the temperature at ROI1 (Figure 5.9). The limited field of 
view prevented a similar assessment of longitudinal perfusion gradients from being 




Figure 5.9 The discriminatory capacity of the longitudinal thermal gradient at baseline 
and following cold challenge in differentiating between disease states in primary RP 
and SSc.  
The longitudinal thermal gradient was calculated by subtracting the temperature overlying the dorsal aspect of the right middle 
MCP from the temperature from ROI 1. B, baseline assessment at 23°C; t 0, assessments immediately following 60s 
cold challenge at 15°C; t5, perfusion 5 minutes post cold challenge etc. The bold lines indicate the median value 





quartiles respectively and equals the range in most instances. Individual outliers are numbered and depicted as 
circles if their value sits between 1.5(IQR) and 3(IQR) of the quartile.   
 




To my knowledge, this is the first study to simultaneously evaluate subjective and objective 
assessments of digital vascular function in RP and SSc. Whilst many studies have evaluated 
the convergent validity of novel techniques using other established non-invasive 
microvascular imaging modalities, it is surprising that more work has not attempted to 
elucidate determinants of self-report assessment of RP severity and agreement with objective 
assessments of digital vascular function. In this study, I have highlighted some of the pitfalls 
of relying upon patient self-report for the assessment of digital vascular function in patients 
with RP, in addition to building on our previous validation work of LSCI for this purpose.  
 
5.5.1 Limitations of self-report assessment of RP activity in primary RP and SSc 
I have raised specific personal concerns regarding self-report in previous chapters including 
diary fatigue, habituation, and the influence of season and coping strategies adopted by 
patients. Many of these concerns were brought to my attention by patients themselves when 
coaching them on RCS diary completion as part of this study.  
 
I have been able to explore some of these limitations further in this work. For example, there 
is a significant failure rate for completion of the diary (~10%) despite careful tuition of patients 
on completion of the diary at the outset of the study. This issue must be considered when 
calculating sample sizes for studies incorporating the RCS diary. I explored the impact of 
seasonal variation in weather and as expected, I have demonstrated a lower burden of RP 
symptoms (assessed using the RCS score) during Spring/Summer compared with 
Autumn/Winter. This effect of season on self-report assessment of RP severity could be more 
robustly investigated by undertaking paired analysis of RCS diary parameters within the same 
patients 6 months apart. I considered whether our results could be due to selection bias 
caused by more severely affected patients being recruited early in the study (December 
2010). I do not think this was the case. Similar numbers of patients with primary RP and SSc 
were recruited in Autumn/Winter and Spring/Summer. Many patients who expressed an 
interest in the study shortly after our written approach in November 2010 were not screened 
until mid 2011 due to either personal preference and/or delayed recruitment due to the time-
limiting effects of the study design. Furthermore, patients identified at a later stage of the 
recruitment window were also recruited in Autumn/Winter months (Oct 2011-Feb 2012). 
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There was no such association between season and digital perfusion before and following a 
standardized cold challenge assessed using LSCI, which appears to be a major advantage of 
LSCI. There appeared to be an association between season and skin temperature at the 
palmer aspect of the digital pulp assessed using IRT despite a 20 minute acclimatization 
period designed to negate the effects of external temperature on peripheral vascular function. 
The explanation for this finding is unclear but may include subtle differences in core 
temperature affected by season that a 20-minute period of acclimatization period cannot 
eradicate. This did not appear to influence skin temperature at other ROIs, which would 
perhaps favour the use of dorsal digital assessment of vascular function (e.g. ROI 1). The 
inability of some patients to sit for the duration of the cold challenge test with their forearm 
suppinated to allow palmer assessment, and the tendency for the fingers to involuntarily flex 
during assessments, provides additional support for future imaging studies to concentrate on 
the dorsal aspect of the hands during microvascular assessment. There have been conflicting 
results on whether objective assessments of vascular function are influenced by season 
(Klein-Weigel et al., 2003, Gardner-Medwin et al., 2001). Seasonal differences in perfusion of 
the digits assessed using LDF in patients with primary RP has previously been noted 
(Gardner-Medwin et al., 2001). Evaluation of impact of season was not a primary objective of 
my study and my study design was not the preferred method to explore this hypothesis. 
Nonetheless, my findings support those of previous studies that have identified the impact of 
seasonal variation in self-report assessment of RP symptoms (Watson et al., 1999). 
Additional work is required to establish whether the impact of season on objective 
assessment of digital vascular function can be adequately attenuated by an acclimatization 
period and/or pre-test procedures (e.g. local warming) as this would represent an important 
advantage of objective assessment over self-report in future therapeutic trials of RP. 
 
Gender appears to influence RP symptoms with males experiencing significantly fewer 
attacks of RP. This may reflect gender-related differences in completing the diary although 
objective assessment using IRT and LSCI suggests these findings genuinely reflect greater 
perfusion of the digits in males compared with females. There is a well-established female 
predominance for RP, possibly related to differences in temperature homeostasis and the 
influence of sex hormones (Greenstein et al., 1996). No information was collected regarding 
the sex-hormone status of females participating in the study to explore this further. It would 
be important to consider the influence of gender should one consider using absolute values 
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obtained using subjective and objective assessment of digital vascular function as diagnostic 
aids or to guide treatment need or response. 
 
The RCS diary parameters lacked the discriminant capacity to differentiate between primary 
RP and SSc, although the strongly held conviction of most clinicians would argue the degree 
of vascular dysfunction in SSc is greater than in primary RP. Similarly, the RCS diary failed to 
differentiate between patients with SSc with a history of DU/DP and those without. There was 
close agreement between RCS diary parameters and other self-report measures of RP 
activity such as the SHAQ RP VAS. Strong associations were also found between the RCS 
diary parameters and self-report assessment of other organ manifestations that can not easily 
be explained on the basis of disease pathogenesis and associations (e.g. RCS score and 
SHAQ GI VAS, Spearman’s Rho 0.61, Table 5.2). Whilst these associations could be 
genuine, I have encountered this phenomenon in previous work exploring fatigue, quality of 
life and disability in SSc and suspect it reflects patient-specific health beliefs with some 
patients consistently scoring highly in self-report assessment of unrelated aspects of their 
health and vice versa (Strickland et al., 2012). 
 
Finally, I have demonstrated close agreement between IRT and LSCI in the dynamic 
assessment of digital vascular function in RP and SSc, but poor correlation between these 
techniques and patient self-report assessment of RP severity using the RCS diary. To my 
knowledge, this is the first study to establish this. It seems subjective and objective 
assessments provide differing information on digital vascular function. This may account for 
the lack of efficacy of novel potent vasodilatory therapies (such as ERAs) in clinical trials of 
SSc, which have relied upon patient self-reports of RP severity. Use of subjective self-report 
may be appropriate if the sole purpose of such studies is to examine symptomatic efficacy of 
such treatments (e.g. in primary RP) but may fail to identify the potentially disease modifying 
effect that substantial improvements in digital perfusion may exert on ischaemic 
complications and tissue fibrosis in SSc. In this way, the limitations of self-report measures 
such as the RCS diary may be restricting access for patients to effective therapies in the 
management of SSc.  
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5.5.2 Further validation of LSCI and IRT in the assessment of digital vascular function 
in RP/SSc 
I have extended the validation work for LSCI and IRT undertaken in Chapter 4 to the 
assessment of digital vascular function in patients with primary RP and SSc.  
 
Once again, I was able to demonstrate close agreement between IRT and LSCI in the 
assessment of digital perfusion before and following cold challenge. Reproducibility of both 
techniques was good to excellent but lower than in healthy controls. I was surprised to see 
comparable, if not superior reproducibility with LSCI compared with IRT. I had expected the 
greater sensitivity of LSCI to have a negative effect on reliability studies but this was not the 
case. I was not surprised to see lower ICC values in our patient groups compared with 
healthy controls as subjects with healthy circulation would not be expected to demonstrate 
significant variation in digital perfusion under standardized assessment conditions. 
Nonetheless, reproducibility of both IRT and LSCI remained good to excellent in RP/SSc. 
Relatively little work has considered the reproducibility of the RCS diary. One might expect it 
to be excellent over the short term but the influence of seasonal variation highlighted by this 
work would be expected to negatively affect reliability over longer periods. Objective 
assessment of vascular function under standardized conditions may fare better in this regard 
but this needs to be demonstrated in future studies.  
 
Both IRT and LSCI successfully differentiated between healthy controls and disease states. 
Neither IRT nor LSCI, however, could differentiate between primary RP and SSc using the 
ROIs I chose for assessment. In contrast, by adopting the thermographic DDD, I improved 
the discriminatory capacity of IRT and it is possible the discriminatory capacity of LSCI could 
be improved by optimizing the imaging endpoints chosen (perhaps by evaluating flux 
gradients or through composite scores derived from simultaneous assessment of multiple 
digits). It would be preferable to assess perfusion in multiple digits. I was unable to achieve 
this in this study due to the restricted field of view of LSCI and our determination to compare 
perfusion at the volar and dorsal aspect of the fingers. I have previously identified a superior 
discriminatory capacity by using multiple digits over single digits when using IRT to 
differentiate between primary RP and SSc (Pauling et al., 2011b). It would be feasible to 
assess perfusion of all the fingers (excluding thumbs) of one hand using LSCI, which may 
improve the discriminatory capacity of LSCI.  
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I was interested to note the higher perfusion in patients with SSc and a history of DU/DP. This 
may be explained by greater use of vasodilatory therapy and/or the higher proportion of 
males in this group. It is possible that male patients with SSc have a lower threshold for 
developing digital ischaemic complications than women. Alternatively, DU/DP associated with 
localised hypoperfusion may occur in association with normal, or even increased, perfusion of 
surrounding tissues. Asymmetry in digital perfusion is typical of SSc and I have only 
assessed digital perfusion at small regions of interest within individual digits. Additional work 
incorporating a larger number of patients is needed to explore these possibilities further.  
 
This work has considered the application of LSCI to evaluate cutaneous perfusion in AVA-rich 
and AVA-poor regions of the digits. The discriminatory capacity of LSCI in differentiating 
between glabrous and non-glabrous regions was reduced in SSc in comparison with primary 
RP and healthy controls. This was not unexpected and reflects greater similarity in perfusion 
between ROIs due to vascular dysfunction and lower perfusion within glabrous regions. IRT 
did identify differences in perfusion at ROIs 1 and 3 when compared with ROI 2, but in 
contrast to healthy controls, this reflected lower perfusion within the distal glabrous ROIs, 
presumably secondary to AVA dysfunction.  
I have not considered the possible impact of sclerodermatous skin on flux values caused by 
alterations in tissue absorption and reflection following tissue re-modelling (section 1.5.3). We 
are planning further work using LSCI to compare perfusion within areas of sclerodermatous 
skin, unaffected skin, healed DU/DP and active ulceration.  
5.6 Conclusions 
In this chapter, I have highlighted challenges in the assessment of digital vascular function in 
primary RP and SSc. I will discuss the implications of my findings for the future assessment 
of digital vascular function in RP/SSc, both in clinical practice and therapeutic trials in Chapter 
8. It is imperative we develop better methods for assessing peripheral vascular function in RP 
to facilitate improved access to treatment, and better assessment of treatment efficacy, in 
view of the high cost and restricted availability of novel vasoactive drugs, such as ERA, in the 
treatment of SSc. 
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Chapter 6 Platelet function, eicosanoid biosynthesis 
and oxidative stress in primary Raynaud’s 
phenomenon and systemic sclerosis 
 
Among red and white cells small corpuscles are visible, having at the 
beginning the appearance of very delicate and pale erythrocytes. 
They rapidly modify their shape, becoming spinous and adhering to 
the glass...showing a tendency to stick to other similar corpuscles 
and to form aggregates....  
 
Hayem M.G. (1878),  
Recherches sur revolution des hematies dans le sang de I'homme et des vertebres. Arch. 
Physiol. Norm. Pathol. 10: 692-734. 
6.1 Introduction 
In Chapter 1, I reviewed the significant body of evidence that supports enhanced platelet 
activation in RP and SSc. Many of these studies incorporated heterogeneous populations of 
patients with both primary and secondary RP. Whilst SSc formed the large majority of 
patients with secondary RP studied, many studies enrolled patients with other rheumatic 
diseases, often characterised by severe RP, including mixed connective tissue disease 
(MCTD) and systemic lupus erythematosis (SLE). Few studies to date have specifically 
evaluated platelet function in well-characterised cohorts of primary RP and SSc. In this 
chapter, I will report the findings of work evaluating platelet function, eicosanoid synthesis 
and oxidative stress in primary RP and SSc. I shall first provide a description of the various 
methods available for assessing platelet function, which have influenced the design of this 
work. In addition, I shall describe the inter-play between platelet function, eicosanoid 
synthesis and oxidative stress. I shall specifically describe the biosynthesis, biological 
function and pathogenic significance in SSc of a recently discovered family of compounds 
that are important biomarkers of oxidative stress in vivo (F2-isoprostanes).  
 
6.1.1 Assessment and Quantification of Platelet Function  
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Despite the large number of diseases in which excessive platelet activation occurs, there is 
no definitive test of platelet function to facilitate targeted therapy and assessment of treatment 
efficacy. Methods for evaluating platelet function are typically labour intensive, expensive and 
require a degree of technical expertise, which has limited their use, both in therapeutic trials 
and clinical practice. The various laboratory methods available for the assessment and 
quantification of platelet activation and their respective merits and limitations are summarized 
in Table 6.1. 
Table 6.1. Methods for the quantification and assessment of platelet function in 
humans.  





Platelet count and morphology 
           Platelet number 
           MPV 





Bone Marrow examination 
 
 
Platelet aggregometry (e.g. to 








Biomarkers (plasma or urine) 
of platelet activation e.g. vWF, 





Cheap and readily 
available 
 












of platelet function e.g. 
reversible and irreversible 
aggregation 
 
Assessment of platelet 






Only associated with major platelet 
dysfunction e.g. ITP 
 
False positives e.g 




Invasive, non-specific, major 
variability 
 
Invasive and expensive 
 
 
Time consuming, labour intensive, 








Not always specific to platelet 
function (e.g. endothelium derived 
vWF). Affected by anticoagulant (e.g. 
PF-4 and heparin) and renal function 
(e.g. TG) 
 
MPV, mean platelet volume; PDW, platelet distribution width; ITP, idiopathic thrombocytopenic purpura; ADP, 
adenosine diphosphate; AA, arachidonic acid; TG, -thromboglobulin; PF-4, Platelet factor 4; TXB, 
Thromboxane B2; vWF, von Willebrand’s factor; ELISAs, Enzyme Linked Immunosorbent Assays.  
 
Adapted from references (Gurney et al., 2002, Kottke-Marchant and Corcoran, 2002) and elsewhere. 
 
Platelet number, structure and the bleeding time 
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The formation of platelets follows cytoplasmic fragmentation from megakaryocytes and is 
under the control of humoral agents such as thombopoietin. The normal platelet count is 
between 150 and 350x109/L (Kamath et al., 2001). An elevated platelet count 
(thrombocythaemia) can be associated with an increased thrombotic tendency whereas a 
reduction in the platelet count (thrombocytopenia) typically causes increased bleeding 
phenomena.  Quantification of the platelet count is the crudest method for detecting major 
platelet abnormalities but is often normal in primary disorders of platelet function such as 
Glanzmann's thrombasthenia (abnormality in gpIIb/IIIa receptors). For disorders associated 
with normal thrombocytosis, quantification of the bleeding time was the first widely available 
method for detecting inherent platelet dysfunction. The platelet count and bleeding time are 
less useful in those conditions associated with, but not defined by, platelet dysfunction e.g. 
atherosclerosis. In such conditions platelet structure may still provide evidence of platelet 
function. Resting platelets are smooth discoid structures with a diameter of 1-2m and a 
mean cell volume of 5-6 fl (Kamath et al., 2001). The mean platelet volume (MPV) is 
incorporated in automated Full Blood Count (FBC) analysis and is an often overlooked 
parameter despite providing useful information regarding in vivo platelet activation. Activated 
platelets transform from discoid structures to swollen spheres upon activation, increasing 
their apparent size. An increase in MPV has been associated with macrovascular diseases 
such as hypertension, acute myocardial infarction and diabetes (Coban et al., 2005, Park et 
al., 2002, Nadar et al., 2004). The MPV also increases ex vivo in response to collagen and 
hypothermia induced platelet activation (Park et al., 2002). The platelet distribution width 
(PDW) is another measure of platelet size that may provide evidence of platelet activation. 
For example, the PDW is elevated in diabetics following acute coronary events (Hendra et al., 
1988). 
 
Light Transmission Aggregometry 
Light transmission aggregometry (LTA) or platelet aggregometry (PA) was developed by 
Borna in the early 1960’s and quickly regarded as the “gold standard” for platelet function 
testing (Born and Cross, 1963, Born, 1962). The method is simple and has been described in 
further detail previously (section 2.7). LTA is not a direct measure of physiological platelet 
function as it tests platelet activation under low shear stress, in free solution (within platelet 
rich plasma) and does not therefore accurately simulate in vivo haemostasis. Other limitations 
                                               
a
 Gustav V. R. Born (b1921-) is the son of the physicist and Nobel Prize winner Max Born (1882-1970) and uncle 
of the singer Olivia Newton-John. I had the pleasure of meeting Gustav Born at the 2011 UK platelet meeting in 
Cardiff where he recounted tales of spending time with his father’s close friend and colleague Albert Einstein 
before fleeing Nazi Germany with his family prior to the outbreak of WW2.  
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of LTA relate to its labour intensity and logistical difficulties such as the time constraints 
following blood collection. 
 
Platelet membrane glycoproteins 
The outermost layer of the platelet (the glycocalyx) expresses glycoproteins following 
activation. For example, P-selectin translocates from the intracellular granule membrane to 
receptors on the glycocalyx following activation. Increased membrane expression of P-
selectin identified using flow cytometry is a useful marker of platelet activation (Kamath et al., 
2001). Shed plasma soluble P-selectin levels have also been used successfully as markers of 
platelet activation and response to anti-thrombotic medication. For example, sP-selectin 
levels are reduced in hypertensive patients taking aspirin (Nadar et al., 2004, Nadar et al., 
2006, Gurney et al., 2002). Further work is required to investigate the use of assays 
developed to measure other membrane bound and circulating glycoproteins including 
glycoprotein V, glycoprotein Ib, glycoprotein IIb/IIIa and glycocalicin, which may also allow ex 
vivo quantification of platelet activation (Gurney et al., 2002). 
 
Circulating platelet derived mediators 
Platelets release a large array of mediators from intracellular granules and the OCS following 
activation (Table 1.1). Many of these factors (e.g. ATP) are too ubiquitously expressed to be 
seriously considered useful biomarkers of platelet activation (Gurney et al., 2002). Other 
biomarkers are stored but not produced in platelets and hence circulating levels do not 
specific relate to platelet activation (Kamath et al., 2001). For example, serotonin is chiefly 
manufactured in enterochromaffin cells within the gastrointestinal tract. Other granule-release 
products are more platelet-specific and thus form potentially attractive biomarkers for platelet 
activation. Many early studies evaluated plasma levels of platelet factor 4 (PF-4) and -
Thromboglobulin (-TG) as biomarkers of platelet activation. These classical -granule 
proteins are both members of the C-X-C subfamily of chemokines and derived from 
proteolysis of platelet basic protein (Klinger, 1997). One potential consideration where SSc is 
concerned is the effect of renal impairment on circulating levels of -TG and PF-4. There is 
also little evidence of any direct pathogenicity of these chemokines, although it is possible 
they attract leukocytes, and promotes the inflammatory response at areas of endothelial 
damage and secondary platelet activation. The CD40 ligand is potentially of greater interest 
due to its potential contribution to both fibrosis and humoral and cell-mediated immune 
responses in the pathogenesis of SSc (sections 1.4.3 and 1.4.4). Platelets are the major 
reservoir of circulating sCD40L and plasma levels have been used successfully as 
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biomarkers of platelet activation. Similarly, whilst TGF expression is not exclusive to 
platelets and is produced by many cells, platelets are a major source of circulating TGF. 
Indeed, TGF was originally identified in the alpha granules of platelets (Lev et al., 2007). 
Plasma levels of TGF- have been associated with platelet count and aggregability in pre-
eclampsia (Peracoli et al., 2008), and it is plausible that platelets are an important source of 
TGF at sites of vascular injury promoting tissue healing but also helping to drive pro-fibrotic 
signaling and peri-vascular fibrosis in SSc.  
 
Eicosanoid biosynthesis 
Measurement of metabolites of the arachidonic acid pathway is a more established method of 
assessing platelet function. Thromboxane A2 (TxA2), and its more stable metabolite TxB2, is 
the obvious candidate, but others include lipooxygenase (LOX) eicosanoids such as 12-
Hydroxyeicosatetraenoic acid (12-HETE) and the leukotrienes. An important recently 
discovered family of eicosanoids are the F2-isoprostanes, which provide an attractive link 
between oxidative stress, platelet function and eicosanoid biosynthesis. F2-isoprostanes are 
potentially attractive biomarkers of oxidative stress in SSc and may contribute to 
pathogenesis. It is the potential contribution of oxidative stress to the pathogenesis of SSc 
that I shall now divert my attention. 
 
6.1.2 Oxidative stress and its potential contribution to the pathogenesis of SSc 
 
Oxidative stress 
Reactive oxygen species (ROS) are formed as by-products of aerobic metabolism during the 
intermediate steps required to reduce molecular oxygen to water (Sies, 1997). Examples of 
ROS are the superoxide anion (-O2-, one electron reduction state of O2), hydrogen peroxide 
(H2O2) and the hydroxyl radical (-OH). ROS are capable of intense tissue damage, which has 
led to the evolution of a host of anti-oxidant defence mechanisms, which are equally 
important as O2 in the survival of aerobic organisms (Halliwell, 2007). Oxidative stress 
describes an imbalance between ROS and anti-oxidant defence systems that has the 
potential to cause tissue damage (Halliwell, 2007). ROS have potentially beneficial roles such 
as regulation of gene expression and ROS destruction of invading pathogens at sites of 
inflammation, which might explain the evolutionary acceptance to attenuate, rather than 
eliminate, the threat of ROS-mediated tissue damage (Halliwell, 2007, Sies, 1997). Anti-
oxidant pathways include enzymatic catabolism (e.g. superoxide dismutase and catalase) 
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and non-enzymatic micronutrients (e.g. glutathione, carotene, vitamin C and E) capable of 
“scavenging” free radicals from the circulation. Another important scavenger of ROS is the 
potent vasodilator nitric oxide (NO). Exogenous antioxidant treatment in diseases 
characterised by increased ROS formation such as diabetes and coronary heart disease, has 
been shown to enhance endothelium-dependent vasodilatation by potentiating the local 
action of NO which might otherwise have been consumed (Moncada, 2006). 
 
Platelet function, eicosanoid formation and oxidative stress: The F2-isoprostanes 
Platelets are themselves capable of generating ROS, primarily as a result of arachidonic acid 
metabolism by COX and the activation of the platelet isoform of NADPH oxidase (Davi and 
Patrono, 2007). COX products also accelerate the removal of local NO. In addition to ROS 
formation, platelets are themselves activated in environments of oxidative stress. For 
example, ROS can induce lipid peroxidation of cell membrane phospholipids leading to the 
production of compounds such as F2-isoprostanes which, like COX products, are potent 
activators of platelets.  
 
F2-isoprostanes are formed following non-enzymatic free-radical oxidation of arachidonic acid 
(Cracowski et al., 2002b). The process is random and up to four regioisomers (with differing 
side chains) can form, of which up to 8 isomers can exist for each regioisomer i.e. up to 64 
F2-isoprostanes in total, but their biological functions are similar. Their name derives from 
isoprostanes being isomeric to prostaglandins and due to the presence of an F-type 
cyclopentane (prostane) ring. They are attractive biomarkers of oxidative stress owing to the 
fact that levels are not influenced by dietary lipid content, they are stable in urine and levels 
are responsive to changes in oxidative stress following anti-oxidant therapy (Cracowski et al., 
2002b).  
F2-isoprostanes can be measured in serum, plasma and urine. Urinary quantification is the 
preferred method owing to the potential for ex vivo formation and the relatively short half-life 
in blood products. Indeed, F2-isoprostanes were initially discovered as an auto-oxidation 
product of plasma samples stored at -20°C highlighting the propensity for ex vivo lipid 
oxidation. An important consideration when investigating urinary levels of isoprostanes in SSc 
is the presence of renal failure as clearance of isoprostanes is reliant on both renal filtration 
and metabolism. The preferred method for measuring F2-isoprostanes is gas 
chromatography-mass spectroscopy (GC/MS) (Cracowski, 2006). Enzyme linked 
immunoassays have been developed but report lower levels of F2-isoprostanes than for 
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GC/MS owing to their specificity for a limited number of F2-isoprostane isomers (Proudfoot et 
al., 1999).  
Oxidative stress in primary RP and SSc  
Oxidative stress is thought to be an important mechanism of cellular injury contributing to the 
pathogenesis of systemic sclerosis and a number of factors combine to create a highly 
oxidative environment (Gabrielli et al., 2008). Repeated hypoxic and reperfusion injury 
secondary to vascular dysfunction in SSc generate ROS (Simonini et al., 2000). Intravascular 
factors such as monocytes and platelets are thought to contribute a rich source of ROS in 
SSc (Sambo et al., 1999). ROS have been implicated in several key pathogenic pathways in 
SSc including endothelial damage, up-regulation of adhesion molecules, B and T cell 
activation (King et al., 2006), platelet activation (De la Cruz et al., 1992), fibroblast 
proliferation (Mulder, 2000, Erre and Passiu, 2009) in addition to fragmentation of auto-
antigens and auto-antibody formation (Casciola-Rosen et al., 1997). Endothelial cells are 
particularly prone to ROS damage owing to a low capacity to produce free radical scavenging 
enzymes such as catalase (Shingu et al., 1985). These factors are thought to combine to lead 
to a vicious cycle of tissue ischaemia, oxidative stress, endothelial damage, vasoconstriction 
and additional tissue ischaemia (Herrick, 2005). Oxidative stress may be of particular 
importance in the early stages of the disease process, and of greater pathogenic significance 
in lcSSc versus dcSSc (possibly reflecting the greater degree of vascular dysfunction in 
lcSSc) (Simonini et al., 1999). Animal models have demonstrated significant increases in 
smooth muscle ROS production in response to cooling, possibly due to electron leakage to 
O2 and decreased efficiency of ROS scavengers at lower temperatures (Bailey et al., 2005). 
In such models, the administration of exogenous anti-oxidants did not influence alpha 
adrenoceptor vasoconstriction at 37°C, but significantly reduces vascular responses at 28°C 
(Bailey et al., 2005). These findings, which have recently been replicated in humans using 
ascorbic acid, provide an attractive framework linking cold exposure, oxidative stress and 
vascular dysfunction (Yamazaki, 2010). 
 
Levels of circulating scavengers of ROS e.g. ascorbic acid and selenium are lower in primary 
RP and SSc compared with healthy controls, particularly in smokers (Herrick et al., 1994). 
Likewise, levels of native antioxidants such as catalase and superoxide dismutase are also 
reduced in SSc (Balbir-Gurman et al., 2007). 
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F2-isoprostanes have a number of biological functions relevant to SSc including 
vasoconstriction (probably via TxA2 receptor stimulation), mitogenesis, platelet activation, 
immune cell endothelial adhesion, endothelial apoptosis and collagen production in fibrosing 
disorders (Erre and Passiu, 2009, Cracowski and Ormezzano, 2004, Comporti et al., 2008). 
Increased levels of F2-isoprostanes and other markers of lipid peroxidation e.g. 
malondialdehyde have been demonstrated in SSc (Balbir-Gurman et al., 2007, Cracowski et 
al., 2002a, Volpe et al., 2008, Cracowski et al., 2001, Stein et al., 1996) but not primary RP 
(Cracowski et al., 2002a). In addition to inadvertently highlighting the unwanted potential for 
ex vivo artefactual generation of F2-isoprostanes in serum, Ogawa et al. identified 
associations between F2-isoprostane levels and ILD and autoantibody formation that warrants 
further investigation (Ogawa et al., 2006, Cracowski, 2006). 
Use of antioxidants in the management of RP and SSc 
Several studies have evaluated the use of antioxidant therapy in RP and SSc, suggesting 
some benefit on vascular disease in SSc. An early study of oral N-acetyl cysteine (NAC) 
therapy failed to achieve benefit over 1 year, although the study was limited by small study 
numbers (n=11), blunt clinical non-vascular endpoints such as oral aperture and hand spread 
and the potential reduced bioavailability of oral NAC due to extensive first pass metabolism 
(Furst et al., 1979). A subsequent open-label study suggested promising improvements in RP 
severity, digital ulcer count and digital arteriolar perfusion (assessed using plethysmography) 
following intravenous NAC therapy in patients with SSc (Sambo et al., 2001). Denton et al. 
reported superior efficacy of probucol compared with low dose nifedipine in reducing 
Raynaud’s symptoms in patients with both primary RP and SSc (Denton et al., 1999). Herrick 
et al. meanwhile were unable to demonstrate any improvement in RP severity, thermographic 
response to cold stress or markers of endothelial dysfunction following treatment with an 
array of micronutrients, although the potential for carry-over effect following each treatment 
period hampered data analysis (Herrick et al., 2000). Few studies have investigated F2-
isoprostanes levels in therapeutic trials of antioxidants for patients with SSc. A neatly 
designed RCT investigating treatment with vitamin E in SSc evaluated urinary F2-
isoprostanes and LDPI assessment of peripheral vascular function (before and following total 
body cooling) but was unable to demonstrate any differences between treatment and placebo 
groups (Cracowski et al., 2005). 
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Other studies have explored the potential anti-oxidant effects of established vasodilator 
therapy in SSc. For example, treatment with dihydropyridine calcium channel antagonists 
(nifedipine or nicardipine) have been shown to reduce markers of oxidative stress (carbonyl 
residues, advanced oxidation protein products, malondialdehyde and nitrosothiols) in SSc 
(Allanore et al., 2004). It was not known whether this related to a direct antioxidant effect or 
secondary to improved vascular perfusion, although subsequent wok suggested nifedipine 
could directly attenuate monocyte ROS production in SSc (Allanore et al., 2005b). There was 
no reduction in urinary levels of 8-iso-PGF2α (a member of the F2-isoprostane family) after 1 
day (n=4) or 3 days (n=10) following a single infusion of iloprost (Volpe et al., 2008). This 
study enrolled a small number of patients with SSc already incorporated onto a cyclical 
regime of monthly iloprost infusions as part of their disease management creating significant 
potential for carry-over effect (Volpe et al., 2008). In contrast, others have demonstrated 
significant reductions in urinary F2-isoprostane levels following 5 days intravenous iloprost 
therapy in patients with SSc and post hoc analysis suggested the effect was greatest in those 
patients with early lcSSc (Erre et al., 2008). Other studies have demonstrated improvements 
in oxidative status (serum malondialdehyde, and activity of catalase and superoxide 
dismutase) following iloprost therapy in patients with SSc (Balbir-Gurman et al., 2007). 
6.2 Aims and Objectives 
 
The principal aim of this chapter is to explore the relationship between platelet function, 
eicosanoid biosynthesis and oxidative stress in both primary RP and SSc. 
 
The specific objectives of this chapter are to explore: 
1. Explore inter-relationship between platelet number, platelet morphology, plasma 
viscosity, LTA, eicosanoid biosynthesis, plasma biomarkers of platelet activation and 
peripheral microvascular function (using RCS diary, IRT and LSCI) in patients with 
primary RP and SSc 
2. Evaluate differences in platelet number, platelet morphology, plasma viscosity, LTA, 
eicosanoid biosynthesis and plasma biomarkers of platelet activation between 
patients with primary RP and SSc 
3. Evaluate the influence of season on platelet number, platelet morphology, plasma 
viscosity, LTA, eicosanoid biosynthesis and plasma biomarkers of platelet activation in 
patients with primary RP and SSc 
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6.3 Subjects and Methods 
6.3.1 Patient eligibility and recruitment 
The patients were selected from patients recruited to participate in the study reported in 
Chapter 5 (section 5.3). Patients currently taking anti-platelet agents or NSAIDs were 
excluded from the analyses undertaken in this chapter due to the expected effects of such 
treatments on platelet function and eicosanoid biosynthesis. No attempt was made to exclude 
patients taking anti-oxidant treatments due to the pleiotropic anti-oxidant effects of numerous 
drugs.  
 
6.3.2 Study design and endpoints 
The patients were seen at weeks 0 and 2 for cold challenge assessment and clinical 
assessment as described in section 5.3.3. Patients were issued with a universal container at 
their 1st assessment to allow collection of a fasting mid-stream urine collection on the morning 
of their second assessment (as outlined in section 2.5.5). Patients with SSc completed the 
SHAQ at their first assessment and all patients were trained on completion of the RCS diary 
between assessments 1 and 2. At the end of the 2nd assessment patients provided a sample 
of blood as described in section 2.5.1. 
 
Patient demographics and clinical data 
Information was collected from participants (with the help of their medical records) at 
enrollment regarding clinical phenotype, disease duration, age, gender, smoking history and 
medication usage (as described in section 2.3.1). Patients were subsequently divided 
according to season of enrollment into Autumn/Winter (October-March) and Spring/Summer 
(April-September) as described in section 5.3.3.  
 
Platelet number, structure and haemorrheological endpoints 
Automated FBC analysis and PV were evaluated on the day of assessment as described in 
section 2.6.1. The FBC analysis allowed us to assess the platelet count, MPV, PDW and 
plateletcrit (PCT). 
 
Light transmission aggregometry 
LTA using the agonists ADP (working concentrations of 20mol/L 10mol/L, 5mol/L, and 
2.5mol/L) and AA (working concentrations of 1.64 and 0.82 mmol/L) were undertaken as 
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described in section 2.7 using plasma prepared as described in section 2.5. All LTA 
assessments were undertaken within 1 hour of sample collection. 
 
Circulating plasma markers 
Platelet free plasma was prepared as described in section 2.5.4. Plasma levels of human 
soluble P-selectin, human soluble CD40 ligand (sCD40L), and human TGF- were measured 
using separate commercially available ELISAs (R&D systems) as described in 2.8. Plasma 
was stored at -80ºC for batch analysis. 
 
Urinary eicosanoid metabolites 
Urinary levels of the stable metabolite of TxA2 (11-dehydro-TxB2) and prostacyclin (3-dinor-6-
keto-PGF1) were measured in unaltered urine. Urinary F2-isoprostanes were measured in 
urine containing BHT antioxidant to avoid artefactual ex vivo lipid peroxidation following 
collection. The methods for sample collection, preparation and assaying quantifying these 
eicosanoid metabolites are described in full in sections 2.5.5 and 2.9. Urine was stored at -
80ºC before being transferred (in dry ice) to the eicosanoid research laboratory at Nashville, 
Tennessee for batch analysis. 
 
Vascular outcome measures 
Subjective assessment of digital vascular function was undertaken using the RCS diary 
completed between assessments 1 and 2 as described in section 2.3.3. Objective 
assessment of digital vascular function before and after cold challenge was undertaken using 
LSCI and IRT as described in section 2.4. Image analysis was undertaken as described in 
section 2.4.4 using the endpoints described in section 5.3.3. 
6.3.3 Statistical analysis 
All data is presented as median values (and interquartile range [IQR]) unless otherwise 
stated. Correlations were assessed using Spearman’s rank correlation coefficient (rs). 
Categorical data were compared using the Fisher’s exact test. Between group comparisons 
of unpaired data used the Mann Whitney U test. All data was analysed using SPSS version 
18.0. All tests were 2-tailed and a p value of <0.05 was considered statistically significant. 
Despite the large number of individual comparisons, no Bonferroni adjustment correction 
factor was applied to the analyses. Where relevant, I have highlighted significant 
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associations, which may have occurred as a result of type I error and I have guarded against 
over-interpretation of the findings.  
6.4 Results 
6.4.1 Patient recruitment and demographics 
Of 43 patients recruited to the microvascular imaging study described in the previous chapter, 
only 34 were eligible for inclusion in this analysis of eicosanoid biosynthesis and platelet 
function. Five patients were taking anti-platelet agents at enrollment (n=4 aspirin, n=1 
clopidogrel). Two patients were taking regular NSAID therapy. Two patients inadvertently 
took aspirin during the run-in phase precluding any useful analysis of platelet function in this 
study.14 One patient had a supply of meloxicam (an NSAID) for arthritic symptoms but had 
not required this in the 2 weeks prior to or during the study, and was therefore included in the 
analysis.  
 
In total, data was available for 34 patients (17 with primary RP and 17 with SSc). The majority 
of patients with SSc had lcSSc (n=14) with the remaining patients being classified as dcSSc 
(n=2) and lSSc (n=1). The baseline demographics of patients with primary RP and SSc are 
presented in Table 6.2.  
 
The age of onset was significantly lower in the primary RP group as expected (20.5 vs. 35 
years, p=0.03). The groups were otherwise similar for age, gender, vasodilator therapy use 
and smoking history. A similar proportion of patients were recruited in Spring/Summer vs. 
Autumn/Winter. The clinical features of patients with SSc are presented in Figure 6.1. 
  
                                               
14 This emerged on direct questioning at assessment 2 in one patient. In the second patient, platelet 
aggregometry using the agonist AA was highly suspicious of aspirin usage. The patient was contacted and it was 
clarified that the OTC paracetamol preparation she had been taking also contained aspirin. There was a third 
patient in whom aspirin use was suspected due to the appearance of the aggregation curves. She had taken an 
OTC flu-remedy preparation but re-checked its contents and confirmed it had not contained aspirin. 
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Table 6.2 Baseline demographics of group.  
All data expressed as median (IQR) unless otherwise stated. * Mann-Whitney U test for comparing distribution across unpaired 
groups and Fisher’s exact test to compare frequencies of categorical data 
 
 Primary RP Systemic 
Sclerosis 
p value * 











Age in years (IQR) 49.6 (20) 53.6 (19.9) 0.13 
Age at RP onset in years (IQR) 20.5 (24) 35 (13) 0.03 
Age at diagnosis in years (IQR) 42.5 (6) 45 (16) 0.79 
Smoking  (%, unless stated)     
Current 
Ex 



















     Autumn/Winter 









Platelet count (IQR) 269.5 (62.5) 257 (87) 1.00 
Vasodilator therapy (%) 4 (23.5) 8 (47.1) 0.28 
Figure 6.1 Clinical phenotype of patients with SSc.  
lcSSc, limited cutaneous SSc; dcSSc, diffuse cutaneous SSc; lSSc, limited SSc; DU, digital ulceration; DP, digital pitting; GI, 











































Subjective assessment of digital vascular function using the RCS diary was unavailable for 1 
patient with primary RP due to inaccurate completion of the diary and 1 patient with SSc who 
failed to return the completed diary. No analysis (LTA, FBC/PV or plasma biomarkers) was 
available for 1 patient (primary RP) in whom venesection was unsuccessful on first attempt 
and who declined a second attempt of blood collection. No LTA results were available in 
another patient with primary RP in whom the citrated sample for LTA studies clotted during 
collection. Plasma biomarkers and haematological indices were available for this participant. 
The full complement of LTA analyses (all concentrations of ADP and AA) was available for 
21/32 (65.6%) of participants. Of the remaining patients, the majority (7/11, 63.6%) only 
lacked a single concentration analysis (typically due to insufficient PRP [as outlined in section 
2.7.5]). In the remaining 4 patients (12.5%), 2 or more concentrations were missing, typically 
due to insufficient plasma. Urine samples for eicosanoid biosynthesis were available for all 
participants.   
 
6.4.2 Inter-relationship between platelet number, platelet morphology, plasma 
viscosity, LTA, eicosanoid biosynthesis, plasma biomarkers of platelet activation and 
peripheral microvascular function (using RCS diary, IRT and LSCI) in patients with 
primary RP and SSc 
 
The following analyses use pooled data from patients with primary RP and SSc unless stated.  
 
Platelet number, structure and haemorrheological parameters 
There was significant internal correlation between the platelet count and the PCT, MPV and 
PDW (Table 6.3). As expected, the correlation between MPV and PDW was strong (rs 0.94, 
p<0.001). There was no correlation between platelet number or morphology and either the 
parameters of the RCS diary or objective assessment of vascular function using LSCI. An 
interesting relationship between platelet number/structure and thermographic assessment of 
digital vascular function assessed using the DDD (as opposed to individual ROI 
assessments) was identified (Table 6.3). A significant negative correlation between platelet 
count and the DDD immediately following cold challenge (t0) was identified (rs -0.478, 
p=0.006). Significant negative correlations were also identified between the PV and the DDD 
at baseline and at 5, 10 and 15 minutes post-cold challenge (i.e. indicating a higher PV or 
platelet count is associated with lower peripheral vascular perfusion, Table 6.3). Significant 
positive correlations were identified between both the MPV and PDW, and the DDD at 
 168 
baseline and t0 (with strong trends for a similar relationship at t10 and t15, Table 6.3). These 
findings suggest the larger the platelets, the better the digital perfusion, which was contrary to 
our initial hypothesis that increased platelet activation would be associated with more 
profound vasculopathy (further discussion will follow). 
Table 6.3 Correlation between platelet number, structure and PV with the 
thermographic assessment of digital vascular function in primary RP and SSc 
DDD, distal dorsal difference; PDW, platelet distribution width; PCT, plateletcrit; MPV, mean platelet volume; PV, plasma 
viscosity; B, baseline; t0, 0mins post-cold challenge; t5, 5mins post-cold challenge etc. rs, Spearman’s Rho; Sig, significance. 
Significant results are highlighted on bold. n=33 (*n=32) 
 




























































































Light transmission aggregometry studies 
 
There was no relationship between platelet number/morphology and LTA results. Positive 
correlations were, however, identified between PV and the maximum % aggregation to ADP 
20μmol/L (rs 0.441, p=0.019), ADP 2.5μmol/L (rs 0.437, p=0.016) and between PV and 
maximum gradient of aggregation for ADP 2.5μmol/L (rs 0.542, p=0.002) and AA 1.64mmol/L 
(rs 0.545, p=0.006). These findings suggest a possible link between haemorrheological 
factors and intrinsic platelet aggregability. Aggregation to low concentration (2.5-5mol/L) 
ADP was significantly lower in males than females.  For example, the median maximum % 
aggregation to 2.5μmol/L ADP was 27 in males vs. 68 in females (p=0.037). The median 
maximum % aggregation to 5μmol/L ADP was 60 in males vs. 77 in females (p=0.018).  
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There were no consistent correlations between the results of LTA and the individual 
parameters of the RCS diary or objective assessment of digital vascular function using IRT or 
LSCI at individual ROIs. As with platelet number and structure, an interesting trend was 
observed when comparison was made between LTA and thermographic assessment of 
digital vascular function using the DDD (as opposed to individual ROI assessments). Weak, 
but statistically significant negative correlations, were observed between the DDD at both t10 
and t15 post-cold challenge and max % aggregation to ADP concentrations of 20μmol/L and 
10μmol/L (rs between -0.445 to-0.392, p<0.05). These findings suggest more pronounced 




There was a moderate correlation between urinary levels of F2-isoprostanes and urinary 11-
dehydro-TxB2 (rs 0.612, p<0.001, Figure 6.2) and between urinary 2,3-dinor-6-keto-PGF1 and 
11-dehydro-TxB2 (rs 0.537, p=0.001, Figure 6.2). There was no correlation however between 
urinary levels of F2-isoprostanes and 2,3-dinor-6-keto-PGF1 (rs 0.298, p=0.09, Figure 6.2). 
 
There were consistent moderate negative correlations between urinary F2-isoprostanes levels 
and platelet aggregometry to a range of ADP concentrations (Table 6.4). In contrast, there 
was no association between platelet aggregometry using ADP and urinary levels of 2,3-dinor-
6-keto-PGF1 and/or 11-dehydro-TxB2. Similarly, there were no associations between 
eicosanoid biosynthesis and LTA to AA. 
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Figure 6.2 Inter-relationship between urinary eicosanoid levels in patients with SSc and 
primary RP  
Correlation coefficients reported as Spearman’s rho with associated p values. A) F2-isoprostanes vs. 11-dehydro-TxB2, B) 11-




Table 6.4 Correlation between platelet aggregability to ADP and urinary F2-isoprostane 
levels in patients with primary RP and SSc  
(n=34) 
 
 ADP concentration 












































There were some interesting associations between objective assessment of digital vascular 
function and eicosanoid biosynthesis at baseline and immediately following cold challenge 
(Table 6.5) using IRT. For example, there were consistent significant negative correlations 
between IRT assessments (at each ROI before and immediately following cold challenge) 
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and levels of both F2-isoprostanes and 11-dehydro-TxB2 (Table 6.5). Significant correlations 
were also identified for some of the corresponding LSCI assessments (most notably ROI3 at 
baseline, Spearman’s Rho -0.489, p=0.004, Table 6.5). There were fewer significant 
correlations between 2,3-dinor-6-keto-PGF1 levels and assessment of digital vascular 
function using LSCI and IRT (Table 6.5) although possible trends might have been 
strengthened with larger patient numbers.  
 
There was no correlation between urinary levels of F2-isoprostanes or 11-dehydro-TxB2. And 
self-report assessment of digital vascular function (using individual components of the RCS 
diary). Moderate positive correlations were identified meanwhile between urinary levels of the 
vasodilator 2,3-dinor-6-keto-PGF1 with duration (rs 0.418, p=0.017) and frequency (rs 0.492, 
p=0.005) of RP attacks using the RCS diary, which are not easily explained. There was no 
correlation between the overall RCS score and urinary 2,3-dinor-6-keto-PGF1 levels. 
Table 6.5 Relationship between eicosanoid biosynthesis and objective assessment of 
digital microvascular dysfunction at baseline (B) and immediately following cold 
challenge (t0).  
All values reporyed as Spearman’s rho correlation coefficients. LSCI, laser speckle contrast imaging; IRT, infrared 
thermography; rs, Spearman’s rho; ROI, region of interest. B, baseline; t0, immediately following cold challenge. Significant 
results highlighted in bold. 
 
 LSCI IRT 
ROI 1 ROI 2 ROI 3 ROI 1 ROI 2 ROI 3 
























































































Plasma biomarkers of platelet activation 
There was a significant positive correlation between plasma levels of TGF- and sCD40L (rs 




There were moderately positive correlations between levels of sP-selectin and the platelet 
count (rs 0.497, p=0.003) and PCT (rs 0.482, p=0.004). There were no associations between 
platelet number and/or structure with circulating levels of sCD40L or TGF-. A positive 
correlation was identified between PV and levels of sCD40L (rs 0.404, p=0.02), which may 
reflect the importance of sCD40L in adaptive immune function and inflammation.   
 
There was no consistent relationship between the plasma biomarkers and LTA. Significant 
positive correlations were identified between sCD40L and both 2,3-dinor-6-keto-PGF1 (rs 
0.449, p=0.009) and 11-dehydro-TxB2 (rs 0.436, p=0.011). Plasma TGF- levels correlated 
with both F2-isoprostanes (rs 0.404, p=0.02) and 11-dehydro-TxB2 (rs 0.519, p=0.002). There 
were no associations between circulating sP-selectin levels and urinary eicosanoid levels. 
 
There was no correlation between plasma biomarker levels and subjective (RCS diary) or 
objective (IRT and LSCI) assessment of peripheral vascular function. 
 
6.4.3 Evaluate differences in platelet number, platelet morphology, plasma viscosity, 
LTA, eicosanoid biosynthesis and plasma biomarkers of platelet activation between 
patients with primary RP and SSc 
 
Platelet number, platelet morphology and plasma viscosity 
The platelet count did not differ between primary RP and SSc (median 269.5 vs. 257, 
p=1.00). Similarly, there were no differences in platelet structure assessed using the mean 
platelet volume (MPV, p=0.326), platelet distribution width (PDW, p=0.217) or plateletcrit 
(PCT, p=0.465) between primary RP and SSc. The plasma viscosity (PV) was higher in SSc 
than primary RP (median [IQR] 1.7 [0.15] vs. 1.6 [0.11], p=0.006). There was a trend for 
higher platelet counts in patients with SSc with a history of DU (median 301.5 vs. 254, 
p=0.078). The MPV (median 9.5 vs. 10.7fL, p=0.005) and PDW (median 10.5 vs. 12.2, 
p=0.01) were significantly lower in patients with SSc with a history of DU. There were similar 
trends for the platelet count (p=0.088) and MPV (p=0.07) in patients with SSc and a history of 
digital pitting. No other associations between clinical phenotype in SSc and platelet 




Light transmission aggregometry 
Examples of aggregometry traces following addition of varying concentrations of the agonist 
ADP in a patient with primary RP and a patient with SSc are presented in Figure 6.3. 
 
Platelet aggregation (Maximum % aggregation and % aggregation at 5 minutes) was 
significantly higher in SSc compared to primary RP to low to medium working concentrations 
(2.5mol/L-10mol/L ADP) of ADP (p<0.05 for all comparisons, Table 6.6). Percent 
aggregation to high concentration ADP (20mol/L) and AA (1.64 and 0.82mmol/L) did not 
differ between groups, possibly representing a supramaximal dosing effect (i.e. these doses 
precipitated maximal aggregation in both patient groups redcuing the discrimatory capacity of 
the test). The maximum gradient of aggregation did not generally help differentiate between 
patients groups, with the exception of 1.64mmol/L AA, which was significantly greater in SSc 
compared with primary RP (41 vs. 36 respectively, p<0.05). 
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Figure 6.3. Examples of aggregometry curves from a patient with primary RP and a patient 
with SSc using serial decreasing working concentrations of ADP agonist 
1=20 μmol/L; 2=10 μmol/L; 3=5 μmol/L and 4=2.5 μmol/L respectively. Traces in A are derived from a patient with primary RP. 
Traces in B are derived from a patient with SSc. Note the rapid extensive primary waves of aggregation in the patient with SSc to 
all concentrations of ADP. At the lowest concentration of 2.5μmol/L there are distinguishable primary and secondary waves of 
aggregation (representing initial aggregation to ADP and a secondary wave following platelet granule release). In the patient with 
primary RP, meanwhile, there is a lower degree of aggregation to lower concentrations of ADP with reversal of the primary wave 
of aggregation at 2.5μmol/L due to failure to stimulate granule release and subsequent de-aggregation during the 5-minute 





Table 6.6 Outcome of platelet aggregometry to varying concentrations of adenosine 
diphosphate (ADP) and arachidonic acid (AA) in primary RP and SSc 
Max%, maximum % aggregation during 5 minutes post agonist; % 5 mins, % aggregation after 5 minutes post agonist; Gmax, 





 p<0.05 vs. primary RP; * p=0.089 vs. primary RP 
 
  
Agonist and concentration 
  Adenosine diphosphate Arachidonic acid 
  20 μmol/L 10 μmol/L 5 μmol/L 2.5 μmol/L 1.64mmol/L 0.82mmol/L 
Max % SSc 80 (9) 79 (7) 
†
 78 (10) 
†
 69.5 (29) 
†
 81.5 (7) 76 (8) 
 1° RP 75 (10) 74 (12) 69 (17) 40.5 (45) 80.0 (12) 79 (16) 






81.5 (7) 76 (8) 
 1° RP  75 (10) 74 (12) 69 (17) 40.5 (54) 80 (12) 79 (16) 





1° RP  42 (12) 39.5 (15) 32 (5) 21.5 (7) 36 (10) 40 (12) 
 
Eicosanoid biosynthesis 
Urinary levels of 11-dehydro-TxB2 (medians 425 vs. 382 pg/mg creatinine [Cr], p=0.26), 3-
dinor-6-keto-PGF1 (160 vs. 122 pg/mg creatinine, p=0.079) and F2-isoprostanes (1.00 vs. 












Figure 6.4 Eicosanoid biosynthesis in SSc and primary RP 
A) levels of urinary 11-dehydro-TxB2, B) levels of urinary 2,3-dinor-6-keto-PGF1 and C) levels of urinary F2-isoprostanes 
 
The bold lines indicate the median value and boxplots indicate IQR. The whiskers reveal range of data points that 




 quartiles respectively and equals the range in most instances. Individual 
outliers are numbered and depicted as circles if their value sits between 1.5(IQR) and 3(IQR) of the quartile. 





Circulating plasma biomarkers of platelet activation 
Circulating sCD40L was higher in SSc compared to primary RP although this trend failed to 
achieve statistical significance (median 62 vs. 52.3pg/ml, p=0.087). Levels of TGF- and sP-
selectin did not differ between patients with primary RP and SSc (Table 6.7).  
 
Table 6.7 Circulating plasma biomarkers of platelet activation in primary RP and SSc 
All values expressed as median (IQ range). Mann Whitney U test used for between group comparisons. 
 
 Primary RP SSc p value (primary RP 
vs. SSc) 
TGF- (pg/mL) 2177.4 (2048.3) 2540.9 (3193.3) 0.488 
sCD40L (pg/mL) 52.3 (20.7) 62 (33.2) 0.087 




6.4.4 Evaluation of the influence of season on platelet number, platelet morphology, 
plasma viscosity, LTA, eicosanoid biosynthesis and plasma biomarkers of platelet 
activation in patients with primary RP and SSc 
 
There was no relationship between season of enrollment and either PV, platelet number, 
platelet morphology, LTA studies or circulating plasma biomarkers of platelet activation.   
Urinary levels of F2-isoprostanes were significantly greater in patients enrolled in the 
Autumn/Winter months compared with Spring/Summer (median 1.255 [IQR 0.435] vs. 0.70 
[0.51] ng/mg Cr, p=0.001, Figure 6.5A). Similarly, urinary 11-dehydro-TxB2 levels were also 
greater in the Autumn/Winter (466.5 (206) vs. 348.5 (133) pg/mg Cr, p=0.025, Figure 6.5B). 
Urinary levels of 2,3-dinor-6-keto-PGF1 meanwhile were not influenced by season (133.5 
(91) vs. 156.5 (98) pg/mg creatinine, p=0.96). 
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Figure 6.5 Influence of season on eicosanoid biosynthesis.  
A) Influence of season on F2-isoprostane formation and B) Influence of season on thromboxane formation. 
 
BThe bold lines indicate the median value and boxplots indicate IQR. The whiskers reveal range of data points 




 quartiles respectively and equals the range in most instances. Individual 
outliers are numbered and depicted as circles if their value sits between 1.5(IQR) and 3(IQR) of the quartile. 







This is the first study to simultaneously explore a range of methods for assessing platelet 
activation, incorporating assessments of eicosanoid biosynthesis and oxidative stress, in 
patients with primary RP and SSc. In addition to replicating the findings of previous studies 
such as those demonstrating increased platelet aggregability in SSc, we have also identified 
some novel associations that help inform our understanding of the contribution of platelets 
and oxidative stress in the pathogenesis of SSc. I shall discuss the relevance of these novel 
findings, in the context of previous work, in further detail here. 
6.5.1 Platelet number and morphology in primary RP and SSc 
 
We were unable to identify any differences in platelet count or morphology between primary 
RP and SSc. A higher total platelet count in whole blood has been identified from patients 
with the CREST variant of SSc compared with healthy controls (Price et al., 1991). In this 
study, the MPV and PDW did not differ between SSc and healthy controls (Price et al., 1991). 
In contrast, a recent study has demonstrated an increased MPV in primary RP compared with 
healthy controls (Shemirani et al., 2012). We did not assess platelet structure in healthy 
controls but did not identify any differences in platelet count or platelet morphology between 
patients with primary RP and SSc.  
 
The relationship between platelet count/morphology and objective evidence of digital vascular 
dysfunction using both IRT and a history of DU, was contrary to my original hypothesis that 
an increase in platelet size would provide evidence of in vivo activation of platelets and their 
contribution to vascular dysfunction in primary RP and SSc. It may be that we harvested 
“exhausted” platelets (i.e. smaller) from participants with severe vascular disease in whom 
platelet activation had already occurred. The local cold challenge assessment may have 
contributed to this (Park et al., 2002). There were 2 reasons for undertaking venesection 
following the cold challenge. Firstly, we did not want the physical trauma relating to 
venesection to interfere with the acclimatization period prior to vascular assessment. We also 
wanted to minimize the period between venesection and sample processing for both LTA 
studies and the storage of plasma to prevent ex vivo platelet activation. Further work is 
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needed to explore the determinants of abnormal platelet structure and effects of local cold 
exposure in larger numbers of patients with primary RP and SSc.  
 
6.5.2 Light Transmission Aggregometry in primary RP and SSc 
 
Many studies have identified increased platelet aggregability in both primary RP and SSc 
when compared with healthy controls, to a panel of agonists including adrenaline (Hutton et 
al., 1984), ADP (Wilkinson et al., 1989, Cuenca et al., 1990, Lau et al., 1993), collagen 
(Goodfield et al., 1988, Wilkinson et al., 1989, Lau et al., 1993, Goodfield et al., 1993), 
serotonin (5-HT) (Beretta et al., 2008, Biondi and Marasini, 1989) and AA (Reilly et al., 1986). 
Many of these studies incorporated a heterogeneous mix of patients and only a few studies 
have specifically compared platelet aggregation in patients with primary RP and SSc and 
have resulted in conflicting results (Cuenca et al., 1990, Biondi and Marasini, 1989, Wilkinson 
et al., 1989).  
 
We have demonstrated greater aggregation of platelets to ADP in patients with SSc 
compared with primary RP, which supports the findings of earlier studies (Cuenca et al., 
1990, Biondi and Marasini, 1989). We did not identify differences in LTA to AA, possibly due 
to a ceiling effect arising from the concentrations we chose for analysis. The discriminatory 
capacity of ADP in differentiating between primary RP and SSc was better for lower working 
concentrations of ADP. The single study to solely compare primary RP with healthy controls 
failed to identify differences in aggregation to the agonists AA, ADP and Platelet Activating 
Factor (Dowie et al., 1990). We did not collect data on healthy controls to explore this further. 
We did not extend our work to include functional studies to establish why in vitro platelet 
aggregation to ADP under low shear stress was higher in SSc compared with primary RP. 
The underlying cause for this may be due to inherent differences in platelet ADP responses 
between disease states or different plasma constituents (e.g. thromboxane and thrombin 
levels) leading to enhanced aggregatory responses to ADP. The trend for higher urinary 
levels of 3-dinor-6-keto-PGF1 in SSc compared to primary RP suggests dampening of ADP 
signaling via PGI2 induced cAMP formation was not the cause of increased aggregation to 
ADP (Figure 1.4).  Future functional studies could evaluate the possible contribution of 
extracellular platelet activators (e.g TxA2) and/or inhibitors (e.g. adenosine). Studies 
exploring selective blockade of the intracellular signaling pathways down stream of P2Y1 and 
P2Y12 receptors (summarized in Figure 1.4) may help to establish evidence of inherent 
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differences in platelet function to account for increased aggregation to low concentration ADP 
in SSc.   
 
The impact of gender on platelet aggregation to agonists including ADP has been noted 
previously in healthy controls but this is the first study to demonstrate this in patients with RP 
(Becker et al., 2006, Otahbachi et al., 2010). The association between LTA and PV we 
identified may be the result of elevated fibrinogen levels in SSc which can influence both 
platelet aggregability and PV (Meade et al., 1985, Landolfi et al., 1991). Further work would 
be needed to explore this hypothesis. 
 
The association between platelet aggregation and peripheral vascular function following local 
cold challenge has not been identified previously. The strength of the association was weak 
but deserves further consideration as it provides an attractive pathological framework linking 
platelet dysfunction, cold exposure and digital vascular function in RP, particularly in the 
context of SSc. The association we have identified also highlights an additional potential 
advantage of the DDD over absolute assessments at individual ROIs (as was noted in the 
chapter 5 when exploring the discriminatory capacity of the DDD vs. individual ROIs in 
differentiating primary RP and SSc).  
 
6.5.3 Eicosanoid biosynthesis in primary RP and SSc 
 
We did not identify any differences in urinary 11-dehydro-TxB2 levels between primary RP 
and SSc. No previous studies have compared thromboxane biosynthesis between patients 
with primary RP compared with SSc. Plasma TxB2 levels are higher in SSc compared with 
HC (Herrick et al., 1996, Wilkinson et al., 1989) but studies evaluating plasma levels of TxB2 
in primary RP have not identified differences compared with healthy controls (Dowie et al., 
1990). We might therefore have expected to see a difference in thromboxane synthesis 
between primary RP and SSc in our study.  Urinary levels of 2-3 dinor TxB2 (a stable urinary 
metabolite of TxB2) are elevated in SSc compared with HC, and rise in response to total body 
cooling (Reilly et al., 1986). We did not explore the effect of total body cooling but have 
identified higher 11-dehydro-TxB2 levels in Autumn/Winter compared with Spring/Summer. 
This has not previously been investigated but provides a tantalizing glimpse into the potential 
relationship between season and platelet function, as well as potentially highlighting the 
importance of patients with RP in maintaining their core and peripheral temperatures during 
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the colder months to avoid excessive platelet activation. Previous work suggests local cooling 
(forearm and hand) does not have the same influence on TxA2 biosynthesis in SSc (Hutton et 
al., 1984, Sakamoto et al., 1999, Mikhailidis et al., 1986). 
 
Measurement of metabolites of TxB2 in plasma compared to urine may tell us more about the 
degree of platelet activation that occurs within the peripheries. Sampling blood collected from 
the antecubital fossa will yield venous blood from the hands and digits where peripheral 
activation of platelets secondary to cold exposure and/or endothelial damage may have 
occurred.  Measuring urinary metabolites however provides a more accurate assessment of 
total TxB2 formation. The present study was not designed to explore this hypothesis.  
 
Previous work has identified higher levels of urinary 11-dehydro-TxB2 and F2-isoprostanes in 
SSc compared with healthy controls but failed to identify a significant correlation between the 
2 biomarkers (Cracowski et al., 2001). We did identify a strong correlation between urinary 
F2-isoprostanes and 11-dehydro-TxB2. This provides evidence of the association between 
platelet function and oxidative stress that was discussed in section 6.1.2. The significant 
negative correlations we identified between urinary F2-isoprostane levels and LTA to ADP is 
not be easily explained. 
  
We identified a strong trend for higher urinary 2,3-dinor-6-keto-PGF1 in SSc compared with 
primary RP. A trend of this nature was previously noted in a study by Reilly et al. who 
reported higher urinary levels of 2,3-dinor-6-keto-PGF1 in SSc compared with healthy 
controls (Reilly et al., 1986). In their study, levels of 2,3-dinor-6-keto-PGF1 rose in response 
to total body cooling which the authors postulated was secondary to a platelet-vascular 
interaction. In contrast to urinary 11-dehydro-TxB2 and F2-isoprostanes, levels of 2,3-dinor-6-
keto-PGF1 were not influenced by seasonal variation. 
 
In contrast to work by Cracowski et al., we did not identify higher levels of urinary F2-
isoprostanes in SSc compared with primary RP (Cracowski et al., 2002a). F2-isoprostane 
levels were higher in the Autumn/Winter possibly due to increased oxidative stress secondary 
to ischaemia/reperfusion injury. This has not previously been demonstrated and provides 
interesting insight into the potential relationship that may exist between seasonal variation in 
temperature and oxidative stress.  
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Perhaps our most interesting findings were the relationship between eicosanoids and 
peripheral vascular function. This is the first study to demonstrate a negative correlation 
between urinary levels of both F2-isoprostanes and 11-dehydro-TxB2, (both powerful 
vasoconstrictors) with digital perfusion assessed using IRT. This needs to be further 
investigated in larger numbers of patients. In the next chapter, we shall explore whether anti-
platelet therapy has the potential to augment the relationship between platelet function and 
peripheral vascular tone to promote vasodilation in patients with RP and SSc.  
6.5.4 Plasma biomarkers 
 
The choice of plasma biomarkers in this study was not restricted to molecules with a high 
specificity to platelets. Only soluble P-selectin has a significant degree of platelet specificity 
whereas sCD40 and TGF- are produced by several cell types. Nonetheless, the major 
source of circulating levels of all 3 molecules is platelets and each has previously been used 
as a biomarker of platelet activation. The close correlation between sCD40L and TGF- 
suggests common pathways for expression and release of these mediators, although the lack 
of correlation of sCD40L and TGF- with circulating plasma levels of sP-selectin, platelet 
number and platelet morphology would suggest platelets may not be the primary source of 
these biomarkers in RP and SSc. Both sCD40L and TGF- did, however, correlate with 11-
dehydro-TxB2 biosynthesis which may provide evidence of platelet activation contributing to 
the circulating levels of these biomarkers.  
 
Several studies have identified higher circulating levels of the soluble form of P-selectin (sP-
selectin) in SSc compared with healthy controls (Olewicz-Gawlik et al., 2010, Blann et al., 
2003, Sfikakis et al., 1999, Iannone et al., 2008, Gruschwitz et al., 1995). We were unable to 
demonstrate a difference in circulating levels of sP-selectin between SSc and primary RP. 
Previous studies have not identified increased P-selectin expression in primary RP although 
platelet-monocyte and platelet-neutrophil interactions were enhanced in both primary RP and 
SSc compared with healthy controls ((Pamuk et al., 2007). We did identify associations 
between sP-selectin levels and both platelet number and structure in RP and SSc. 
 
We were unable to demonstrate higher circulating TGF- in patients with SSc compared with 
primary RP. There have been conflicting reports as to whether circulating levels of TGF- ß 
are elevated in SSc compared with healthy controls (Dziadzio et al., 2005, Solanilla et al., 
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2009, Snowden et al., 1994). Further work incorporating larger number of patients is required 
to evaluate circulating TGF- levels and possible disease associations in SSc. 
 
Increased circulating sCD40L levels have been identified in the plasma and serum of patients 
with SSc (Allanore et al., 2005a, Komura et al., 2004). Elevated levels of sCD40L have been 
associated with early disease course in lcSSc (Komura et al., 2004) and a more vascular 
phenotype (PAH and DU disease) (Allanore et al., 2005a). We were unable to demonstrate 
any association between sCD40L levels (or levels of TGF- and sP-selectin) with objective or 
subjective assessments of peripheral vascular function in primary RP and SSc. This is the 
first study to specifically compare levels of sCD40L in patients with primary RP and SSc, and 
there was a strong trend to suggest levels of sCD40L were higher in SSc. We did not identify 




The chief limitation of this study is the relatively small cohort size. Approximately one quarter 
of patients recruited to the microvascular imaging study were already taking anti-platelet 
medication or NSAIDs, which precluded any useful assessment of platelet function.  
6.6 Conclusions 
In this chapter, I have reported the most comprehensive study of platelet function and  
eicosanoid biosynthesis in patients with primary RP and SSc. I have identified several novel 
areas of interest that may have important translational therapeutic implications and need to 
be explored further in larger studies of this kind. I shall further discuss the implications of our 
findings in the context of future work in Chapter 8.  
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Chapter 7 Evaluating the effects of asasantin retard 
on platelet function, oxidative stress and peripheral 
vascular function in primary Raynaud’s phenomenon 
and systemic sclerosis 
 
“In its more aggravated forms diffuse scleroderma is one of the most 
terrible of all human ills. Like Tithonus,a to “whither slowly”, and like 
him to be “beaten down and marred and wasted” until one is literally a 
mummy, encased in an ever-shrinking, slowly contracting skin of 
steel, is a fate not pictured in any tragedy, ancient or modern.”  
 
William Osler, 1898 
Journal of cutaneous genito-urinary diseases 
 
7.1 Introduction 
In previous chapters, I have outlined the potential contribution of platelets to peripheral 
vascular dysfunction in primary RP and SSc. I have also reviewed the evidence to support 
the contribution of platelets to dysregulated immune function and fibrosis in the context of 
SSc. A major contributory factor to the largely disappointing outcomes of previous therapeutic 
trials of anti-platelet agents in primary RP and SSc was the lack of sensitive validated 
endpoints for assessing digital vascular function. A large (multicentre) placebo-controlled 
RCT using a validated patient reported outcome measure of RP severity (such as the RCS 
diary) may be the preferred method for establishing the benefits of anti-platelet therapy on the 
frequency, duration and severity of RP attacks in primary RP, where the chief goal of therapy 
is arguably to improve subjective peripheral vascular function. This approach may not be the 
preferred method for evaluating the effects of anti-platelet agents in SSc for the following 
reasons. Firstly, in chapter 5 I demonstrated the lack of agreement that exists between the 
RCS diary parameters and objective peripheral microvascular assessment. This may lead to 
                                               
a
 Tithonus was granted immortality by Zeus at the request of his lover Eos, but she failed to request eternal youth. 
Tithonus indeed lived forever but “when loathsome old age pressed full upon him…he could not move nor lift his 
limbs…..and no more has strength at all, such as once he had in his supple limbs” (Homeric Hymn to Aphrodite)   
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a type 2 error and failure to identify potentially disease-modifying improvements in vascular 
function (e.g. on frequency of DU) by subjective assessment of vascular function alone. This 
can be illustrated by the contrasting findings of previous studies of ERA therapy in SSc 
described in chapter 5. I have previously highlighted additional specific limitations of self-
report assessment of RP severity in the context of SSc; most notably habituation and difficulty 
discerning discreet RP attacks from persistent vasculopathy secondary to irreversible 
changes in vascular morphology. Finally, restricting the evaluation of anti-platelet agents in 
SSc to peripheral vascular function alone fails to consider the potential beneficial effects of 
anti-platelet therapy on immune dysfunction and fibrosis in SSc. Consequently, the optimal 
study design for a therapeutic trial of anti-platelet agents in SSc would require a long-term 
(over several years), large (multicentre) RCT incorporating validated objective peripheral 
microvascular imaging endpoints and quantifiable objective clinical biomarkers of end-organ 
dysfunction (e.g. the forced vital capacity to assess lung function, frequency of DU, mean 
pulmonary artery pressure on right heart catheterization etc.). There is a fear amongst 
clinicians that such studies will never be undertaken in SSc due to the lack of industry support 
for trials exploring the pleiotropic effects of established, low-cost therapies. The challenges in 
demonstrating treatment efficacy using anti-platelet agents can be illustrated by considering 
the original RCTs that were undertaken to evaluate the efficacy of asasantin retard in the 
secondary prevention of stroke (ESPS-2 and PRoFESS studies) which necessitated 
recruitment of over 26,000 patients with established cerebrovascular disease.  
 
Despite a lack of supportive evidence, recommendations are beginning to emerge to support 
the pragmatic use of low-dose aspirin in the management of SSc patients with severe digital 
ischaemia (Wigley, 2012). Whilst acknowledging the strong therapeutic rationale for using 
anti-platelet agents for vascular manifestations of SSc, this approach fails to consider the 
potential anti-inflammatory and anti-fibrotic benefits of anti-platelet agents. It also fails to 
consider the potential enhanced therapeutic potential of alternative anti-platelet agents 
beyond COX inhibition, or the combined use of low-dose aspirin and other anti-platelet 
agents, which have proved so effective in the management of atherosclerotic disease. These 
issues could be addressed by first undertaking proof-of-concept studies to establish the anti-
platelet agent, or combination thereof that warrant further evaluation. There are 2 approaches 
by which this could be achieved. Experimental animal models of SSc (namely genetic or 
chemically induced forms of fibrosis) offer one potential avenue to explore the anti-fibrotic 
effects of anti-platelet therapy. This approach was successfully adopted in the study by Dees 
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et al. described in section 1.4.5 which identified a potential role for clopidogrel in reducing 
serotonin-induced dermal fibrosis in genetic and chemically-induced experimental models of 
fibrosis (Dees et al., 2011). The slowly progressive nature of skin and organ fibrosis in SSc, 
along with the challenges in quantifying fibrosis, would necessitate a large long-term study to 
demonstrate such an effect in human trials of SSc. The chief limitation of experimental 
models of fibrosis is the extent to which the findings of such work can be translated into 
humans. Murine models attempting to reproduce the vascular changes of SSc are under 
development and may play a more prominent role in biological proof-of-concept studies of 
vasoactive drugs in the future (Maurer et al., 2009). With the emergence of sensitive 
microvascular imaging techniques, there is greater enthusiasm to evaluate novel vasoactive 
medications by undertaking short-term proof-of-concept clinical trials in humans (e.g. 
(Herrick, 2012)). Small early-phase exploratory studies lack the power to draw conclusions on 
safety and efficacy but facilitate the incorporation of complex endpoints that would be 
unfeasible in large multicentre studies. This approach may reduce the number of novel 
compounds being evaluated in expensive phase 3 trials, which contributes so greatly to the 
high cost of novel therapies being licensed for use in humans. In this chapter I shall adopt 
such an approach to evaluate the effects of anti-platelet therapy in primary RP and SSc but 
before undertaking such work, I first had to consider the most appropriate anti-platelet agent, 
or combinations thereof, to investigate.   
7.2 Anti-platelet agent(s) with the greatest therapeutic 
potential in primary RP and SSc 
The ideal exploratory study of anti-platelet agents would use varying doses of several 
individual anti-platelet agents and combinations thereof. Such an approach would not be 
feasible in an orphan disease such as SSc and has forced us to consider the most attractive 
anti-platelet agent, or combination of agents, for further evaluation based on their biological 
action. Some agents were immediately excluded due to low future feasibility. For example, 
the non-peptide inhibitors of glycoprotein (GP) IIb/IIIa receptors (e.g. tirofiban and abciximab) 
are effective anti-platelet agents but require parenteral administration. This has limited their 
role to the acute management of coronary events and they could never be seriously 
considered for the management of chronic diseases such as SSc. Aspirin is the most 
established anti-platelet agent, irreversibly acetylating platelet COX, inhibiting the production 
of TxA2 and preventing further platelet activation. In view the potent vasoconstrictive 
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properties of TxA2 and previous work exploring endothelial dependent vasodilator effects of 
aspirin in primary RP (Easter and Marshall, 2005), we were keen to include aspirin therapy in 
this study. Using aspirin in combination with other agents enhances the effects of aspirin. For 
example, combining aspirin with the P2Y12 receptor antagonist clopidogrel enhances the 
efficacy of aspirin in the early secondary prevention of acute coronary events. I have 
previously discussed a potential anti-fibrotic role for clopidogrel in SSc (Dees et al., 2011) and 
it has been suggested clopidogrel increases the bioavailability of NO which may have 
vasoprotective effects in SSc (Heitzer et al., 2006). The combination of aspirin and 
clopidogrel, however, increases the risk of gastrointestinal (GI) bleeding (Diener et al., 2004); 
a major consideration in SSc which itself can be associated with indolent GI bleeding. 
Furthermore, the principle mode of action of clopidogrel would not be expected to exert 
vasoactive effects that would necessarily improve vascular outcomes in primary RP and SSc. 
In contrast, the adenosine reuptake inhibitors (e.g. dipyridamole) directly promote 
vasodilation in addition to other pleiotropic effects, which may be beneficial in RP, particularly 
in the context of SSc (Kim and Liao, 2008). Dipyridamole inhibits the nucleoside transporter 
responsible for the uptake of adenosine. Adenosine is released by endothelial cells and 
platelets as a breakdown product of ATP and is a potent vasodilator and powerful inhibitor of 
platelet aggregation. Dipyridamole also selectively inhibits phosphodiesterase reducing 
platelet activation (by increasing intra-platelet levels of cAMP) and promoting vasodilation 
(both through potentiating the local action of NO and inhibiting phosphodiesterase-mediated 
degradation of cGMP which itself promotes relaxation of vascular smooth muscle cells). 
Other phosphodiesterase inhibitors (e.g. cilostazol) have been used specifically for their anti-
platelet actions. Additional effects of dipyridamole include increased endothelial production of 
prostacyclin (a vasodilator), antioxidant properties and anti-inflammatory actions including 
inhibition of the monocyte-platelet interaction and reduced recruitment and activation of 
neutrophils and lymphocytes to sites of injury (Kim and Liao, 2008). Forearm vascular 
resistance studies suggest the vasodilatory properties of dipyridamole can be explained more 
by the potentiation of the adenosine mechanisms rather than via NO or other cGMP-mediated 
actions (Gamboa et al., 2005). Dipyridamole may also reduce fibrosis by inhibiting TGF--
induced transdifferentiation of fibroblasts to myofibroblasts through NO-cGMP pathways 
(Dunkern et al., 2007). Dipyridamole has also been shown to reduce PDGF levels in the sera 
of patients with SSc (Takehara et al., 1987).  
The co-administration of dipyridamole with aspirin (asasantin retard) increases the protective 
effect of aspirin in secondary prevention of stroke (Diener et al., 1996). Asasantin retard 
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contains a combination of aspirin 25mg and modified release dipyridamole 200mg. It is 
generally safe and well tolerated, and the bleeding rate is not significantly higher than that 
observed with aspirin as monotherapy, unlike other combinations of anti-platelet agents, e.g. 
clopidogrel plus aspirin (Diener et al., 2004, Diener et al., 1996). 
As discussed in Chapter 1, the combination of aspirin and dipyridamole has been evaluated 
previously in primary RP and SSc with disappointing results (van der Meer et al., 1987, 
Beckett et al., 1984). Neither of these studies incorporated sensitive objective markers of 
peripheral vascular function, and may therefore have failed to identify improvements in 
vascular function with the potential to improve clinical outcomes in sufficiently powered long-
term studies of RP and SSc. Consequently, I felt there was sufficient ground to reconsider the 
potential therapeutic benefits of this combination of anti-platelet agents in primary RP and 
SSc. 
In this chapter, I shall report the findings of an investigator-led single-centre proof-of-concept 
study evaluating the short-term effects of asasantin retard therapy on peripheral vascular 
dysfunction, platelet function and eicosanoid biosynthesis in primary RP and SSc. 
7.3 Methods  
7.3.1 Study design 
 
The study was a short-term phase 2 exploratory open-label study and formed an extension to 
the initiial 2 week assessment of peripheral vascular function and platelet function reported in 
previous chapters. This second phase to the study immediately following the initial run-in 
phase. The study design is summarised in Figure 7.1. Eligible participants were issued with 
untampered open-label asasantin retard (aspirin 25mg/modified relase dipyridamole 200mg) 
at assessment 2 (week 2) to be taken as a single capsule orally twice daily. The study 
medication was commenced on the evening of their second assessment (week 2).  
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Figure 7.1.  Summary of study design 
 
The initial 2-week run-in phase formed the basis of the work described in chapters 5 and 6. Eligible patients were given the 
opportunity to enter the second interventional stage of the study, which involved open-label use of asasantin retard prior to a 
post-treatment assessment at the end of week 4.  
 
   Stage 1             Stage 2 






Patients were issued with a second 2-week RCS diary for completion during the treatment 
phase of the study. Participants attended the clinical measurement department of the 
RNHRD for a 3rd assessment at week 4, taking the last of the asasantin retard capsules on 
the morning of their last assessment. The assessment at week 4 was identical to the 
assessment at week 2 (as described in section 6.3.2), incorporating a cold challenge 
assessment and collection of blood and urine for assessment of platelet function and 
eicosanoid biosynthesis.  
7.3.2 Patient selection 
 
This open-label study formed a sub-study of patients targeted and recruited using the 
eligibility criteria described in section 5.3.1. and 5.3.2. for the previously reported work 
evaluating peripheral vascular outcomes and platelet function in primary RP and SSc.  
Patients were excluded from entering the interventional second phase of the study if they 
fulfilled the following exclusion criteria: 
 
1) current use of aspirin, dipyridamole or alternative anti-platelet agent 
2) primary bleeding diathesis or platelet disorder 
3) anticoagulation with warfarin 
4) history of peptic or duodenal ulceration 
5) history of intolerance or allergy to aspirin, dipyridamole or other non-steroidal anti-
inflammatory medication. 
   6) Current use of oral corticosteroids and/or non-steroidal anti-inflammatory drugs  
7.3.3 Trial endpoints 
 








A summary of the trial-related procedures and outcomes is presented in Table 7.1.  
Table 7.1. Assessments undertaken at each visit of study 
 
IRT, infrared thermography; LSCI, laser speckle contrast imaging; LTA, light transmission aggregometry. 
* participants with SSc  ** participants in stage 2 of the study        
      
Consent Form X    
 




   
Raynaud’s Condition Score (Black et al., 
1998) (recorded by participant in 2 week 









Scleroderma Health Assessment 











X X X 
Urine sample (eicosanoid studies)   X X 
Blood sample (LTA and plasma biomarkers)   X X 
Document suspected adverse 
events/reactions 
   X 
 
 
Screening Week 0 Week 2 Week 4 ** 
 
The following endpoints were chosen for analysis.  
Primary endpoints 
The primary endpoint for the study was the RCS diary during stages 1 and 2 to assess impact 
of asasantin retard on the mean daily frequency, mean daily duration and impact (RCS score) 
of RP attacks. 
Secondary endpoints 
The secondary endpoints were objective assessment of digital vascular function at baseline 
(assessment 2 at week 2) and following cold challenge using IRT and LSCI as described in 
section 5.3.3 and elsewhere. 
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Tertiary endpoints 
Assessment of LTA, eicosanoid biosynthesis, circulating plasma biomarkers, platelet number, 
platelet morphology, PV, was undertaken as described in section 6.3.2 and elsewhere.  
7.3.4 Tolerability, safety and compliance monitoring 
 
Information on changes to medications, drug compliance and tolerability was collected at the 
final assessment. Patients were asked to report missed doses by documenting this on the 
relevant dates in the RCS diary. Participants were issued with a 60 capsules of asasantin 
retard and were asked to return unused medication at their final visit. The unused capsules 
were returned to pharmacy and counted for compliance monitoring. Participants were asked 
to report any changes to their medication usage or side effects at assessment 3. Medicine 
and Healthcare products Regulatory Agency (MHRA) definitions were used to classify 
adverse events (Table 7.2). Adverse events were considered adverse drug reactions (ADR) if 
they were reported as potential undesirable events in the summary of product characteristics 
(most recent version available on eMC dated14.12.2011). 
Table 7.2. Classification of adverse events 
 
Adverse event / 
experience (AE) 
any untoward medical occurrence in a subject to whom a 
medicinal product has been administered, including occurrences 
which are not necessarily caused by or related to that product. 
Adverse drug reaction 
(ADR) 
any untoward and unintended response in a subject to an 
investigational medicinal product which is related to any dose 




an adverse reaction the nature and severity of which is not 
consistent with the information about the medicinal product in 
question set out in the summary of product characteristics for that 
product 
Serious adverse event 
(SAE) or serious 
adverse drug reaction 
(SADR) or suspected 
unexpected serious 
adverse reaction 
any adverse event, adverse reaction or unexpected adverse 
reaction, respectively, that: 
(a) results in death 
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(SUSAR) (b) is life-threatening 
(c) requires hospitalisation or prolongation of existing 
hospitalisation 
(d) results in persistent or significant disability or incapacity 
(e) consists of a congenital anomaly or birth defect. 
Important medical events that may not be immediately life-
threatening or result in death or hospitalisation but may jeopardise 
the patient or may require intervention to prevent one of the other 




7.3.5 Statistical analysis 
 
Assuming that the common standard deviation for the RCS is 1.8 (Black et al., 1998), it was 
estimated that a sample size of 19 patients in each group (primary RP and SSc) would have 
a 90% power to detect a difference in mean change in total RCS from baseline of -2.0 with a 
0.050 two-sided significance level. Anticipating a potential 20% patient withdrawal during the 
study period, we hoped to recruit 25 patients with primary RP and 25 patients with SSc to the 
study.  
 
All results are presented as median values (and interquartile range [IQR]), unless otherwise 
stated. Between group comparisons of unpaired data used the Mann Whitney U test. 
Comparison of paired data (e.g. comparing endpoints before and after treatment) used the 
Wilcoxon signed-rank test. The Fisher’s exact test was used to examine differences between 
categorical variables. 
 
All data was analysed using SPSS version 18.0. All tests were two-tailed and a p value of 







Nineteen patients were recruited to the study. Of the 43 patients recruited for assessment in 
stage 1 of the study (described in section 5.4.1), only 22 were eligible for entry into the 
interventional phase of the study (stage 2) at screening. Five patients were taking anti-platelet 
agents at enrollment (n=4 aspirin, n=1 clopidogrel). Two patients were taking regular NSAID 
therapy. Five patients were taking corticosteroids (one of whom was also taking warfarin and 
another was taking aspirin). Six patients had a history of NSAID intolerance and 2 patients 
had a history of intolerance to aspirin. One patient had a history of peptic ulceration. One 
patient was excluded as a recent endoscopy had confirmed an erosive gastritis and it was felt 
inappropriate to treat with aspirin at the time of the study. 
 
Of the 22 patients initially eligible for phase 2 of the study, 3 were excluded prior to treatment 
with asasantin retard; one patient who chose to withdraw from the interventional phase of the 
study as her RP symptoms were well controlled (enrolled during summer) and she did feel 
treatment was required and two patients who had inadvertently used aspirin in run-in phase 
of study (as reported in section 6.4.1). 
 
Four patients withdrew from the study due to adverse events related to the study drug (see 
below for further details). The clinical features of the 15 participants who completed the study 
are presented in Table 7.3. There were no significant differences between patients with 
primary RP compared with SSc for age, gender, age at symptom onset, age at diagnosis, 
smoking history or vasodilator use (Table 7.3). All patients enrolled in the study had lcSSc 
(possibly reflecting exclusion of all patients receiving corticosteroids). Five patients carried 
ACA, 2 patients carried anti-Scl-70 and 2 patients carried anti-U3-RNP autoantibodies. The 




Figure 7.2 Clinical features of patients with SSc who completed the study (n=9).  
 
Table 7.3 Baseline demographics of participants who completed the study 
All data expressed as median (IQR) unless otherwise stated.  
* Mann-Whitney U test for comparing distribution across unpaired groups and Fisher’s exact test to compare frequencies of 
categorical data 
 
 Primary RP (n=6) SSc (n=9)  p value * 












Age in years (IQR) 45.6 (21.3) 53.6 (13.4) 0.07 
Age at RP onset in years (IQR) 18 (23) 35 (10) 0.19 
Age at diagnosis in years (IQR) 42 (17) 40 (13) 0.96 
























































Clinical features of patients with SSc 
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7.4.2 Subjective assessment of RP severity 
 
RCS diary 
There was a significant reduction in both the mean daily RCS score (median 2.29 [2.27] 
vs.1.11 [1.52], p=0.006) and the frequency of RP attacks (median 2.04 [2.67] vs. 1.32 [2.66] 
RP attacks per day, p=0.039) following treatment with asasantin retard (Figure 7.3). The 
duration of RP attacks was not affected by treatment with asasantin retard (median daily 
duration of RP attacks 20 [52.2] vs. 18.6 [40.6] minutes, p=0.19). 
Figure 7.3 Impact of asasantin retard on Raynaud’s Condition Score 
The bold lines indicate the median RCS score and boxplots indicate IQR. The whiskers reveal range of data points 
that sit within 1.5(IQR) of the 1st and 3rd quartiles respectively and equals the range in most instances. Individual 
outliers are numbered and depicted as circles if their value sits between 1.5(IQR) and 3(IQR) of the quartile. 
Outliers are depicted as stars if their value is 3(IQR) from the adjacent quartile. 
 
 





Descriptive data for thermographic assessment at each ROI and the DDD, at baseline and 
following cold challenge are presented in Table 7.4. There were no significant changes in skin 
temperature at any of the 3 regions of interest within the hands or for the DDD for the right 3rd 
finger, at any time point before or following cold challenge, following treatment with asasantin 
retard therapy (p>0.05 for all comparisons, Table 7.4). 
 
LSCI assessments 
Descriptive data for LSCI assessment at each ROI, at baseline and following cold challenge, 
are presented in Table 7.4. There were no significant changes in perfusion flux values after 
treatment with asasantin retard therapy at any of the 3 regions of interest within the hands, 
before or following cold challenge (p>0.05 for all comparisons, Table 7.5). 
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Table 7.4. Effect of 2 weeks asasantin retard therapy on thermographic assessment of 
digital vascular function in primary RP and SSc  
All values expressed as temperature in degrees Celsius (interquartile range). The distal dorsal difference (DDD) was calculated 
by subtracting the temperature overlying the dorsal aspect of the right middle MCP from the temperature from ROI 1. B, baseline 
assessment at 23°C; t 0, assessments immediately following 60s cold challenge at 15°C; t5, perfusion 5 minutes post cold 
challenge etc.  
 
p>0.05 for all comparisons between perfusion before and after treatment.  
 
n=15 unless stated. *n=14 
 
n=15   B t0 t5 t10 t15 
ROI 1 Baseline 25.3 (8.3) 21 (2.6) 24.3 (5.1) 25.5 (8.4) 26.2 (8.5) 
2 weeks 27.9 (7.8) 21.4 (3.5) 23.3 (9.8) 25.8 (10.2) 28.5 (10.3) 
ROI 2 Baseline 27.1 (8.6) 21.1 (3.3) 23.4 (4.9) 27.7 (7.8) 29.2 (9.1) 
2 weeks 30.2 (7.0) 22.0 (3.3) 25.5 (7.9) 26.3 (9.8) 29.1 (10.1) 
ROI 3 Baseline 28 (8.4) 21.1 (2.7) 23.4 (5.3) 26 (11.8) 27.4 (11.9) 
2 weeks 26.5 (8.5) 21.7 (3.7) 23.4 (8.8) 25.5 (11.3) 26.8 (10.6) 
DDD Baseline -0.64 (2.93) -1.6 (2)* -2.1 (4.5) -1.6 (5.5) -1.8 (4.3) 
2 weeks -1.2 (2.8) -1.3 (2.3) -2.0 (6.4) -1.5 (4.7) -1.6 (3.1) 
 
Table 7.5 Effect of 2 weeks asasantin retard therapy on LSCI assessment of digital 
vascular function in primary RP and SSc 
All values expressed as arbitrary flux units (interquartile range). ROI, region of interest; B, baseline assessment at 23°C; t 0, 
assessments immediately following 60s cold challenge at 15°C; t5, perfusion 5 minutes post cold challenge etc. 
 
p>0.05 for all comparisons between perfusion before and after treatment. 
 
n=15  B t0 t5 t10 t15 
ROI 1 Baseline 271 (261) 212 (172) 249 (182) 311 (311) 332 (278) 
2 weeks 364 (289) 254 (172) 271 (370) 349 (413) 373 (386) 
ROI 2 Baseline 147 (408) 89 (39) 122 (231) 161 (286) 176 (322) 
2 weeks 264 (286) 103 (50) 89 (256) 176 (187) 188 (222) 
ROI 3 Baseline 657 (920) 208 (315) 241 (696) 502 (823) 381 (936) 
2 weeks 570 (760) 219 (392) 359 (674) 405 (791) 433 (763)  
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7.4.4 Eicosanoid biosynthesis 
There was a reduction in urinary 11-dehydro-TxB2 levels following treatment with asasantin 
retard (398 [198] vs. 157 [170] pg/mg, p=0.001, Figure 7.4). There was also a significant 
reduction in urinary 2,3-dinor-6-keto-PGF1 following asasantin retard therapy (147 [93] vs. 
135 [130] pg/mg, p=0.017). There was no significant change in urinary F2-isoprostane levels 
following asasantin retard (median 1.00 vs. 0.938, p=0.39). 
Figure 7.4. Urinary 11-dehydro-TxB2 levels before and following treatment with 
asasantin retard 
Values expressed as medians (interquartile range). The bold lines indicate the median value and boxplots indicate IQR. The 
whiskers reveal range of data points that sit within 1.5(IQR) of the 1st and 3rd quartiles respectively and equals the range in 
most instances. Individual outliers are numbered and depicted as circles if their value sits between 1.5(IQR) and 3(IQR) of the 




7.4.5 Light Transmission aggregometry 
The results of LTA analyses before and after asasantin retard therapy are presented in Table 
7.6. There was a significant reduction in % aggregation (maximum % aggregation and at 5 
minutes post-agonist) for all working concentrations of ADP and AA (Table 7.6, p<0.005 for 
all comparisons). There was a significant reduction in Gmax for aggregation with both 




Table 7.6 Impact of asasantin retard on LTA assessments to varying concentrations of 
adenosine diphosphate (ADP) and arachidonic acid (AA) in primary RP and SSc 
Max%, maximum % aggregation during 5 minutes post agonist; % 5 mins, % aggregation after 5 minutes post agonist; Gmax, 





p<0.005 vs. baseline 
 
  
Agonist and concentration 
  Adenosine diphosphate Arachidonic acid 
 
 




80 (11) 79 (7) 78 (16) 52 (49) 82 (11) 75 (13) 
2 weeks 68 (7)
 §
 62 (10) 
§
 43 (13) 
§
 27 (8) 
§
 8 (8) 
§
 7 (4.5) 
§
 
% 5 mins 
Baseline  80 (11) 79 (7) 78 (16) 52 (51) 82 (11) 75 (13) 
2 weeks 62 (10) 
§
 55 (14) 
§
 32 (23) 
§
 16 (9.5) 
§
 7 (4) 
§




Baseline 44 (12) 42 (11) 35 (9) 25 (10) 40 (10) 37 (5) 
2 weeks 47 (10) 42 (7) 36 (3) 25 (6.5) 4 (1) 
§




7.4.6 Circulating plasma biomarkers 
Treatment with asasantin retard did not lead to significant changes in levels of sP-selectin 
(18.1 (4.9) vs. 18.6 (5.7) pg/ml, p=0.21), sCD40L (62.0 (11.2) vs. 58.9 (34.6) pg/ml, p=0.53) 
or TGF- (1290.9 (2159.8) vs. 2084.2 (3931.2) pg/ml, p=0.23).  
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7.4.7 Plasma viscosity and platelet number/structure 
There was an apparent weak trend for the PV to fall following treatment with asasantin retard 
(1.68 vs. 1.61, p=0.13). The HCT, platelet count, PDW, PCT and MPV did not change 
following treatment with asasantin retard (p>0.05 for all comparisons). 
7.4.8 Tolerability, safety and compliance 
A list of all adverse events reported in patients receiving asasantin retard is presented in 
Table 7.7.  
Table 7.7 Adverse events reported during trial 
Data expressed as n (%) unless stated. Differences between primary RP and SSc evaluated using Fisher’s exact test 
 





     No adverse events 
     Fatigue 
     Sebaceous cyst 
     Cellulitis 
     Facial acne 


























Adverse Drug Reactions 
     Headache 
























Serious Adverse Events 












Withdrawn from study 
     Total number of withdrawals 
     Headache 


















There were no significant differences between AE event rates between primary RP and SSc. 
Only one participant completed the study without experiencing any new AEs. Headaches 
were the commonest reported ADR affecting 84.2% (16/19) of participants. The frequency of 
headaches was similar in primary RP and SSc (p=1.00). The mean headache severity was 
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5.3/10 when patients felt able to quantify (n=14 of 16 participants reporting headache). Three 
patients (15.8% of all participants) were withdrawn from the study due to headaches within 
the first 2 days of administration. In 7 of the participants reporting headache (43.8%), 
symptoms improved with repeat dosing and had resolved by the second week of therapy. Six 
patients experiencing headache (37.5%) reported symptoms persisting throughout the 2 
week study period, although some reduction in frequency/severity of headaches was reported 
in 2 of these participants. One patient (5.3%) was withdrawn on day 2 after reporting 
symptoms consistent with hypersensitivity (globus sensation in throat). Hypersensitivity to 
asasantin retard is a commonly reported side effect affecting between 1 and 10% of 
recipients. Only one patient (5.3%) experienced dyspepsia after the first dose and was 
withdrawn after experiencing a severe headache after her second dose. One patient (5.3%) 
reported a single episode of diarrhoea. One patient with lcSSc and a longstanding history of 
upper gastrointestinal dysmotility experienced possible oesophageal obstruction and was 
admitted to hospital (constituting a serious adverse event). A therapeutic upper GI endoscopy 
was undertaken which appeared to resolve the blockage and excluded an associated upper 
GI bleed. There were no reported bleeding events and the Hb did not fall by greater than 
1.0g/dL in any patient. Similarly, the median Hb level was similar before and following 
treatment with asasantin retard (13.0g/dL vs. 12.7g/dL, p=0.068). The serum creatinine did 
not rise above normal range for any patient following treatment and there was no significant 
difference between the median serum creatinine before and after asasantin therapy (n=14, 65 
vs. 64.5, p=0.699). 
7.4.9 Compliance monitoring 
At the second assessment, participants were asked to disclose any missed doses on the 
RCS diary. Further enquiries were made about missed doses at the final assessment. In 
addition, the unused capsules were counted back by the pharmacists (n=32 for full 
compliance). Of the 15 patients who completed the study, 7 (46.7%) denied any missed 
doses and returned the correct number of capsules. Two patients admitted missing 1 and 3 
capsules respectively, which was confirmed on recording number of capsules returned. One 
patient reported missing a single dose due to headache, but capsule counting confirmed a 
total of at least 8 missed doses. Another patient admitted 1 missed dose but returned 3 more 
capsules than expected. Three patients denied any missed doses but returned 1 more 
capsule than expected. One patient admitted omitting a single dose but returned fewer 
capsules than expected (n=29). She had inadvertently discarded some capsules in error and 
denied taking additional treatment to account for this discrepancy. 
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7.5 Discussion 
The results of this study do not provide compelling evidence to support the use of asasantin 
retard in primary RP and SSc. We identified improvements in RP severity assesed using the 
RCS diary parameters but this may be secondary to the influence of the placebo effect and/or 
diary fatigue. The high pevalence of headaches suggests a vasodilatory effect but may be 
secondary to confirmation bias as patients were provided with verbal and written warning 
them of this potential side effect of treatment with asasantin retard. A double-blinded placebo-
controlled cross-over study would have negated the influence of such bias and was originally 
considered for the study design. The over-encapsulation process required to manufacture 
identical placebo and active treatments would have created very large capsules and 
influenced tolerability. An alternative method we considered was to provide a separate 
combination of low-dose aspirin 25ng and modified release dipyridamole (and matching 
placebos). This approach would have increased the number of tablets and may also have 
affected tolerability and compliance. Each approach would have necessitated additional 
assessment visits which may have affected recruitment. I justified the open-label study 
design, despite the many inherent limitations, due to the objective nature of the majority of 
endpoints chosen for assessments. Another major limitation of the study was the study size. 
In chapter 1, I was critical of previous trials of anti-platelet agents due to the small study size 
and use of a heterogeneous mix of patients with primary RP and SSc. And yet, in this 
chapter, I have reported the findings of an equally small study and undertaken primary 
analysis using pooled data from patients with primary RP and SSc. As a feasibility study, we 
have demonstrated the challenges recruiting patients with primary RP and SSc to a single 
centre investigator-led study of anti-platelet therapy. We approached almost 200 potential 
patients for inclusion of the study and had expected interest to be higher. Enrollment was also 
influenced by strict eligibility criteria which prevented patients receiving NSAIDs, antiplatelet 
agents or steroids from entering the study. This accounted for a large proportion of our 
patients, particularly those with dcSSc and/or SSc-associated inflammatory arthropathy who 
were under-represented in this study. Other factors that may have contributed to low 
enrollment (some of which were expressed by potential participants) include low patient 
perception of likely treatment efficacy, need for invasive blood tests and an unnecssary 
concern regarding the use of “laser-derived” imaging modalities. Whilst I failed to achieve my 
original sample size calculation, the study was evidently adequtaely powered to identify 
improvements in the RCS diary parameters, although the relevance of the improvements we 
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identified is questionable as outlined above. Nonetheless, we would have preferred the study 
to be larger.  
 
Despite these limitations, there were strengths to our study which has enhanced our 
understanding of the effects of anti-platelet therapy and the pathogenesis of peripheral 
vasculopathy in primary RP and SSc. I originally hypothesised that this combination of agents 
would promote basal digital vascular perfusion through several pathways including 
adenosine-mediated vasodilation, potentiation of local NO and reduced circulating 
vasoconstrictors such as thromboxane.  There was no evidence to support this from the 
microvascular imaging data. I had also hypothesised that vasoconstriction to local cold 
challenge would be reduced following anti-platelet therapy due to reduced cold-induced 
platelet activation and local release of vasocontrictors. Primary analysis of both 
thermographic and LSCI data failed to support this hypothesis which may represent a true 
lack of contribution of platelets in mediating cold-induced digital vasoconstriction. Irreversible 
morphological vascular changes in SSc may have blunted microvascular responses to 
intravascular factors in SSc. Previous studies have successfully used laser-derived methods 
to demonstrate the vasodilator effects of anti-platelet therapy in RP. For example, Easter et 
al. were able to demonstrate increased endothelium-dependent vasodilation in patients with 
primary RP (n=15) following aspirin therapy using laser doppler flowmetry (Easter and 
Marshall, 2005). In this study, a higher dose of aspirin was used (600mg) and the immediate 
vascular effects were assessed on the day of drug administration. I raised concerns regarding 
reproducibility of siting laser doppler probes in chapter 1, however this study benefited from 
assessing immediate changes in blood flow 30 minutes post-administration. We could have 
incorporated a similar assessment after administration of the first dose of asasantin retard 
although this would have been at the expense of the LTA studies which were undertaken by 
myself immediately following each assessment visit.  
 
We demonstrated predictable effects of asasantin retard therapy on LTA, providing ex vivo 
confirmation of the influence of asasantin retard on platelet activation to ADP and AA. This 
confirmed that platelets were not resistent to the effects of treatment with anti-platelet therapy 
in primary RP and SSc. We also demonstrated an expected reduction in in vivo thromboxane 
biosynthesis. Nonetheless, the magnitude of the reduction in thromboxane synthesis was 
lower than I had anticipated. Previous studies have demonstrated reductions in thromboxane 
synthesis of 85-90% in stroke patients following low dose aspirin 40mg daily (Tohgi et al., 
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1988, Tohgi et al., 1992). In the present study, total thromboxane biosynthesis was reduced 
by approximatley 60% of pre-treatment levels. This suggests higher than expected in vivo 
platelet activation despite anti-platelet therapy. Possible causes may include endothelial 
damage and high circulating levels of other platelet activators (such as the isoprostanes). We 
were also interested in the effects of asasantin retard therapy on prosctacyclin production. 
Low-dose aspirin is generally thought to be insufficient to reduce COX-derived endothelial 
prostacyclin biosynthesis (Tohgi et al., 1992). Dipyridamole is thought to increase endothelial 
prostacyclin production (Kim and Liao, 2008). Furthermore, it has been noted that COX 
inhibition can shunt arachidonic acid down alternative pathways (Duffield-Lillico et al., 2009). 
Consequently, I hypothesised that we may identify an increase in urinary 2,3-dinor-6-keto-
PGF1 levels following asasantin retard therapy but I actually identified a significant reduction. 
This may be a consequence of endothelial dysfunction in RP. The combined effects of a 
suboptimal reduction in thromboxane biosynthesis, further offset by an unexpected reduction 
in endogenous prostacyclin production may have contributed to the lack of objective 
vasodilatory response to treatment with asasantin retard. Sakamoto et al. identified differing 
pulmonary vascular responses to cold challenge in patients with secondary RP (10 MCTD, 4 
SSc) (Sakamoto et al., 1999). They identified an imbalance in thromboxane and prostacyclin 
biosynthesis favouring vasoconstriction in patients who exhibited a pulmonary vasopressor 
response to local cold challenge (Sakamoto et al., 1999). This suggests the contribution of 
platelets and eicosanoid biosynthesis may differ across patients with similar underlying 
conditions. I attempted a similar post hoc analysis in our patients but could not identify any 
trends to suggest a similar phenomenon in our cohort (data not presented). 
 
Dipyridamole is thought to have anti-oxidant effects but we could not identify any change in 
urinary F2-isoprostane levels following asasantin retard. Isoprostanes have been used 
successfully when assessing the efficacy of antioxidants such as vitamin E in clinical studies 
of cystic fibrosis, diabetes mellitus and homozygous homocysteinuria (Cracowski et al., 
2002b). Similarly, urinary F2-isoprostane levels have been used to demonstrate the anti-
oxidant properties of established vasodilatory therapy such as iloprost in SSc (Erre and 
Passiu, 2009, Erre et al., 2008).  
 
We were unable to demonstrate any reduction in circulating plasma levels of biomarkers of 
platelet function (sP-selectin, TGF- and sCD40L). There was a trend for the PV to fall 
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following treatment but we could not present any convincing data to support a role for anti-
platelet agents in potentially augmenting pro-inflammatory or pro-fibrotic pathways. 
7.6 Conclusions 
In summary, we have been unable to provide compelling evidence of improved digital 
vascular function following asasantin retard in primary RP and SSc. We have highlighted the 
challenges in undertaking single-centre proof-of-concept studies of this nature. We need a 
validated standardised approach to digial microvascular assessment that can be adopted 
across several speciailist centres to support future studies of novel potential vasoactive 
mediators in RP. We have identified some interesting observations regarding the effects of 
anti-platelet therapy on eicosanoid biosynthesis in RP that would benefit from further work 
involving larger numbers of patients. Large cross-sectional studies incorporating both patients 
taking anti-platelet agents (for other indications) and those not receiving anti-platelet therapy 
may be the easiest way to undertake such work in the first instance. I shall address the 
important issue of whether the findings of this study should dissuade us from undertaking 




Chapter 8 - Discussion 
‘ …and may the struggle continue until this most obstinate diseases is 
made to give up its secrets.‘ 
 
   Professor Gerald P Rodnan (1927-83) 
 
8.1 Introduction 
I have discussed the outcomes, limitations and the relevance of my findings in the context of 
previous research in the respective discussion sections of the previous chapters. I will not 
replicate such discussion here but shall attempt to bring together the broader aspects of my 
findings with a strong emphasis on the implications for future research.  
8.2 Challenges surrounding patient-reported assessment of 
peripheral vascular function in RP and SSc 
 
Assessment of peripheral vascular function, both clinically and objectively assessment using 
mirovascular imaging tools, is essential in the diagnosis of RP and SSc. The initial clinical 
diagnosis of RP typically relies upon a characteristic history, often in the absence of clinical 
signs. A history of increased sensitivity to cold in conjunction with biphasic digital colour 
changes has been proposed as the minimum requirement for a definite diagnosis of RP 
(Brennan et al., 1993). Indeed the presence of characteristic digital colour changes forms a 
central component of the classification criteria for early SSc (LeRoy and Medsger, 2001). In 
this thesis, I have highlighted specific limitations of patient self-report of RP severity using the 
RCS diary. Such limitations of self-report may extend to subjective assessment of digital 
vascular colour changes in possible RP. Vasoconstriction is an important component of 
healthy thermoregulation and we all experience a degree of visible digital colour change in 
response to cold exposure if the stimulus is sufficient. Such observations led an early 20th 
Century physician to dryly note ‘we are all subjects of Raynaud’s phenomena to a greater or 
lesser degree’ (Hutchinson, 1901). There are notable differences in psychosomatic testing in 
patients with primary and secondary RP that may result in over-reporting and under-reporting 
of symptoms in primary RP and in SSc respectively (Bayle et al., 1990). Such factors may 
account for the high reported prevalence of RP symptoms (~30%) in patients with 
fibromyalgia syndrome (FMS); a syndrome of sensitization of central pain pathways that 
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would not be expected to manifest with a peripheral vasculopathy. Indeed, the presence of 
true peripheral microvascular dysfunction in FMS would provide an interesting hypothesis for 
sympathetic medicated pain in this condition. The poor correlation between subjective and 
objective assessment of digital vascular function in patients with FMS would suggest “true” 
RP is not a feature of FMS (Dinerman et al., 1986, Bennett et al., 1991). It is my own 
conviction that such patients experience and report “cold intolerance” and objective 
assessment of digital microvascular function may help identify such patients. Similar issues 
may arise in primary RP and may explain the large variation we have identified in previous 
work looking at peripheral microvascular function in primary RP (mean DDD at 23°C -1.79 
with a standard deviation of 2.6) (Pauling et al., 2011b). In future, greater emphasis may be 
placed on objective assessment of microvascular dysfunction when diagnosing primary RP. 
This would have clear therapeutic implications, as “cold intolerance” in the absence of 
microvasculopathy would be expected to respond poorly to vasoactive medication whereas 
neuromodulatory agents may be highly effective at lessening the impact of such symptoms. 
 
Surprisingly few studies have validated self-report of colour changes along side objective 
assessment of digital vascular function. We have commenced work evaluating self-reported 
colour changes in patients undergoing thermographic assessment of RP symptoms to 
examine the relationship between underlying diagnosis, self-report of colour changes and 
objective assessment of digital vascular function. This work may provide a platform for future 
studies designed to develop better methods for differentiating “true” RP from “cold 
intolerance” which would have obvious implications for the management of these potentially 
pathologically distinct conditions. 
 
8.3 The need for improved peripheral vascular endpoints in 
therapeutic trials of RP and SSc 
 
An additional important reason for assessing digital vascular function is to evaluate treatment 
efficacy, both in clinical practice and therapeutic trials of RP. Great strides have been made 
to refine clinical disease activity scores in other rheumatic disorders such as the successful 
application of the DAS-28 assessment in rheumatoid arthritis (RA). These tools have become 
invaluable in drug development and guiding clinicians in treatment decisions concerning the 
use of novel expensive therapies such as biological agents. In terms of outcome measures, 
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SSc is perhaps 20 years behind RA; in no small part due to the complexities associated with 
measuring disease activity in a slowly progressive clinically heterogeneous disease. 
 
At present, only the RCS diary has been recommended for use in the assessment of 
peripheral vascular function in therapeutic trials of RP (Merkel et al., 2003, Khanna et al., 
2008). Perhaps this is appropriate in the evaluation of treatments for primary RP, where the 
primary goal of treatment is to reduce symptom severity, and the vascular insult is generally 
insufficient to cause ischemic necrosis of the digits or vascular compromise in other organs. 
Even so, the magnitude of the placebo effect will necessitate large studies to confirm the 
superior efficacy of active treatment in placebo-controlled studies. The design of such studies 
would also need to consider the impact of seasonal variation on RCS diary outcomes, which 
may be a strong rationale for undertaking short-term rather than long-term studies.  
In SSc, confining assessment of vasoactive treatments to RP symptoms has major 
limitations. We have noted specific issues arising from application of the RCS diary in SSc 
such as habituation, coping strategies and difficulty discerning discreet RP attacks from 
background vascular dysfunction secondary to irreversible morphological microvascular 
abnormalities. Such factors are likely to lead to under-reporting of RP symptoms in SSc. 
Figure 8.1 presents the visual appearance and corresponding objective digital microvascular 
assessments in a patient with long-standing ACA-positive lcSSc, complicated by recurrent 
DU and digital necrosis, who took part in my study. Despite compelling objective evidence of 
profound peripheral vascular dysfunction, the patient reported relatively mild symptoms 
(Figure 8.1). In this example, as across the group as a whole, there was no relationship 
between subjective and objective assessment of peripheral vascular function. I have 
previously used the findings of studies evaluating ERA therapy in SSc as an example of the 
disparity that can emerge between subjective and objective appraisal of the treatment 
efficacy (Nguyen et al., 2010, Rosato et al., 2010). The lower incidence of SSc-PAH in 
patients receiving dihydropyridine calcium antagonists provides a tantalizing glimpse into the 
potentially disease-modifying potential of modest vasodilator therapy on long-term outcomes 
in SSc (Steen and Medsger, 2003). It is possible only objective microvascular imaging is 
capable of identifying such modest improvements in peripheral vascular outcomes. The use 
of such tools may facilitate proof of-concept studies examining the pleiotropic effects of widely 
available, cheap and safe treatments. The potential long-term impact of such drugs, even in 
the absence of notable beneficial effects of RP severity, should not be ignored. 
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Figure 8.1 Objective assessments of digital vascular function in a patient with lcSSc complicated by recurrent digital ulceration 
The photograph demonstrates the visual appearance  of the hands on arrival for assessment with evidence of digital shortening of index fingers due to previous necrotic episodes. The thermographic 
image was taken during the baseline of digital vascular function prior to cold challenge.  The laser speckle contrast images taken at 13second intervals during baseline and following cold challenge 
demonstrate poor perfusion of the digits at baseline and following cold challenge. Despite the convincing and consistent objective evidence of digital microvascular compromise, the same patient 
reported a SHAQ RP-VAS of 0.0/3.0, a mean daily RCS score 0.21/10, mean daily frequency of RP attacks of 2.36 and mean daily duration of RP attacks of 28.86 minutes which is consistent with 
relatively mild RP symptoms. 
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The work reported in this thesis has evaluated IRT and LSCI, but neither method has 
emerged as superior to the other. I have not considered other non-invasive methods for 
assessing cutaneous perfusion. A multicentre collaborative grant application has been 
submitted to Arthritis Research UK to evaluate IRT and LDI in SSc. This work will be an 
important step in validating such methods for future clinical trials. In Chapter 3, I have 
highlighted the need for a consensus statement from interested stakeholders to devise a 
standardised approach to thermographic protocol and endpoints in future clinical trials of RP. 
This will facilitate easier comparison of the efficacy of drugs across studies. The 
thermographic DDD (Clark et al., 1999, Anderson et al., 2007), which has been successfully 
applied to the classification of RP, may be similarly successful as an endpoint for use in 
therapeutic trials. There is great enthusiasm amongst members of the UK Scleroderma Study 
Group to undertake multicentre collaborative studies to work towards these objectives in the 
future. 
 
8.4 Further validation of LSCI as a novel microvascular 
imaging tool in RP and SSc 
 
The work I have undertaken thus far has concentrated on validating LSCI as a method for 
assessing digital microvascular reactivity (as a proxy for RP severity). I chose the cold 
challenge to facilitate dynamic assessment of microvascular function but other methods for 
testing autonomic function and vascular reactivity exist that I have not yet considered. 
Similarlly, additional work is required to evaluate the clinical application of LSCI to assess 
other cutaneous microvascular abnormalities that occur in SSc including ischaemic 
cutanoeus lesions (ranging from digital ulceration [DU] to gangrene) and telangiectasia. LSCI 
could be used to further evaluate the association between microvascular dysfunction and 
cutaneous fibrosis in SSc. In this section, I shall outline future research directions that will 
allow us to realise the full potential of LSCI in the assessment of RP, particularly in the 
context of SSc.  
 
8.4.1 Dynamic assessment of digital vascular function 
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The cold challenge assessment 
There are many methods for assessing peripheral vascular reactivity in humans. I have 
undertaken dynamic assessment of microvascular function using a local cold challenge. On 
face value, the cold challenge is attractive in its attempt to recreate the local conditions 
responsible for attacks of RP in vivo although it is not without its limitations. Most notably, few 
patients with RP actually experience what they would consider an attack of RP during the 
study, and the local cold challenge is more accurately an assessment of vascular reactivity to 
local cold exposure. In SSc, the cold challenge assessment assess the combined effect of 
reversible excessive vascular reactivity to cold and the irreversible obliterative 
miroangiopathy that occurs over time. A specific limitation of a thermographic cold challenge 
(upon which much of the existing literature exists) is the influence of conductive and 
convective heat transfer during the test itself (e.g. heat loss into water bath during cold 
challenge and heat gain from deep tissues during re-warming) on changes in skin 
temperature, which are generally attributed solely to changes in microvascular perfusion. The 
reproducibility of the cold challenge has been questioned (Herrick and Clark, 1998) and 
studies have identified better reproducibility of baseline assessments compared with those 
following cold challenge (Bartelink et al., 1993). The additional time considerations of a well-
conducted cold challenge (between 30 and 60 minutes depending on protocol) is another 
limiting factor of the cold stress test.  
 
Nonetheless, the cold challenge unquestionably provides useful information on vascular 
reactivity that can not be derived from static assessment alone, and further work should refine 
microvascular endpoints derived from the cold challenge and better define what these tell us 
about digital vascular structure and reactivity.  
 
Other methods for the dynamic assessment of digital microvascular function 
Other methods for dynamically assessing digital microvasciular function have been 
developed but not yet assessed using LSCI in RP and SSc. The warm challenge (e.g. 30°C 
waterbath) provides information on maximal vasodilatation, and has been incorporated as an 
initial step in subsequent cold challenges tests to assess vascular dysfunction in RP and SSc 
(Clark et al., 1999, Anderson et al., 2007). The iontophoresis of vasodilator chemicals has 
been used for LDI assessment of endothelial-dependent and endothelial-independent 
vasodilation (Anderson et al., 2003). LSCI could be similarly applied to these techniques and 
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may provide new insights into cutaneous microvascular abnormalities in RP and SSc. An 
initial observation of mine was the sensitivity of LSCI to stressors of autonomic nervous 
system function. For example, sneezing, deep breaths and emotion all affected the LSCI 
trace. LSCI may facilitate assessment of central and peripheral autonomic neural control of 
peripheral vascular function in primary RP and SSc. Moreover, LSCI may be more sensitive 
than existing methods for assessing autonomic dysfunction in humans such as heart rate 
variability and respiratory analysis.  
 
There are other methods for assessing vasoreactivity and since we commenced our work, 
another group have published a study evaluating the discriminatory capacity of LSCI to 
differentiate between healthy controls, primary RP and SSc after dynamic tests of vascular 
function including the local cold challenge and post-occlusive reactive hyperaemia (PORH) 
(Della Rossa et al., 2012). This is an emerging field and other studies are underway 
evaluating LSCI in the dynamic assessment of digital vascular function in patients with RP 
and SSc (e.g. use of the PORH test in the ongoing SPECIES study [NCT01743612]).  
 
8.4.2. Comparison of LSCI with other objective methods for assessing tissue perfusion 
I have undertaken preliminary validation work of LSCI alongside the “silver standard” IRT. We 
are the first to undertake such work in RP and SSc. In section 1.5.4 I have outlined previous 
studies that have compared LSCI with other microvascular imaging modalities including NC, 
LDF and LDI. Only one study to date has compared LSCI with laser Doppler techniques in 
RP and SSc (Murray et al., 2009). This limited assessment with LSCI to the nailfold. 
Additional work is required to compare these techniques over broader regions of interest in 
view of the differing tissue penetration of LSCI over laser Doppler techniques. Without such 
work, it is difficult at this stage to comment as to which technique will emerge as superior. 
Both have advantages and limitations leading to my personal conviction that specific roles 
may be identified for each of these complementary techniques in the assessment of SSc.  
8.4.3 Use of LSCI to assess natural history of DU progression and treatment response 
in SSc 
 
To date, no studies have used LSCI to explore the natural history of DU progression and 
healing in SSc. LSCI has been successfully applied to the assessment of burns and may help 
to guide initiation of treatment and assessment of treatment efficacy of DU in SSc (Stewart et 
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al., 2005). A study of DU progression in SSc would facilitate development of LSCI (and IRT) 
parameters for the assessment of vasodilatory treatment efficacy as many of these patients 
go on to receive intravenous iloprost therapy.  A study of this nature should include 
simultaneous assessment with other techniques (most notably IRT) and would be an 
important step in developing existing and novel endpoints for clinical trials and to justify 
ongoing use of costly therapies such as ERA therapy in SSc. A critical component of such a 
study would be to establish whether vasoactive therapies such as iloprost have any effects on 
peripheral vascular function in patients late in the course of SSc when the reversible 
microangiopathy has evolved into an obliterative vasculopathy with capillary loss and relative 
avascularity of affected tissues.  
 
8.4.4 Use of LSCI to assess telangiectasia morphology and function in SSc 
 
Telangiectases are benign cutaneous vascular malformations that are present in the skin of 
the majority of patients with SSc. They are an important cause of iron deficient anaemia when 
present within the gastrointestinal tract of patients with SSc. Cutaneous matt telangiectases 
are harmless but are associated with body image dissatisfaction in SSc (Ennis et al., 2013). 
Objective assessment of these dilated post-capillary venules may provide important clues on 
the pathogenesis of SSc. Novel treatments are under development to better manage 
telangiectases and LDI has been successfully used to assess treatment efficacy (Murray et 
al., 2012). No studies to date have used LSCI in the assessment of cutaneous telangiectases 
in SSc.  
 
8.4.5 Use of LSCI to explore the relationship between microvascular disease and 
cutaneous fibrosis in SSc 
The pathogenesis of cutaneous tissue remodelling and fibrosis in SSc is complex. LeRoy 
proposed a vascular hypothesis whereby microvascular dysfunction was an essential pre-
requisite to subsequent tissue fibrosis in SSc. In support of this paradigm, it had been noted 
that RP symptoms predate other clinical manifestations by several years in the majority of 
patients with SSc. Histological studies of skin biopsy material have helped delineate the 
temporal sequence of the key events that lead to tissue fibrosis. The initiating event is 
thought to be microvascular injury, perivascular inflammation involving cells of the innate and 
adaptive immune systems, secretion of extracellular factors that lead to remodelling of the 
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extracellular matrix, activation of fibroblasts/differentiation to myofibroblasts with subsequent 
increased collagen formation and tissue fibrosis. Against the “vascular hypothesis” is the 
paucity of evidence that vasoactive therapy can slow the progression of tissue fibrosis in SSc 
and the rapid progression of cutaneous fibrosis typical of patients carrying anti-RNA 
polymerase antibodies within weeks of the onset of RP symptoms (Cavazzana et al., 2009). 
Similarly, some patients with profound microvascular dysfunction never go on to develop skin 
fibrosis (Poormoghim et al., 2000) whereas other patients can develop significant fibrosis in 
the apparent absence of significant microcirculatory abnormalities. There are many other 
factors beyond microvascular dysfunction contributing to self-sustaining fibroblast activation 
in SSc and it is likely the exact contribution of pathological factors differs across the disease 
spectrum, with common pathways found within specific serological sub-groups of SSc (and 
their characteristic clinical phenotype).  
 
I have previously discussed clinical assessment of cutaneous fibrosis in SSc using the 
validated modified Rodnan Skin Score [mRSS] (Clements et al., 1993, Clements et al., 1995). 
There are limitations to the mRSS. Firstly, it is a measure of disease severity and not activity. 
For example, it lacks the sensitivity to quantify specific components of cutaneous anatomy 
e.g. dermal thickness. Observer subjectivity on dermal thickness leads to unacceptably high 
levels of inter and intra-observer variability (25% and 12% respectively) for the purposes of 
small short interventional studies (Clements et al., 1995). The mRSS lacks the sensitivity to 
identify potentially important sub-clinical skin changes in unaffected skin and/or identify 
changes in short-term therapeutic studies. Finally, the mRSS loses discriminatory capacity 
when used in mixed cohorts of lcSSc and dcSSc (e.g. a score of 11/51 can describe a patient 
with mild dcSSc or severe lcSSc). Objective methods for assessing skin disease in SSc have 
been developed (e.g. plicometers, durometers, elastometers and cutometers) and used 
successfully in cross-sectional studies and clinical trials of SSc. These methods have been 
comprehensively described in a recent review (Moinzadeh et al., 2012) and whilst they 
overcome some of the limitations of clinical palpation, they also generally lack the sensitivity 
to identify sub-clinical changes in cutaneous re-modelling. For this reason, recent attention 
has focussed on methods that facilitate direct visualisation and quantification of cutaneous 
structure and function. High frequency ultrasound (HFUS) is a novel method for quantitative 
assessment of skin abnormalities in SSc. Initial studies applying HFUS to measure skin 
thickness easily distinguished between SSc and healthy controls (Serup, 1984, Akesson et 
al., 1986, Sedky et al., 2013). Measurements of the depth of dermis and subcutis can be 
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made alongside quantitative assessment of the echogenicity of the cutaneous tissues to 
provide information on the nature and extent of tissue remodelling that is present. Early pilot 
work reported good correlation between HFUS and assessment of skin thickness using 
palpation (Scheja and Akesson, 1997). In contrast, recent work evaluating HFUS in the digits 
of patients with SSc have identified poor correlation between dermal thickness and mRSS 
scores at the same sites (Di Geso et al., 2011). Correlation between skin 
thickness/echogenicity and fibroblast proteoglycan biosynthesis within biopsy specimens of 
assessed skin have been identified (Hesselstrand et al., 2002). Differences in HFUS 
appearances have been identified between lcSSc and dcSSc affected skin (Hesselstrand et 
al., 2008, Hesselstrand et al., 2002). HFUS assessment of skin thickness and echogenicity at 
the hand (between the second and third MCP joints of the right hand) and forearm (dorsal 
aspect, 3cm proximal to the wrist) correlates well with both local and global mRSS 
assessment, indicating assessment of a single site may provide an accurate reflection of total 
skin involvement (Hesselstrand et al., 2008). HFUS assessment of skin thickness can 
accurately discriminate between patients in the oedematous, fibrotic and atrophic phases of 
the disease (Kaloudi et al., 2010). Reliability of HFUS is better than the mRSS for assessing 
skin changes in SSc with excellent intra and inter-relater reliability (Scheja and Akesson, 
1997, Kaloudi et al., 2010, Di Geso et al., 2011). An attempt have been made to use HFUS 
assessment of skin thickness and echogenicty in a therapeutic trial of SSc (Hashikabe et al., 
2005). HFUS has also been used to assess tendon thickening in SSc (Tagliafico et al., 2011). 
HFUS can be adapted to evaluate tissue elasticity (Iagnocco et al., 2010, Di Geso et al., 
2011). Ultrasound elastography (UE) has been used in oncology to help detect malignant 
lesions. Only one study has evaluated UE in patients with SSc, identifying dermal 
abnormalities in elasticity in clinically affected and unaffected skin (Iagnocco et al., 2010).  
 
HFUS has also been used to assess microvascular changes at the nailfold in SSc and 
compared changes with those directly visualised using nailfold capillaroscopy (Keberle et al., 
2000, Kim et al., 2008, Lee et al., 2006). Combining HFUS with power Doppler would provide 
a novel method for assessing cutaneous microcirculatory abnormalities such as 
telangietcasia. To date, no studies have used LSCI alongside HFUS to explore the 
relationship between microvascular abnormalities and fibrosis in affected and unaffected skin 
in SSc in vivo. Such work would provide fascinating insight into shared and divergent 
pathological pathways across the spectrum of SSc disease.  
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8.4.6 Use of LSCI to explore cutaneous microvascular abnormalities in animal models 
of SSc 
 
Animal models have been developed to replicate the clinical pheneotype of SSc to further 
understand the pathobiology of the disease and as a platform for pre-clinical proof-of-concept 
studies of novel therapeutics. I shall not provide a detailed description of the many available 
models that have emerged which have been reviewed elsewhere (Denton, 2012). In brief, 
early animal models such as the tight skin mouse 1 (Tsk1) focussed on cutaneous fibrosis. A 
second tight skin mouse (Tsk2) had an associated inflammatory phenotype with autoantibody 
formation that more closely mirrored human SSc.  A well defined abnormalitity of TGF-
signalling was not a feature of either of these models which led to the development of a 
novel mouse model in which fibroblast-specific expression of a non-signalling TGF- receptor 
(the TRII∆k-fib mouse) leads to features closely mirroring SSc including perivascular fibrosis 
and pulmonary vasculopathy (Denton et al., 2003, Derrett-Smith et al., 2010). The emergence 
of the Fra-2 transgenic mouse strain is an exciting new model which displays a clinical 
phenotype encompassing the pathological hallmarks of SSc; peripheral vasculopathy, 
inflammation and fibrosis (Maurer et al., 2009). In addition to genetically modified animal 
models of SSc, the clinical features of SSc can be induced experimentally e.g. hypoxia-
induced PAH and bleomycin-induced fibrosis in susceptible mouse strains.  
 
The use of imaging modalities provides an opportunity to evaluate the progression of fibrosis 
and vasculpathy in animal models of SSc non-invasively. Recent work has used HFUS to 
assess skin fibrosis in genetic and experimentally induced murine models of SSc (Elhai et al., 
2013). The use of LSCI to assess peripheral vascular function in animal models of SSc has 
not yet been attempted but would has the potential to allow the dynamic assessment 
microvascular abnormalities in vivo.  This could greatly improve the sensitivity of pre-clinical 
proof of concept studies of novel therapeutic agents in SSc. 
8.5 The contribution of platelets to the pathogenesis of 
primary RP and SSc 
 
The last few years has seen an re-emergence of interest in platelets and the pathogenesis of 
SSc. For example, Kahelah and colleagues have recently presented work at the American 
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College of Rheumatology meeting suggesting platelet-derived thrombospondin-1 may be an 
important contributor to endothelial cell apoptosis in the vasculopathy of early SSc (Kahaleh, 
2012b). Improving our understanding of the contribution of platelets to the pathogenesis of 
RP and SSc was the overarching basis of this thesis. We have identified interesting 
differences in platelet function between primary RP and SSc. The work undertaken in this 
thesis has not allowed us establish whether excessive platelet activation is an important 
initiating event in the pathogenesis of these conditions or a secondary event of no 
pathobiological significance. There are many areas of platelet biology that are yet to be 
explored in RP and SSc which are beyond the remit of this discussion. In this section, I shall 
outline future research directions that may help us further establish the action of platelets 
(and endothelial cells) in RP and SSc, before offering final thoughts on the future use of anti-
platelet agnets on RP and SSc. 
8.5.1 Eicosanoid biosynthesis in RP and SSc 
 
The vasoactive properties of eicsoanoids, particularly the prostanoids is well established and 
they have an important role in the management of peripheral and pulmonary vascular 
complication of SSc (Kowal-Bielecka et al., 2009). In recent years attention has shifted to the 
role of eicosanoids in fibrosing conditions such as SSc and IPF. There are 2 major families of 
eicosanoids; the prostanoids produced following COX activity and leukotrienes/lipoxins 
formed by lipoxygenase (LOX) activity (Figure 8.2). The prostanoids PGE2 and PGI2 are 
antifibrogenic, but their local effects may be diminished at sites of fibrosis (e.g the lungs in 
IPF) by the competing more potent pro-fibrotic effects of PGF2 (Castelino, 2012). Both PGE2 
and PGI2 analogues have been shown to prevent experimentally-induced lung fibrosis in 
murine models (Castelino, 2012). Similarly, LOX activity leads to the biosynthesis of 
leukotrienes and lipoxins with opposing profibrotic antifibrogenic actions (Castelino, 2012, 
Chwiesko-Minarowska et al., 2012). Bronchoalveolar lavage (BAL) levels of profibrotic LTB4 
and LTE4 are elevated in SSc-ILD compared with SSc without ILD and healthy controls 
(Castelino, 2012). Furthermore, LOX12/15 expression and activity differs between patients 
with SSc, RA and HC (Endo, 2012, Castelino, 2012). Genetic polymorphisms of LOX 
activating protein may enhance the susceptibility to ILD in SSc (Kowal-Bielecka, 2012). 
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Figure 8.2 Eicosanoid biosynthesis pathways 
PG, prostaglandin; TxA2, thromboxane; COX, cyclooxygenase; HPETE, 5-hydroperoxyeicosatetraenoic acid. 
 
Adapted from Eicosanoid synthesis. Wikipedia Commons. Available from: 
http;//commons.wikimedia.org/wiki/File:Eicosanoid_synthesis.svg (accessed 2
nd




My work has concentrated on prostacyclin, thromboxane and isoprostane biosnthesis in 
relatively small numbers of patients with primary RP and SSc. Nonetheless, we identified 
some interesting associations between urinary levels of these biomarkers with peripheral 
vascular function and seasonal variation. We also paradoxically identified significantly greater 
urinary 2,3-dinor-6-keto-PGF1 levels in patients with SSc-ILD compared to patients with SSc 
without ILD. We would like to undertake additional work in larger numbers of patients, and 
with a larger variety of urinary eicosanoids (including products of LOX) to further evaluate the 
relationship between eicosanoid biosynthesis and vascular and fibrotic phenotypes in SSc.  
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8.5.2 Use of anti-platelet agents in primary RP and SSc 
 
The original premise of this thesis was to evaluate the role of anti-thrombotic therapy in RP 
and SSc. My short-term open-label study of asasantin retard has not helped to establish a 
proof-of-concept for anti-platelet therapy in primary RP and SSc. In the presence of a good 
therapeutic rationale but in the absence of a good evidence base, the use of low-dose aspirin 
has been proposed for patients with SSc and severe digital iscahemia (Wigley, 2012). This 
pragmatic approach seems intuitive but does not consider the breadth of anti-platelet 
treatments available and the combination thereof that offers the greatest therapeutic 
potential. We chose the combination of asasantin retard and dipyridamole due to the 
vasodilatory potential of this combination.  
 
This use of anti-platelet therapy in SSc may be greatly influenced by emerging evidence of 
increased macrovascular disease in SSc (Man, 2012). Greater recognition of macrovascular 
disease in SSc may increase the use of anti-platelet therapy in patients with established 
macovascular abnormalities but is unlikely to extend to the use of anti-platelet agents early in 
the course of the disease where their impact could be greatest. 
 
My attempts of developing a proof-of-concept for asasantin retard use within the context of a 
short-term interventional study illustrate the challenges facing researchers attempting work of 
this kind. The strict exclusion criteria and possible patient-perception on likely efficacy had a 
major impact on our ability to recruit to this study. The optimal study would be a long-term 
multicentre study including large numbers of patients with SSc. The costs of a study of this 
nature make it very unlikely that such work will ever be undertaken. We were unable to 
extend this study to additional participating centres because current microvascular imaging 
set-up across centres has yet to be standardised to a level whereby this would be feasible. I 
believe proof-of-concept studies of this nature should initially concentrate on the immediate 
vasoactive effects of a single-dose of therapy. Promising results should lead to longer term 
studies evaluating the short-term impact of therapy on a wide range of vascular and biological 
outcomes, before finally embarking on larger phase 3 studies to evaluate safety and efficacy 
of therapy. This approach to drug development, whilst laborious, may have the desired effect 
of excluding non-contenders early in the course of drug development, and actually expedite 
the emergence of new treatments at a lower cost.  
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8.5.3 Use of murine models of SSc to establish a proof-of-concept for the use of anti-
thrombotic therapy in SSc 
Only a single study has used murine models of SSc to develop a proof-of-concept for anti-
platelet therapy in SSc (Dees et al., 2011). Despite the obvious limitations of animal models 
of disease, this approach does allow us to undertake dose-ranging studies of one or more 
anti-platelet agents and combinations thereof. As animal models of SSc are refined to more 
closely resemble human disease, such work will prove invaluable in developing therapeutic 
strategies in the pre-clinical setting. Such models may now provide the only feasible method 
for investigating pleiotropic action of existing low-cost drugs (e.g. statins) in SSc, helping to 
increase therapeutic options in this disease.  
 
8.6 Conclusions 
This thesis exemplifies the many challenges facing clinicians seeking new avenues for 
investigating and managing the peripheral microvascular abnormalities that occur in RP and 
SSc. I hope that the findings of this thesis have made a useful contribution to existing 
knowledge and bring us a little closer to understanding the complex relationship between RP 
and SSc, and better ways of assessing and managing these conditions. The work has 
certainly instilled in me a passion for the complexities of these disorders and I hope to 
contribute to the shared efforts until, to quote the late Gerald Rodnan, “this most obstinate of 
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Appendix 1 Healthy Volunteer Participant Information Sheet 
 
 
PARTICIPANT INFORMATION SHEET 
 
Assessment of the cold stress test in healthy 
volunteers 
 
Researchers: Dr J Pauling MRCP, Dr J Shipley PhD, Dr N Harris PhD, & Prof N J McHugh MD 
FRCP 
 
We would like to invite you to take part in our research study. Before you decide we would like you 
to understand why the research is being done and what it would involve for you. Dr Pauling will go 
through the information sheet with you and answer any questions you have. We’d suggest this should 
take about 15 minutes. Talk to others about the study if you wish. Part 1 tells you the purpose of this 
study and what will happen to you if you take part. Part 2 gives you more detailed information about 




What is the purpose of this study? 
This is a study of healthy volunteers with 2 objectives. Firstly, it is designed to assess how 
reproducible measurements of finger blood flow (after submersing your hands in cool water) are 
when measured on 2 occasions, one week apart. This information will help inform the design of 
future trials that will assess finger blood flow in patients with Raynaud’s phenomenon and systemic 
sclerosis (patients who often experience problems with the circulation in their fingers). The second 
part of the study will assess how background room temperature affects finger blood flow response to 
submersing hands in cool water. 
 
Why have I been invited? 
We wish to undertake this study on 15 healthy volunteers.  
 
Do I have to take part? 
No. It is up to you to decide to join the study. We will describe the study and go through this 
information sheet. If you agree to take part, we will then ask you to sign a consent form. You are free 
to withdraw at any time, without giving a reason.  
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What will happen to me if I take part?  
We will ask you to attend the Clinical Measurement Department at the Royal National Hospital for 
Rheumatic Diseases, on 3 occasions over a 2 week period. Each assessment will last approximately 
40 minutes. At each assessment we will measure the affects of submersing your hands in cool water 
on the blood flow to your fingers. 
 
Expenses and payment 
We are unable to pay volunteers for taking part but participants can be reimbursed any travel 
expenses they have incurred should they wish.  
 
What will I have to do? 
We will ask you to attend the Clinical Measurement Department at the Royal National Hospital for 
Rheumatic Diseases, on 3 occasions over a 2 week period. Each assessment will take place 
between 9 o’clock and 12 o’clock in the morning and last approximately 40 minutes. All participants 
will be asked to refrain from alcohol, nicotine and caffeine for 4 hours prior to the assessment. At 
each assessment you will be seated in a quiet room, wearing your light clothing (i.e. jumpers and 
overcoats removed) for a period of 20 minutes acclimatisation at either 23 degrees Celsius (for 
assessments 1 and 2) or 18 degrees Celsius (assessment 3). We will then measure the surface 
temperature of your skin (using a thermal imaging camera), and the blood perfusion (using a laser 
Doppler imager), of your fingers held at a comfortable position in front of you. We will place your 
hands in cellophane gloves and place them into a bowl of water cooled to 15 degrees Celsius for 1 
minute. We will then remove the gloves and place your hands back in position on the platform in 
front of you. Repeat measurement of the surface temperature and blood perfusion of your fingers 
will be performed on removal of the gloves and at subsequent regular intervals, for a period of 15 
minutes. This is the end of the experiment. 
 
What are the possible disadvantages and risks of taking part? 
 
We do not anticipate any risks or side-effects from undertaking the assessments. The only risk or 
burden relates to your attendance to the clinical measurement department on 3 separate occasions. 
The measurements do not involve any contact with your body and you will not feel the 
measurements being taken. Neither device involves any ionising radiation (e.g. X-rays). There are 
no needles or blood tests. The laser used in the perfusion imager is very weak in strength and when 
used appropriately is incapable of causing harm to humans e.g. burns to the skin or eyes. 
 
What are the potential benefits of taking part? 
The study will not help you but the information we get from this study will help improve the 
management of people with Raynaud’s phenomenon and systemic sclerosis. 
 
What happens when the research study stops? 
Once all participants have completed the study, the findings will be analysed. A summary of the 
findings will be sent to you and more detailed discussion can be arranged at your request. The 
results may be used in order to make a published report in a scientific journal as this may help other 
rheumatologists in their research. 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible harm you 
might suffer will be addressed. The detailed information on this is given in Part 2. 
 
Will my taking part in the study be kept confidential? 
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Yes. We will follow ethical and legal practice and all information about you will be handled in 
confidence. The details are included in Part 2. 
 
If the information in Part 1 has interested you and you are considering participation, please 




What will happen if I don’t want to carry on with the study? 
You are free to withdraw from the study at any time without giving a reason. Any data collected 
prior to your withdrawal may still be used in the final data analysis. 
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the researchers 
who will do their best to answer your questions [01225 465 941]. If you remain unhappy and wish to 
complain formally, you can do this by contacting the Patient Advice and Liaison Service (PALS). 
Details can be obtained from Laura Davies (telephone: 01225 473424).  
 
In the event that something does go wrong and you are harmed during the research and this is due 
to someone’s negligence then you may have grounds for a legal action for compensation against 
the Royal National Hospital for Rheumatic Diseases but you may have to pay your legal costs. The 
normal National Health Service complaints mechanisms will still be available to you (as outlined 
above).  
 
Will my taking part in the study be kept confidential? 
Yes. All participants will be issued with a unique identifier code which will be used to label all data 
collected as part of the study e.g. laser Doppler and thermal imaging results etc. All data will be 
stored in a locked filing cabinet or electronically on password protected computers. A cross-
referencing list matching participants with their unique identifier code will be locked in a filing 
cabinet along with an electronic version stored on an NHS password protected computer. All 
identifying information will be removed if the data is written up for publication. Any information about 
you which leaves the hospital will have your name and address removed so that you cannot be 
recognised. Monitors and auditors from NHS Research & Development (R&D) offices may require 
access to participants' personal data to verify or cross check data. 
 
Data will be retained for a period of 5 years to allow any necessary cross checking of data. The 
anonymised data collected may be used in future studies. Professor Neil McHugh will be 
responsible for the safe storage and disposal of the data collected from this study. 
 
Who has reviewed the study? 
All research in the NHS is looked at by independent group of people, called a Research Ethics 
Committee, to protect your interests. This study has been reviewed and given favourable opinion by 
Bath Research Ethics Committee.  
 
What will happen to the results of the research study? 
The results from all the participants will be grouped together for analysis and used to write a 
scientific paper which will be published. Individual participants will not be identified as part of the 
publication. A summary will be sent to all participants and arrangements can be made to discuss 
the relevance of the results in person with Dr. Pauling should participants wish.  
 
Who is organising and funding the research? 
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The research will be undertaken by Dr John Pauling and is being sponsored by the Royal National 
Hospital for Rheumatic Diseases. It is being funded by the Raynaud’s and Scleroderma 
Association.  
 
Further information and contact details 
Thank you for taking the time to read this Participant Information Sheet. Dr Pauling is happy to 
answer any questions you may have. If you wish to receive further information please contact Dr 
John Pauling via telephone (01225 465 941) or via e mail (John.Pauling@rnhrd.nhs.uk ). 
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Appendix 2 Healthy Volunteers Consent Form 
 
 




Assessment of the cold stress test in healthy 
volunteers 
Name of Principal Researcher:  
Dr John D Pauling, Research Fellow, Royal National Hospital for Rheumatic Diseases 
 
_______________                     ________________                    __________________  
Name of participant                  Date                                             Signature  
 
_______________                    ________________                    ___________________ 
Name of person                        Date                                             Signature  
taking consent  
   Please 
initial box 
1. I confirm that I have read and understand the information sheet dated 11.11.09 (version 2.1) for the 
above study. I have had the opportunity to consider the information, ask questions and have had these 




2. I understand that my participation is voluntary and that I am free to withdraw at any time without 




3. I understand that data collected during the study, may be looked at by individuals from regulatory 
authorities or from the Royal National Hospital for Rheumatic Disease NHS Trust, where it is relevant 
to my taking part in this research. I give permission for these individuals to have access to my records.  
 
 
4. I understand that anonymised data from this study may be used in future studies undertaken at the 
Royal National Hospital for Rheumatic Diseases. 
 
 







Appendix 3 Asasantin Retard Participant Information Sheet 
 
 
PARTICIPANT INFORMATION SHEET 
Asasantin retard therapy in the management of 
Raynaud's phenomenon 
 
Researchers: Dr J Pauling MRCP, Dr J Shipley PhD, Dr N Harris PhD, & Prof N J McHugh MD 
FRCP 
 
We would like to invite you to take part in our research study. Before you decide we would like you 
to understand why the research is being done and what it would involve for you. Dr Pauling will go 
through the information sheet with you and answer any questions you have. We’d suggest this should 
take about 15 minutes. It is important that you are entirely happy with the study so you may wish to 
discuss it with your family, friends and other professionals who treat you. Part 1 tells you the purpose 
of this study and what will happen to you if you take part. Part 2 gives you more detailed information 




What is the purpose of this study? 
This study will investigate a new treatment for use in the management of Raynaud’s phenomenon. 
The treatment is called asasantin retard which has already been used for many years in the 
management of stroke disease. Asasantin retard is a combination of low dose aspirin and 
dipyridamole, and works by altering the function of platelet cells that are involved in clot formation 
following injury. It also acts as an antioxidant. It is generally a safe and well tolerated drug (see 
below for further details). 
 
Previous studies have demonstrated that platelet cells contribute to the development of Raynaud’s 
phenomenon. We believe that asasantin retard, by altering platelet cell function and reducing 
oxidative stress, may improve the symptoms of patients with Raynaud’s phenomenon. Our short-
term study (4 weeks) is designed to explore whether treatment with asasantin retard reduces 
frequency and severity of attacks of Raynaud’s phenomenon, improves blood flow to the fingers 
during cold stress test (see below), alters levels of blood stream markers of platelet function and 
reduces oxidative stress. 
 
Why have I been invited? 
You have been invited to take part because you have Raynaud’s phenomenon. Your Raynaud’s 
phenomenon may be part of another disease called systemic sclerosis.  
 
Do I have to take part? 
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No. It is up to you to decide to join the study. You are free to withdraw at any time, without giving a 
reason.  
 
What will happen to me if I decide to take part?  
We will arrange an appointment to discuss the study in more detail. We will describe the study and 
go through this information sheet. If you agree to take part, we will then ask you to sign a consent 
form indicating you have read and understood the information you have been given.   
 
Dr Pauling will have access to your medical records to assess your eligibility for inclusion in this 
study. It is also important for the researchers to record information about you and your conditions. 
Some of this information is general, such as age, ethnicity, and occupation. Other information is 
more specific, such as the length of time you have been ill and the seriousness of your condition. In 
addition we will gather information about all the medication that has been prescribed for you, 
currently and in the past. We will also ask questions about your smoking history. Other clinical 
information, such as your auto-antibody profile will be relevant to the study. One of the reasons for 
collecting this information is so that the researchers can exclude from the study any person for 
whom asasantin retard may potentially pose a risk.  
 
The study itself lasts a total of 4 weeks and is divided into two parts, each lasting 2 weeks. Part 1 
involves monitoring your condition over a 2 week period without additional treatment. Part 2 involves 
monitoring your condition whilst taking asasantin retard tablets. Throughout the study period you will 
be asked to keep a diary of the frequency and severity of your Raynaud’s attacks. People who suffer 
from Raynaud's phenomenon adopt a variety of strategies to avoid precipitating attacks. It is 
important that you continue these strategies but your behaviour at home or outside should remain as 
consistent with the best ways you have found of managing your condition as possible.  
 
We will ask you to attend the Clinical Measurement Department at the Royal National Hospital for 
Rheumatic Diseases, on 3 occasions during the 4 week period. These assessments will take place 
at the start of the study, at the end of the first 2 weeks and at the end of the 4 weeks period. Each 
assessment will last approximately 40 minutes. The following diagram may make the process more 
clear. 
 
  2 week “run-in” phase    2 week treatment period 





   Week 0     Week 2     Week 4 
Assessment 1            Assessment 2             Assessment 
3 
 
Any patients who cannot be prescribed asasantin retard, or any patients who would rather not take a 
study medication can still provide valuable information for the study by allowing us to measure their 
response to the cold stress test for Assessment 1, and then keeping a diary for two weeks and 
allowing us to repeat the cold stress test for Assessment 2. This will help to broaden our knowledge 
of the condition and the assessment techniques we use to monitor disease severity and response to 
treatment. 
 
Expenses and payment 
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We are unable to pay volunteers for taking part but participants will be reimbursed any travel 
expenses they have incurred attending the assessment visits.  
 
What will I have to do? 
We will make an appointment for you to attend for a baseline assessment at the Clinical 
Measurement Department at the Royal National Hospital for Rheumatic Diseases. This will take 
place between 9 o’clock and 12 o’clock in the morning and last approximately 40 minutes. You will 
be asked to refrain from vigorous exercise, alcohol, nicotine and caffeine for 4 hours prior to the 
assessment. You will be seated in a quiet room, wearing your light clothing (i.e. jumpers and 
overcoats removed) for a period of 20 minutes acclimatisation at a comfortable 23 degrees Celsius. 
We will then measure the surface temperature of your hands (using a thermal imaging camera), and 
the blood perfusion of your fingers (using a laser Doppler imager), held at a comfortable position in 
front of you. We will place your hands in cellophane gloves and place them into a bowl of water 
cooled to 15 degrees Celsius for 1 minute. We will then remove the gloves and place your hands 
back in position on the platform in front of you. Repeat measurement of the surface temperature and 
blood perfusion of your fingers will be performed on removal of the gloves and at subsequent regular 
intervals, for a period of 15 minutes. In addition to the above, participants with systemic sclerosis will 
be asked to complete a health assessment questionnaire (the Scleroderma Health Assessment 
Questionnaire) at the first assessment visit only. You will be issued with a diary to allow you to 
record the frequency and severity of your Raynaud’s phenomenon on a daily basis for the following 
2 weeks. A second assessment will take place after the first 2 weeks has elapsed. You will undergo 
a further cold challenge test as outlined above. We will also collect a urine and blood sample from 
you at your second visit. You will not take any study medication in the first 2 weeks.  
 
Those taking part in the second part of the study, will be issued with a prescription for a 2 week 
supply of asasantin retard at the second assessment. The study medication will be dispensed from a 
local pharmacy without you incurring any dispensing charge. After 2 weeks treatment with asasantin 
retard, a third and final assessment will be undertaken with a further cold challenge, blood and urine 
tests. Enquiry will be made as to whether you have experienced any possible side effects of the 
treatment.  The study ends following the third assessment.  
 
Pregnant ladies will not be recruited to the study and all ladies of child bearing age will be required 
to practice a medically acceptable form of contraception throughout the duration of the study. 
 
What alternative treatments are available for the management of Raynaud’s phenomenon? 
There are other treatments available for the management of Raynaud’s phenomenon such as 
calcium channel antagonists (e.g. nifedipine) and selective serotonin reuptake inhibitors (e.g. 
fluoxetine). If you are already taking these treatments, you will be able to continue with them during 
this study. If you have not tried them previously, then we would not start them at the same time as 
this study as they might interfere with the results of the trial. However, you may wish to consider 
their use as an alternative to the trial or alternatively, after the study has been completed.  
 
What are the possible disadvantages and risks of taking part? 
The majority of patients who take asasantin retard don’t experience any side effects. The commonest 
side effect patients have reported is a headache. This is caused by vasodilation (opening up) of the 
blood vessels within the brain and is regarded as a harmless side effect. This vasodilation (opening 
up) is one of the reasons we wish to investigate asasantin retard use in Raynaud’s phenomenon and 
headaches are a reported side effect of all the effective treatments available for managing Raynaud’s 
phenomenon. Thankfully, headaches usually subside within a few days, even if treatment is 
continued, and would be expected to disappear on stopping treatment (which is short acting).  
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The second potential side effect is gastric irritation and bleeding. Aspirin can irritate the wall of the 
gastrointestinal tract and any subsequent bleeding could be more extensive due to the altered platelet 
function and disturbed clot formation. The risk of this side effect is extremely low. In a previous large 
study the risk was approximately 4 in 100 when treatment was continued for a period of 2 years. The 
maximum period of treatment for this study is 2 weeks which will reduce this risk of this potential 
side effect significantly. Pre-menopausal ladies may notice their period is slightly heavier if they have 
a period during the 2 week treatment period. 
 
We do not anticipate any significant risks or side-effects from undertaking the assessments and the 
greatest inconvenience for yourself is the time you would commit to attending the hospital. Blood 
samples at each assessment will only be taken by a medically trained Research Fellow with 
considerable experience, but there is a possibility of some pain or a small bruise. The “cold stress 
test” involves placing your hands in a bowl of cool water (around 15°C) for 1 minute and then 
observing your hands for the following 15 minutes as they warm up. This test has been used in 
many trials of patients with Raynaud’s phenomenon and it would be considered unusual for this test 
to set off an episode of Raynaud’s phenomenon. The measurements we perform do not involve any 
contact with your body and you will not feel the measurements being taken. Neither device involves 
any ionising radiation (e.g. X-rays). The laser used in the laser Doppler imager is very weak in 
strength, and when used appropriately is incapable of causing harm to humans e.g. burns to the skin 
or eyes.  
 
What are the potential benefits of taking part? 
You may notice some improvement in the frequency and severity of your Raynaud’s attacks but this 
cannot be guaranteed, and the purpose of the study is to establish whether asasantin retard therapy 
could have a role in the treatment of Raynaud’s phenomenon. You may benefit from closer 
monitoring and supervision during the study period. Participants may also gain satisfaction from 
knowing that their contribution may help future patients with Raynaud’s phenomenon and systemic 
sclerosis. 
 
What happens when the research study stops? 
At the end of the study, the study medication will be stopped even if you have experienced benefit. 
Additional research would be required before we could consider long-term use of asasantin retard 
for the management of Raynaud’s phenomenon. You will have the opportunity to discuss alternative 
treatments for Raynaud’s phenomenon with Dr Pauling. Once all participants have completed the 
study, the findings will be analysed. A summary of the findings will be sent to you and more detailed 
discussion can be arranged at your request. The results will be used in order to make a published 
report in a scientific journal.  
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible harm you 
might suffer will be addressed. The detailed information on this is given in Part 2.  
 
Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be handled in 
confidence. The details are included in Part 2.  
 
If the information in Part 1 has interested you and you are considering participation, please 





What will happen if I don’t want to carry on with the study? 
You are free to withdraw from the study at any time without giving a reason. Any data collected prior 
to your withdrawal may still be used in the final data analysis. Existing samples stored can be 
removed and destroyed on withdrawal from the study at your request. 
 
What if there is a problem? 
If you have any acute medical problems during the study it is important that you let us know. We will 
provide you with contact details of who to contact should you develop any new problems.  
 
If you have a concern about any aspect of this study, you should ask to speak to the researchers 
who will do their best to answer your questions [01225 448 444]. If you remain unhappy and wish to 
complain formally, you can do this by contacting the Patient Advice and Liaison Service (PALS). 
Details can be obtained from Laura Davies (telephone: 01225 473424).  
 
In the event that something does go wrong and you are harmed during the research and this is due 
to someone’s negligence then you may have grounds for a legal action for compensation against the 
Royal National Hospital for Rheumatic Diseases but you may have to pay your legal costs. The 
normal National Health Service complaints mechanisms will still be available to you (as outlined 
above).  
 
Will my taking part in the study be kept confidential? 
Yes. All participants will be issued with a unique identifier code which will be used to label all data 
collected as part of the study e.g. Raynaud’s diary, laser contrast speckle imaging and thermal 
imaging results etc. All data will be stored in a locked filing cabinet or electronically on password 
protected computers. A cross-referencing list matching participants with their unique identifier code 
will be locked in a filing cabinet along with an electronic version stored on an NHS password 
protected computer. All identifying information will be removed before data is written up for 
publication. Any information about you which leaves the hospital will have your name and address 
removed so that you cannot be recognised. Monitors and auditors from NHS Research & 
Development (R&D) offices may require access to participants' personal data to verify or cross 
check data. 
Data will be retained for a period of 15 years to allow any necessary cross checking of data. 
Anonymised data collected may be used in future studies. Professor Neil McHugh will be 
responsible for the safe storage and disposal of the data collected from this study. 
 
What if relevant new information becomes available?  
Sometimes during the course of a research project, new information becomes available about the 
treatment which is being studied. If this happens, the lead researcher will tell you about it and 
discuss whether you wish to continue in the study. If you decide to continue, you will be asked to 
sign an updated consent form. It is also possible, that on receiving new information, the lead 
researcher may consider it to be in your best interests to withdraw from the study. They will explain 
the reasons for this. If the study is stopped for any other reason, you will be told why.  
 
Involvement of the General Practitioner/Family Doctor 
It is essential that we inform your GP if you choose to take part in the study to ensure your GP is 
aware that you are taking study medication should you encounter any problems. For this reason, we 
will not recruit you to the study if you are unwilling for us to inform your GP. We will provide your GP 
with a copy of this information sheet as well as a copy of a document called the ‘study protocol’ 
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which gives the same information as this sheet but in more technical terms. If you wish to have a 
copy of this study protocol, please ask the research fellow.  
 
What will happen to any samples I give? 
Blood samples will be analysed in the laboratory of the Bath Institute for Rheumatic Diseases and 
within the laboratory of the Royal United Hospital in Bath. They will be stored in a locked freezer 
before and after analysis. The samples will be anonymised and labelled with your unique identifier 
code. They will be stored by the research team for a period of 15 years before being destroyed 
along with the cross referencing list. With your permission, if research within the 15 year storage 
time identifies any additional blood markers relevant to this field of research then the frozen samples 
may be used to measure these. Urine samples will be stored anonymously in a locked freezer within 
the Bath Institute for Rheumatic Diseases prior to analysis. They will then be destroyed. The 
samples will be used to assess platelet function and levels of oxidation stress.  
  
Will any genetic tests be done? 
No. 
 
Who has reviewed the study? 
All research in the NHS is looked at by independent group of people, called a Research Ethics 
Committee, to protect your interests. This study has been reviewed and given favourable opinion by 
Bath Research Ethics Committee.  
 
What will happen to the results of the research study? 
The results from all the participants will be grouped together for analysis and used to write a 
scientific paper which will be published. Individual participants will not be identified as part of the 
publication. A summary will be sent to all participants and arrangements can be made to discuss the 
relevance of the results in person with Dr. Pauling should participants wish.  
 
Who is organising and funding the research? 
The research will be undertaken by Dr John Pauling and is being sponsored by the Royal National 
Hospital for Rheumatic Diseases. It is being funded by the Raynaud’s and Scleroderma Association.  
 
Further information and contact details 
Thank you for taking the time to read this Participant Information Sheet. Dr Pauling is happy to 
answer any questions you may have. If you wish to receive further information please contact Dr 
John Pauling via telephone (01225 448 444) or via e mail (John.Pauling@rnhrd.nhs.uk ) 
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Appendix 4 Study Interest Form 
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Participant Number:  
CONSENT FORM 
 
Asasantin retard therapy in the management of Raynaud's 
phenomenon 
 
Name of Principal Researcher: Dr John D Pauling 
 
 
 Initial box 
1. I confirm that I have read and understand the information sheet dated 13.08.10 (version 1.2) for the above study. 
I have had the opportunity to consider the information, ask questions and have had these answered satisfactorily.  
  
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time without giving any 
reason, without my medical care or legal rights being affected.  
 
 
3. I understand that relevant sections of my medical notes and data collected during the study, may be looked at by 
individuals from regulatory authorities or from the Royal National Hospital for Rheumatic Disease NHS Trust, 
where it is relevant to my taking part in this research. I give permission for these individuals to access my records.  
 
4. I understand that anonymised data from this study may be used in future studies undertaken at the Royal National 
Hospital for Rheumatic Diseases. 
 
 
4.    5. I am not currently pregnant or breastfeeding and agree to practice a medically acceptable method of birth 
control throughout the study period (or withdraw from the study in advance) 
 
 
6. I agree to extra blood and urine samples being taken for this research. 
 
7. I agree for my blood samples to be used for future research within the next fifteen years and that it may not be 
possible to inform me of the nature or results of this future research. 
 
8. I agree to my GP being informed of my participation in the study.  
9. I agree to take part in part 1 of the study 
 











_______________                            ________________                    __________________  
Name of participant                          Date                                             Signature  
 
 
                                               ________________                    ___________________ 
Name of person taking consent       Date                                             Signature  
 












Appendix 7 Example of Raynaud’s Condition Score Diary 
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Full title:  
A short-term open-label single site pilot study 
evaluating the use of asasantin retard therapy in 
the management of Raynaud’s phenomenon. 
 






Platelet Aggregometry  




The PAP4 platelet aggregometer was purchased from alpha laboratories with the intention 
for its sole use as part of this study. The aggregometer was fully serviced and calibrated 
prior to delivery. In view of the infrequent use of the device (for approximately 30 minutes, 
up to 3 times per week) and the short duration of the study (18 months), it was agreed no 
additional formal servicing or calibration would be undertaken by alpha laboratories during 
the study itself. The aggregometer should be sent for a formal service should it be used in 
future studies. This summary shall describe in house QC assessments undertaken to 





All Quality Control (QC) assessments were undertaken by Dr J Pauling using plasma 
donated by Dr J Pauling. The QC assessments were derived from approved 
recommendations concerning quality control (H58-A Platelet Function Testing by 
aggregometry; Approved guideline).  
 
Assessments of the standardisation of the instrument was undertaken setting 100% 
transmission with PPP and baseline with PRP. The PRP cuvette was removed and a 
second PPP cuvette inserted to ensure the chart deflected to 100%. A second PRP cuvette 
was added to ensure the chart deflected back to 0%. Finally, 0.1 ml or 0.225ml of PPP was 
added to the cuvette containing PRP diluting the sample by a factor of 33% and 20% 
respectively. 
 
Aggregometry experiments were undertaken across the dose range of ADP (1.25 to 10 
μmol/L) used in the study. These QC assessments were undertaken to evaluate the 
instrument and operator, and not the agonists used. For this reason, no studies were 
undertaken using alternative agonists such as arachidonic acid. QC assessments were 
undertaken over 3 consecutive days (6th-8th February 2012) using plasma donated by J 
Pauling. Six 0.109M 3.2% citrate vacutainer bottles were filled. Platelet rich plasma (PRP) 
and platelet poor plasma (PPP) was prepared as undertaken in the study and described in 
detail in the platelet aggregometry SOP. All assessments were undertaken using ADP (lot 
no 07000076, Exp 02.2013). The ADP had been reconstituted on the 26th January 2012 to a 
working concentration of 10 μmol/L. Working concentrations of 5, 2.5 and 1.25 μmol/L were 
created with repeated 1:1 dilution of 125 μL of agonist and purified water.  
 
On assessments 1 and 2, the assessments were undertaken with the agonists as per the 
study protocol (10, 5, 2.5 and 1.25 μmol/L) on 2 occasions (allowing duplicate 
assessments). Surplus PRP at assessment 2 allowed additional assessments with the 10 
μmol/L concentration. This was repeated at the 3rd assessment, although the order of the 
assessments was changed to facilitate analysis of duplicate samples across separate 
channels. Additional PRP allowed additional assessments with the 1.25μmol/L 
concentration.  In total, 13 duplicate assessments were undertaken exceeding the 
recommended minimum of 10 assessments. 
 
Finally, assessment of the temperature within the cuvettes was undertaken using post-
aggregation samples on the 1st March 2012. The temperature was assessed using a 





A descriptive analysis of the tests for standardisation and linearity are reported. The 
coefficient of variation (CV) for each aggregation endpoint (maximum aggregation, 
aggregation at 5 minutes and initial slope of aggregation) is calculated using the 
following formulae:  
 
n being the number of data pairs and x1 and x2 duplicate measurements.   
 




All data can be verified using enclosed hard copy printed reports generated by the PAP-4 




The instrument is designed to only allow aggregation experiments to be undertaken when 
the incubation chambers have reached a temperature of 37ºC. The instrument is switched 
on 30 minutes before operation and indicates when the channels are ready for analysis.  
 
The stir bar speed for each channel can be checked by pressing the stir bar speed buttons 
at any stage. These are routinely checked prior to aggregation experiments to ensure they 
remain set at 920rpm.  
 
Instrument functionality and linearity 
 
Assessments of instrument standardisation confirmed accurate standardisation with 
repeated values of 100% for PPP and 0% for PRP. These assessments were undertaken 
primarily using channel 1 of the aggregometer. At assessment 2, all channels were checked 
individually. No transmissions of >103% were obtained for PPP providing reassurance of 
the quality of the instrument and PPP preparation (i.e. platelet free). Tests for linearity gave 
readings slightly below expected (up to 8%) values. The mean deflection for the 33% 
dilution was 27.4%. The 20% dilution undertaken on 08.02.2012 was slightly below at 19%. 
 
Table 1. Assessments of instrument functionality and linearity.  
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06.02.2012 1 1% 99% 1% 100% 31%  
07.02.2012 1 0% 100%   29%  
2 1% 100%   25%  
3 1% 103%   26%  
4 1% 100%   26%  
08.02.2012 1 0% 101%    19% 
 
Platelet aggregation curves. For each aggregation experiment, the endpoints chosen were 
(as in study) %aggregation at 5 minutes, maximum percent aggregation and initial slope of 
aggregation. The results are presented in Table 2. 
 





Channel 5 minutes Maximum 
aggregation 
Initial slope of 
aggregation 
06.02.2012 ADP 10  1 79 79 54 
ADP 5  2 80 80 45 
ADP 2.5  3 78 78 36 
ADP 1.25  4 20 23 25 
ADP 10  1 80 80 45 
ADP 5  2 79 79 41 
ADP 2.5  3 75 75 35 
ADP 1.25  4 33 33 24 
07.02.2012 ADP 10  1 75 75 33 
ADP 5  2 77 77 30 
ADP 2.5  3 57 57 32 
ADP 1.25  4 8 18 22 
ADP 10  1 75 75 49 
ADP 5  2 74 74 42 
ADP 2.5  3 80 80 35 
ADP 1.25  4 38 38 20 
ADP 10  1 80 80 50 
ADP 10  2 78 78 48 
08.02.2012 ADP 10  1 80 80 42 
ADP 10  2 80 80 42 
ADP 5  3 79 79 40 
ADP 5  4 79 79 29 
ADP 1.25  2 31 31 19 
ADP 1.25  3 33 33 19 
ADP 1.25  1 52 52 23 
ADP 1.25  2 23 23 20 
 
The CVs for the combined analysis are presented in Table 3. The CVs for all endpoints 
were approximately 15%. This is likely to reflect the fact that reproducibility of aggregation 
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curved is dependent upon biological variation of responses to agonist, operator competency 
and instrument accuracy. There was greater variability to low agonist concentrations. Table 
4 presents the CVs for samples stimulated with higher dose agonists (10, 5, 2.5 μmol/L 
concentrations only). The CVs for %aggregation improved significantly to 7.2%. There was 
no change in the CV for initial slope of aggregation (~14%). The CVs for % aggregation 
improve further to 1.28% if analyses are restricted to 10 and 5 μmol/L alone (despite the use 
of fewer analyses which would be expected to increase variability). High agonist 
concentrations tend to result in complete aggregation (80% deflection on aggregation 
curves) whereas low agonist concentrations result in a more finely balanced ex vivo 
equilibrium between aggregation and disaggregation. This leads to repeatable primary wave 
aggregation, followed by subsequent disaggregation. At that stage, platelets can continue to 
disaggregate, stabilise or the release of platelet activators from platelet granules can result 
in a secondary wave of aggregation. It is likely subtle differences in the biological responses 
of samples to low agonist concentrations account for the increased variation in these 
samples. Consistent findings across different channels of the aggregometer with higher 
doses suggest this variation is not the result of instrument failure or poor operator 
competency.  
 
Table 3. CVs generated for each aggregation endpoint for all studies (n=13 in 
duplicate).  
 




Initial slope of 
aggregation 
Mean 62.42307692 62.92307692 34.61538462 
Standard deviation 9.790105 8.600089 4.988448 
Coefficient of 
Variation 15.68347 13.66762 14.41107 
 
Table 4. CVs for each aggregation endpoint for higher concentrations of agonists (10, 
5 and 2.5 μmol/L only). n=9 duplicate pairs. 
 




Initial slope of 
aggregation 
Mean 76.94444444 76.94444444 40.44444444 
Standard deviation 5.542763 5.542763 5.925463 
Coefficient of 




The PAP-4 aggregometer will only allow assessments to be undertaken when the cuvette 
holding bay is heated to 37ºC. The temperature in each channel was assessed using a 
calibrated digital thermometer (Model 2751-K Digitron Instrumentation Ltd). The results are 
reported in Table 5. 
 
  
 Channel 1 Channel 2 Channel 3 Channel 4 
 
Temperature 36.5 ºC 36.8 ºC 
 
36.7 ºC 36.7 ºC 
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All temperature measurements were within 0.5ºC of the target temperature which was 




These experiments have confirmed acceptable instrument functionality and operator 
competency. We have highlighted increased variability at lower agonist concentrations 
which will need to be considered when analysing the results of assessments using lower 
agonist concentrations in the study. None of the QC checks have raised concerns regarding 




Print outs from aggregometry experiments 6th – 8th February 2012-02-08 
 
Platelet Function Testing by Aggregometry; Approved Guideline. Clinical and Laboratory 
Standards Institute. H58 A. Vol 28, no 31, Page 24 
 
 
